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Abstract
EBV is a prevalent human herpesvirus which is implicated in the aetiology of several 
human malignancies, including Burkitt’s Lymphoma and several other cancers of 
lymphoid/epithelial origin. Infection of primary B lymphocytes in vitro with EBV 
leads to expression of a restricted set of EBV latent genes and subsequent 
immortalisation of cells into continuously proliferating lymphoblastoid cell lines 
(LCLs). Eleven viral genes are expressed in latently-infected (immortalised) B cells, 
of which just six are critical for transformation. These include latent membrane 
protein 1 (LMP1) and five nuclear antigens (EBNA1, -2, -3A, -3C and -LP ).
The first part of this study was undertaken in order to investigate the mechanism of 
EBV-mediated deregulation of cell growth by examining its effects on the mRNA 
levels of a range of cell cycle inhibitor genes using ribonuclease protection assay 
(Chapter 3). Significantly elevated p21 mRNA levels was found to be a characteristic 
feature of the transition from EBV latency type I infection (expressing EBNA1 only) 
to type III infection (expressing all 11 latent EBV genes) of Burkitt Lymphoma (BL) 
cells, with elevated expression detected in EBV-immortalised lymphoblastoid cell 
lines, consistent with previous reports. Western blot analysis confirmed a similar 
degree of upregulation at the protein level. p21 (WAF1/CIP1) is an important nuclear 
protein with cyclin-dependent kinase (cdk) inhibitory activity, which can promote 
cytostasis by blocking cell cycle progression at the Gi and/or G2 phases of the cell 
cycle and by inhibiting PCNA-dependent DNA replication. As EBNA2 and LMP1 
are both central to the immortalisation process, the contributions of each of these 
proteins to the observed p21 upregulation was investigated using a tetracycline- 
regulatable gene expression system in an EBV-negative BL background. This 
revealed an important role for LMP1, but not for EBNA2 when expressed singly. 
LMP1 is defined as a classical oncogene and its profound effects on cell growth are 
well-documented. The observed LMP1-mediated upregulation of p21 was found to 
be a B cell-specific effect, and was not detected in a second BL-derived cell line 
which lacks the characteristic c-myc translocation. In addition, the effect is likely to 
be p53-independent. On further investigation into the mechanism of upregulation, no 
transactivation of the p21 promoter was detected while enhanced p21 mRNA
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stability was found to be important in the LMP1-mediated effect. Further studies will 
be required to characterise the molecular basis of this stabilisation.
The precise functions of the EBNA3 proteins are unclear, although persistent 
expression of these genes against negative selective pressure by cytotoxic T 
lymphocytes in vivo is consistent with important roles for all three members of this 
protein family. In attempting to identify potential protein binding partners for 
EBNA3B, the yeast two hybrid system (YTHS) was employed to screen two cDNA 
libraries. Both libraries yielded only false positives, including two EBNA3B-specific 
interactions. However, this type of result is well-documented as a recurring problem 
associated with use of YTH systems.
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CHAPTER 1
INTRODUCTION
1
1 . 0  E p s t e i n - B a r r  V i r u s
1.1 Classification and Structure
Epstein-Barr virus is a ubiquitous member of the herpesvirus family. The herpesviruses 
are a family of almost 100 DNA viruses found commmonly in humans and animals. 
Classification of this family, established on the basis of similarity in biological 
properties, places EBV in the gammaherpesvirus subfamily, the other two main 
subfamilies being alpha- and betaherpesviruses. EBV is the most extensively studied and 
the only human herpesvirus in the gammaherpesvirus subfamily and is the prototype 
virus of the genera lymphocryptovirus. EBV was originally discovered in 1962 when it 
was suggested that EBV may be important in the aetiology of African Burkitt’s 
Lymphomas (Burkitt, 1962). Characteristic of gammaherpesviruses, EBV exhibits a 
tropism for lymphoid cells and a capacity to induce cell proliferation in vivo, resulting in 
transient or chronic lymphoproliferative disorders. In vitro, many gammaherpesviruses, 
like EBV, can immortalise the infected cell. The current classification of herpesviruses 
does not help in determining evolutionary relatedness based on genome organisation and 
structural similarities. The distinction between alpha, beta and gamma herpesviruses has 
been somewhat blurred by more detailed molecular studies and by the discovery of new 
viruses that co-express the structural features of one subfamily and at least some 
biological properties of another. Thus, taxonomists have renamed EBV human 
herpervirus 4 (HHV-4).
Like other herpesviruses, a mature EBV virion has a toroid-shaped protein core that is 
wrapped with double-stranded DNA this is surrounded by an icosahedral capsid with 
162 capsomers (Figure 1.1). The capsid is surrounded by an amorphous material, the 
tegument, composed of globular proteins. The envelopes of herpesviruses have 
numerous glycoprotein spikes, but EBV differs from most other herpesviruses in the 
predominance of a single glycoprotein in the outer envelope (Kieff, 1996).
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Fig. 1.1. Schematic representation of herpes virus structure.
1.2 EBV genome structure
The EBV genome is a linear, double stranded 172 Kb DNA with a guanine/cytosine 
content of 60% (Kieff, 1996). The genome encodes an estimated 100 genes, but like 
many viruses there is complicated differential splicing of RNA transcripts and the 
number of proteins produced may be greater (Kieff, 1996). The EBV genome was 
completely sequenced from the EBV strain B95-8, initially cloned as a BamHl fragment 
library. For this reason, nomenclature of open reading frames (ORFs), for transcription 
or RNA processing, is based on their location within specific BamHl fragments (Baer et 
al., 1984). For example, the BARF1 ORF is found in the BamHl A fragment (BA) and 
it is the first ORF (FI) extending in a rightward (R) direction. On the basis of the 
presence and location of repeated sequences greater than 100 base pairs, herpesviruses 
can be divided into 6 structurally distinct groups, identified as A -  F. As such, EBV is 
classed as a group C virus, where both terminal and internal repeat sequences are present 
throughout the viral genome, which sub-divide it into well-defined unique seqences. A 
simplified schematic representation of the EBV genome shown below (Figure 1.2) 
illustrates this feature.
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Figure 1.2. A schematic representation of the EBV genome (adapted from IARC Monographs, 1997). 
The genome is divided into repeat regions, 0.5 Kb terminal direct repeats (TR) and 3.0 Kb internal direct 
repeats (IR) that divide the genome into short and long largely unique sequence domains (US and UL). 
The BamH 1 fragments are represented by the letters below the red line. The BamHl fragment location of 
the EBV latent genes are indicated below the fragments. EBER: EBV-encoded RNA; EBNA: EBV 
nuclear antigen; LMP: latent membrane protein; LP: leader protein.
The major DNA repeat elements serve as landmarks on the EBV genome map, however, 
serial passage of virus infected cells frequently results in differences in the number of 
tandem repeat reiterations (Dambaugh et al., 1980; Heller et al., 1981; Brown et al., 
1986; Siaw et al., 1986). Some of these repeats encode proteins and this can explain 
differences in protein sizes observed on immunoblots and can also serve as an important 
marker in identifying virus strains, or virus infected cells (Kieff, 1996). It has been 
found that some EBV genes expressed during latent and lytic infection have no 
homology with other herpesvirus genes and may have arisen from cellular DNA. The 
EBV latent gene BCRF1 is the most striking example of an acquisition from the cell 
gene pool. BCRF1 is nearly identical to human interleukin 10 (IL-10) in primary amino 
acid sequence (Moore et al., 1993).
Two EBV types circulate in most human populations (Gerber et al., 1976; Young et al., 
1987; Rowe et al., 1989). These genomes formerly known as type A and type B are 
now referred to as type-1 and type-2. The genomes are almost identical except for the
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genes that encode some of the Epstein-Barr nuclear antigens (EBNAs) such as EBNA2, 
EBNA3A, 3B, 3C and EBNALP, in latently infected cells (Bornkamm et al., 1980). 
Apart from these genes, the genomes appear to have little differences beyond those 
which characterise individual EBV strains. The differences in type-1 and type-2 EBV 
genomes are reflected in type-specific and type-common epitopes for antibodies (Young 
et al., 1987) and T-cell recognition (Moss et al., 1988). As type-1 EBV is more 
common in developed societies, most EBV immune human sera from these countries 
react preferentially or exclusively with type-1 EBNA2, EBNA3A, 3B, 3C and EBNALP. 
African sera are almost evenly split in their serological reactivity, however, the recovery 
of type-2 virus from blood is unusual (Young et al., 1987; Rowe et al., 1989), perhaps 
because EBV type-2 infected lymphocytes grow less efficiently in vitro than their type-1 
infected counterparts (Rickinson et al., 1987). Different viral strains within types-1 and - 
2, based on significant DNA sequence heterogeneity have been found within the genome 
of EBV isolated in certain geographical areas or even from the same area. These 
polymorphisms may cause amino acid substitution in viral proteins and may even affect 
peptides that are important for the immune control of viral infection.
1.3 EBV strategy of infection
Under normal circumstances EBV infection is restricted to humans. Target cell tropism 
is usually limited to B cells and epithelial cells, although the expanding list of virus- 
associated tumours serves to illustrate that the target cell tropism of EBV in vivo is much 
broader than was originally anticipated. The conditions and mechanisms that allow EBV 
infection of these diverse cell types are, however, in most cases unknown. Nevertheless, 
EBV infection of primary B-lymphocytes in vitro involves binding of CD21 on the B- 
lymphocyte plasma membrane. CD21 (also known as CR2) is the receptor for the C3d 
component of complement. After binding, aggregation of CD21 in the plasma 
membrane, co-aggregation of surface immunoglobulins (slg) and internalization of EBV 
into cytoplasmic vesicles occurs (Nemerow and Cooper, 1984; Carel et al., 1990). The 
virus envelope then fuses with the vesicle membrane, releasing the nucleocapsid and 
tegument into the cytoplasm. Penetration is usually complete within 1-2 h.
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Superinfection of established BL cell lines is somewhat different in that EBV binding 
does not result in as significant a patching of CD21 and slg and the envelope fuses with 
the plasma membrane, releasing the nucleocapsid and tegument into the plasma 
membrane. The observed differences in mode of infection between primary B- 
lymphocytes and BL cells are likely to be due to the cytoskeletal abnormalities of the 
tumour cells (Kieff, 1996). The EBV outer envelope glycoprotein gp350 and gp220 
form the CD21 ligand. The interaction of CD21, gp350 and gp220 mediates EBV 
adsorption (Tanner et al., 1987; Nemerow et al., 1987; 1989). Another EBV 
glycoprotein gp85, has been implicated in the fusion of the EBV envelope with the 
vesicle membrane. Monoclonal antibodies to gp85 inhibit the fusion of the EBV 
envelope and the cell membrane (Miller and Fletcher, 1988). Little is known about EBV 
capsid dissolution, genome transport to the cell nucleus or DNA circularization. By 
comparing EBV to other DNA viruses that replicate in the nucleus it may be suggested 
that the cytoskeleton is likely to mediate EBV capsid transport to the nucleus (Dales and 
Chardonet, 1973).
Two forms of EBV-cellular infection are recognised, latent and replicative (or lytic). 
Cell transcription factors probably determine if latent or lytic infection ensues after the 
genome enters the nucleus and circularizes (Kieff, 1996). In vitro experiments show that 
most human peripheral blood B-lymphocytes are susceptible to EBV infection. The 
virus does not usually replicate in recently-infected B-lymphocytes, which instead 
become stably latently infected. In latent infection, virus penetrates the cell and remains 
present either as circular episomal DNA (formed through fusion of the terminal repeats) 
or, less frequently, as linear DNA integrated into the host genomic DNA. Episomes, 
present in low copy numbers in the host cell nucleus, are copied by host cell DNA 
replicating enzyme and pass to daughter cells in mitosis (Joske and Knecht, 1993). 
Episomal DNA is also likely to be necessary for lytic cycle EBV DNA replication.
A specific set of nuclear (EBNA) and membrane (LMP) protein and small RNA 
(EBERs) viral gene products maintain the latent infection and cause the previously 
resting B-lymphocytes to continuously proliferate (Mark and Sugden, 1982). The effect
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on cell growth is immediate and efficient, with most cells entering DNA synthesis 48-72 
hours after EBV infection. The EBV infected proliferating B-lymphocytes are similar to 
activated B-lymphocytes in their secretion of immunoglobulin and their adherence to 
each other (Klein, 1987; Zhang et al., 1991). Approximately 1 in every 105-106 of the B- 
lymphocytes purified from the peripheral blood of previously infected people are 
latently infected with EBV. These latently infected B-lymphocytes may be cultured and 
will proliferate into long-term lymphoblastoid cell lines (LCL) (Sixbey and Pagano, 
1985). LCL outgrowth is the simplest means for establishing immortal cell lines from 
individual humans for chemical, biological and genetic analysis. Although epithelial 
cells are fully permissive for lytic EBV infection in vivo, infection of epithelial cells in 
vitro has proved inefficient, and thus, most of our knowledge of latent or lytic EBV 
infection in vitro is based on infection of B lymphocytes.
1.4 EBV Latent Infection
Because EBV-infected lymphocytes are growth-transformed by the virus, they can be 
grown indefinitely in culture and are amenable to detailed biochemical analyses 
including investigation of the mechanism of latent genome persistence and of cell 
growth transformation. At least 11 EBV genes are expressed in latent infection. Two of 
these encode small, non-polyadenylated RNAs (EBER1 and EBER2), six encode 
nuclear proteins (EBNA1, 2, 3A, 3B, 3C and LP) and three encode integral membrane 
proteins (LMP1, 2A and 2B). Six of these genes are essential for the immortalization of 
primary B cells (EBNA1, 2, 3A, 3C, -LP and LMP1). Transcription of nuclear proteins 
is initiated at RNA polymerase II-dependent promoters in the BarnRl C (Cp) and 
BamHl W (Wp) regions of the viral genome (Rogers et al., 1992).
The EBV genome circularises in the infected cell nucleus within 12-16 hours of 
infection. At about the same time, the Wp promoter initiates rightward transcription. The 
first viral proteins to be expressed in B cells upon EBV infection, namely EBNA2 and 
EBNALP are believed to play critical roles in the early stages of the immortalization 
process (Alladay et al., 1989; Rooney et al., 1989; Alfieri, et al., 1991). EBNA2 and
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EBNALP are initially transcribed from the very strong promoter Wp, which is present in 
multiple copies in the major internal repeat and are detectable within 12-16 hours post­
infection. Once immortalization is established, Wp activity declines and transcription of 
the EBNA genes switches to using the Cp promoter (Woisetschlaeger et a l, 1990). All 
EBNA coding mRNAs are derived from the same transcriptional unit by alternative 
splicing and alternative polyadenylation (Figure 1.3.). The coding exons for most of the 
EBNAs are towards the 3' end of the mRNAs and are preceded by the highly spliced 
leader exons, which are encoded within the major internal repeat of the genome (Farrell,
1995). The infected B cells enter the first S phase approximately 40 h after the virus 
penetration (Sample and Kieff, 1990; Alfieri et al, 1991), at which stage all the EBNA 
and LMP proteins have reached detectable levels, with all 11 latent proteins being 
detectable by 72 h post-infection.
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Figure 1.3 A simplified outline of the splicing of the EBV nuclear antigen coding mRNAs. Transcription 
initiation is shown to arise from the Cp promoter. The EBNA gene mRNAs all derive from the same 
transcription unit by alternative splicing and alternative polyadenylation.
The usual outcome of B-lymphocyte infection with EBV is a persistent latent infection. 
Three forms of latent infection have been characterised in EBV-carrying B-cell lines and 
EBV-carrying tumour biopsy samples. Thus, latency types I, II and III may be 
distinguished on the basis of expression of EBV latent genes and promoter usage 
(Sample et a l, 1986; 1991; Rowe et al., 1986; 1987). Type-I latency is characterised by 
the expression of a single EBV protein, EBNA1 (Rowe et a l, 1987), together with high 
copy numbers of EBER1 and EBER2 (Rymo, 1979; Howe and Shue, 1989). The classic
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features of latency I are exhibited in endemic (BL) biopsies and in early passage cell 
lines derived from these tumours (Rowe et a l, 1987). Cells in latency II resemble 
latency I cells in that they express EBNA1 and the EBER RNAs, but also express 
LMP1, LMP2A and LMP2B. Nasopharyngeal carcinoma (NPC) and Hodgkin’s disease 
(HD) are two EBV-related clinical conditions which exhibit the latency 2 program. 
Explanted BL cells grow continuously in culture and on serial passage some retain the 
phenotype of the original biopsy (type-I). However, during prolonged culture in vitro 
many BL cell lines show a dramatic phenotypic drift, with increased expression of B- 
cell activation antigens and adhesion molecules and the appearance in the culture of 
clumps of more lymphoblastoid-like cells (type-III). As the group-III phenotype cells 
dominate the culture, they frequently lose expression of CD 10 and CD77 (which are BL- 
associated markers), while other LCL associated markers, such as CD40, intercellular 
adhesion molecules and Bcl-2 are up-regulated (Rooney et al., 1986; Rowe et a l, 1987; 
Henderson et a l, 1991). Type-III cells express the full set of EBV latent genes as well 
as cellular genes such as CD23 and a ligand for the EBV receptor CD21 (Wang et a l, 
1987). Two EBV-associated diseases best exemplify the latency III program, infectious 
mononucleosis (IM) and post-transplantation lymphoproliferative disorder (PTLD) 
which is a potentially fatal immunoblastic lymphoma in transplant patients. The pattern 
of EBV latent gene expression is illustrated in Table 1.1 below.
Type of 
latency
Gene Product Examples Reference
I EBERs, EBNA1 Burkitt’s lymphoma Rowe et al., (1987)
Gastric Carcinoma Imai et al., (1994)
II EBERs, EBNA1, Hodgkin’s disease Deacon et al., (1993)
LMP1, 2A, 2B, Nasopharyngeal carcinomi Hitt et al., (1989)
BARFO Brooks et a l, (1992)
III All EBV latent genes PTLD, IM Young et al., (1989)
Tierney et al., (1994)
Other EBERs, EBNA1, 2 Smooth muscle tumours Lee et al., (1995)
Table 1.1. Pattern of EBV latent gene expression, (adapted from the IARC monograph, 1997). PTLD, 
Post-transplant lymphoproliferative disorder, IM infectious mononucleosis.
1.5 EBV Latent Genes
1.5.1 EBNA1
EBV nuclear antigen 1 is required both for latent replication of the EBV genome and as 
a regulator of viral gene transcription (Speck and Strominger, 1987; Sugden, 1989) and 
is the only EBV latent gene which is detectable in all EBV infected cells. This 73 kDa 
protein consists of a short amino-terminal region a 20 kDa - 40 kDa, glycine alanine 
repetitive sequence flanked by arginine rich sequences and a highly charged acidic 
carboxy terminal sequence (Hennessy and Kieff, 1983). During latent infection of 
human host cells, EBV genomes are maintained as double-stranded DNA episomes that 
replicate once every cell cycle (Adams, 1987, Yates and Guan, 1991). The carboxy 
terminus of EBNA1 determines its nuclear localisation by interacting with a specific 
protein that is homogeneously distributed on chromosomes (Harris et al., 1985; Petti et 
al, 1990). This property is likely to be important for segregation of episomes into 
progeny nuclei during mitosis. Part of EBNA1 is also associated with the nuclear
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matrix. EBNA1 is the only EBNA that continues to be made during lytic infection 
(IARC Monograph, 1997).
Although most of the EBNAs bind to DNA cellulose, only EBNA1 has sequence- 
specific DNA binding properties. The specific EBNA1 cognate sequence is a partial 
palindrome: TGGAT AGC AT AT GCT ATCC A for which EBNA1 has a high affinity. 
EBNA1 binds as a dimer to two components of the latent cycle origin of replication, ori 
P and it is the only virus encoded trans-acting factor required for episomal maintenance 
of the EBV genome (Ring, 1994). The replication origin is composed of 20 tandem 
repeats of the EBNA1 binding site, spaced about 1 Kb away from the 20 repeats are a 
further 4 copies of the binding site, 2 in dyad symmetry and two in tandem. The dyad 
symmetry component is stringently required for episome replication. The interaction of 
EBNA1 with the tandem repeats and dyad symmetry sites is co-operative and results in 
high-order structures that lead to bending of the DNA, distortion of the duplex and 
looping out of the intervening sequences (Frappier and O’Donnell, 1991; Orlowski and 
Miller, 1991; Frappier and O’Donnell, 1992). Regions of the protein important for DNA 
binding and transactivation of ori P are located in the carboxy-terminal third of the 
protein (Ambinder et al., 1991) (see Figure 1.4). Furthermore, ori P acts as an EBNA1 
dependent enhancer and plays a crucial role in the regulation of viral transcription from 
both the C and the LMP1 promoter in growth-transformed cells (Sugden and Warren, 
1989; Gahn and Sugden 1995).
Gly-Ala
98 327 641
459 607
Dimerizalion
DNA binding
W ! fiTTT
Transcriptional 
4.*>U 041 activation
42 76
■ h  4— Nuclear localization
379 387
Figure 1.4 Functional domains of EBV nuclear antigen 1 (EBNA1). The Gly-Ala box is a repetitive 
region composed entirely of glycine and alanine, it varies in length between viral strains. Adapted from 
Farrell, 1995.
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The promoter from which the EBNA1 gene is transcribed differs between cell types. In 
EBV transformed LCLs all the EBNA genes are derived from a highly spliced transcript 
that is generated by transcription from the C or W promoters located on the BamHl C 
and W fragments respectively (Middelton et al., 1991). A recent study has indicated that 
RNA transcripts from latently infected early passage type-I BL cells, in the absence of a 
stimulus to induce virus replication, is initiated from a promoter distinct from Fp located 
in the adjacent Bam H I-Q fragment (Nonkwelo et al., 1995). This promoter is 
designated Qp. Qp does not contain a recognisable TATA box, which is consistent with 
multiple sites of transcription initiation from Qp (Nonkwelo et al., 1996). Additionally, 
EBNA1 can negatively autoregulate expression within receptor plasmids containing both 
Fp and Qp through two binding sites downstream of the 3'-most Qp start site (Sample et 
al., 1992; Snug et al., 1994). Following the switch from latent to lytic infection EBNA1 
transcription is controlled by the Fp upstream of Q (Lear et al., 1992).
EBNA1 can bind RNA in vitro through arginine/glycine motifs (Snudden et al., 1994). 
EBNA1 also activates expression of the lymphoid recombinase genes (RAGs) through 
an as yet unidentified mechanism (Srinivas and Sixbey, 1995). Activation of the RAGs 
could promote chromosomal rearrangements and translocations and possibly also 
facilitate viral integration. This may indicate that EBNA1 can activate expression of 
critical cellular genes and affect cellular growth control. Expression of EBNA1 in EBV 
negative cell lines has no obvious effect upon cellular growth characteristics. However, 
the expression of EBNA1 in the B cells of transgenic mice has been shown to be 
associated with the development of lymphocytic lymphoma and leukaemia suggesting 
that EBNA1 predisposes the mouse lymphocytes to oncogenic change (Wilson and 
Levine, 1992).
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1 . 5 . 2  E B N A 2
EBNA2 plays a central role in the immortalisation of primary B lymphocytes by EBV, 
and is one of the first genes to be expressed during this process. The EBNA2 gene 
encodes an 83 kD protein which localises in large nuclear granules and is associated 
with nucleoplasmic chromatin and nuclear matrix fractions (Petti et al, 1990). The 
EBNA2 protein is overall acidic, containing a polyproline region, a glycine-arginine 
repeat and a highly acidic carboxy terminus (Dambaugh et al., 1984). Like EBNA-LP 
and EBNA1, EBNA2 is phosphorylated on serine and threonine residues and must 
undergo significant post-translational modification in addition to phosphorlyation as the 
size of the nascent protein is smaller than that of the stable intranuclear EBNA2 (Kieff, 
1996). EBNA2 is a specific trans-activator of latent viral genes and certain cellular 
genes including the B cell activation marker, CD23 (Wang et al, 1987, 1990, 1991), the 
B lymphocyte differentiation marker, CD21 (Cordier et al, 1990) and the c-fgr oncogene 
(Knutson, 1990). Viral genes transactivated by EBNA2 include LMP1 (Abbot et al., 
1990; Ghosh and Kieff, 1990; Wang et al., 1990b; Tsang et al., 1991; Fahraeus et al,
1993), LMP2 (Tsang et al., 1991) and the cis-acting element upstream of the Cp 
promoter (Walls and Perricaudet, 1991; Sjoblom et al, 1995).
Three regions have been located which appear to be stringently required for 
transformation and the trans-activating activity of EBNA2, between amino acid residues 
95-110, 280-337 and 425-462 (see Figure 1.5). While the role of the 95-110 region is 
unclear, the 425-462 region is essential due to its acidic //-¿ms-activating characteristics. 
Detailed analysis of this region indicates that it is similar in many respects to the 
prototype VP 16 acidic domain (Cohen and Kieff, 1991, Cohen, 1992) The 425-462 
domain shares with VP 16 an affinity for the transcription factors TFIIB, TAF40, TFIIH 
and RPA70 suggesting a critical role for this region in recruiting these factors to 
EBNA2-responsive promoters. The main function of the 280-337 region is to mediate 
interactions with DNA sequence-specific binding proteins as EBNA2 is unable to 
interact directly with its responsive elements. Thus, targeting of EBNA2 to specific 
DNA sequences is achieved through the exploitation of a ubiquitously-expressed cellular
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DNA-binding protein, RBP-Jk (CBF1). Interaction of EBNA2 with RBP-Jk has been
demonstrated in vitro (Grossman et al, 1994; Henkel et al, 1994) and in vivo 
(Yalamanchilli et al, 1994).
Pro
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Figure 1.5 Functional domains of EBY nuclear antigen 2 (EBNA2). The pro box is a region 
composed entirely of proline, it varies in length between viral strains. Adapted from Farrell 1995.
EBNA2 activates gene expression through a common cis-regulatory element found in 
both viral and cellular promoters. EBNA2 response elements (E2RE) have been 
characterised upstream of the EBV LMP-1, LMP-2A and Cp promoters as well as the 
CD23 promoter. Each E2RE includes MNYYGTGGGAA, which includes the cognate 
sequence for RBP-Jk, CGTGGGAA. Additional protein binding sites are present in 
E2REs: for example, mutation of the Spi-1 (a member of the ets family of transcription 
factors, also known as PU.l) binding site has a profound effect on the responsiveness of 
the LMP1 promoter (Johannsen et al, 1995; Laux et al, 1994a). Spi-l/PU.l is also likely 
to be an important member for many of the cellular genes that are activated by EBNA2 , 
as it is frequently involved in B lymphocyte-specific gene transcription.
RBP-Jk is a highly-conserved repressor protein which is part of a signaling pathway 
initiated at the Notch receptor (Tun et al., 1994). Upon ligand binding, the cytoplasmic 
domain of Notch is assumed to be cleaved off the membrane and translocated to the 
nucleus where it activates target genes by converting the RBP-Jk repressor protein to an 
activator (Artavanis-Tsakonas et al., 1995). Notchl is a human Notch first identified at
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the breakpoint of a recurrent chromosomal translocation associated with a subset of 
human T-cell acute lymphoblastic leukaemia/lymphomas (T-ALL) (Aster et al., 1997). 
A truncated oncogenic form of Notch 1 has been identified in human T-ALLs and 
EBNA2 has been found to mimic this constitutively activated Notch in its mode of 
action through binding of RBP-Jk, thus linking EBNA2 to cell transformation. 
Mutational analysis of the EBNA2-responsive regions of the various promoters reveals a 
high similarity between EBNA2- and Notchl-transactivation regarding the crucial cis- 
elements. In a recent study, activated Notchl stably introduced into EBNA2-negative 
BL cell lines, in a regulatable fashion, modulated expression of most but not all EBNA2- 
regulated cellular genes (Strobl et al, 2000). In the same study, stable introduction of an 
activated Notchl expression construct into an LCL with an oestrogen-dependent 
EBNA2-oestrogen receptor fusion protein (EREB2-5 cells) revealed that after oestrogen 
withdrawal activated Notchl was not sufficient to maintain proliferation. From these 
data, it may be concluded that EBNA2 exerts additional functions apart from triggering 
the Notch pathway, in the process of B cell immortalisation.
A consistent feature of BL cells is the transcriptional activation of the proto-oncogene c- 
myc by chromosomal translocation (Bornkamm et al., 1988; Spencer and Groudine, 
1991). The most frequent translocation t(8;14) fuses the c-myc gene locus on 
chromosome 8 to the constant region of the Ig heavy chain gene locus on chromosome 
14. Since BL cells are thought to proliferate through activation of the c-myc gene the 
growth promoting function of EBNA2 may not be required in the setting of BL. A novel 
function of EBNA2 has been described using an oestrogen responsive system whereby 
the expression of EBNA2 is controlled by the presence or absence of oestrogen (Jochner 
et al., 1996). EBNA2 down-regulates surface IgM expression and transcription of the 
lg-|0. locus very efficiently. In BL cell lines with the t(8:14) translocation, down- 
regulation of Ig-p, is associated with concomitant transcriptional shut-off the c-myc gene, 
reflecting the fact that c-myc is under the control of Ig heavy chain locus in these cells. 
The function of EBNA2 as a negative regulator of Ig-|X provides an explanation for the 
growth inhibiting effect of EBNA2 in cells carrying a t(8; 14) translocation (Jochner et 
al., 1996). The down regulation of IgM expression by EBNA2 may also provide an
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explanation for the long standing observation that EBV negative BL cells in culture tend 
to have higher levels of Ig expression than their EBV positive counterparts (Benjamin et 
al, 1982; Cohen et a l, 1987; Magrath et a l, 1990). Ig-fi and c-myc are down-regulated 
by EBNA2 at the transcriptional level and the transcription of Ig-ji and c-myc are 
affected by EBNA2 simultaneously. This suggests that EBNA2 is mediating its effect 
on expression through a common target, presumably a transcription factor (Jochner et 
al, 1996).
EBNA2 not only plays a key role in the cascade of events leading to B cell 
transformation but is also essential for the maintenance of the transformed state. Using 
an LCL conditional for functional EBNA2 expression in the presence of oestrogen, it 
has been found that cells deprived of functional EBNA2 entered a quiescent non­
proliferative state reminiscent of normal resting B cells or die by apoptosis (Kempkes et 
al, 1995). Functional EBNA2 was shown to be required at both the Gi and G2 phases of 
the cell cycle, while a role in terminating S phase could not be excluded. It could be 
concluded from the findings of this study that EBNA2 induces B-cell activation and 
entry into the cell cycle by inducing and maintaining the expression of early Gi- 
regulating proteins.
A more recent study using an LCL conditional for functional EBNA2 expression (as 
described above) has found that the transcription of the proto-oncogene c-myc was 
activated by EBNA2, but the precise mechanism of this transcription activation remains 
to be elucidated (Kaiser et al., 1999). It was also concluded that in contrast to c-myc and 
LMP1, neither cyclin D2 nor cdk4 is a direct EBNA2 target. Cyclin D2 and cdk4 are 
both elements of the basic cell cycle machinery and drive cell cycle progression in early 
Gi. Since it has been shown that different B cell activation protocols can induce cyclin 
D2 and cdk4, it may be that the induction of proliferation by EBNA2 is a secondary 
event potentially driven by the primary viral and cellular EBNA2 targets (Kaiser et al., 
1999).
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1 . 5 . 3  E B N A - L P
The EBNA leader protein (also known as EBNA-5) is so named because it is encoded by 
the 5' leader sequence of bicistronic mRNAs specifying the other EBNAs. The 
translation initiation codon for EBNA-LP is created by a splicing event that occurs near 
the 5' end of the message (Sample et al., 1986; Speck et al., 1986; Rogers el al., 1990). 
The EBNA-LP protein is composed of amino-terminal repetitive segments followed by a 
unique carboxy-terminal sequence. Thus, EBNA-LP is frequently observed as a ladder 
of proteins in gel electrophoresis which differ in the number of amino-terminal repeats 
due to the fact that the repetitive part of the protein is derived from exons in the major 
internal repeat of the virus, which varies in copy number in any EBV population 
(Hammerschmidt and Sugden, 1989). The protein is strongly associated with the 
nuclear matrix, with an unusual distribution as illustrated by immunofluorescence 
microscopy - a proportion is diffusely spread through the nucleus while the rest is 
concentrated in a few granules frequently distributed in curved linear arrays (Petti et al, 
1990; Jiang et al., 1991).
Although EBNA-LP appears to be important at least for initiation of B cell 
transformation, it’s precise role has not been well characterised. Previous work has 
focused attention on cell cycle-related effects of EBNA-LP expression (Allan et al, 
1992; Inman and Farrell, 1995; Kitay and Rowe, 1996). A role in cell cycle regulation is 
suggested by the finding that, along with EBNA2, EBNA-LP is the first viral gene 
product detected upon primary infection of resting lymphoblasts Also, EBNA-LP mutant 
virus-immortalised cells show delayed transit through the Gi phase of the cell cycle. 
Association of EBNA-LP with pRb and p53 has been suggested based on in vitro 
biochemical interaction and colocalization of EBNA-LP with pRb as detected with one 
antibody and not another, however the in vivo relevance of this is unknown (Jiang et al., 
1991; Szekely et al., 1993). Transient transfection of EBNA-LP and EBNA2 into 
primary B-lymphocytes co-stimulated with gp350 indicated that the two proteins co­
operate in the induction of Go to Gi transition as marked by induction of cyclin D2, 
however, the mechanism of action remains unclear (Sinclair et al., 1994). Furthermore,
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EBNA-LP phosphorylation is dependent on the cell cycle stage (Kitay and Rowe, 1996). 
Recent studies suggest that this protein greatly enhances EBNA2-induced trans­
activation of LMP1 expression through interaction with the EBNA2 acidic trans­
activation domain (Harada and Kieff, 1997).
1.5.4 LMP1
Latent membrane protein 1 (LMP1) is one of six EBV proteins essential for 
immortalisation of normal resting B cells. LMP1 demonstrates the features of a classical 
oncogene, as defined by its ability to transform rodent fibroblast cell lines and render 
them tumorigenic. LMP1 is the only EBV gene that has transforming effects in non­
lymphoid cells. In both Rat-1 (Wang et al, 1985) and BALB/c 3T3 (Baichwal and 
Sugden, 1988) cells, LMP1 expression permits growth at lower serum concentrations, 
and promotes anchorage-independence and loss of contact inhibition. Furthermore, 
LMP1 has pleiotropic effects when expressed in cells that are natural targets for EBV 
infection, human lymphocytes and epithelial cells. There is also evidence of synergy of 
LMP1 with EBNA2 in upregulating certain cellular proteins (Rowe, 1995; Wang et al,
1990). In epithelial cells, LMP1 blocks normal differentiation, a property which, 
together with the upregulated levels of CD40 and the epidermal growth factor receptor 
(EGFR) (Fahraeus et al, 1988), may be important in the pathogenesis of undifferentiated 
carcinoma of the nasopharynx. In primary NPC biopsies, the expression of EBV latent 
genes is more restricted than in latently infected B lymphocytes. One study of rare 
preinvasive NPC lesions has demonstrated LMP1 expression in all cells in 100% of 
cases, suggesting an important role for this protein in the development of this 
malignancy (Rajadurai et al, 1995). LMP1 is toxic when expressed at high levels in both 
lymphoid and epithelial cell lines, a shared phenotype that indicates that one or more of 
it’s activities or its level of expression must be regulated to permit survival of the host 
cell (Farhaeus et al, 1988).
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LMP1 mRNA is the second most abundant viral transcript in latently infected cells 
(Fennewald et a l , 1984; Sample and Kieff, 1990). Expression of LMP1 in B lymphoma 
cell lines induces many of the phenotypic changes characteristic of EBV-mediated 
immortalisation of primary lymphocytes. LMP1 induces cell size increase, cell 
clumping, increased villous projections, increased vimentin expression and modulates 
expression of a range of cell surface receptors that are mediators of signaling events that 
affect cellular activation or proliferation. These include CD23 (low affinity IgE receptor) 
and CD21 (C3d/EBV receptor), CD39, CD40, CD44 and class II major 
histocompatibility complex (MHC II), adhesion molecules such as ICAM-1, LFA-1 and 
LFA-3 and the B cell promoting cytokine, 1L-10 (Wang et a l , 1988b; Birkenbach, 1989; 
Wang et a l , 1990a; Liebowitz e t a l , 1992; Peng and Lundgren 1992; Nakagomi et a l , 
1994; Zhang et a l , 1994a; Kieff, 1996). In contrast, expression of CD 10 is decreased by 
LMP1 (Wang et a l , 1990). Although LMP1 obviously plays an important role in EBV- 
mediated B cell immortalisation, the signal transduction pathways leading to modulation 
of cellular gene expression have not been fully elucidated.
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1 . 5 . 4 . 1  L M P 1  s t r u c t u r e
The LMP1 gene product, encoded by 3 exons, consists of a 20 amino acid hydrophilic 
amino-terminal cytoplasmic domain, 6 markedly hydrophobic transmembrane domains 
(alpha helicase transmembrane segments each 20 amino acids long) separated by short 
reverse turns (each 10 amino acids in length) and a 200 amino acid carboxy-terminal 
cytoplasmic terminus that is rich in acidic residues (Figure 1.6).
Cytoplasm
Plasma membrane
COOH
NH2 CTAR1 CTAR2
Figure 1.6 Schematic representation of LMP1 (adapted from Puls and others, 1999). LMP1 consists of 
an N terminal cytoplasmic domain, six hydrophobic transmembrane domains separated by reverse turns 
and a 200 amino acid C-terminal domain (CTD). Two signaling domains, CTAR1 and CTAR2 are located 
in the CTD and has been shown to interact with TNFR-associated factors TRAF1-3 and TRADD, 
respectively as indicated in the figure.
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LMP1 migrates on SDS-PAGE between 58 and 63 kDa depending on the EBV strain. 
The transmembrane domains enable LMP1 to posttranslationally insert into membranes 
and to accumulate in aggregates (Hennessy et a l , 1984; Liebowitz et a l , 1986). Live-cell 
protease cleavage experiments indicate a cytoplasmic orientation of the amino- and 
carboxy-terminal domains and an extrinsic plasma membrane orientation of the first 
outer reverse turn domain (Liebowitz et a l , 1986). Shortly after being synthesised, 
LMP1 is phosphorylated on serine and threonine residues in the carboxy-terminal 
domain and becomes tightly bound to the cell cytoskeleton (Liebowitz et a l , 1987). A 
substantial proportion of LMP1 (at least half) localises to a patch at the periphery, where 
it is closely associated with vimentin intermediate filaments (Liebowitz et a l , 1987). 
Unbound, nascent LMP1, as determined by detergent-solubility, has a half-life of less 
than 2 hours, while the insoluble, phosphorylated, cytoskeleton-associated form, has a 
half life of 3-15 hours (Moorthy and Thorley-Lawson, 1990, 1993a). LMP1 is 
transcribed during lytic infection and full size LMP1 is incorporated into virions, 
indicating that virion-associated products may affect the growth of newly-infected cells 
(Mann et a l , 1985).
1.5.4.2 Signal Transduction by LMP1
The structure of LMP1 as a membrane protein with cytoplasmic amino-terminal and 
carboxy-terminal domains as outlined above, is just one of several characteristics which 
are consistent with it stimulating existing cellular signal transducing pathways. L M P l’s 
oncogenic activity correlates with its ability to attach to the cytoskeleton, localise in 
patches in the plasma membrane and turn over rapidly (Liebowitz et a l , 1996; Mann and 
Thorley-Lawson, 1987). These are properties which are shared with activated growth 
factor receptors. As an integral membrane protein, LMP1 acts like a constitutively active 
receptor (Gires et a l , 1997) and shares certain characteristics with members of the TNFR 
family (reviewed by Kieff et a l , 1996). In a manner similar to other members such as 
CD30, CD40 and TNFR1, LMP1 binds specific TNFR associated factors (TRAFs) 
which have been found to associate directly with it’s carboxy-terminal region
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(Figure 1.6). Moreover, LMP1 activates the transcription factor NFkB and the c-Jun N- 
terminal kinase 1 (JNK1, also known as stress activated protein kinase) cascade by 
pathways which involve TRAF molecules. Since LMP1 acts in a ligand-independent 
manner, it replaces the T cell-derived activation signal necessary to sustain indefinite B 
cell proliferation.
Although LMP1 and CD40 share very little protein homology, their shared functions 
have led to suggestions that LMP1 may mimic B cell activation processes which are 
physiologically triggered by CD40-CD40 ligand signals. Recently, it was reported that 
LMP1 activates B cells to secrete Ig and IL-6 and rescues them from B cell receptor- 
mediated growth arrest analagous to CD40 signaling, and that LMP1 and CD40 
signaling pathways interact cooperatively in inducing B cell effector functions (Busch 
and Bishop, 1999). Also, in EBV-immortalised B cells lacking a functional EBNA2 
protein, CD40 activation and LMP1 expression result in the same phenotype of 
prolonged cell survival and DNA synthesis (Zimbler-Strobl et a l , 1996). These and other 
similarities, including the ability to upregulate genes such as CD54 (ICAM1) and to 
affect cell growth and apoptosis have led to the suggestion that LMP1 signaling is 
similar or even identical to CD40 signaling. However, in Jurkat T cells, while ligand- 
induced CD40 signaling was found to be impaired, LMP1 was demonstrated to be fully 
functional, therefore indicating that signaling by LMP1 and CD40 differ (Floettmann et 
a l , 1998). Two regions within the cytosolic domain of LMP1 have been found to effect 
cell signaling. One of these, the carboxy-terminal activation region-1 (CTAR1), binds 
members of the TRAF family of proteins and the other, CTAR2, binds the TNFR 
associated death domain protein (TRADD). Using mutated LMP1 genes in Jurkat cells, 
it has been shown that LMP1 loses it’s ability to upregulate the CD54 cell surface 
marker, when either the CTAR1 or CTAR2 domain is non-functional, thus behaving like 
CD40. However, the CTAR1 domain of LMP1, which shares a TRAF binding sequence 
motif with CD40, differs from CD40 in being unable to activate NFkB in Jurkat cells 
(Floettmann et a l , 1998).
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Activation of NFkB involves two independent domains in the cytoplasmic C-terminal 
tail; the TRAF-interacting site which associates with TRAFs 1,2,3 and 5 via a PXQXT/S 
core motif and a TRADD interacting site. Although NFkB appears to mediate the 
upregulation of many genes by LMP1 eg. A20 (Laherty et a l , 1992), it has become clear 
in recent years that NFkB has only a partial role to play in LMP1 induced B cell 
activation. For example, ICAM-1 and CD71 were shown to be upregulated in the 
presence of a dominant inhibitory IkB mutant. The characteristic LMP1-mediated cell 
size increase was similarly unaffected in the absence of NFkB activation (Liljeholm et 
a l , 1998). Also, induction of EGFR in epithelial cells by LMP1 or CD40 is mediated 
through a signaling pathway which is distinct from NFkB (Miller et a l , 1997).
LMP1 expression also results in activation of the c-Jun N-terminal kinase (JNK) cascade 
(Kieser e t a l , 1997; Epiopolos, 1998), an effect which is mediated exclusively through 
CTAR2 and can be dissociated from NFkB induction. A recent study identified the 
extreme 8aa of the CTAR2 region as important for JNK signaling via a mechanism 
involving TRAF2 and TRADD (Eliopoulos e t a l , 1999). Using a tetracycline-regulated 
LMP-1 allele, JNK was shown to be an effector of non-toxic LMP1 signaling in B cells. 
JNK was also shown to mediate activation of the AP-1 transcription factor, a dimer of 
Jun/Jun or Jun/Fos proteins (Kieser et a l , 1997) which is readily acitivated by growth 
factors and mitogens. The JNK cascade is complicated by having at least eleven known 
upstream MAP kinase kinase kinases (ASK1, Tpl-2, DLK, TAK1, MEKK1,2,3,4 and 
MLK1,2,3) that may regulate the pathway in different cell types and in response to 
different stimuli (Ip and Davis, 1998). In addition to activation of NFkB/JNKI, LMP1 
engages the p38 mitogen activated protein kinase cascade, leading to activation of the 
transcription factor, ATF2. While, like NFkB activation, p38 is induced via the CTAR1 
and CTAR2 regions, the 2 pathways are primarily independent, with evidence 
suggesting a divergence of signals downstream of TRAF2. Using a highly specific 
inhibitor of p38, SB203580, LMP1 -mediated IL-6 and IL-8 expression was found to 
utilise the p38 pathway (Eliopoulos et a l , 1999).
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As outlined above, LMP1 appears to mimick the molecular functions of TNFR1. 
However, TNFR1 regulates a wide range of cellular responses including apoptosis, 
whereas LMP1 constitutes a transforming protein. The molecular function of TRADD in 
LMP1 signaling has been found to differ from its role in TNFR1 signal transduction. 
JNK activation by TNFR1 involves Cdc42, whereas LMP1 signaling to INK is 
independent of p21 Rho-like GTPases (Cdc42 has been implicated in several STPs, 
including organisation of the actin cytoskeleton and activation of both JNK and NFkB). 
Thus, although both LMP1 and TNFR1 interact with both TRADD and TRAF2, the 
different topologies of the signaling complexes correlate with substantial differences 
between LMP1 and TNFR1 signal transduction to JNK (Kieser e t a l , 1999). In support 
of this, activation of JNK and NFkB by the TN Fa and IL-1 receptors and by LMP1 in 
fibroblasts was found to occur independently of Cdc42. Moreover, signaling to Cdc42 
and to JNK/NFkB occurred through distinct pathways and members of the TRAF and 
TRADD families were not required for Cdc42 activation (Puls et a l , 1999). Further 
studies are in progress in an effort to identify molecules capable of interacting with the 
transmembrane or loop regions of LMP1 as potential candidates for mediating Cdc42 
activation.
LMP1 expression in a continuous human B-lymphoblast cell line causes steady-state 
increases in intracellular free calcium and acid production (Wang e t a l , 1998). A 
transient increase in intracellular free calcium is a prominent immediate manifestation of 
B lymphocyte activation (reviewed by Cambier e t a l , 1987). As a plasma membrane 
protein with multiple membrane-spanning domains, LMP1 could be a channel protein or 
could interact with a channel protein. Thus, modification of an ion channel could 
directly or indirectly lead to the observed increase in intracellular free calcium. Since 
measurements of radioactive calcium uptake or efflux in LMP1 expressing versus 
nonexpressing cells do not reveal a difference, the mechanism is more likely to be 
indirect (Wang e t a l , 1998). Many of the effects of increased intracellular free calcium 
are transmitted by the calcium receptor calmodulin which, upon binding calcium, 
activates a diverse family of effector molecules. An important component of the calcium 
signaling cascade in mammalian cells is a family of serine-threonine-specific, calcium-
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calmodulin-dependent protein kinases, whose members have been implicated in a broad 
array of cellular processes including cell cycle progression and gene expression 
(reviewed by Hanson and Schulman, 1992). One member of this family of kinases, CaM 
kinase-Gr (a multifunctional calcium-calmodulin-dependent protein kinase type Gr) has 
been found to be upregulated by LMP1 in the EBV-negative cell line, BJAB. This 
kinase is absent from primary human B lymphocytes but is expressed in EBV- 
transformed B-lymphoblastoid cell lines (Mosialos et a l , 1994). CaM kinase Gr was 
reported to mediate cell cycle progression in Xenopus eggs (Lorca et a l , 1993) and may 
have a similar role in EBV-transformed B lymphocytes. The LM Pl-induced kinase is 
activated in B lymphocytes by increased intracellular free calcium in response to surface 
IgM crosslinking (Mosialos e t a l , 1994).
1.5.5 LMP2A and 2B
The LMP2 gene is transcribed as two alternatively-spliced mRNAs which encode 
LMP2A and -2B proteins, also known as terminal proteins -1 and -2  (Laux et a l . , 1988; 
Sample e t a l . , 1989). LMP2A and -2B  are found in latently-infected, growth 
transformed lymphocytes in vitro, in different human tumours and in latently infected B 
cells in vivo. LMP2A, but not LMP2B, is detectable in B lymphocytes isolated from 
peripheral blood of EBV sero-positives (Qu and Rowe, 1992) and LMP2 transcripts as 
well as antibodies against the proteins have been detected in patients with 
nasopharyngeal carcinoma (Brooks e t a l , 1993). The LMP2 mRNAs are formed by 
transcription and splicing across the joined termini of the circularised EBV genome as it 
is present in latently infected cells. (Laux et a l . , 1988; Sample e t a l ., 1989). The two 
messages consist of different 5' exons and eight common exons and are predicted to 
encode nearly identical proteins differing only in the length of their hydrophilic amino 
termini (Ring, 1994). Transcription of the LMP2A starts 3Kb downstream of the LMP1 
transcription start site (Laux e t a l . , 1988; Sample et a l ., 1989). The LMP2B and LMP1 
promoters form bi-directional transcription units containing a common EBNA2 
responsive element, while a separate EBNA2 response element regulates LMP2A 
transcription (Zimber-Strobl, e t a l . , 1993). LMP2A and 2B are 54 and 40 kDa in size 
respectively. Both proteins are predicted to encode twelve highly hydrophobic
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membrane-spanning domains and are localized to patches in the plasma membrane of 
infected cells, in close association with LMP1 (Longnecker and Kieff, 1990). LMP2A 
and 2B are not required for EBV mediated immortalization but they do improve 
efficiency of transformation (Longnecker e t a l . , 1992; Brielmeir et a l . , 1996). The 
LMP2 proteins are phosphorylated on serine, threonine and tyrosine residues 
(Longnecker et a l . , 1991) and have been shown to interact with src-family tyrosine 
kinases in EBV-infected B cells (Burkhardt e t a l . , 1992) They have also been associated 
with another stably phosphorylated tyrosine kinase s y k  ( M i l l e r  e t a l, 1 9 9 5 ) . These 
interactions suggest that the LMP2s play a role in transmembrane signal transduction 
(Kieff, 1996). LMP2A has been shown to inhibit anti-immunoglobulin-mediated Ca2+ 
mobilization, PKCy2 activation and anti-immunoglobulin-induced reactivation of the 
lytic cycle, which can be bypassed by TPA with Ca2+ ionophores (Miller et a l . , 1994b, 
1995a). These data are consistent with a model in which LMP2A sequesters the receptor 
associated tyrosine kinase, blocking its autophosphorylation and downstream signaling 
events (Miller e t a l . , 1995a).
1.5.6 EBV-encoded RNAs (EBERs)
EBER expression lags behind that of the other EBNA and LMP proteins and is delayed 
until after the initiation of DNA synthesis (Alfieri et a l , 1991). The two EBV-encoded, 
small nonpolyadenylated RNAs, EBER1 and EBER2, are by far the most abundant EBV 
RNAs in latently infected cells, with an estimated abundance of 107 copies per cell. 
They are usually transcribed by RNA polymerase III although polymerase II may also be 
involved. M ost EBERs are located in the nucleus and are associated at the 3' terminus 
with the cellular La antigen (Howe and Steiz, 1986; Howe and Shu; 1989). EBER 1 and 
2 have extensive sequence similarity to adenovirus VA1 and VA2 and cell U6 small 
RNAs, both of which form similar secondary structures and complex with La protein 
(Rosa e t a l . , 1981; Glickman e t a l . , 1988). The role of the EBERs is unclear but based 
on the functions of VA and U6 RNAs two alternative roles have been proposed for the 
EBERs. Firstly, the EBERS can partially complement VAI-mediated inhibition of 
activation of an interferon-induced protein kinase, which blocks transcription by
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phosphorylating the protein-synthesis initiator factor eIF-2a. Secondly a possible role of 
the EBERs is the splicing of the primary EBNA and LMP1 mRNA transcripts 
(suggested by the partial complementarity to RNA splice sites). Although the delayed 
expression of the EBERs appears to be incompatible with both of these proposed 
functions, nevertheless, the earlier events in primary B-cell infection are sensitive to 
interferon (IF) and EBERs may play a role in blocking eIF-2 kinase (Thorley-lawson, 
1980; 1981). EBV recombinants in which the EBERs have been deleted can initiate 
primary B cell infection and growth transformation in the same way as wild-type virus, 
and no differences have been observed in the growth of LCLs infected with EBER- 
deleted and control virus or in the permissiveness of these cells for lytic infection 
(Swaminthatan et a l , 1991).
1.5.7 EBNA-3A, -3B and -3C
Examination of the coding sequences of the EBNA-3A, EBNA-3B and EBNA-3C (also 
known as EBNA3, EBNA4 and EBNA6, respectively) genes reveals that each is 
composed of one short and one long exon (of similar sizes in all three genes). The genes 
are similar in structure and are tandemly located in the B a m K l  region of the EBV 
genome (Bodescot et a l , 1986; Joab e t a l , 1987; Peit et a l , 1988; Kerdiles et a l , 1990). 
These features have led to the proposal that the EBNA-3 genes may have arisen by gene 
duplication, although there is little overall homology between the protein sequences. The 
proteins are remarkably hydrophilic overall, contain unusual clusters of charged amino 
acids, and have similarly positioned clusters of negatively charged amino acids. The 
type 1 EBNA-3A, -3B and -3C genes encode proteins which migrate on SDS gels at 
145, 165 and 155 kDa, respectively. Comparison of the primary sequences of EBNA-3 
proteins reveals a similar organisation (Le Roux et a l , 1994) as follows (see Figure 1.6).
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1. a ca. 90 amino acid hydrophilic N-terminal end,
2. a region of 220 -230 residues that shows 23 - 28% amino acid identity,
3. a region of short sequences rich in negatively- and positively-charged amino 
acids,
4. a proline-rich C-terminal half containing repeated polypeptide domains.
hytibopMIc 
1 r*®^on9*
m :
Charaad rtgiont Prolin» rich fqion wWi rapM O
320 450
I
992
1 e-3C
1 95 |
■
325 440
I I
938
EBNA-38
1 90 310 400 944
EBNA-3A
fcfllofl oi hoMioQy
Amino add :
3A/36:29%
Figure 1.7 Structural and sequence similarités among the EBNA3 family of proteins. In the charged 
regions, sequences rich in basic amino acids are shown in white, sequences rich in acidic amino acids are 
shown in black, sequences rich in both types of charged residuesare checkered. Amino acid identity was 
scored between residues 90 and 320 of each EBNA3 protein using Kanehisa’s sequence comparison 
program (Fortini and Artavanis-Tsakonas, 1994).
The EBNA-3s encode more than half of the translated open reading frames in latently 
infected growth-transformed lymphoctes. However, their precise functions in vivo are as 
yet poorly understood. It is considered likely that the three proteins have unique 
functions since recombinant EBVs that carry null mutations in either EBNA-3A or 
EBNA-3C are nonimmortalising (Tomkinson and Kieff. 1992; Tomkinson et a l , 1993). 
This implies that EBNA-3A and -3C individually possess different functions that are 
essential for immortalisation and which cannot be complemented by other members of
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the EBNA-3 family. In constrast, in vitro experiments have shown that EBNA-3B is not 
critical for EBV latent infection, cell growth transformation or lytic virus replication 
in B lymphocytes (Tomkinson and Kieff, 1992). EBNA-3A, -3B and -3C each include 
epitopes that are frequently recognised by EBY-immune cytotoxic T lymphocytes 
(CTLs). Given the importance of EBNA-3A, -3B and -3C epitopes in CTL recognition 
of EBV-infected lymphocytes (Gavioli et a l . , 1992) strains with deletions of all or part 
of each of the EBNA-3 proteins would have been expected to have arisen and been 
identified if these proteins were not important for infection in vivo.
There is increasing evidence that EBNA3C, like EBNA2, functions as a trans-activator 
of both cellular and viral genes. Transfection of an EBNA3C expression construct into 
an EBV negative BL cell line has been shown to result in the upregulation of the EBV 
receptor CD21 (Wang et a l . , 1990). Furthermore, expression of EBNA3C in the Raji 
cell line (in which the EBV genome is deleted for most of the EBNA3C open reading 
frame) induces an up-regulation of LMP1 and the cellular proteins CD23 and vimentin 
(Allday e t a l . , 1993; Ring, 1994). EBNA-3C can co-operate with activated Ha-ras in the 
transformation of primary murine fibroblasts. EBNA-3C has a glutamine-proline-rich 
domain which can substitute for the acidic transactivation domain of EBNA2 and a 
similar glutamine-proline-rich domain has been found in EBNA-3B (Cohen and Kieff,
1991). A novel transcription activation function for EBNA-3A, perhaps analagous to 
that reported previously for EBNA-3C, was recently revealed although there is no 
substantial sequence homology between the two proteins in the parts involved in 
transcription activation (Marshall and Sample, 1995).
W hen stably expressed in group I DG75 BL cells, EBNA-3B, has been found to 
upregulate vimentin as well as surface expression of the activation antigen, CD40, while 
the Burkitt’s Lymphoma-associated antigen BLA/CD77 is down-regulated (Sillins and 
Sculley, 1994). Functional analogies have been drawn between EBNA-3B and the EBV 
latent membrane protein, LMP-1. It is thought that EBNA-3B and LMP-1 may co- 
ordinately regulate CD40 and vimentin levels, as LMP1 has also been found to 
upregulate both these proteins. In addition, a further study found that DG75 cells
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induced to undergo apoptosis in response to serum starvation were protected in the 
presence o f EBNA-3B (Sillins and Sculley, 1995), a feature also common to LMP1. Cell 
enlargement has been observed as a prominent feature of EBNA-3B-expressing BL 
clones (Wang et a l , 1988). Thus, EBNA-3B may have the potential to contribute in 
several different ways to the transformation process.
The most widely documented and common function of the EBNA3 proteins is their 
capacity to inhibit EBNA2-mediated activation of the TP1 and LMP1 promoters in 
transient expression assays (Le Roux et a l , 1994; Marshall and Sample, 1995; Robertson 
et a l , 1995). EBNA2 is a key transactivator of a wide spectrum of viral and cellular 
genes (see section 1.5.2) and interaction with the RBP-Jk transcription factor is critical 
for the specific targeting of EBNA2 to the responsive elements of many of these genes. 
By destabilizing RBP-Jk and EBNA2/RBP-JK complexes from binding to their cognate 
RBP-Jk binding sites (see Figure 1.8), EBNA3A, 3B and 3C proteins have been shown 
to inhibit the transcriptional activation of EBNA2 responsive promoters (Le Roux et a l . ,
1994). EBNA3 proteins are thus believed to counter balance and finely tune the action 
of EBNA2 (Waltzer e t a l . , 1996; Robertson et a l . , 1996; Zhao et a l ., 1996).
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As EBNA2 can also be recruited to promoters through interaction with other factors 
such as the proteins from the PU. 1 family, inhibition of EBNA2-mediated transcriptional 
activation by the EBNA3 proteins could be restricted to promoters activated through 
RBP-Jk binding sites. This could represent a way to differentially regulate certain viral 
or cellular genes (Waltzer et a l . , 1996). For example, by inhibiting transactivation of the 
Cp promoter, a feedback loop of inhibition by EBNA3 proteins of their own synthesis is 
created. Furthermore, it has been suggested that by inhibiting EBNA2-mediated 
transactivation, EBNA-3A, -3B and -3C could down-regulate the expression of EBV 
latent proteins that bear epitopes provoking the anti-EBV cytotoxic T cell response, thus 
allowing EBV to escape host immune surveillance. It could also be important to down- 
regulate LMP1 expression, as LMP1 has been shown to be toxic to the cells when 
overexpressed. However, all the data demonstrating the inhibitory effect of the EBNA-3
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proteins on EBNA-2 activation are based on over-expression assays and may not pertain 
specifically to effects at physiologic levels of protein.
RBP-Jk was originally identified and erroneously named as a potential recombinase that 
appeared to bind to the immunoglobulin kappa J region (Matsunami et a l , 1989). RBP- 
Jk is now known to be a ubiquitous sequence-specific DNA-binding repressor protein 
that is a key mediator of the transcriptional regulatory effects of certain proteins, 
including EBNA2 (Abbott e t a l . , 1990; Cohen and Kieff, 1991; Henkel et a l , 1994; Laux 
et a l , 1994; Ling et a l . , 1994; Zimbler-Strobl et a l , 1994) and is a key component of the 
Notch signaling pathway. By using RBP-Jk as a target for EBNA2 and the EBNA3s, 
EBV effectively subverts the ability of B cells to control the expression of particular 
genes. Moreover, EBNA2 mimics cellular Notch which normally binds RBP-Jk and 
activates B cell genes in response to stimuli. RBP-Jk is known to be a key mediator of 
signaling from activated notch receptors in neural and muscular development (Fortini 
and Artavanis-Tsakonas, 1994; Jarriault, 1995; Goodburn, 1995; Artavanis-Tsakonas,
1995). Since constitutive notch activation is an important aetiologic factor in human T 
cell leukaemia (Ellison et a l . , 1991), RBP-Jk is also implicated in leukaemogenesis. 
Thus the level of steady state association of EBNAs with RBP-Jk is likely to be 
important in EBV-driven B lymphocyte proliferation.
Since RBP-Jk is a critical component of EBNA-2 interaction with response elements, the 
binding of EBNA-3A, -3B and -3C to RBP-Jk likely indicates that RBP-Jk is also a 
critical mediator of EBNA-3 interactions with response elements (Le Roux e t a l , 1994; 
Allday and Farell, 1994; Robertson, 1995; Marshall and Sample, 1995; Robertson et a l ,
1996). In addition it has been suggested that the EBNA3 proteins could transactivate 
transcription by regulating the interaction of RBP-Jk with DNA. Thus, dissociation of 
the RBP-Jk repressor protein from DNA could activate promoters with RBP-Jk sites. A 
weakness in this model, however, is the lack of an apparent need for the size and 
complexity of the EBNA-3 gene family, since the N-terminal domain of one EBNA-3 
protein would suffice for this effect.
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All three EBNA3 family members have been shown to bind RBP-Jk domains 
(preferentially the smaller isoform) via their amino-terminal in B lymphoblasts 
(Robertsonet et a l . , 1996). In vitro-translated EBNA-3A binds about 30-fold less 
efficiently than EBNA-3B and about 4-fold less efficiently than EBNA-3C to GST- 
RBP-Jk, but in vivo-expressed EBNA-3A, -3B and -3C bind similarly to RBP-Jk. The 
lower efficiency of binding of full-length vitro-translated EBNA-3 A appears to be due to 
an inhibitory effect of the C-terminus when the protein is translated in vitro (Robertson 
et a l . , 1996). The yeast two hybrid system has been used to delineate the sequences of 
both EBNA-3C and RBP-Jk mediating the interaction between these two proteins. It was 
found that a Jk domain of 56 amino acids (aa 125-181) was sufficient to bind EBNA-3C, 
while a conserved 74 aa domain of EBNA-3C and -3B  (aa 181-257), was sufficient to 
interact with the Jk protein (Hsieh e t a l , 1996). Another report suggests that the EBNA3 
site lies between amino acids 90 and 138. It was found that, EBNA-3A amino acids:l- 
138, EBNA-3B amino acids:l-311 and EBNA-3C amino acids:l-183 were sufficient for 
RBP-Jk interaction, while EBNA3B amino acids: 1-109 showed less or no binding 
(Robertson e t a l . , 1996). These interacting domains overlap with the most highly 
conserved domain (aa 90-320) among the EBNA-3 proteins.
An alternative interpretation of the significance of the binding of EBNA3 proteins to 
RBP-Jk which may be equally relevant is the proposal that RBP-Jk acts to buffer the 
levels of active EBNA3 proteins, where RBP-Jk-EBNA3 complexes represent inactive 
forms of the EBNA3 proteins. There is considerable evidence that the levels of EBV 
transforming proteins have to be tightly regulated in LCLs and although the binding of 
EBNA3 proteins to RBP-Jk counterbalances the activation effects of EBNA2 on the Cp 
promoter (which dives transcription of the EBNA3 genes), Cp is in fact only partially 
dependent on EBNA2-RBP-Jk in LCLs (Evans et a l , 1996). This alternative model 
supposes that there are novel functions unrelated to RBP-Jk binding for EBNA-3A and 
EBNA-3C in EBV transformation and is supported by the limited sequence homology 
exhibited between the EBNA3 proteins. The relationship of the exon structures and 
protein sequences is only significant in the N-terminal parts of the proteins and although 
all three proteins have repetetive sequence elements in the C-terminal regions, these are
32
unrelated at the sequence level. Also, it is unlikely that EBV would require four large 
viral proteins comprising 79% of the sequence complexity of the six viral proteins 
required for transformation to control signaling through RBP-Jk.
As outlined above, much evidence exists to indicate that the EBNA3 proteins should be 
regarded as transcriptional regulators (Bourillot e t a l , 1996; Cludts and Farrell, 1998). 
However, the effects of each of the EBNA3 proteins on cell promoters differ and are 
distinct from those of EBNA2 (Wang e t a l . , 1990; Sillins and Sculley, 1994). Also, the 
different effects of EBNA-3C, -3B and EBNA2 observed in non-EBV-infected BL cells 
likely indicate a role for other protein-protein interactions as determinants of 
transcriptional effects of the EBN A3 proteins on specific cell genes. Thus, like EBNA2, 
EBNA3 proteins may be dependent on interactions with factors other than RBP-Jk, and 
the role of the EBNA3 proteins can be expected to be more complex than a retro-control 
on RBP-Jk-EBNA2-activated genes. The identification and characterisation of other 
potential cellular partners for the EBNA3 proteins is required for a better understanding 
of their precise role in EBV immortalisation.
1.6 Genes of the Lytic Viral Cycle
In the study of viral replication, lytic infection is usually induced by chemicals (Luka et 
a l ., 1979; Saemundsen et a l . , 1980; Laux et a l ., 1988b) as only a small fraction of 
latently infected B-lymphocytes spontaneously enters the productive cycle. In these cells 
the viral DNA is amplified several hundred fold by a lytic origin of DNA replication, o r i  
L y t  (Hammerschmidt and Sugden, 1988). Phorbol esters are among the most 
reproducible and most broadly applicable inducers, their effect is probably mediated by 
protein kinase C activation of Jun-fos interactions with AP-1 upstream of the immediate 
early virus genes (Farell e t a l . , 1983; 1989; Farell 1992; Laux et a l ., 1988). Some LCL 
cell lines can be induced to permit viral replication in about 10% of cells. Alternatively, 
the Akata cell line which carries an LMP2A-deleted virus can be induced by cross- 
linking of surface immunoglobulins (slg) to the extent that more than 50% of the cells 
enter the lytic cycle (Takada, 1984; Takada and Ono, 1989). A second approach to
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investigating viral replication is to induce the lytic cycle by superinfection of Raji cells 
with defective EBV from the P3HR-1 cell line (Mueller-Lantzsch et a l . , 1980). Raji is 
an EBV-positive BL cell line with an unusually high EBV episome copy number, it is 
defective for DNA replication and late gene expression thus is tightly latent (Polack et 
a l ., 1984a). Defective virions from P3HR-1 contain rearranged DNA molecules in 
which the intermediate early tr a n s -activator of the lytic cycle are expressed after 
superinfection (Cho e t a l . , 1984; Miller e t a l . , 1984). After induction, cells that have 
become permissive to viral replication undergo cytopathic changes characteristic of 
herpesviruses, including migration of nuclear chromatin, synthesis of viral DNA, 
assembly of nucleocapsids, envelopment of the virus by budding through the inner 
nuclear membrane and inhibition of host macromolecular synthesis (IARC Monograph,
1997).
Studies with such cell lines has allowed the division of EBV replicative proteins into 
early antigens (EA), membrane antigens (MA) and virus capsid antigens (VCA). Early 
antigens are further subdivided into EA-D (diffuse) and EA-R (restricted) due to a 
different sensitivity to methanol fixation (Henle e t a l . , 1971a; 1971b) (see Figure 1.8). 
Virus gene expression follows a temporal and sequential order (Farrell, 1992; Takada 
and Ono, 1989). Some virus genes are expressed independently of new protein 
synthesis, early after induction and are classified as immediate early genes. Early lytic 
virus genes are expressed slightly later and their expression is not affected by inhibition 
of viral DNA synthesis (Kieff, 1996).
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Thymidine Kinase BXLF1
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Figure 1.9 A schematic representation of early and late EBV gene expression. The VCA the MA
and the EA are illustrated, their open reading frames are written in bold.
1.6.1 Immediate Early genes
After P3HR-1 superinfection of Raji or slg cross-linking of Akata cells in the presence 
of protein synthesis inhibitors, three leftward mRNAs are transcribed. The BZLF1, 
BRLF1 and BFLF4 encoded proteins are potent transactivators of early EBV lytic gene 
expression (Takada and Ono. 1989; Marschall etal., 1991; Kieff, 1996). The functional 
and physical interaction of BZLF1 with NFkB is an important mediator of LMP1 effects 
in EBV latent infection. BZLF1 can also downregulate the EBNA Cp promoter perhaps 
facilitating the transition from latent to lytic infection (Kenny el al., 1989; Sinclair et at,
1992). A recent study has found that BZLF1 inhibits both cellular diffentiation and cell
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cycle progression in epithelial cells. In HeLa and SCC12F (human keratinocyte) cells, 
BZLF1 induced a G2/M block, whereas in fibroblasts a G l/S  block was induced. The 
exact mechanism of this block is unknown, but activation of the cell cycle inhibitors p21 
and p27 was not observed (Mauser e t a l , 1998). In a different study, BRLF1 was shown 
to bind Rb in vivo shortly after induction of the viral lytic cycle in EBV-infected Akata 
cells. This interaction may initiate cell cycle progression and facilitate viral DNA 
synthesis during lytic replication (Zacny et a l , 1998).
1.6.2 Early genes
The early genes are expressed when the lytic cycle is induced in the presence of 
inhibitors of DNA synthesis. By this criterion at least 30 EBV mRNAs are early gene 
products (Hummel and Kieff, 1982a,b; Baer et a l . , 1984). Two very abundant early 
proteins have been mapped to specific DNA sequences. The BALF2 protein is 
homologous to the HSV DNA binding protein ICP8 and is important in DNA replication 
(Hummel and Kieff, 1982a; Kieff, 1996). The BHRF1 protein, which is expressed in 
moderate abundance, has extensive collinear homology with b c l-2  (Pearson et a l .,  
1983a; Austin et a l ., 1988). BHRF1 can protect EBV negative BL cells from apoptosis 
(Me Carthy e t a l ,  1996), however, EBV recombinants lacking the BHRF1 ORF are fully 
capable of initiating and maintaining cell growth transformation and they can also enter 
the lytic cycle and produce virus (Lee and Yates, 1992; Marchini e t a l ,  1991). Several 
of the early genes are linked to DNA replication, as indicated in Figure 1.9. Transfection 
experiments demonstrate that some of these genes are activated in the process of cell 
differentiation in the absence of other viral gene products, suggesting a possible role of 
cellular factors in regulating the productive cycle, at least in certain cell types (Marshall 
et a l , 1991).
1.6.3 Late genes
The late genes code for structural glycoproteins or proteins that modify the infected cells 
in order to permit viral envelopment or egress (IARC Monograph, 1997). Among the
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non-glycoproteins, the major nucleocapsid protein is encoded by BCLF1, BNRF1 
encodes the major external nonglycoprotein of the virion and BXRF1 is likely to encode 
a basic core protein. The BFRF3 ORF encodes the tegument protein, (see figure 1.1) 
and VCA p l8 , which is strongly immunogenic in humans (Kieff, 1996). The genes 
encoding the EBV glycoproteins are illustrated in bold in figure 1.8. The late BCRF1 
gene, which is located in the middle of the EBNA regulatory domain between o r i - P  and 
Cp, is a close homologue of the human IL-10 gene, with nearly 90% collinear identity in 
amino-acid sequence (Moore e t a l ,  1990; Vieira et a l ,  1991; Touitou et a l ,  1996). 
BCRF1 has most of the activity of human IL-10, including negative regulation of 
macrophages and NK cell functions and inhibition of IF y production. Thus, virally 
expressed IL-10 may have a local effect on these responses to reactivate infection (IARC 
Monograph, 1997).
1.7 EBV-associated non-malignant diseases
1.7.1 Infectious mononucleosis
Infectious mononucleosis (IM) is an acute disease associated with primary EBV 
infection, characterised by fever, pharyngitis and lymphadenopathy. The illness, 
commonly known as glandular fever, is the classical syndrome caused by EBV. Primary 
infection with EBV during early childhood is normally sub-clinical (Henle and Henle, 
1970), but the severity of disease increases with advancing age, and infection during or 
after adolescence can give rise to IM in up to half of the infected individuals (Henle and 
Henle, 1979). Clinically apparent IM tends to be a disease of the socio-economic 
advanced countries where a greater number of people escape infection in childhood, 
with a peak incidence occurring in people from 15-25 years of age (Strauss, 1988). 
Hormonal changes and maturation of the immune response are thought to be possible 
reasons for this maturation-related incidence of disease. After infection there is a 30-50 
day incubation period, followed by a 3-5 day period where mild symptoms are
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experienced, these include headache, malaise and fatigue. In more than 80% of cases a 
sore throat will occur during the first week. Fever with temperatures reaching 39.5°C or 
higher lasts for about 10 days and then falls gradually over an additional 7-10 days. 
Although the tetrad of fever, fatigue, pharyngitis and lymphadenopathy are typical, 
patients may have all or only some of these features. Splenomegaly is observed in about 
50% of IM cases, chemical hepatitis is present in most patients and a few develop frank 
jaundice (Merck Manual, 1992). The disease generally runs its course within a few 
weeks, but more protracted cases of greater than a few weeks occur occasionally. 
Prolonged symptoms of fatigue are also associated with chronic fatigue syndrome (CFS) 
and there has been some speculation that EBV plays a role in the pathogenesis of CFS, 
although little objective evidence supports this hypothesis. While IM is usually a benign, 
self-limiting disease, complications may ensue, including rupture of the spleen. 
Neurological complications, interstitial nephritis with renal failure and interstitial 
pneumonitis have also been reported (Imoto e t a l . , 1995; Mayer e t a l . , 1996; 
Morgenlander, 1996; Sriskandan e t a l . , 1996). Fatal mononucleosis usually occurs only 
in individuals showing severe immunodeficiency (Miller, 1990), for example, renal 
transplant recipients may develop fulminant mononucleosis or monoclonal B cell 
malignancy.
The acute phase of virus infection is characterised by a well-defined serological pattern, 
which includes the absence of antibodies to EBNA and the presence of IgM antibodies 
to structural components of the virion, anti-VCA (viral capsid antigen) and anti-MA 
(anti-membrane or envelope antigen). Antibodies to early components of the viral 
replication cycle called early antigens (EA) are also readily detected (Henle and Henle, 
1979). IgM antibodies to VCA evolve quickly with infection, persist for weeks to 
months and do not reappear. Thus their detection is presumptive evidence of recent 
primary infection. Antibodies to EA of the diffuse or restricted types develop in most 
primary infections and wane with time (Horwitz et a l . , 1985). The appearance of 
antibody to EBNAs usually occurs weeks to months after infection. EBNA is present in 
all cells containing the viral genome, whether latently or productively infected 
(Rickinson, 1986). Transcriptional analysis suggests that a type-III EBV latency prevails
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in infectious mononucleosis, with expression of the full set of EBV latent genes, 
including CpAVp-driven EBNA1 (Falk et a l . , 1990; Tierney et a l . , 1994). A more 
detailed analysis of EBV gene expression at the level of the single cell reveals, however, 
a more heterogeneous picture. Only a subset of cells coexpress EBNA2 and LMP1, 
characteristic type-III latency. Most cells appear to be EBER positive but negative for 
EBNA2 and LMP1, suggesting a type-I latency and some large immunoblasts are seen 
which appear to express LMP1 in the absence of EBNA2 - type-II latency. There are 
also many small lymphocytes that express EBNA2 but no detectable LMP1. It is 
uncertain if this represents a new type of latency or a transitory phenomenon 
(Niedobitek et a l . , 1997b).
1.7.2 X-linked Lymphoproliferative syndrome
Also known as Duncan’s syndrome, the X-linked Lymphoproliferative syndrome (XLP) 
is a hereditary immunodeficiency disorder characterised by a self-destructive immune 
response to primary EBV infection (Provisor et a l . , 1975; Purtilo, 1976). Patients are 
usually asymptomatic until they encounter EBV, but may present symptoms of 
immunodeficiency prior to EBV infection. After primary EBV infection, the majority of 
patients (approximately 63%) develop IM with a fatal outcome. Patients who survive 
the primary infection are at high risk of developing malignant lymphoma (24%), 
hypogammaglobulinaemia or aplastic anaemia (29%). The XLP gene has been localised 
to Xq25 and the region spanning the smallest deletion in patients has been cloned 
(Lamartine et a l , 1996; Lanyi et a l , 1995). Identification of the function of this gene is of 
prime importance for a better understanding of the complex interaction between EBV 
and its host (IARC Monograph, 1997). The only curative treatment for X-linked 
lymphoproliferative syndrome is allogenic bone-marrow transplantation (Williams e t a l . ,  
1993). In the future it should be possible to identify carriers of the genetic defect, 
provide appropriate genetic counselling, and diagnose the disease in u te ro .
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1 . 7 . 3  O r a l  h a i r y  l e u k o p l a k i a
Oral hairy leukoplakia is an epithelial lesion of the tongue which was originally 
described in HIV-infected individuals but was subsequently found in immunosuppressed 
transplant patients. Detection of this lesion is a significant indicator of HIV-induced 
immunosuppression and is highly predictive of the subsequent development of AIDS. 
Oral hairy leukoplakia manifests itself as a raised white lesion, typically located at the 
lateral border of the tongue, but which may extend to other parts of the oral mucosa 
(Merck Manual, 1992). Although the histopathologic features are characteristic of 
human papillomavirus, clear evidence for the presence of EBV has come from 
immunocytochemistry with monoclonal antibodies, from electron microscopic 
morphology, and from DNA studies with EBV probes. Southern blot hybridisation 
provided clear evidence for the presence of EBV in complete linear form and in very 
high copy number, localised to the superficial epithelial cells. The expression of viral 
lytic cycle antigens e.g. BZLF1 and VCA, have been shown, indicating that epithelial 
cells may support EBV replication (Greenspan et a h , 1985; Gilligan e t a h , 1990a; 
Young et a h , 1991). Expression of BZLF1 and VCA, are restricted to the more 
differentiated upper epithelial cell layer (Greenspan et a h , 1985; Young et a h , 1991). In 
contrast to the abundance of the virus in the upper epithelial cells, viral genomes and 
EBV gene products associated with latent infection are absent from the basal or 
parabasal epithelial cells of oral hairy leukoplakia (Thomas et a h , 1991). Together with 
the absence of a detectable episomal population of EBV genomes, this indicates that oral 
hairy leukoplakia is an isolated focus of lytic EBV infection, with no detectable latent 
phase (IARC Monograph, 1997). Regression of oral hairy leukoplakia can be induced 
by treatment with acyclovir, indicating that this lesion is indeed caused by EBV 
(Resnick et a h , 1988).
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1.8 E B V - a s s o c i a t e d  m a l i g n a n t  d i s e a s e s .
1.8.1 Burkitt’s Lymphoma
Although the incidence in Europe and the USA is low (2-3 cases per million children per 
year in the USA), Burkitt’s lymphoma (BL) is the most common childhood cancer in 
certain parts of equatorial Africa and Papua New Guinea, with an annual incidence of 
more than 50 cases per million children below the age of sixteen. In fact, Burkitt’s 
lymphoma now accounts for 30-70% of childhood cancers in equatorial Africa. The 
high incidence of BL in these locations is associated with geographic and climatic 
features, determined by altitude in East Africa and by rainfall in West Africa, coincident 
with holoendemic malaria (Haddow,1963; Burkitt, 1969, 1983; O’Connor, 1970). The 
fact that malaria infection might be a cofactor in the development of BL is supported by 
the observation that individuals with malaria have a reduced T-cell response to EBV- 
infected cells. This disease is more common in males than in females with an average 
age at onset of seven years. BL is a poorly differentiated malignant lymphoma in which 
the tumour cells show little variation in size or shape. The tumour cells are monoclonal 
B lymphocytes and they contain characteristic chromosomal translocations (Manolov 
and Manalova, 1972; Manalova et a l . , 1979; Rowe and Gregory, 1989). The jaw is the 
most frequently involved site for tumours and the commonest presenting feature in 
patients with BL in equatorial Africa (Burkitt, 1958; 1970a) and Papua-New Guinea 
(Burkitt, 1967). Jaw tumours seem to be age dependent, occurring most frequently in 
young children, very young children often have orbital or maxillary tumours (Olurin and 
Williams, 1972). Involvement of the CNS (about 33 % of cases), ovaries, kidneys, liver 
and mesentery are also prominent in BL.
Burkitt’s lymphoma is classified as a non-Hodgkin’s lymphoma, invariably of B-cell 
origin, with B-cell markers such as CD19, CD20, CD22 and CD79a and surface 
immunoglobulin always detectable. The surface immunoglobulins are usually IgM 
(IARC Monograph, 1997). Other surface markers that are expressed in most BLs 
include CD10 and CD77 but CD23 and CD5 are absent (Ham s et a l . , 1994). BL cells
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express low levels of HLA class I adhesion and activation molecules such as CD54, 
CD1 la/18 andCD 58 (Massucci et a l . , 1987; Billuad et a l . , 1989; Anderson et a l . , 1991).
In the areas of Africa where BL is endemic, about 95 % of the tumours contain EBY 
DNA and express EBNA1 (Geser et a l . , 1983). However, in parts of the world where 
BL is sporadic (Western Europe and the Americas), only about 15-20% of BL tumours 
contain EBV DNA, indicating that EBV is not essential for formation of the tumour. 
Therefore, EBV may not play a direct role in the pathogenesis of BL, but may simply 
increase the risk of development of BL by virtue of it’s ability to immortalize B cells 
(including the cell population that gives rise to Burkitt’s lymphoma) (Klein, 1979). This 
hypothesis is consistent with the lack of expression of EBV latent genes (e.g. EBNA2, 
EBNA3 and LMP) known to be necessary for the transformation of B cells (Alfeiri et 
a l . , 1991; Woisetschlaeger, e t a l . , 1991). The only latent gene invariably expressed in 
Burkitt’s lymphoma, EBNA1, has never been shown to have transforming functions 
(Rowe et a l . , 1988; Rowe et a l . , 1987; 1992; Sample et a l . , 1991; Magrath et a l . , 1993).
The discovery of non-random chromosomal translocations associated with Burkitt’s 
lymphoma (Bernheim et a l . , 1981) paved the way to an understanding of the genetic 
derangements that are a central component of its pathogenesis. It has been observed that 
the chromosomal breakpoint on chromosome 8, band q24 is common to all three of the 
observed translocations in BL and that the breakpoints are located on chromosome 14, 2 
and 22, at the heavy- and light-chain immunoglobulin loci (Croce et a l . , 1979; Lenoir et 
a l . , 1982; Me Bride e t a l . , 1982). The t(8; 14) is the most frequent location of a 
breakpoint in African BL occurring in 75% of tumours and in 50% of Brazilian tumours 
(Gutierrez e t a l . , 1992). The net consequence of translocation appears to be that c-myc 
is regulated as if it were an immunoglobulin gene, i.e. it is constitutively expressed in 
these immunoglobulin-synthesising tumour cells.
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1 . 8 . 2  N a s o p h a r y n g e a l  C a r c i n o m a
Nasopharyngeal carcinoma (NPC) is a rare malignant tumour in most populations, 
however, it is highly prevalent in Southern China where it represents the most common 
tumour in males. W ithin China itself, the rate of NPC decreases from south to north 
(Parkin e t a l . , 1997) with more moderate rates seen in the Inuit population and in other 
parts of Southeast Asia and North Africa. (Ho, 1978). NPC is a disease with a 
remarkable racial and geographical distribution. It constitutes 75-95% of all malignant 
tumours occurring in the nasopharynx in low risk populations and virtually all of those 
in high risk populations (Ho, 1971; Levine and Connelly, 1985). The rates of NPC are 
higher in men than in women in most populations studied and the number of cases 
increases steadily with age with a peak incidence at around 45-54 years of age in high- 
risk populations (Parkin et a l . , 1997), although in low-risk populations a peak incidence 
in young adults has been observed (Doll e t a l , 1970).
The high incidence of NPC among the Cantonese population of China was first 
described by Ho in 1971, who also observed that salted fish is the principal source of 
supplemented food in the diet of these people (which consists mainly of rice). Further 
studies revealed that salted fish consumption was significantly related to the risk for 
developing NPC tumours and increasing frequency of intake was consistently associated 
with increased risk. The association with salted fish was stronger when exposure 
occurred during childhood as compared with adulthood (Huang e t a l . , 1981). 
Carcinogenic volatile nitrosamines have been detected in Chinese salted fish, however, 
their precise role in NPC has yet to be determined (IARC Monograph, 1997).
NPC is derived from poorly differentiated epithelial cells and arises in the surface 
epithelium of the posterior pharynx (Parkin et a l . , 1986). In about half the cases of NPC 
the presenting sign is a cervical mass resulting from spread to regional lymph nodes. 
Other symptoms may include nasal obstruction, postnasal discharge, impairment of 
hearing, tinnitus or otitis media. NPC may metastasise to the skeleton, the spine, the 
liver, lung and skin as well as to the peripheral lymph nodes (Miller, 1990). A strong 
association between NPC and EBV is suggested by detectable DNA sequences in almost 
all cases of types-2 and -3  NPC as ascertained by DNA/DNA or cRNA/DNA
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hybridisation in biopsy samples (Pagano et a l , 1975). EBV infection is an essential step 
in the progression to malignancy. It has been shown that EBV DNA in NPC is clonal, 
arising from a single EBV infected cell (Raab-Traub and Flynn, 1986b). EBV has been 
detected in dysplastic lesions of the nasopharynx in individuals with high IgA titres the 
cell suggesting involvement of EBV prior to the carcinomatous state (Pathmanathan et 
a l , 1995). NPC is unlikely to be the result of primary EBV infection as it occurs 
primarily in adults in high-incidence areas where initial EBV infection occurs during 
childhood (Parkin e t a l , 1984). Studies have shown that NPC patients frequently possess 
elevated serum antibodies to two EBV lytic cycle antigens, viral capsid antigen (VCA) 
and early antigen (EA) (Henle and Henle, 1976; Ho et a l . , 1976). Serum detection of 
these antibodies is a routine diagnostic test for NPC in South-east Asia.
The detection of EBV DNA and EBERs has been useful in identifying carcinomas that 
have metastasised to lymph nodes when the primary tumour has not been identified 
(Ohshima et a l . , 1991; Chao et a l . , 1996). Transcriptional expression of EBV latent 
genes in NPC cells has been studied by northern blotting/hybridization (Raab-Traub et 
a l . , 1983; Gilligan et a l . , 1990; Karran e t a l . , 1992). BARFO, LMP2, EBER and 
EBNA1-coding transcripts are always expressed in NPC cells and LMP1 is detected in 
50% of tumours (Fahraeus e t a l . , 1988; Brook et a l . , 1992). Occasionally lytic cycle 
early genes are also detected in a few cells (Luka et a l . , 1988; Cochet et a l . , 1993).
1.8.3 H odgkin’s disease
Hodgkin’s disease is the commonest variant of the malignant lymphomas, accounting 
for about half of all cases. The disease is most common between the ages of 20 and 40 
but may occur at any age, usually presenting with lympadenopathy, but sometimes with 
fever, night sweats, weight loss and pruritis. Though the cell of origin of this tumour is 
still not known, histologically, HD is characterised by mononuclear Hodgkin cells (HC) 
and their multinucleated variants, the Reed-Sternberg cells (RS). The Rye classification 
distinguishes four major types of Hodgkin’s disease: nodular lymphocyte-predominant, 
nodular sclerosis, mixed cellularity and lymphocyte-depleted (Luka and Butler, 1966,
44
Harris e t a l . , 1994). It is now accepted that lymphocyte-depleted HD represents a 
separate tumour entity and is considered separately from the other three classical forms 
of HD. Increasing evidence suggests that HD is not a single entity but rather a 
heterogeneous group of diseases (Harris et a l . , 1994). The clinical representation of HD 
varies with geographical location and in the western world HD usually arises as a 
unifocal lesion in cervical lymph nodes. Continuous spread of the tumour to adjacent 
lymph nodes gives rise to enlarged nodes. With spread of the tumour through lymphatic 
channels, other organs are involved, the preferential sites of involvement including the 
spleen and distant lymph nodes. Subsequently as the disease becomes more aggressive, 
other organs are involved, including the liver and the kidney. Bone-marrow involvement 
in HD is indicative of extensive tumour infiltration (Kaplan, 1980).
In most western populations, very few cases occur among children, a rapid increase in 
incidence among teenagers is seen followed by a peak at about age 25, the incidence 
then plateaus with a second peak with increased age. There is an excess in males which 
is more pronounced at older ages (Mac Mahon, 1957). In poorer populations there is an 
initial peak in childhood only among boys with a relatively low abundance among young 
adults followed by a late peak in those of advanced age (Correa and O ’Connor, 1971). 
There is evidence that the risk factor for HD in young adulthood through middle age is 
associated with higher education, higher social class, fewer siblings, less crowded 
housing and early birth rank. All of these factors lead to increased susceptibility to late 
infections with the common childhood infections, which tend to be more severe (IARC 
Monogragh, 1997).
Following a report by Weiss and colleagues of EBV DNA in 50% of Hodgkin’s disease 
(HD) tissues (Weiss et a l . , 1987), the role of EBV in HD has been subjected to intense 
scrutiny (Joske and Knecht, 1993). In situ hybridisation has disclosed the presence of 
the virus in virtually all tumour cells in EBV-positive cases, consistent with the 
detection of monoclonal EBV genomes in DNA extracted from most HD tissues. These 
findings indicate that EBV infection of Hodgkin-Reed-Sternberg cells takes place before 
clonal expansion. Pallesen e t a l . , (1991a) and Herbst et a l . , (1991) reported that the EBV
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in HD has a restricted latent phenotype of EBNA1 and usually LMP1, LMP2A and 
LMP2B without detectable EBNA2 expression, as in NPC. These finding have been 
widely replicated. In multiple specimens of HD from case studies, molecular evidence 
of clonal EBV genomes with specifically restricted expression of latent viral proteins in 
the RS cells was found in 30-50% of cases. EBV genome status appears to be uniform 
in involved nodes within patients and over time in those patients studied longitudinally 
(Delsol et a l . , 1992; Brousset e t a l . , 1994). The consistency of the finding of clonal 
EBV and the expression of LMP1 in about half of HD cases argues strongly against a 
passenger role for EBV in these cases. Seroepidemiology findings in multiple case 
studies show that patients with HD can be distinguished by an altered antibody profile to 
EBV. Thus, the available evidence stongly implicates EBV as a factor in the 
pathogenesis of EBV-positive HD.
The risk of HD after diagnosis of IM has been evaluated and this study revealed that 
overall there was a threefold increase in the risk of developing HD. Also, essentially all 
HIV-1 infected patients with HD have a higher rate of EBV positivity. Generally these 
patients present with advanced HD and show a relatively poor prognosis (Moran e t a l . ,  
1992; Tirelli et a l . , 1995).
1.8.4 Post-transplant lymphoproliferative disorders
Post-transplant lymphoproliferative disorders (PTLD) are a major complication in 
allograft recipients, occurring in 1-20% of patients. The incidence tends to be lowest for 
renal transplant patients and highest for lung transplant patients which may reflect the 
amount of immunosuppressive therapy associated with the latter (Nalesnik and Starzl, 
1994; Montone et a l . , 1996). In PTLD the tumours proliferate unchecked due to the 
absence of adequate T-cell tumour suppression. The tumours can be polyclonal or 
monoclonal as determined by analysis of EBV terminal repeats or cellular gene 
rearrangement status (Joske and Knecht, 1993). It is believed that the pathogenesis of 
the condition starts with EBV driven polyclonal B-cell proliferation, eventually leading
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to fully developed malignant lymphoma. Typically B-cells in these lymphoproliferations 
express a broad spectrum of virus-encoded latent proteins, including EBNA1, EBNA2 
and LMP1. This type-III form of latency is similar to that found in LCLs in vitro and 
accordingly these cells usually display an LCL pattern of cellular gene expression, 
including lymphocyte activation and adhesion molecules (Young e t a l . , 1989; Thomas el 
a l . , 1990). However, considerable variability has been found in EBV gene expression in 
and between lesions with type-I and type-II latency also observed (Delecluse et a l . ,
1995).
1.8.5 AIDS-related lymphomas
In the US lymphomas are 60 times more frequent in AIDS patients than in the general 
population (Beral e t a l . , 1991). Non-Hodgkin’s lymphomas are very common in HIV 
infected individuals, primarily at extranodal sites, particularly common are primary 
central nervous system lymphomas (Krogh-Jensen et a l . , 1994). Morphologically, 
AIDS-related non-Hodgkin’s lymphomas fall into two broad groups; diffuse large B-cell 
non-Hodgkin’s lymphomas, which often show a prominent immunoblastic component 
and Burkitt’s lymphoma and Burkitt’s-like lymphoma. Superficially the pathogenesis is 
the same as PTLD; EBV-immortalised B lymphocytes proliferate unchecked due to 
decimated T-cell numbers resulting in oligo- or monoclonal B-cell proliferations (Joske 
and Knecht, 1993). The two types of AIDS-related non-Hodgkin’s lymphomas show 
striking differences in their relationship to EBV, suggesting different pathogenic 
mechanisms. M ost diffuse large B-cell non-Hodgkin’s lymphomas and all AIDS-related 
central nervous system lymphomas are EBV-positive (MacMahon et a l . , 1991). Diffuse 
large B-cell lymphomas have been reported to occur relatively late in AIDS patients 
(Gaidano and Dalla-Favera, 1995) and more advanced depression of the immune system 
is a risk factor for their development (Pedersen et a l . , 1991). Most AIDS-related non- 
Hodgkin’s lymphomas appear to be monoclonal both with respect to their antigen 
receptor genes and to the EBV episomes, however, there may be rare polyclonal cases 
(Ballerini e t a l . , 1993; Delecluse et a l . , 1993).
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HIV appears to contribute to the pathogenesis of some EBV-associated AIDS-related 
non-Hodgkin’s lymphomas by inducing severe immunosuppression, leading to a loss of 
EBV-specific T-cell immunity (MacMahon e t a l . , 1991). As EBV-positive, AIDS- 
related B-cell lymphomas consistently lack the HIV genome, a direct contribution of 
HIV to tumorigenesis beyond suppression of the immune system is unlikely (Knowles,
1993). The relative risk for AIDS-related non-Hodgkin’s lymphomas increases with 
duration of HIV infection and to a certain extent with immune suppression (Munoz et 
a l . , 1993). BL is up to one thousand fold more frequent in HIV-positive individuals than 
in the general US population (Beral e t a l . , 1991) and the tumour is EBV-positive in 
about 20% of cases (Beral et a l . , 1991). AIDS related BL, both EBV-positive and EBV- 
negative, have been consistently shown to harbour the characteristic c-myc 
translocation. These translocations have been detected in a minority of diffuse large B- 
cell lymphomas and cases with morphological features between large B-cell lymphomas 
and BL (Ballerini el a l . , 1993; Delecuse et a l . , 1993; Bhatia e t a l . , 1994). Other genetic 
changes implicated in the pathogenesis of AIDS-related non-Hodgkin’s lymphoma 
whether EBV-associated or not, include p53, N-ras and K-ras point mutations and 
deletions in the long arm of chromosome 6 (Gaidano and Dalla-Favera, 1995). HIV- 
positive individuals who develop HD are more likely to have advanced extra-nodal 
disease, not to respond to therapy and to die of opportunistic infections than those with 
HD alone (Ames, et a l . , 1991).
The detection of EBV in T-cell lymphoma opposes the well established process of B-cell 
lymphotrophisim of the virus in vitro. The interpretation of the detection of EBV in T- 
cell non-Hodgkin’s lymphomas and an assessment of the role of the virus in the 
pathogenesis of T-cell lymphoma are complicated by two factors. Firstly, if EBV 
infection of certain T-cells in vitro leads to predominantly lytic infection, EBV infection 
of T-cells may be accidental rather than part of the viral strategy to establish persistent 
infection. Such infection of cells not adapted to latent infection may contribute to the 
development of EBV-associated T-cell lymphomas. Secondly, in many cases the virus 
is detected in only a small proportion of tumour cells (Anagnostopoulos et a l . , 1996). 
Although the virus may be present at the onset of the neoplastic process it may
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subsequently be lost from the tumour cell. While there is some evidence to suggest this 
may happen in vitro it has not yet been shown in vivo. The alternative scenario would 
be a secondary infection of established neoplastic T-cells with the virus, this would 
exclude the virus from an initial role in neoplasia but would be compatible with a role of 
the virus in contributing to the disease process. The frequent expression of LMP1 in T- 
cell lymphomas would seem to argue in favour of such a role (d’Amore et a l . , 1992). 
However, the role of EBV in T-cell related malignancies remains uncertain.
1.8.6 Other tumours
EBV has been detected in the vast majority of gastric lymphoepithelial carcinomas and 
in a high proportion of lymphoepithelial carcinomas of the lung and salivary gland. A 
smaller proportion of gastric adenocarcinomas is also EBV-associated. EBV DNA has 
been detected occasionally in epithelial tumours at a wide variety of other anatomical 
sites. An aetiological role for EBV in lymphoepithelial and adenocarcinomas has not 
been conclusively established. Smooth-muscle tumours in immunosuppressed 
individuals uniformly contain EBV, indicating a possible causal role for the virus in this 
setting (IARC Monographs, 1997).
1.9 Aims
The purpose of this study was to investigate the functions of two important EBV latent 
proteins. LMP1 is an integral membrane protein with an essential role in the 
immortalisation of primary B cells. It was proposed to explore the role of LMP1 in 
interfering with cell cycle control by studying its effects on the expression of a panel of 
cell cycle-related genes using ribonuclease protection assays. The effect of LMP1 
expression was also compared to that of EBNA2 (the other main effector of phenotypic 
change in EBV-immortalised B cells). EBNA3 comprises a family of three related latent 
nuclear proteins, EBNA3A, EBNA3B and EBNA3C. EBNA3B is the only member of 
the family which is not required for immortalisation and it was proposed to investigate 
its role by screening for interacting proteins using the yeast two hybrid system.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 BIOLOGICAL MATERIALS
2.1.1 Cell lines
Table 2.1. Cell lines used in this study
Cell Line EBV
Status
Cell
Classification
Description
DG75 EBV negative 
BL
Lymphoid B cell line derived from an Israeli Burkitt- 
like lymphoma case (Ben-Bassat et al., 1977).
DG75 tTA Stable
transfectant
EBV negative BL cell line stably transfected with the 
tetracycline-regulated transactivator only 
(Floettmann et al., 1996).
DG75tTA
EBNA2
Stable
transfectant
Tetracycline regulated system whereby the 
expression of EBNA2 can be induced by the removal 
of tetracycline from the growth media (Floettmann et 
al., 1996).
DG75tTA
LMP1
Stable
transfectant
Tetracycline regulated system whereby the 
expression of LMP1 can be induced by the removal 
of tetracycline from the growth media (Floettmann et 
al, 1996).
Mutu 1 + Type I Early passage BL cell line expressing EBNA1 as the 
only viral gene (Gregory et al., 1990).
Mutu 3 c95 + Type III Stable clone of the early passage BL cell line Mutu 1 
which has, upon serial passage in culture, “drifted” to 
express the full compliment of EBV latent genes 
(Gregory et al., 1990).
BL41, 
BL41-B958, 
IARC 171.
+
+
+
Type I 
Type III 
LCL
These cells are a matched set. BL41 is an early 
passage BL cell line expressing EBNA1 as the only 
viral protein, BL41 B958 is the cell line stably 
transformed with the EBV virus strain B958 
expressing all the EBV latent genes, (Calender et al., 
1987) IARC 171 is a spontaneously transformed 
Lymphoblastoid cell line derived from the same 
patient (Andersson et al., 1991).
BL72 III 
IARC 307
+
+
Type III 
LCL
These cells are a matched pair, BL72 is a group 3 BL 
cell line expressing all EBV latent genes. IARC 307 
is a spontaneously transformed LCL from the same 
patient (Rowe et al., 1990).
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BL74
IARC 290B
+
+
Type I 
LCL
These cells are a matched pair, BL74 is a group 1 BL 
cell line expressing only EBNA1. IARC 290B is a 
spontaneously transformed LCL from the same 
patient.
Ag876 + Type IH Type III BL cell line expressing all the EBV latent 
genes (Dambaugh etal., 1984).
X50-7 + LCL Spontaneously transformed LCL (Miller et al„ 
1984).
Jurkat T cell Acute T-lymphocytic leukemic cell line (Brattsand, 
etal., 1990).
C33A, - Epithelial cell
C33A Neo, * These are cervical epithelial cell lines. C33A is the
C33A LMP1. parental cell line, C33A Neo is stably transfected 
with an empty vector, C33A LMP1 is stably 
transfected with a vector constiutively expressing 
LMP1 (Miller et a l, 1995).
All BL cell lines and LCLs were obtained from Professor M artin Rowe, University 
of Cardiff, Wales. The epithelial cell lines C33A were a gift from Dr Nancy Rabb- 
Traub University of North Carolina, USA.
2.1.2 Antibodies
PE2, T2.78, E3C.A10.3 and CS1-4 (antibodies specific for EBNA2, EBNA-3A, 
EBNA-3C and LM P1, respectively) were gifts from  Professor M artin Rowe, 
University o f Cardiff, Wales. The antibodies were supplied as cell culture 
supernatants and stored at 4°C or -20°C prior to dilution.
Monoclonal Antibody
A nti-p21/W AFl 
Anti-p53 
Anti-Rb 
Anti-c-Myc 
Anti-HA 12 CA5
Anti-mouse-alkaline phosphatase (AP) conjugate 
Rabbit anti M ouse IgG 
Goat anti-rabbit HRP
Supplier
Santa Cruz, SC-6246
Santa Cruz, SC -126
Santa Cruz, SC -102
Calbiochem
Boehringer Mannheim
Promega
Dako
Dako
5 2
2 . 1 . 3  B a c t e r i a l  s t r a i n s
E .c o l i  D H 5a, genotype: F-, e n d  A l, hsdR17 (i\-,m k=), s u p E 4 4 , th i -1,A,-, re c  A l, g y r  
A96, re l A1 ,<j) 80/ac Z5M15.
2.1.4 Y east s tra in s  (S a c c h a r o m y c e s  c e r e v is ia e )
Yeast strains w ere grown in YPD medium at 30°C, while selection for plasmids was 
carried out by growing yeast in Yeast Nitrogen Base (YNB) medium without amino 
acids (Difco) which was supplemented with appropriate combinations of the 
following amino acids where required: leucine (60 |ng/ml.), tryptophan (40 jig/ml.), 
histidine (20 jxg/ml.), uracil (20 jig/ml.) denoted +L+T+H+U respectively. YNB 
plates were supplemented with sugars as indicated: 2% (w/v) glucose or 2 %  (w/v) 
galactose + 1 %  (w/v) raffinose.
EGY48 ( U R A 3  T R P 1  H I S 3  6 L e x A  o p e r a t o r - L E U 2 )  The L e x A o p - L E U 2  gene is 
normally not transcribed and the yeast are auxotrophic for leucine.
Y187 (M A T a  g a l4  g a l8 0  h is 3  t r p l - 9 0 1  a d e 2 - 1 0 1  u a r 3 - 5 2  l e u 2 - 3 ,- 1 1 2  U R A 3  
G A L —> la c Z  m e t-) was made by crossing Y153 and GGY171 (Fields and Song, 
1989).
2.1.5 P lasm ids
pTAg Cloning vector from R&D Systems
2.1.5.1 Y TH S-A  plasm ids
All plasmids used in YTHS-A were gifts from Dept, of Biochemistry, TCD and are 
summarised in Table 1.
pEG202 A yeast - E. coli shuttle vector, pEG202 is a derivative of 202 that contains 
an expanded polylinker region. Bait proteins expressed from this plasmid contain aa
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1 to 202 of LexA, which include the DNA binding and dimérisation domains (see 
Chapter 4, Figure 4.4).
pNLEX A derivative of pEG202 in which an additional nuclear localisation signal 
has been inserted in to the unique EcoR l site. This destroys the EcoR l site at the N 
terminus but retains the site at the C terminus. Therefore the EcoR l site in pNLEX is 
also unique.
2.1.5.2 YTHS-B plasmids
pAS-1 CHX (pAS-2) bait plasmids (see chapter 4, Figure 4.10) cDNA library DNA 
and all control plasmids used in YTHS-B were gifts from Dr Stephen Elledge, Bayor 
College of M edicine, Texas. Plasmids used in verification of specificity experiments 
were gifts from D r Geraldine Butler, D epartm ent of Biochemistry, UCD.
2.1.6 Oligonucleotides
Genosys Biotechnologies Europe Ltd. 
EBNA-3A
Forward primer 
Reverse primer 
EBNA-3B 
Forward primer
5’ ATC GGG CCA TGA TCA A AC TGG ACA AGG A 3 ’ 
5' TGT TAT AAC GTG ATC AAA GGC CTG CCC C 3 ’
5' CG CGG ATC CTG AAG AAG CGT GGC TCA G 3’ 
Reverse prim er (1575 bp) 5' CG CGG ATC CAG TAG GGT TGC CAT AAC CC 3' 
Reverse prim er (837 bp) 5 ’ CG CGG ATC CGA ACT CGG TTT TTC GTG CC 3’ 
EBNA-3C
5 ’ CGC GGC TCC TGG AAT CAT TTG AAG GAC AGG 3’ 
CGC GGA TCC ATC GAC GAT GGA TCT TCG G 3 ’
5 ’ CCA GCC TCT TGC TGA GTG GAG ATG 3’
5 ’ GAC AAG CCG ACA ACC TTG ATT GGA G 3’
5’ TTC AGT ATC TAC GAT TC 3’
Forward primer 
Reverse primer 
BCOl 
BC02  
pTA g
2.1.7 Commmercial kits and restriction enzymes
All restriction enzymes were supplied by Boehringer Mannheim.
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Klenow enzyme (DNA Polmerase I large fragment) was supplied by Biolabs (#21 OS) 
Enhanced Chemiluminesence substrate (ECL)Amersham 
Riboquant mutiprobe RPA : Pharmingen
In Vitro Transcription kit (#45004K)
M ultiprobe Tem plate set HCC-2 (#5409IP)
RPA kit (#45014K)
Qiagen Tip -100 
RPA kit
Taq DNA polymerase 
The LigATor 
T7 Sequencing kit 
Capture-Tec pH ookl System 
Luciferase Assay System
2.2 C H E M IC A L  M A T E R IA L S
Protein prestained markers 
35S labeled dATP 
a 32P labeled UTP 
dNTPs 
RNase A 
M arvel 
Chloroform 
Isopropanol 
Dimethyl formamide
Sigma-Aldrick-Fluka Chemical Co.:
Urea, Dithiothreitol (DTT), Coomassie Blue R, BCIP/NBT, Tetracycline, Liquid 
Phenol, Nitocellulose, Ampicillin, Potassium acetate, Tween-20, Bovine serum 
albumin (BSA), Sodium azide, Sigmacote, Ammonium phosphate, M ineral oil, a - 
Thiol-glycerol (ATG), PMSF, MOPS, BCS, Formaldehyde, 
Diethylenepyrocarbonate (DEPC), Salmon Sperm DNA Type III sodium salt 
(D1626), Polyethylene Glycol (PEG), Cycloheximide, 3-AT, ß-mercaptoethanol, all
NEB
Amersham 
Amersham 
Pharmacia Biotech 
Pharmacia Biotech 
Premier Beverages 
ROM IL 
ROM IL 
Riedel-de-Haën
Qiagen
Pharmingen
Perkin Elmer and Boehr. Mannheim.
R&D Systems
Pharmacia
In vitro gen
Promega (#E1500)
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amino acid supplements (see Appendix), actinomycin D, M icophenolic acid, 
Xanthine, aqueous mountant.
Merck:
Boric acid, Ammonium persulphate, Sodium acetate, M agnesium chloride, Glucose, 
Sodium chloride, Potassium chloride, Sodium hydroxide, Sodium dodecylsulphate, 
Calcium chloride, Glycine, Methanol.
BDH:
TEMED, Bromophenol blue, Potassium dihydrogen phosphate, Potassium hydrogen 
phosphate, Sodium phosphate, Glycerol, Tris(hydroxymethyl)methylamine, EDTA, 
M agnesium sulphate, Ethidium bromide, Isoamyl alcohol, Hydrochloric acid, Acetic 
acid, Methanol, Isopropanol.
Boehringer Mannheim:
Agarose, Low melt agarose, IPTG, Hygromycin B, Geneticin (G418), Leupeptin. 
Oxoid:
Agar technical, Bacto-Tryptone, Yeast extract.
Difco:
YNB without amino acids 
KODAK:
X-ray film, X-ray film developer, X-ray film fixer.
National diagnostics:
Acrylagel, Bis-acrylagel.
Gibco-BRL:
RPMI 1640, Foetal calf serum, Pencillin, Streptomycin, L-Glutamine, Hepes, 
Sodium Pyruvate, 1Kb D NA ladder, (3-galactosidase (X-gal).
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Promega:
lOObp DNA ladder.
Calbiochem:
Staurosporine, SB203580 p38 inhibitor.
2.3 DNA MANIPULATION
Preparation o f all solutions used in chapter two are outlined in the Appendix .
2.3.1 Storage of DNA samples
DNA samples were stored in TE buffer pH 8.0 at 4°C. EDTA was used to chelate 
heavy metal ions that are needed for DNase activity while storage at pH 8.0 
minimises deamidation. DNA was also stored in sterile distilled H 2O (dH20 ).
2.3.2 Equilibration of phenol
As DNA partitions into the organic phase at <pH 7.8, phenol was prepared by 
equilibration to pH 8.0 with TrisCl pH 8.0 as follows: Solid phenol was melted at
68°C, hydroxy quinoline was added to a final concentration o f 0.1% (w/v) (acts as an 
antioxidant, a chelator of metal ions, and an RNase inhibitor). An equal volume of 
buffer (0.5 M TrisCl pH 8) was then added to the liquefied phenol and stirred for 15 
min. After allowing the two phases to equilibrate, as much as possible of the upper 
aqueous phase was removed. The extraction was repeated using equal volumes of 
0.1 M  TrisCl pH 8 until the pH o f the phenol was > 7.8. An equal volume of TrisCl 
pH 8 and 0.2% (w/v) (3-mercaptoethanol were then added to the phenol, which was
stored at 4°C  in the dark until required.
2.3.3 Phenol/chloroform extraction and ethanol precipitation
Phenol/chloroform extraction and ethanol precipitation was carried out to purify and 
concentrate nucleic acid samples as follows: An equal volume of
phenol/chloroform/isoamyl alcohol (25:24:1) was added to the DNA solution,
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vortexed to an emulsion and centrifuged for 10 min at 12,000 x g. The upper 
aqueous phase was removed, taking care not to take any material from the inteiphase, 
and this was placed into a fresh autoclaved eppendorf. An equal volume of 
chloroform/isoamyl alcohol (24:1) was added to the aqueous phase, vortexed as 
before and centrifuged for 5 min at 12,000 x g. Again the upper aqueous phase was 
removed to a fresh tube. One tenth volume of 3 M sodium acetate (pH 5.2) was 
added to the solution of DNA, mixed and then 2 and a half volumes of 100% (v/v) 
ethanol was added. This mixture was vortexed and incubated at room temperature 
for 5 min (when dealing with very small quantities of DNA, samples were 
precipitated in ethanol at -20°C  overnight). DNA samples were then centrifuged for 
30 min at 12,000 x g at 4°C, the supernatant was removed and pellets were washed 
with 1 ml 70% (v/v) ethanol to remove excess salts. The tube was centrifuged for 5 
min at 10,000 x g, the supernatant was removed and pellets were air dried for 10-15 
min. Pellets were resuspended in an appropriate volume of sterile Tris-EDTA (TE) 
(pH 8.0) or sterile dH20 .
2.3.4 Restriction digestion of DNA
Restriction enzymes bind specifically to and cleave double-stranded DNA at specific 
sites within or adjacent to a particular sequence known as the recognition site. The 
restriction enzymes used were supplied with incubation buffers at a concentration of 
10X (working concentration IX). DNA was digested with restriction endonucleases 
for identification purposes or to linearise or cut fragments from a plasmid. DNA 
digests were performed by adding the following, usually to a final volume of 20|U,1.
200 ng - 1 |LLg o f DNA (Final concentration of <300 ng/jo.1)
1 |il o f enzym e/|ig of DNA solution (-1 0  U).
10 X buffer to a final concentration of IX  
dH20  to the final volume required 
The reaction was gently mixed, centrifuged, then incubated for 2 h at the optimum 
enzyme temperature (between 25°C and 50°C, usually 37°C).
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2.3.5 Cohesive Ligation of DNA
Two fragments o f DNA may be ligated in one of 2 ways. The majority of restriction 
endonucleases digest DNA leaving either a 5' or a 3' overhang, in which two 
compatible cohesive ends may be ligated by cohesive ligation. Alternatively, blunt- 
ended ligation may be required. Cohesive-end ligations of equimolar amounts of
vector and insert DNA (<1 fig) were generally carried out overnight at 16°C in a 
commercial ligation buffer (5 mM  ATP) with 10 units of T4 ligase/ml. As small a 
volume as possible is recom meded for ligation reactions and usually the total volume
of reactions was 10 |il. After ligation, the samples were heated to 10 min at 70°C to 
inactivate the ligase (this appears to improve transformation efficiencies), and stored 
on ice until required.
2.3.6 Blunt-ended ligation of DNA
Blunt-ended ligations are usually less desirable than cohesive-end ligations due to 
their much lower efficiency. Nonetheless, blunt-ended ligations were required in 
cases where restriction enzymes generated blunt ended DNA molecules. Also, if two 
compatible cohesive DNA ends cannot be generated, it is sometimes necessary to fill 
in the unmatched bases of the 5 ’ or 3 ’ overhangs and carry out a blunt-ended ligation 
reaction. The large fragment of E .c o l i  DNA polymerase I (Klenow, Biolabs) was 
used for this purpose in the following reaction: DNA was resuspended at a
concentration of 50 |0.g/ml in IX  Eco Pol buffer (supplied with the Klenow), dNTPs 
were added to a final concentration of 33 |iM  each, 1 jil of Klenow was added and 
the reaction was placed at 25 °C for 15 min. The enzyme was inactivated by heating 
to 70°C for 10 min. This DNA was then purified by phenol/chloroform extraction 
and concentrated by ethanol precipitation (2.3.3). Ligation reactions were then 
performed as for cohesive-end reactions (2.3.5)
2.3.7 BamHl linkers
Synthetic linkers (8-12 bp) containing a restriction site for an enzyme which 
generates cohesive ends in DNA molecules may be ligated to the ends of DNA 
fragments in order to improve the efficiency of blunt-ended ligations. Thus, a high
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concentration of B am H l linker termini (4-20 p.m) was ligated to the relevant insert 
DNA at a 2-3 : 1 concentration ratio over target DNA. The resulting ligations were 
then digested with B am H l and purified by phenol/chloroform extraction and ethanol 
precipitation. Due to the very high concentration of excess linker molecules, DNA 
was further purified by extraction from  low melt agarose (2.3.7). Ligations were then 
carried out as for cohesive-end reactions (2.3.5).
2.3.8 Dephosphorylation of linearised plasmid DNA
During ligation, T4  DNA ligase will catalyse the formation of a phosphodiester bond 
between adjacent nucleotides only if  one contains a 5' phosphate group and the other 
contains a 3' hydroxyl group. Recircularisation of plasmid DNA can therefore be 
minimized by removing the 5' phosphate groups after treatment with calf intestinal 
alkaline phosphatase enzyme (CIP). Digested DNAs (<100 ng/jj,l) were 
dephosporlylated using CIP in a 100 |iil volume (CIP was added 1 unit/100 pmoles 
for cohesive termini and 1 unit/2 pmole for blunt termini). The solution was 
vortexed, centrifuged briefly and incubated for 30 min at 37°C. This was followed by 
an enzyme dénaturation step achieved by heating to 75°C for 10 min. DNA was then 
purified by phenol/chloroform extraction and ethanol precipitation (2.3.3).
2.3.9 Preparation of competent cells
The calcium chloride (CaCh) method was employed to prepare competent bacterial 
cells for transformation o f DNA. An E .c o l i  strain (D H 5a) was streaked from a 
frozen glycerol stock on to an LB agar plate and incubated at 37°C overnight. An 
isolated colony was then picked using a sterile inoculating loop and used to inoculate 
5 ml of SOB (appendix A) broth. This culture was incubated in a shaking incubator 
at 200 rpm  overnight at 37°C. An aliquot of this starter culture (2 ml) was then used 
to inoculate 100 ml of sterile SOB in a conical flask and incubated at 37°C with 
shaking to an O .D .640 nm of between 0.4 and 0.8 (approximately 2 h). The cells were 
then transferred to two sterile 50 ml falcon tubes and incubated on ice for 10 min 
followed by centrifugation at 4,000 x g for 10 min at 4°C. Cell pellets were gently 
resuspended in 25 ml of 100 mM  ice-cold CaCl2, and incubated on ice for a further
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20 min. Centrifugation was carried out as before (4,000 x g at 4°C for 10 min) 
followed by removal of the supernatant. Finally cells were resuspended in a 1% 
(w/v) volume of CaCl2. Competent cells were stored on ice and used within 24 hr.
2.3.10 Transformations
Two hundred microliters of competent cells were added to a pre-chilled 
microcentifuge tube containing 10 pil of DNA at a concentration of -100  ng/10 fil. 
The contents were mixed gently and incubated on ice for 30 min, during which time 
an aliquot o f SOC (appendix A) was pre-heated at 42°C. At the end of the incubation 
on ice, cells were heat-shocked at 42°C for 90 s followed by incubation on ice for a 
further 2 min. One mililiter of preheated SOC was then added to the cells which 
were incubated at 37°C in a shaking incubator for 1 h 10 min. The cells were 
concentrated by centrifugation after which -8 0 0  |al of supernatant was removed and 
discarded. The cells were resuspended in the remaining supernatant and plated out 
with the appropriate controls on LB plates containing ampicillin and incubated 
overnight at 37°C. Only bacteria which took up ampicillin-resistant plasmid DNA 
grew on LB Amp plates. Recombinant colonies were thus used to inoculate 5 ml 
aliquots of LB broth containing ampicillin which were then incubated overnight at 
37°C. DNA minipreparations were subsequently prepared using fresh cultures as 
described in section 2.3.10.
2.3.11 Small scale preparation of plasmid DNA (miniprep)
This method is a modification of a protocol from M aniatis et al, 1978. A single 
bacterial colony was used to inoculate 5 ml of LB medium (with appropriate 
antibiotic) and incubated overnight at 37°C. An aliquot (1.5 ml) of this culture was 
added to a sterile microfuge tube and centrifuged for 30 s at room temperature, the 
remainder was stored at 4°C. Supernatant medium was removed from  the tube, 
leaving the pellet as dry as possible. The pellet was then resuspended thoroughly in 
100 |il of ice-cold solution I by vigorous vortexing. To this, 200 jil of freshly 
prepared solution II was added and the tube contents were mixed by inverting the 
tube rapidly 5-6 times. Ice-cold solution III (150 (il) was added and the tubes were
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vortexed gently for 10 s. The lysate was centrifuged for 5 min at 12,000 x g and the 
supernatant was transferred to a fresh tube, taking care not to carry over any of the 
white precipitate. An equal volume o f phenol/chloroform/isoamyl alcohol (25:24:1) 
was added, mixed by vortexing and centrifuged for 5 min at 12,000 x g. The upper 
aqueous phase was removed to a fresh tube, to which 2 volumes of 100% (v/v) 
ethanol were added, the solution was vortexed and centrifuged for 5 min at 12,000 x 
g. After discarding the supernatant, the pellet was washed with 200 |a.l 70% (v/v) 
ethanol, centrifuged as before and the supernatant was removed. The pellet was air- 
dried for 10-15 min. A fter resuspending in  50 i^l of TE (pH 8.0), 1 jLil of DNase-free 
RNase A (20 ug/ml) was added, tubes were vortexed, incubated at 37°C for 1 h, then 
stored at 4°C. Glycerol stocks of all bacterial cultures were prepared at this stage by 
the addition of 0.5 ml o f a 50% (v/v) glycerol solution to 0.5 ml of the overnight 
bacterial culture of interest and storing at -80°C.
2.3.12 Qiagen™ plasmid DNA purification protocol
Plasmid DNA was purified using the QIAGEN-tip 100 isolation system from 
Promega. All buffers used are described in appendix A. A glycerol stock of the 
bacteria of interest was streaked out on LB ampicillin agar and incubated overnight 
at 37°C. An isolated colony from this plate was used to inoculate a 5 ml LB 
ampicillin starter culture and incubated in a shaking incubator (-300  rpm) at 37°C for 
8 h. One millilitre o f the starter culture was used to inoculate 25 ml of LB ampicillin 
in a 250 ml sterile flask and incubated overnight in a shaking incubator at 37°C. The 
following day, cultures were harvested at an optimal O.D.6oonm of between 1 and 1.5. 
The following centrifugation steps were carried out using a JA-20 rotor in a 
Beckman centrifuge. The bacteria culture was transferred to a centrifuge tube and 
centrifuged by spinning at 6,000 x g for 15 min at 4°C. The supernatant was 
removed and the pellet was dried by inverting the tube on tissue paper and allowing 
the supernatent to drain off. The bacterial pellet was resuspended completely in 4 ml 
of cold Buffer P I containing RNase, 4 ml of freshly prepared Buffer P2 was added 
and tubes were incubated at room temperature for 5 min. Following incubation, 10 
ml o f prechilled Buffer P3 was added, immediately mixed by gentle inversion of the
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tube (5-6 times). Tubes were then incubated on ice for 20 min before centrifugation 
for 1 hr at 20,000 x g at 4°C.
The Qiagen-tip 100 was equilibrated by applying 4 ml of QBT buffer and allowing 
the column to empty by gravity. The column does not dry out at this stage as the 
flow of buffer will stop when the buffer reaches the upper filter. After the 
centifugation step the supernatant was removed immediately from the tube without 
disturbing the pelleted material and applied to the column by filtering through 1MM 
filter paper. The QIAGEN-tip was washed with 2 x 10 ml of Buffer QC. DNA was 
then eluted with 5 ml of Buffer QF. DNA was precipitated by adding 0.7 volumes of 
room-temperature isopropanol and centrifuging immediately at 15,000 x g for 30 min 
at 4°C. Supernatant was then carefully removed and the DNA pellet was washed with 
70% (v/v) ethanol, allowed to air dry for 5 min and re-dissolved in a suitable volume 
of TE or dE^O. DNA was then quantified by spectrophotometric analysis as 
described in section 2.3.15.
2.3.13 Agarose gel electrophoresis of DNA
Electrophoresis through agarose gels is the standard method used to separate, 
identify and purify DNA fragments. The technique is simple, rapid to perform and 
can be used for the isolation of DNA fragments.
An appropriate quantity o f agarose or low melt agarose was added to 100 ml IX  TBE 
/TAE buffer based on the percentage agarose gel required. Increasing the percentage 
agarose (1.8-2.0%) in the gel was generally used to improve resolution of smaller 
DNA fragments while separation of larger DNA molecules was observed more 
readily on low percentage gels (0.6-0.8%). The agarose was completely dissolved by 
boiling and after sufficient cooling (~60°C) the gel was cast into the Hybaid 
horizontal gel electrophoresis system and a comb was inserted for formation of 
sample wells. The gel was allowed to set before filling the chamber with IX 
TBE/TAE and removing the comb. Sample buffer containing bromophenol blue as a 
tracking marker was added to each sample before loading up to a maximum volume 
of 20 [il per well. DNA sample buffer was also added to 500 ng of a 1 Kb or 100 bp 
DNA ladder which was loaded as a size marker. The gel was run at constant voltage 
(5 V/cm), usually at -1 0 0  V, for 1-2 h. W hen complete, the gel was stained in
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ethidium bromide (0.5 mg/ml) for 30 min, placed in distilled water to destain for 15 
min and viewed under UV illumination.
2.3.14 Isolation of DNA from agarose gels
Low melting point agarose gels were prepared in IX  TAE buffer (gel isolation is not 
earned out in TBE buffer as borate ions are difficult to remove from the resultant 
DNA solution). Ethidium  bromide was added to the samples before electrophoresis 
so as to minimise manipulations with the fragile low melting point agarose gels. 
After electrophoresis, the gels were viewed under 70% UV illumination. The time of 
exposure to UV light was kept to a minimum, as overexposure to UV would cause 
damage to the DNA. The DNA band of interest was excised from the gel using a 
clean scalpel, excess agarose was cut away to minimise the size of the gel slice 
which was then placed in a sterile microfuge tube.
2.3.15 Purification of DNA by Gene Clean Method
This method was used to purify DNA from  low-melt agarose gels. Under UV 
illumination, the appropriate band was excised from the gel using a clean, sharp 
scalpel and placed in an eppendorf. After estimating the weight of the excised piece 
of gel, 2-3 volumes o f N al was added to the agarose. This was then incubated at 
55°C or until the agarose had dissolved. Approximately, 2 (il o f silica 325 mesh glass 
beads were then added and the tube contents were mixed by vortexing. The mixture 
was then left at room  temperature for 5 - 1 0  min, before spinning for 20 s at 12000 x 
g. The supernatant was removed and discarded. The pellet was resuspended in 200pl 
wash solution by vortexing and then pelleted at 12000 x g as before. This wash step 
was repeated twice to fully remove residual agarose and salt contaminants. The DNA 
pellet was resuspended in -1 0  |ul TE or sterile dH20  by vortexing. Finally, DNA was 
eluted from glass beads by incubation at 55°C for 10 min, glass beads were then 
pelleted by spinning at 12000 x g for 10 min. The supernatant was removed to a fresh 
tube and retained for further analysis. The purified DNA was stored at 4 °C..
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2 . 3 . 1 6  S p e c t r o p h o t o m e t r i c  a n a l y s i s  o f  n u c l e i c  a c i d s
DNA and RNA concentration was determined by measuring the absorbance at 260 
nm, which is the wavelength at which nucleic acids absorb maximally (Xmax). A 50 
Hg/ml preparation o f pure DNA has an absorbance of 1 unit at 260 nm while 40 
Hg/ml of pure RNA also has an absorbance reading o f 1 at this wavelength. The 
purity of an RNA or DNA preparation was determined by reading absorbance at 260 
nm, the A,max for nucleic acids and at 280 nm, the A.max for proteins and obtaining the 
ratio for these absorbances. Pure DNA and RNA have A260/A 280 ratios of 1.8 and 2.0 
respectively. Low er ratios indicate the presence of protein while higher ratios often 
indicate residues of organic reagents.
2.3.17 Polymerase Chain Reaction (PCR)
The polymerase chain reaction (PCR) involves the amplification of specific DNA 
sequences using DNA primers which anneal to the DNA of interest. The primers are 
designed so that one anneals to the forward DNA strand and the other anneals to the 
reverse strand thus allowing polymerisation of both strands by the enzyme Taq DNA 
polymerase. This results in exponential amplification of the sequence of interest. 
PCR protocols varied with respect to the DNA amplified.
P C R  r e a c t io n  m i x
*dNTPs: 10 mM dATP, dTTP, dCTP, dGTP. Final concentration, 0.2 rnM each. 
Reactions were overlaid with 100 )il mineral oil before placing in the minicycler 
(Hybid)
Volume Final Concentration
Template DNA (p7CMVE4)
10X buffer
*dNTPs
Forward prim er (0.1 (ig/pf) 
Reverse prim er (0.1 |ig/|0.1) 
dH20
Taq DNA Polymerase 
Final volume
1 (xl 200 ng or 10 ng
10 nl IX
2 |il 200 n,M
1 nl 100 ng
1 [xl 100 ng
84.5 Hi
0.5 ul 2.5 U
100 Hi
IX
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C y c l i n g  p a r a m e t e r s
1 cycle 
25 cycles 
1 cycle
Holding temperature : 4°C.
**This temperature was based on the Tm (melting temperature) of each primer. 
All PCR products where visualised on agarose gels as outlined in section 2.3.12
94°C 1 min
94°C 1 min
**57°C 1 min
72°C 1.30 min
72°C 5 min
2.3.18 Cloning of PCR products in pTAg
The reamplified PCR products were cloned in to the pTAg cloning vector using the 
LigATor rapid cloning system from R&D systems. In order to reduce the risk of 
removing the A overhang by nuclease contamination unpurified PCR products were 
used for cloning. The use of freshly amplified PCR fragments yielded best results as 
storage of PCR products can lead to loss of the A overhang preventing ligation to the 
pTAg vector. Prior to ligation residual DNA polym erase activity was removed to 
avoid false positives by the addition of an equal volume of chloroform:isoamyl 
alcohol (24:1) to the PCR reaction and vortexing for 1 min. The tube was then 
microcentrifuged for 1 min at room temperature at 12,000 x g. The upper aqueous 
phase was transferred to a fresh tube, 2  jllI  of this aqueous phase was used in the 
ligation reaction. The m aximum volume used was 2 ja.1 as the salts may inhibit the 
ligation reaction.
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2.3.18.1 p T A g  L i g a t i o n  r e a c t i o n
The following reagents were combined in a 1.5 ml microcentifuge tube: 
1 OX Ligase buffer 1 |il
lO O m M DTT 0.5 fil 
0.5 |al 
ljil
2  JLll 
4.5 |il
10 mM ATP
50 ng/|ul pTAg vector 
Amplified fragment 
Nuclease-free water
The tube was vortexed briefly to mix and then microcentrifuged to collect the 
contents. T4 DNA ligase (0.5 pi) was added using a fresh tip and mixed gently 
without vortexing. The ligation reaction was incubated over night at 16°C, then 
placed on ice until required.
Competent cells used for the transformation reaction were provided with the 
LigATor Kit. One 1.5 ml tube contained 40 |U,1 of cells which was sufficient for two 
transformation reactions. Cells were thawed on ice, 20 (0,1 of which were gently 
pipetted into a prechilled sterile 1.5 ml microcentifuge tube. One microlitre of the 
ligation reaction was added to the cells and tapped gently to mix. The cells were 
then incubated on ice for 30 min. SOC media was also provided in the LigATor kit 
and it was thawed at room temperature. After 30 min on ice the cells were heat 
shocked at 42°C for exactly 30 s without shaking or mixing. The transformation 
reactions were then incubated on ice for 2 min, 80 pi of SOC media was added to 
each tube which were placed in a shaking incubator at 37°C for 1 hr. Prepared LB 
agar plates containing IPTG/X-Gal (see appendix A) were placed at 37°C for 30 min 
to equilibrate. Spread plates were prepared using 50 ° f  the transformation 
reaction. The plates were left at room temperature to allow absorption of liquid and 
the incubated at 37°C overnight. pTAg contains a L a c Z a  peptide sequence which 
when functionally produced complements the N-terminal truncated L a c Z  peptide 
synthesised in the competent cells provided in the LigATor Kit. The resulting
2.3.18.2 Transformation reaction
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enzyme (3-galactosidase, cleaves X-gal to give blue colonies. IPTG depresses the 
expression of the L a c Z a  gene in cells containing pTAg. When an insert was cloned 
into the cut pTAg vector the L a c Z a  peptide sequence is interrupted. This interfered 
with the function of the peptide and white colonies were produced on the plates. 
This formed the basis for the selection of colonies containing inserts. Transformed 
(white) colonies were inoculated into 5 ml of LB amp broth and incubated in a 
shaking incubator overnight at 37°C. DNA minipreparations were prepared from the 
resulting cultures as described in section 2.3.10. The presence of inserts and their 
orientation was determined by restriction analysis (as described in section 2.3.4).
2.3.19 Sequencing reactions
A T7 Sequencing ™  Kit from Pharmacia Biotech was used, which is based on the 
dideoxy method of sequencing (Sanger e t a l ,  1977). The major steps involved in 
using T7 DNA polymerase to sequence DNA using a radioactive label were as 
follows; isolation of template DNA as described above, annealing of primer, 
labelling reaction, termination reaction, electrophoresis and autoradiography.
2.3.19.1 Annealing of primer to double stranded template
The concentration of DNA was adjusted to contain 1.5-2.0 |dg of DNA in 32 pi of 
water (32 jxl of miniprep DNA was used in each sequencing reaction). To denature 
the template DNA 8 (Ltl of NaOH was added, the tube was vortexed and centrifuged 
briefly to collect drops and incubated at room temperature for 10 min. To precipitate 
the DNA 7 |Lil of 3 M sodium acetate (pH 4.8), 4 |il of dl I20  and 120 |il of 100% 
(v/v) ethanol
were added to the denatured template, mixed gently and placed at -20 °C overnight. 
The precipitated DNA was collected by spinning at 13,000 x g for 15 min the 
resulting pellet was washed in 70% (v/v) ice cold ethanol the tube was then 
centrifuged for 10 min the supernatant was removed the pellet was air dried and 
resuspended in 10 p,l of dH20 . Two microlitres of undiluted universal primer and 2 
|il o f annealing buffer was added to the template DNA vortexed and centrifuged
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briefly followed by incubation at 65°C for 5 rain. The tube was then transferred to 
37°C for 10 min followed by room temperature for 5 min and then used directly for 
labelling reactions.
2.3.19.2 Labelling reaction
The following were added to the annealed template/primer mix,
Labelling mix (dATP) 3 pi
Labelled dATP (35S) 1 ¡i\
T7 DNA polymerase 2 |il
These were mixed gently by pipetting and incubated at room temperature for 5 min.
2.3.19.3 Termination reaction
Four tubes w ere labelled A,C,G,T for each DNA template, 2.5 pi of each of the “read 
short m ixes” were added to their corresponding tubes and incubated for 5 min at 
37°C. To each of the 4 pre-warmed sequencing mixes, 4.5 |il of the labelling reaction 
was added, mixed by gentle pipetting, and incubated at 37°C for 5 min. Five 
microlitres o f stop solution was added and mixed gently. Four microlitres of each 
reaction was added to a fresh tube, incubated at 75-80°C for 2 min and immediately 
loaded on the sequencing gel. The remainder of the unheated reactions was stored at 
-20°C. Electrophoresis and autoradiography was carried out as described in section 
2.7.4.
2.4 RNA ANALYSIS
2.4.1 RNase free environment
RNA is easily degraded by ubiquitous RNase enzymes and thus stringent measures 
were employed to avoid this potential hazard. All glassware and metal spatulas were 
baked prior to use at 180°C for 8 h in order to inactivate any RNase activity. Sterile 
disposable plasticware is generally considered Rnase-free and thus did not require 
treatment. RNases are resistant to autoclaving but they can be deactivated by the
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chemical diethylpyro-carbonate (DEPC) when it is added to solutions at a final 
concentration of 0.1% (v/v), incubated at room temperature for 18 h and autoclaved. 
Solutions which contain amines such as Tris cannot be DEPC-treated as the DEPC is 
inactivated by these chemicals. Solutions containing these chemicals were prepared 
using DEPC treated H 2O followed by autoclaving. Hands are a major source of 
RNase contamination thus gloves were used at all times and changed frequently.
2.4.2 RNA extraction from cultured cells
Prior to RNA isolation cells were examined by phase contrast microscopy to 
determine the condition of the cells. A viable cell count was performed as described 
in section 2.6.4. RNA was extracted from cultured cells using the commercial 
reagent RNA  ISOLATOR™ . Cells grown in suspension were pelleted and then 
lysed in RNA ISOLATOR™  by repetitive pipetting. One millilitre of RNA 
ISOLATOR™  was used per 1 x 107 cultured cells. The homogenised sample was 
incubated at room  temperature for 5 min to allow complete dissociation of nuclear 
protein complexes, (the procedure may be stopped at this point by storing samples at 
-70°C). Phase separation was achieved by adding 0.2 ml of chloroform per 1 ml of 
RNA ISOLATOR. The samples were covered and shaken gently but thoroughly for 
15 s or until completely emulsified. Samples were incubated at room  temperature for 
15 min. The resulting mixture was centrifuged at 12,000 x g for 15 min at 4°C. 
Following centrifugation the mixture separated into a lower red phenol-chloroform 
phase, an interphase and a colourless upper aqueous phase. The aqueous phase, 
which contains the RNA, was removed to a fresh tube and RNA was precipitated by 
adding 0.5 ml of isopropanol per ml o f RNA ISOLATOR used initially. The 
samples were stored for 10 min at room temperature, then centirfuged at 12,000 x g 
for 10 min at 4°C. The resulting RNA pellet was washed using 1 ml of 75% (v/v) 
ethanol by inverting the tube 5 times. The pellets were then recentrifuged at 10,000 
x g for 5 min at 4°C and the 75% (v/v) ethanol was removed. Pellets were air dried 
and dissolved in DEPC treated upH20 . The resulting RNA preparation was heated to 
60°C and mixed gently to ensure a homogeneous solution prior to aliquoting. An 
aliquot was removed for spectrophotometric and gel electrophoretic analysis.
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2 . 4 . 3  R N A  a n a l y s i s  b y  g e l  e l e c t r o p h o r e s i s
In order to check the integrity of RNA, isolated samples were run on 1.6% (w/v) 
agarose gels. These gels were prepared as outlined in section 2.3.12. The RNA 
samples (5 ¡il) were prepared for electrophoresis by adding 15 (0,1 of RNA sample 
buffer and 3 [xl of RNA loading buffer. The samples were heated to 65°C for 10 min 
prior to loading on the gel, which was run in IX  TAE as described in section 2.3.12. 
As ethidium  bromide is included in the RNA loading buffer the gels did not require 
further staining and could be visualised directly on a UV transilluminator. The 
presence of two strongly staining bands, representing the 28 S and the 18 S 
ribosomal RNAs, indicated intact RNA. Degradation is observed by a smear running 
down the length of the gel.
2.5 PREPARATION OF CELL PROTEIN
Prior to protein isolation cells were examined by phase contrast microscopy to 
determine the condition o f the cell cultures. Viable cell counts were then performed 
as described in section 2.6.3. All buffers required are outlined in Appendix.
2.5.1 Preparation of total cellular proteins
This method was employed to isolate total cellular protein including nuclear proteins 
from  cultured mammalian cells. Approximately 6 x 107 cells from  a cell line were 
used in each protein preparation. Cells were pelleted at 1000 x g for 5 min and 
washed with 10 ml of ice-cold PBS. The cells were then spun at 3,000 x g and all the 
supernatant was removed. The volume of the pellet was estimated and the cells were 
dispersed in five volumes of ice-cold suspension buffer containing freshly-added 
anti-proteolytic enzymes (see Appendix). This step was carried out rapidly to avoid 
proteolytic degradation. An equal volume of 2X SDS gel loading buffer was added, 
immediately after the suspension buffer, at which stage the sample becomes 
extremely viscous. Samples were then placed in a boiling water bath for 10 min. 
W hen required, the DNA in each sample was sheared by sonication for 1 min on full 
power. The resulting lysates were transferred to a microcentifuge tube and 
centrifuged at 10,000 x g for 10 min at room temperature. Supernatants were
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aliquoted and stored at -20°C. Samples were analysed by SDS PAGE, loading 
approximately 6 x 105 cells per lane as described in section 2.6.5.
2.5.2 Protein electrophoresis, preparation of SDS-PAGE gels
A two phase SDS-PAGE system was used to analyse proteins with a 5% stacking gel 
and a 10% resolving gel as outlined below.
Resolving Gel (10 ml)
10 % resolving gel (ml) 15 % resolving gel (ml)
acrylagel 3.33 5.00
bis-acrylagel 1.35 2.03
1.5 M Tris (pH 8.8) 2.50 2.50
distilled water 2.62 0.265
10% (v/v) SDS 0.10 0.10
10% (v/v) APS 0.10 0.10
TEMED 0.01 0.01
Stacking gel (2.5 ml)
5% stacking gel(ml)
acrylamide 0.42
bis-acrylagel 0.168
1 M Tris (pH 6.8) 0.312
upH20 1.55
10% (v/v) SDS 0.025
10% (v/v) APS 0.025
TEMED 0.0025
2.5.3 Polyacrylamide gel electrophoresis (PAGE)
An ATTO protein gel electrophoresis system was used in this study. Glass plates 
were washed with detergent, rinsed first with tap water and then with dH20  and 
finally wiped in one direction with tissue soaked with 100% (v/v) ethanol. The 
gasket was placed about the ridged plate before assembling plates and securing with
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clamps. The resolving gel was then poured to within 2 cm of the top of the larger 
plate, overlaid with 100% (v/v) ethanol and allowed to polymerise for 45 min-1 hr. 
All traces of ethanol were removed by several washes with dH20  and the stacking 
gel was poured. A clean comb was inserted and the gel was again allowed to set. 
The electrophoresis tank was filled with IX  Tris glycine running buffer to the level 
of the horizontal rubber gasket. After polymerisation the gaskets clamp stands and 
comb were removed. Unpolymerised gel was removed by gently rinsing the wells 
with dH20 , the wells were then straightened using a loading tip. The prepoured gels 
were lowered into the buffer at an angle to exclude air bubbles from the gel buffer 
interface. The gel plates were fixed firmly in place with the notched plate innermost. 
The cham ber formed by the inner plates was filled with IX  running buffer, samples 
were loaded and the electrodes were attached. The gels were run at 30 mA for 
approximately 1 hr. W hen complete the plates were removed, separated and the gel 
was either placed in transfer buffer prior to W estern blotting or stained in Coomassie 
blue for 30 min, with agitation. The gel was then placed in several changes of destain 
(see appendix A) with constant agitation, until all background staining was removed.
2.5.4 Western blot analysis
An SDS-PAGE gel was run as described above with pre-stained markers (New 
England Biolabs). Two pieces of 3MM filter paper were cut to the size of the gel as 
was the nitrocellulose membrane. The sponges from  the transfer apparatus along 
with 2 pieces of 3 MM filter paper and the SDS gel were soaked in transfer buffer. 
One sponge was placed on each side of the transfer apparatus and 1 piece of filter 
paper in turn, on each of these. The gel was placed on one piece of filter paper and 
the nitrocellulose membrane which had been briefly soaked in transfer buffer was 
placed directly onto the gel, ensuring that no bubbles were trapped between any of 
the layers. The second piece of filter paper and sponge were then placed on top of 
the membrane, the transfer apparatus was assembled and placed in the blotting 
apparatus with the gel on the side of the negative (black) electrode and the 
nitocellulose on the positive (red) side. The voltage was set at 80 volts for 2 hr. 
After transfer, the apparatus was disassembled and the membrane was washed briefly 
in TBS to remove any traces o f gel, followed by blocking buffer for 1 hr. The 
membrane was then incubated with primary antibody at 4°C overnight. Sodium
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azide was added to each antibody solution to a final concentration of 0.02% (w/v) as 
a preservative thus permitting reuse of the antibody.
2.5.4.1 Alkaline phosphatase detection
This method of detection was used in all immunoblotting experiments, with the 
exception of detection of p21AVAFl expression, which was detected using ECL. 
EBNA-3A expression was detected using either method, but the ECL protocol was 
more optimal. A fter overnight incubation, the membrane was washed twice in TBST 
(0.1%(v/v) Tween-20) for 10 min and once in blocking buffer for 15 min. The filter 
was then incubated in the secondary antibody, a mouse anti-human alkaline 
phosphatase conjugated antibody (Promega) diluted 1/5000 in 5% blotto, for 1-2 h at 
room temperature, followed by washing three times with TBST for 10 min each. All 
the above incubations were carried out with agitation. Membranes were then placed 
in a clean container and covered with BCIP/NBT substrate. The container was 
placed in the dark at room temperature without agitation for 30 min or longer if 
required. The filter was then rinsed in distilled water to stop the reaction, 
photographed then wrapped in cling film to store.
2.5.4.2 ECL detection
This method was used in the detection of expression of p21/W A Fl. After overnight 
incubation, primary antibody was removed and saved for re-use (up to 3 times). The 
membrane was rinsed x 2, then washed for 3 x 10 min in TBST after which rabbit, 
anti-mouse IgG (DAKO, 1:2000) was added for 60 min. The membrane was washed 
as before and incubated in goat, anti-rabbit antibodies (DAKO, 1:2000) for 60 min. 
The final washing step was as follows: rinsed x 2, 1 x 1 0  min followed by 3 x 5 min 
in TBST, with a final 5 min wash in TBS to remove tween. Freshly-prepared 
detection reagent (Amersham) was added such that the entire surface of the 
membrane was covered and left for precisely 60 s. It was important to work quickly 
from this point. The membrane was then carefully lifted and as much as possible of 
the detection solution was allowed to drain from the membrane, which was then 
wrapped in cling-film and exposed to X-ray film in the dark. Initial exposures were 
for one minute, after which the exposure time was reduced or increased accordingly
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having visualised the result by developing the film. p21 was generally detectable 
within one minute of exposure, but exposure times may be extended if  required, as 
the reaction intensity continues to increase up to approximately 20 min.
2.6 CELL CULTURE METHODS
All cell culture techniques were performed in a sterile environment using a Holten 
laminar air flow cabinet. Cells were visualised with an Olympus CK2 inverted phase 
contrast microscope.
2.6.1 Culture of cells in suspension
All media compositions and media supplements are given in appendix A. The cell 
lines DG75, DG75 tTA, DG75 tTA EBNA 2, DG75 tTA LMP1, M utu 1, Mutu 3 
c95, X50-7, BL41, BL41.B958, IARC.171, IARC 307, IARC 290B, Ag876 III, 
BL72 III, and BL74 were maintained in supplemented RPM I 1640 (see Appendix). 
Additional supplements were added to some culture media see section 2.6.2. 
Cultures were seeded at a density of 2 xlO5 to 5 x 105 cells per ml in 25 cm2 flasks 
and expanded in 75 cm2 flasks. Cells were sub-cultured two or three times per week 
by harvesting into a sterile centrifuge tube and centrifuging at 1000 x g for 5 min at 
room  temperature. The cell pellet was resuspended gently in an appropriate volume 
of fresh media and replaced into the tissue culture flask. All cell lines were 
incubated in a humid 5% CO2 atmosphere at 37°C in a Heraesus cell culture 
incubator.
2.6.2 Media supplements
Supplements were added to the growth media of certain cell lines to (a) improve 
cellular proliferation or (b) to select cells containing transfected plasmids (all media 
supplements are outlined in appendix A). L-cysteine is required for the survival and 
proliferation of most group 1 BL cell lines. However L-cysteine is rapidly oxidated 
under normal culture conditions. To improve proliferation of the group 1 Burkitt 
lymphoma cell line M utu 1 a-thioglycerol was added to growth media as a stable 
substitute for L-cysteine. The a-thioglycerol was dissolved in bathocuproine
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disulfonic acid (BCS) which effectively prevents autoxidation of thiols in liquid 
solutions. Sodium pyruvate was also added to protect against H 2O2 which may be 
generated. HEPES was added to maintain an alkaline pH of 7.4.
The cell lines DG75tTA-EBNA2 and DG 75tTA -LM Pl are tetracycline responsive 
cell lines in which the gene of interest is cloned downstream of a promoter 
containing a binding site for a hybrid tetracycline regulated transactivator (tTA) 
which is constitutively expressed from a second co-transfected plasmid. Tetracycline 
binds to the tTA and prevents it binding to the promoter which remains silent, but 
upon removal of tetracycline from the growth medium the tTA binds the promoter 
sequence and activates transcription. These cell lines were maintained in 
supplemented RPM I containing 1 fig/ml of tetracycline. Every three weeks the 
transfected cells were reselected by the addition of 500 |ig/m l of hygromycin B to 
DG75 tTA, 500 (ig/ml of hygromycin B and 1,000 pg/ml of geneticin (G418) to 
DG75 tTA EBNA2 and 800 [xg/ml of hygromycin and 2,000 (ig/ml of geneticin 
(G418) to DG75 tTA LMP1. The stably transfected cell lines C33A Neo and C33A 
LMP1 were maintained in supplemented high-glucose DMEM  containing 600 (ig/ml 
of geneticin. The parental cell line C33A was maintained in supplemented high 
glucose DMEM.
2.6.3 Cell counts
Cell counts were performed using an improved Neubauer haemocytometer slide. 
Trypan blue exclusion dye was routinely used to determine cell viability. Ten 
microlitres of trypan blue was added to 90 |al of a cell suspension and mixed. A 
sample of this mixture was added to the counting chamber of the haemocytometer 
and cells were visualised by light microscopy. Viable cells excluded the dye and 
remained clear while dead cells stained blue. Cell numbers were ascertained by 
multiplying the average cell count based on 4 individual counts by the dilution factor 
(1.1) and by taking into account the volume of the haemocytometer chamber ( lx  10'4 
ml). Thus, counts were expressed as number o f cells per ml.
2.6.4 Cell storage and recovery
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Cell stocks were prepared for long term storage as follows: 1 x 107 cells in
exponential phase were pelleted and resuspended in 800 jlxI of supplemented RPM1 to 
which 100 |Lil of FCS was added, then placed on ice for 10 min. DMSO was added to 
a final concentration of 10% (v/v), mixed gently and transferred to a sterile cryotube. 
The cryotubes were slowly lowered into the gas phase of liquid nitrogen and 
immersed in liquid nitrogen in a cryofreezer (Cooper Cryoservices Ltd). Cells were 
recovered from liquid nitrogen by thawing rapidly at 37°C and transferring to a 
sterile centrifuge tube containing 5 ml of prewarmed supplemented media. The cells 
were centrifuged at 1000 x g for 5 min, the pellet was resuspended in 5-10 ml of 
fresh supplemented medium, transferred to a culture flask and incubated at 37°C in 
5 % C 0 2.
2.6.5 Induction of gene expression using the tetracycline-regulated system
After counting cells, an appropriate volume was pelleted at 1000 x g for 5 min and 
washed x 3 in sterile PBS. Cells were then incubated in supplemented RPM I for 1 h 
at 37°C. Cells were then washed again once in sterile PBS and seeded at 
approximately 2 x 105 cells per ml in the presence or absence of tetracycline. 
Uninduced cells (Tet+) were washed as per induced cells (Tet-) but were constantly 
maintained in the presence of tetracylcine.
2.6.6 Transient transfections
In all cases transiently transfected cells were incubated for 48 h at 37°C in a 5% C 02  
incubator, before harvesting. Total DNA for transfection was normally co­
precipitated in 100% ethanol the day before transfection, then washed in 70% ethanol 
and resuspendcd in a final volume of 30 |ul T.E pH 7.4 (this pH is very important), 
using the same total quantity of DNA per transfection.
2.6.6.1 Electroporation of B lymphocytes
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Cells were passaged 2 days before transfection. On the day of transfection, cells 
should be at about 5-7 x 105 /ml (definitely less than 106). For each transfection a 60 
m m  culture dish with 5 ml complete medium (RPMI 1640/glutamine/10 %FCS) was 
preincubated at 37°C. 107 cells per transfection were spun at 1000 x g for 5 min and 
washed in a small (one fifth) volume of cold complete RPMI. Meanwhile, DNA was 
added to labelled cuvettes (Biorad, 0.4 mm) and placed on ice. Cells were 
resuspended in cold com plete RPM I at 250 (il medium per 107 cells, and added to 
cuvettes. Each cell/DNA mix was pulsed at 270V/960pE (with capacitance 
extender), and time was recorded in millisecs, and returned to ice immediately. Cells 
must not stay longer than 10 min on ice before being transferred to media. Contents 
of cuvettes were transferred to culture dishes using using a micropipette and yellow 
tip, treating cells gently. Cuvettes were washed with media from the culture dish, and 
placed at 37°C in a 5% C 0 2 incubator for the required amount of time.
2.6.6.2 DEAE Dextran-mediated transfection (modified protocol)
Details of all solutions required for this protocol are given in the Appendix section. 
The day before transfection, cells were seeded at 5 x 105 cells/ml. After 24 h in 
culture, cells were counted again -  it was essential for cell numbers to have almost 
doubled before beginning the transfection, thus ensuring that cell growth is in 
logarithmic phase and that cells are at their optimum for the uptake of DNA during 
transfection. Thus, 5 x 105 cells per transfection were pelleted at 900 rpm  for 5 min. 
All traces of media were removed and cells were washed twice in TBS. All traces of 
TBS were carefully removed using a pipette tip. During the washing steps DNA for 
transfections was prepared in 20 ml sterilins. A total o f 5 (ig DNA per transfection 
was found to be optimal. The DNA for each transfection was made up to 50 jllI with 
TE. Cells for each transfection were resuspended in 250 |0,1 TBS and added to the 
DNA mix. Using gentle swirling, the DNA and cells were mixed. 300 p.1 of DEAE 
D extran (1 mg/ml) was then added to each sterilin, which was gently swirled again to 
mix. The transfection cocktails were incubated at room temperature for 30 min with 
gentle swirling every 5-10 min to allow homogenisation. TBS (10 ml) was added to 
each transfection. M ixes were then spun at 900 rpm for 5 min and supernatant was 
removed taking care not to dislodge any cells from the pellet. Each pellet was
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resuspended in 1 ml fresh complete medium. A further 9 ml complete medium was 
added to each sterilin and transfected cells were then transferred to 25 cm2 cell 
culture flasks for incubation.
2.6.7 Stable transfections
2.6.7.1 Preparation of drug curve for G418
DG75 cells were grown in RPM I1640 with 10% FCS until just sub-confluent. Cells 
were then plated in 24-well or 96-well culture plates at a concentration of ~1 x 103 
cells/ml and grown overnight before addition of drugs. As cells can divide once or 
twice in selective media that can kill them, it was important to seed cells at low 
density to ensure that cells did not reach confluency before selection could take 
effect. After 24 h, G418 was added in various quantities of geneticin (G418) as 
follows: 0, 500, 1000, 1500, 2000, 2250, 2500, 3000 ¡J-g/ml and cells were grown for 
10-14 days. All cells were maintained in 500 |ig/m l hygromycin B to select for the 
tTA plasmid and 1 jig/ml tetracycline throughout. M edia was changed every 4 days 
during this time and cells were observed for decline of cell numbers under the 
inverted microscope after one week and every day thereafter. At the end of 10-14 
days incubation, trypan blue exclusion was used to evaluate cellular viability in wells 
which still contained cells. The concentration of G418 which just killed all the cells 
was deemed suitable for use in subsequent selection procedures.
2.6.7.2 Stable transfection and selection of pJef-3A
DG75tTA cells were passaged the day before transfection such that cells were at 
approximately 50% confluency at the time of transfection. Transfections were 
carried out in duplicate on each ocassion. Cells (1 x 107) were transfected with 5 (ig 
pJef-3A by electroporation as per section 2.6.5.1. and were allowed to recover for 24 
h in 9 ml media in the presence of tetracycline. The following day 10 ml of fresh 
media containing drugs was added to give a final concentration of hygromycin B at 
800 |Lig/ml, G418 at 2 mg/ml and tetracycline at 1 (ig/ml. Cells were then plated out
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in 96-well plates at 200 |il per well. Tetracycline is stable for 5 days, therefore media 
was changed every 4 days.
2.6.7.3 Immunocytochemistry (fixation and staining of tissue culture cells)
Expression of EBNA-3A in DG75tTA cells was monitored in clones using 
immunocytochemistry following stable transfection experiments. Prior to starting the 
procedure a bath of methanol and acetone were placed at -20°C for 2 h. A cell 
suspension was prepared o f 1 x 106 cells/ml in supplemented RPMI, 50 fri of this 
suspension was placed in a 1.5 ml microcentifuge tube which had a hole pierced in 
the bottom (20G needle). This tube was then centrifuged in a cytospin onto a clean 
microscope slide at 750 x g for 5 min. The slide was allowed to air dry for 5 min 
then placed in ice-cold methanol for 5 min. The slide was then air-dried briefly and 
placed into an ice-cold acetone bath for 1 min 45 s. This procedure served to fix and 
permeate the cells. Slides were left to air dry overnight. Primary antibody (T2.78 
anti-EBNA3A) was diluted 1/50 in PBS with 5% (v/v) FCS, 30 .^1 of the dilution was 
placed on the cell smear for 30 min in a humid chamber at 4°C. The slide was 
washed ( 3 x 3  min) w ith PBS, taking care to ensure that the slide did not dry out. 
Secondary Ab (Anti-mouse AP, Promega) was again diluted 1/50 in PBS containing 
5% (v/v) FCS, 100p.l was placed on the smear and incubated for 30 min in a humid 
chamber at 4°C. PBS washing was repeated as before and the slide was allowed to 
air dry. Finally, 100 (0,1 o f substrate (BCIP NBT) was added to the smear and colour 
was allowed to develop for a minimum of 30 min. W hen colour was apparent the 
slide was washed with water and viewed under microscope. W hen mounting of slides 
was required, it was im portant not to let slides dry out. A small drop of aqueous 
mountant was added to the slide and a coverslip was placed over the slide without 
trapping air bubbles.
2.6.8 Luciferase assay
Cells for luciferase assay were normally harvested 48 h post-transient transfection. 
After counting cells, an appropriate volume of cells was pelleted at 1000 x g and 
washed twice in sterile PBS. Reporter lysis buffer (IX ; Luciferase Assay System,
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Promega) was added to cells at 20 pil per 106 cells. Lysates were then transferred to 
microcentrifuge tubes and placed on ice. Tubes were vortexed for 10-15 s, 
centrifuged at 12000x g for 2 min and each supernatant was transferred to a fresh 
tube. Samples were stored at -80°C  until required, when 20 |il was taken for assay. 
Samples are stable in lysis buffer over several freeze-thaw cycles. At the time of 
assay, it was im portant to allow sufficient time for detection reagent to come to room 
temperature. In order to obtain a background reading, luciferase activity was assayed 
in initially in the absence of detection reagent. Subsequently, 100 (xl detection 
reagent was added for assay. Luciferase activity levels were adjusted for transfection 
efficiencies, estimated using (3-galactosidase activités from  lacZ reporter construct 
which was co-transfected with all transfections (2.6.6).
2.6.9 P-galactosidase assay
Cells for assay were normally harvested 48 h post-transient transfection. After 
performing a cell count, an appropriate volume of cells was pelleted at 1000 x g and 
washed once in sterile PBS. Cells were resuspended in Reporter lysis buffer (IX ; 
Luciferase Assay System, Promega) at 200 |il per 106 cells and incubated at room 
temperature for 10-15 min. Cells were then centrifuged at 12000 x g for 10 min, each 
supernatant was transferred to a fresh tube and stored at -80°C  until required. Mock 
transfected cells were included as control. Cell extract (30 |il) was added to 3 |il 
100X Mg solution, 66 |ul ONPG and 201 |xl 0.1 M sodium phosphate (see Appendix 
A) and incubated at 37°C for 30 min or until a faint yellow colour had developed. A 
reaction tube was included in which ONPG substrate was omitted to be used to 
obtain a background reading. Reactions were inhibited, when required, by adding 
500 |il 1 M  N a2C0 3 . Optical densities were read at 420nm over a linear range of 0.2 
- 0.8.
2.7 RNASE PROTECTION ASSAY
The ribonuclease protection assay (RPA) is a highly sensitive and specific method 
for the detection and quantitation o f mRNA species. The RiboQuant® RNase
8 1
protection assay system (PharM ingen) was employed during this study. The 
procedure is outlined below.
Day 1: Probe Synthesis
r
RNA preparation
7
Overnight Hybridization
Day 2 : RNase treatment and Purification 
of Protected Probes
Gel preparation
Electrophoresis on Denaturing 
Polvacrvlamide Gel
;
Autoradiography and /or Phosphorimaging
Figure 2.1 Overview of the ribonuclease protection assay protocol.
2.7.1 Probe Synthesis
The [a -32P]UTP, GACU nucleotide pool, DTT, 5X transcription buffer and the 
template DNA set was brought to room  temperature prior to setting up the reactions. 
The following were added to a 1.5 ml microcentifuge tube for each probe synthesis:
RNasin 1 Ml
GACU pool 1 Ml
DTT 2 Ml
5X transcription buffer 4 Ml
Template DNA (HCC-2) 1 Ml
[a -32P]UTP (10 |i.Ci/ |il) 5 Ml
T7 RNA polymerase 1 Ml
The contents of the tube were mixed by gentle pipetting and centrifuged briefly 
followed by incubation at 37°C for 1 hour. The reaction was terminated by adding 2
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|iil of RNase free DNase, mixing gently and incubating at 37°C for 30 min. The 
following reagents were then added to the reactions:
EDTA 20 mM 26 |xl
Tris-saturated phenol 26 |il
Chloroform:isoamyl alcohol (50:1) 25 ¡0.1
Yeast tRNA 2  [i\
The contents were vortexed to an emulsion and centrifuged for 5 min at room 
temperature. The upper aqueous phase was transferred to a fresh tube containing 50 
|il of chloroform:isoamyl alcohol (50:1), the tube was vortexed and microcentrifuged 
(top speed) for 2 min at room temperature. The upper aqueous phase was transferred 
to a sterile 1.5 ml tube to which 50 [il of 4M  ammonium acetate and 250 |il of ice 
cold 100% (v/v) ethanol was added. The tube was inverted to mix and incubated at - 
70°C for 30 min followed by centrifugation at 4°C for 15 min. The supernatant was 
removed and the pellet was washed with 100 of ice cold 90% (v/v) ethanol after 
which the supernatant was removed and the pellet was air-dried for 5-10 min. The 
pellet was solubilised by the addition of 50 jil of hybridization buffer and gentle 
vortexing and contents were collected by brief centrifugation. Duplicate 1 jllI 
samples o f the labelled probe were quantified in a scintillation counter. A maximum 
yield of ~3 x 106 Cherenkov counts/fxl with an acceptable lower lim it of ~3 x 105 
Cherenkov counts/pl was expected. The probe was diluted to approximately 3.9 x 
105 counts/^il, which is recommmended for this particular probe, and stored at -20°C 
until required. Generally probes can only be used for two successive overnight 
hybridizations when labeled with [a -32P]UTP.
2.7.2 RNA preparation and hybridization
RNA was prepared using the RNA isolation method outlined in section 2.4.2 and 20 
Mg o f total RNA was precipitated as follows for each probe hybridization. Each 
RNA sample was made up to 50 |il w ith DEPC-treated upH^O to which 50 |il of 4 M 
am monium acetate and 250 (il o f ice cold 100% (v/v) ethanol were added. The 
samples were mixed by inverting and stored at -70°C for 1 h or at -20°C overnight.
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The precipitated RNA was collected by centrifugation at 12,000 x g for 30 min at 
4°C and the pellet was washed with 90% (v/v) ice cold ethanol. After careful 
removal o f the supernatant and subsequent air-drying, the pellet was resuspended in 
8 |il o f hybridization buffer by gentle vortexing for 3-4 min followed by a brief 
centrifugation. Two microlitres of the probe was then added to each RNA sample 
and mixed by pipetting. A drop of m ineral oil was added to each sample and the 
tubes were centrifuged briefly in the microfuge. Samples were placed in a heating 
block preheated to 90°C, which was immediately turned down to 56°C, allowing the 
temperature to ramp down slowly, and incubated for 12-16 hr. The heating block 
was then turned down to 37°C prior to RNase treatment. Again the temperature was 
allowed to ramp down slowly and then was held at 37°C for 15 m in.
2.7.3 RNase treatments
An RNase reaction solution was prepared by adding 2.5 ml of RNase buffer to 6 |il 
of RNase A + T1 mix, per 20 RNA samples (RNase A 80 ng/|il; RNase T1 250 
U/(il). The RNA samples were removed from  the heating block and 100 jil of the 
RNase cocktail was added underneath the oil into the aqueous layer (bubble). The 
tubes were microcentrifuged for 10 s and incubated for 45 min at 30°C. Before the 
RNase treatment was completed a Proteinase K  mixture was prepared (per 20 
samples) as follows:
Proteinase K buffer (1 X) 390 (il
Proteinase K  (10 mg/ml) 30 jLtl
Y east tRNA (2 mg/ml) 30 (il
An aliquot of 18 (0,1 was added to a sterile 1.5 ml microcentifuge tube for each 
sample. The RNase digests were extracted from  underneath the oil and transferred to 
the tube containing the proteinase K mixture (avoiding transfer of oil). The 
RNase/Proteinase K mixture was vortexed briefly, microfuged quickly and incubated 
for 15 min at 37°C. Tris-saturated phenol (65 jil) and 65 fil of chloroform:isoamyl 
alcohol (50:1) were added to the samples, vortexed to an emulsion then centrifuged 
for 5 min at room temperature. The upper aqueous phase was extracted, avoiding the 
interphase, and transferred to a fresh tube to which 120 (il of 4M ammonium acetate
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and 650 (il of ice cold 100% (v/v) ethanol was added. The tubes were then mixed by 
inversion and were subsequently incubated at -70°C for 30 min. Samples were 
centrifuged for 5 min at 4°C, the pellet was then washed with ice cold 90% (v/v) 
ethanol, the supernatant was removed and the pellet was allowed to air-dry for 5-10 
min. Pellets were resuspended in 5 |ul o f IX  loading buffer (provided in kit). Prior 
to loading onto the gel the samples were heated to 90°C for 3 min and chilled 
immediately in an ice bath.
2.7.4 Electrophoresis
Five percent (w/v) gels were prepared according to the formula given in Appendix. 
The gel apparatus was assembled and gel was cast and generally allowed to set 
overnight (2 h is sufficient). The gel was pre-run for 45 min at 50W  in IX  TBE 
buffer (in upH^O), samples were loaded and electrophoresis was allowed to proceed 
for 2-2.5 h at 50W. After disassembling the apparatus, the gel was lifted from the 
glass plates using a 3MM sheet of W hatmann cut to size and covered with cling film. 
The gel was allowed to drv in the gel-drier for 2 h at 80°C, then was placed in a 
cassette which contained an intensifying screens on each side (optional). The gel was 
subsequently exposed to X-ray film  overnight at -70°C  (or longer if required) before 
developing.
2.8 YEAST TWO HYBRID METHODS
Methods used in YTH-B were similar to those described for YTH-A except where 
stated.
2.8.1 Yeast transformation protocol (modified from Gietz et al., 1992)
A single yeast colony was inoculated in 5 ml YPD broth and incubated at 30°C 
overnight with shaking. This starter culture was diluted in a final volume of 25 ml 
YPD to give an ODéoo of 0.2 (approximately a 1 in 10 dilution) and was then grown 
to an OD600 of betweeen 0.6 and 0.8. Cultures were spun at 3000 x g for 5 min and 
pellets were resuspended in 125 jlxI  0.1 M  lithium acetate. Equilibration was carried 
out in a 30°C waterbath for 15 min. Aliquots of cells (50 |ol) were dispensed into 1.5
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ml sterile eppendorf tubes and 2 |il (1 to 10 fig) DNA plus 5 (il (20 Mg) carrier DNA 
was added (total volume o f added DNA should be no more than 15 |il). The contents 
of each tube were mixed by gently pipetting up and down. The following were then 
added and the contents o f each tube was mixed by gently flicking the tubes: 240 |il 
50% PEG (filter sterilised), 30 (il 10X TE buffer, 30 jlxI 1M lithium acetate, 5 ¡il 
carrier DNA. Tubes were incubated in a 30°C waterbath for 30 min, followed by a 20 
min incubation at 42°C. Tubes were centrifuged at 3000 x g for 5 min, supernatant 
was removed and cells were resuspended in 100 pi sterile distilled water. Each 100 
p,l was spread onto a single YNB plate containing the appropriate concentrations of 
amino acids and incubated at 30°C usually for up to 4 days. (Colonies may take 2 to 
4 days to grow to a diameter of 1-2 mm.)
2.8.2 Transcription Activation Assays
2.8.2.1 X-gal filter lift assays
Five individual colonies from each plate were patched onto the appropriate nutrient 
media and incubated at 30°C for 4 days eg. in YTHS-A, Glu -U-H+T+L and G/R -U- 
H+T+L plates were used to confirm that baits did not transactivate the lacZ 
promoter. Colonies were lifted by overlaying patches on each plate with 
nitrocellulose filters and allowing them  to become wet through. Filters were 
subsequently removed, air-dried for 5 min, and then chilled, colony side up, at -70°C. 
W hatman 3MM filter paper was placed in petri-dishes each containing 3 ml IX  Z 
buffer with 1 mg/ml X-Gal, and allowed to soak through. Filters were then placed 
colony side up on the W hatman paper, incubated at 30°C and monitored for colour 
changes at 30 min, 60 min and overnight.
2.8.2.2 Transactivation of nutrient gene promoters
To test for ability to grow in the absence of a particular nutrient, 5 individual 
colonies from each plate (see transformations above) were patched onto plates 
lacking the appropriate nutrient and incubated at 30°C for 4 days. For example, to
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test for Leu-positive least (YTHS-A), colonies were patched onto Glu-U-H+T-L and 
G/R-U-H+T-L plates.
2.8.3 Repression assay
To ensure that baits entered the yeast nucleus and bind to LexA operators, using the 
Ura+ reporter plasmid, pJK lO l (see table 1). This plasmid expresses high levels of (3- 
galactosidase when gown on galactose-containing medium. pJKlOl also has LexA 
operators positioned between the TATA box and upstream activating site (UAS). 
Transcriptionally inert LexA fusions that bind to the operator in pJK lO l repress 
expression of (3-galactosidase from 2 to 20 fold in the presence of galactose. Plasmid 
pRFHM-1 was used as a positive control for nuclear localisation.
A  rapid, quantitative assay for B-galactosidase activity in liquid cultures was 
employed (adapted from Bartel e t a l , 1993), in which yeast cells are permeabilised 
and the chromatogenic substrate o-nitrophenyl-B-d-galactoside (ONPG) is added in 
excess. After incubation at 30°C, the reaction was stopped by raising the pH to 11, 
inactivating |3-galactosidase. Product formation was determined by 
spectrophotometry.
2.8.3.1 Preparation of cells for (3-galactosidase assay
Y east transformations were performed with the following plasmids using the 
protocol detailed in section 2.8.1.
pJK lO l (negative control) Glu -U+H+T+L
pJK lO l + pRFHM-1 (positive control) Glu -U-H+T+L
A 2 ml overnight culture of each transformation reaction was prepared by inoculating 
colonies in YNB liquid medium as follows and incubating at 30°C with shaking:
pJK lO l + pEG-3B-525 
pJK lO l + pEG-3B-311 
pJK lO l + pLex-3B-525 
pJK lO l + pLex-3B-311 Glu -U-H+T+L
Glu -U-H+T+L
Glu -U-H+T+L
Glu -U-H+T+L
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Pos control - G/R -U+H+T+L
All others - G/R -U-H+T+L
Overnight cultures were diluted by adding 2 mis of the above liquid media and 
grown for 2 to 3 h to an OD 600 of 0.5. Cells were centrifuged at 2500 x g in a tabletop 
centrifuge, resuspended in an equal volume of Z buffer and placed on ice. OD600 for 
each sample was determined (cells in mid-log phase required no dilution to obtain an 
accurate OD reading; however, readings > 0.7 are inaccurate). Two reactions for 
each sample were prepared as follows, with mixing:
a. 100 Ml cells + 900 \x\ Z buffer, b. 50 \il cells + 950 \l \ Z buffer.
One drop of 0.1% SDS and 2 drops chloroform were added to each tube using a 
Pasteur pipette to permeabilise the cells. Samples were then vortexed for 10 - 15 s 
and equilibrated for 15 min in a 30°C waterbath.
2.8.3.2 Assay for P-galactosidase activity
ONPG substrate (0.2 ml of a 4 mg/ml ONPG stock in 0.1 M KPO4, pH 7.0, filter 
sterilised and stored at -20°C) was added to each sample which was then vortexed 
for 5 s. Tubes were immediately placed in a 30°C waterbath and timing was begun. 
W hen a medium yellow colour had developed, the reaction was stopped by adding 
0.5 ml 1 M  Na2C0 3  and the time was noted. (For accuracy, the OD420 should be 0.3 
to 0.7) Cells were centrifuged for 5 mins. at 2500 rpm in a tabletop centrifuge. OD42o 
and OD550 of each supernatant were determined (if the cell-debris has been well 
pelleted, the OD550 - which measures light scattering by cell debris - is usually zero 
and therefore is not necessary to read). Units of activity were calculated using the 
following equation:
U = 1000 X  {OD49D (1.75 X ODssn)!
(t) X (v) X ( O D 6oo) 
where t = time of reaction (min)
v = volume of culture used in assay (ml)
O D 6oo = cell density at the start of the assay 
OD420 = combination of absorbance by o-nitrophenol 
and light scattering by cell debris.
O D 550 = light scattering by cell debris.
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2 . 8 . 4  T r a n s f o r m a t i o n  o f  l i b r a r y  f o r  i n t e r a c t o r  h u n t  ( Y T H S - B )
2.8.4.1 Library transformation (YTHS-B)
The eDNA library in pACT was transformed into yeast strain Y187 using a high 
efficiency protocol (modified from Gietz e t a l , 1992). Transformation was carried 
out by adapting the basic protocol according to section 2.8.1 to large-scale cultures. 
In the case of sequential transformation of bait and library DNA, the transformants 
can be grown in selective media or in YPD before the second transformation; the 
cells loose plasmids at a low rate such that selective pressure is not absolutely 
required at this step. M aintaining transformed cells in selective minimal media gave 
poor growth rate in bulk (400 ml) cultures. Use of YPD complete media speeds up 
growth, but resulted in loss o f bait plasmid unless cells were first maintained for a 
day or so in selective broth in a smaller culture (50 ml). Also high quality carrier 
DNA was found to be critical. Sheared salmon sperm DNA (sssDNA) was prepared 
using the optimised protocol below (Gietz e t a l , 1992) as good quality is especially 
important for transformation of library DNA. The sssDNA quality was assessed by 
agarose gel electrophoresis on a 0.6% gel, which should give a smear of DNA 
ranging 2-15 kb, with an average size of about 7 kb. Oversonication leading to an 
average size of about 2 kb will usually cause a reduction in transformation 
efficiency. In addition, 10% DMSO has been found to increase efficiencies by 3-5 
fold. It is important that LiAc and PEG solutions are freshly prepared. Also heat 
shock should be timed to precisely 15 min.
2.8.4.2 Preparation of carrier DNA
Salmon sperm DNA (Sigma grade III sodium salt) was dissolved in T.E buffer pH
7.5 at a concentration of 10 mg/ml by stirring at room temperature overnight. The 
DNA was sheared by sonicating at 75 % power for 2 x 30 s pulses and aliquoted into 
0.5 ml volumes in eppendorfs. Sheared salmon sperm DNA (sssDNA) was then 
extracted with an equal volum e of phenol followed by phenol/chloroform extraction 
and finally extracted with chloroform as described previously in DNA preparation 
methods. The DNA was then precipitated by adding one tenth volume 3 M sodium 
acetate and 2.5 volumes 100 % ethanol. Tubes were mixed by inversion and spun
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immediately at 12000 x g for 15 min. The DNA pellets were then washed in 70% 
ethanol, dried briefly at room temperature and resuspended in sterile T.E. pH 7.5 at 
5-10 mg/ml. SssDNA was denatured by boiling for 20 min and stored at -2 0  °C. 
D irectly before use sssDNA was reboiled for 5-10 min then chilled on ice.
2.8.5 Harvesting transformants
Plates were placed at 4°C for about 4 h  to harden the agar. Approximately 3 ml TE 
buffer (pH 8.0) was added to each plate and left for 1-2 min. Colonies were collected 
by careful scraping and gentle pipetting as it was important to avoid scraping any 
agar. Cells were washed twice with 3 volumes of TE buffer by pelleting each time at 
2000 x g for 5 min in 20 ml sterile universal containers. The pellet was resuspended 
in glycerol solution to give a final volume of 2 ml. Solutions were then mixed by 
vortexing at low speed and frozen at -80°C in 1 ml aliquots.
2.8.6 Determination of plating efficiency
An aliquot of library transformants was thawed and 100 |il was diluted to l ml in 
YNB G/R -U-H-T+L broth. Cells were then incubated at 30°C with shaking to 
induce the GAL1 promoter on the library. Normally, there is almost no increase in 
cell number during this time and any increase can be neglected when calculating the 
number o f CFUs or transformants to plate onto Leu- selection plates. Serial dilutions 
were then prepared using the same broth and 100 |xl o f each dilution was spread on 
YNB G/R -U-H-T+L plates and incubated for 4 days at 30°C. Colonies were counted 
and used to estimate plating efficiency in colony forming units (CFUs) per unit 
volume of frozen cells. This should be in the order of 108CFUs/100 jlxI.
2.8.7 Selection of interactors
Synthesis of activation-tagged cDNA-encoded proteins was induced by thawing an 
aliquot o f stored transformants and diluting 10-fold in YNB G/R-U-H-T+L broth. 
Cultures were incubated with shaking for 4 h to induce the GAL12 promoter. 
Cultures were incubated with shaking for 4 h to induce the GAL1 promoter. Cells
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were pelleted at 3000 x g for 4 min and resuspended in sterile distilled water. 
Cultures were plated onto YNB G/R -U-H-T-L using 106 CFUs (determined from 
plating efficiency) per 100 mm plate. Plates were incubated at 30°C for 2-5 days, as 
some putative interactors appear sooner than others.
2.8.8 DNA isolation for recovering plasmids from yeast cells
A 2 ml culture of yeast carrying the plasmid of interest was grown in selective 
medium (YNB-L) to stationary phase (about 3 days). A 1.5 ml aliquot of culture was 
transferred to an eppendorf and centrifuged for 30 s at 4000 x g, washed in 200 jj,1 
sterile distilled water at room  temperature and cells were again pelleted at 4000 x g. 
Supernatant was then aspirated off and cells were resuspended in 200 |il breaking 
buffer by pipetting up and down. A volume of acid-washed glass beads equivalent to 
about 200 fil was added, followed by 200 ul of phenol/chloroform/i soamylalcohol at 
a ratio of 25:24:1. Eppendorfs were vortexed at maximum for 2 min and then spun at 
10,000 x g for 5 min at room  temperature. Supernatant was removed and 2.5 volumes 
ethanol was added, mixed and incubated on ice for 10 min (or -20°C  for 1 h). 
Supernatant was again removed and the pellet was washed with 200 |Lil 70% ethanol. 
After air-drying for about 15 min at room temperature, the pellet was resuspended in 
5 fil sterile distilled water.
2.8.9 Preparation of yeast protein lysates for SDS-PAGE
Using colonies from the transactivation assay transformations, overnight cultures of 
the 4 baits were prepared by inoculating in 2 ml. YNB liquid medium containing Glu 
-U-H+T+L and incubating at 30°C with shaking. Controls were similarly prepared as 
follows: EGY48 in 2 mis. YPD (negative control)
pEG202 in 2 mis. YNB/Glu +U-H+T+L (positive control)
Cultures were diluted 1 in 2 by adding 2 ml. YPD and grown for 2 - 3 hours at 30°C 
with shaking to an OD 600 of approx. 0.5. One mililitre of each culture was 
centrifuged at 4000 x g for 15 min and each pellet was resuspended in 2X FSB and 
frozen at -70°C  for a minimum of 15 min. Just before loading, samples were boiled
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for 5 min, spun at 12000 x g for 30 s and 20 fxl of supernatant was used to load the
2.8.10 Western immunoblotting
SDS PAGE and immunoblotting was performed according to standard methods 
section 2.5.2-2.5.4 using 10% acrylamide minigels.
YTHS-A: Proteins were transferred to PVDF membranes by either semi-dry or wet- 
blot techniques. Proteins were transferred to PVDF membrabes (as recommended). 
LexA-EBNA-3B fusion proteins were detected by incubation with anti-LexA 
(1:1000) overnight at 4°C with secondary antibody, Protein A peroxidase (1:1000), 
incubation period of 1 h at room  temperature with shaking. Detection of proteins was 
performed using an ECL detection reagent (Amersham).
Y TH S-B: Nitrocellulose membranes were used in association with anti-HA primary 
antibody (BM). An anti-mouse alkaline phosphatase conjugate (Promega) was used 
as secondary antibody, thus expression was detected using BCIP/NBT substrate.
2.8.11 Dot blotting (YTHS-A)
A total of 5 (il o f each bait sample or control was gradually dotted using a capillary 
tube, onto PVDF membranes, allowing sample to dry between each 1 |il application. 
Detection was as per W estern immunoblot detection procedure using BM 
Chemiluminescence Blotting Substrate (POD). Yeast strain EGY48 was included as 
negative control while EGY48 containing pSH18-34/pSH17-4 served as a positive 
control expressing LexA.
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CHAPTER 3
REGULATION OF CELL CYCLE-ASSOCIATED 
GENES BY LMP1
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3.1 IN T R O D U C T IO N
This study set out to investigate aspects of cell cycle regulation mediated by EBV. To 
this end, the levels of mRNA of a range of cell cycle-related genes were examined by 
RPA in a selection of latency group I and group III cells as well as LCL cell lines. It is 
now generally accepted that the EBV latent gene products are responsible for the 
activation of the resting B cell and the induction of continuous proliferation. As LMP1 is 
a key effector of EBV-mediated transformation of B cells, the contribution of this 
oncoprotein to EBV-mediated deregulation of the cell cycle (in the absence of other 
latent viral proteins) was investigated, based on findings of the preliminary RPA 
experiments using a range of EBV-related cell lines.
3.1.1 T he  Cell Cycle
The cell cycle is a collection of highly ordered processes that result in the duplication of 
a cell. A critical feature of the cell cycle is that it precisely duplicates the cell, and this 
requires that cell cycle events be executed in proper sequence. Sophisticated cell control 
mechanisms must ensure that each round of DNA replication (S phase) is followed by 
cell division (mitosis/M phase) and that one phase should not follow until the other has 
been successfully completed. The cell cycle can conveniently be divided into four 
phases. Chromosome duplication occurs during S phase and chromosome segregation 
plus cytokinesis during M phase. A Gj phase intervenes between M and S, while a G2 
phase separates S from M (Figure 4.1). The pathways that render one cell cycle event 
dependent upon the completion of another are called checkpoints. Checkpoints can be 
thought of as the set of intracellular conditions that must be satisfied for cell cycle 
progression to continue, and thus maintain the order and timing of cell cycle events. 
Checkpoints also monitor the integrity of DNA and mediate cell cycle arrest and repair 
processes in response to DNA damage (reviewed by Elledge, 1996; Weinert and Lydall, 
1993; Murray and Hunt, 1993; Pines 1992; Coats and Roberts, 1996).
We now know that much of the regulation of the cell cycle in eukaryotes is conserved 
throughout evolution and in recent years a great deal of research interest has resulted in
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significant advances in our understanding of these very sensitive and sophisticated 
control mechanisms. In particular, research interests are aimed at understanding the 
breakdown of these controls, which can result in a variety of pathological consequences, 
including tumorigenesis. Oncogenic processes exert their greatest effect by targeting 
particular regulators of G t phase progression (reviewed by Harper and Elledge, 1992; 
Weinert and Lydall, 1993; Hunter and Pines, 1994). During the Gi phase, cells respond 
to extracellular signals by either advancing toward another cell division or withdrawing 
from the cycle into a resting state (Go). Thus, interference with control mechanisms at 
cell cycle checkpoints can lead to uncontrolled proliferation of cells.
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3.1.2 C yclin /cdk  com plexes
Central to cell cycle regulation are a set of serine/threonine protein kinases that are 
activated only when bound by a cyclin partner i.e. cyclin-dependent kinases (cdks / 
catalytic subunits) bind to cyclins (regulatory subunits) to form active cyclin-cdk 
complexes. Nine different cyclins have been identified to date and are designated A 
through I (For reviews, see Sherr, 1993; Pines, 1993). The asssociation of cdks 1 to 7 
with particular cyclins are precisely-timed events in the cell cycle. Cyclin-cdk 
complexes form holoenzymes that phosphorylate the Retinoblastoma-family proteins 
(pRb, p i07, pl30). Phosphorylation results in inactivation of Rb proteins which have a 
central role in negative regulation of the cell cycle. The transcription factors E2F (1-4) 
and DP 1 ( I and 2) which drive the DNA replication machinery are negatively regulated 
by direct interaction with pRb, p i07 and p i30. In this way, cdks drive cell cycle 
progression by removing the inhibitory effect of Rb proteins. The main cyclin/cdk 
complexes formed in vertebrate cells are cyclin D-cdk4 (Go/G|), cyclin E/cdk2 (G |/S), 
cyclin A7cdk2 (S) and cyclin Bl-cdkl (G 2/M ) (reviewed by Pines, 1994). Specific 
substrates for cyclin-cdk complexes include nuclear lamins, histones, oncogenes (e.g. c- 
abl and SV40 large T antigen), tumour suppressor genes (eg. retinoblastoma protein, 
Rb), nucleolin and others. The activated cdk can be inactivated through several 
pathways eg. levels of cyclins are regulated at the level of transcription as well as by 
targeted degradation via the ubiquitin pathway. Cdk activity is further regulated by 
activating or inhibiting phosphorylation, and by small proteins known as the cdk 
inhibitors or the CKIs (Xiong et al, 1993; Harper et al, 1993; El-Deiry, 1993).
3.1.3 C yclin -dependen t k inase  in h ib ito rs  (CK Is)
Recent evidence suggests that regulated inhibition of the cdks is central to cellular 
responses such as differentiation, senescence, DNA damage and perhaps even apoptosis 
(Elledge et al, 1996; Grana and Reddy, 1995; Sherr, 1996). A group of small proteins
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known as the cyclin-dependent kinase inhibitors (CKIs) are central to this regulation 
process. CKIs bind to cyclins, cdks or their complexes, thus inhibiting their activity at 
precisely-timed points in the cell cycle. When cells are exposed to external insults, such 
as DNA-damaging agents, negative regulation of the cell cycle occurs; CDK activities 
are inhibited by CKIs and the cell cycle is arrested in either G| or G2 phase, thus 
preventing cells from prematurely entering into the next stage of the cell cycle before 
their DNA is repaired.
Mammalian cells possess two classes of CKIs which differ in structure, mechanism of 
inhibition and specificity (reviewed in Harper and Elledge, 1996; Sherr and Roberts, 
1995; Xiong, 1996). The p21 or INK family of inhibitors consisting of p21 (CIP1, 
WAF1, SDI1, MDA-6, PIC1), p27 (KIP1) and p57 (KIP2) are general inhibitors of the 
G1S Cdks. Homology between family members is limited to a conserved amino- 
terminal 60 residue domain responsible for kinase binding and inhibition. p27 mediates 
growth arrest induced by transforming growth factor beta (TGF(3), contact inhibition or 
serum deprivation and is thought to play a critical role in negative regulation of cell 
division in vivo (Sherr, 1996). Recently, high level expression of p27 from adenovirus 
(Ad) vectors has been shown to induce apoptosis in tumour cell lines (Wang et al, 1997). 
The second class of CKIs, the INK4 (inhibitor of cdk4) family are specific inhibitors of 
cyclin Dl/cdk4 or cdk6 complexes. This family of ankyrin-repeat proteins includes pl6  
(INK4a), p i5 (INK4b), p i 8 (INK4c) and p i 9 (INK4d). CKIs vary in their ability to 
promote or protect against cell death i.e. while p i6, p i8 and p27 appear to be most 
effective at inducing cell death, p21 and p 19 promote cell suvival (Schreiber et al, 
1999).
It is not yet fully understood why there are so many CKIs and what specific roles the 
individual CKIs have in cell cycle regulation, differentiation and tumorigenicity but 
currently this is an area of active study. Mutations within the p 16 gene and loss of p i 6 
expression are frequent events observed in both tumour cell lines and in various 
carcinomas (Sherr, 1996). The p i 8 and p 19 CKIs have not, as yet, been as well 
characterised. Both are frequently expressed in cells of the myeloid lineage (Schwaller et
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al, 1997) and p i8 is thought to play a pivotal role in terminal differentiation of late- 
stage B cells to plasma cells (Morse et al, 1997).
3.1.4 p21 /W A F l cdk  inh ib ito r.
p21 was the first of the CKIs to be identified (Harper et al, 1993; Xiong, 1993: El-Deiry, 
1993) and has since been found to share homology with p27 and p57 which together 
form a family of universal inhibitors of the G[S cdks. p21 was originally documented as 
an inhibitor of cdk2, cdk4 and cdc2 (cdkl) kinase complexes (Gu et al, 1993; Harper et 
al, 1993; Xiong et al, 1993). More recently it was shown that p21 can also inhibit cdk3 
and cdk6 kinases and that p21 is most effective towards G| cyclins (Harper et al, 1995). 
Indeed when overexpressed in transiently transfected cells, p21 can cause cell cycle 
arrest in a variety of cell lines (Guan et al, 1994; Harper et al, 1995; Medema et al, 
1995), suggesting that it can interfere with cyclin-dependent activity in intact cells. p21 
has also been implicated as an effector of the TGF(3 growth inhibitory signalling 
pathway (Datto et al, 1995). This 21 kDa nuclear protein is a dual specificity inhibitor in 
that it not only binds to cdks but also associates with the DNA replication factor, PCNA 
via the former’s unique carboxy-terminal domain (Warbrick et al, 1995). PCNA 
functions in both DNA replication and repair as a subunit of DNA polymerase delta. 
p21 therefore can directly inhibit DNA replication in the absence of cyclin-cdk 
complexes (Waga et al, 1994) and overexpression of this interaction domain in 
mammalian cells has been reported to reduce the fraction of cells found in the S phase 
cells (Luo et al, 1995). Strikingly, whereas in normal cells most of the cdk-cyclin 
complexes are found associated with p21 (and PCNA), this association is absent in most 
transformed cells (Xiong et al, 1993). An unusual feature of p21 function is that multiple 
inhibitor molecules are required for cdk inhibition, such that complexes containing a 
single inhibitor molecule are catalytically active, whereas those containing multiple p21 
subunits are not. Changes in the stoichiometry of p21 appear to be sufficient to account 
for the conversion (Zhang et al, 1994).
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The p21 gene contains binding sites for the p53 tumour suppressor protein in its 
promoter and studies have shown that the transcription of p21 can be directly regulated 
by p53 (Lee et al, 1995; Haendler et al, 1987). p53-mediated growth arrest as a result of 
genotoxic damage appears to be mediated at least in part by induction of p21 (El-Deiry 
et al, 1993; Dulic et al, 1994). Indeed. p21 has been defined as a cardinal mediator of 
p53-induced G| checkpoint control. Other reports have shown that p21 can be induced 
by p53-independent mechanisms (Michieli et al, 1994; Sheikh et al, 1994). For example, 
in cellular differentiation, p53-independent induction of p21 has been observed as an 
immediate early response to a variety of physiological and chemical stimuli. Various 
researchers have reported that p21 expression has a protective effect against apoptosis 
induced by p53 as well as other agents (Gorospe et al, 1997; Lu et a l, 1998). However, 
despite extensive searches, very few tumours have been shown to have mutations in 
their p21 genes (Harper and Elledge, 1996) and p21-null mice appear to develop 
normally and show no increased incidence of neoplasia (Deng et al, 1995).
3.1.5 p53 and  p R b  tu m o u r sup resso r genes
The fundamental importance of p53 as a tumour suppressor is underscored by the 
statistic that at least one in six of the population will develop cancer due to defective p53 
function. p53 is a 53 kD nuclear multifunctional phosphoprotein which guards the 
stability of the genome by inhibiting cell proliferation when DNA damage occurs 
(Canman and Kastan, 1995). One way the p53 protein acts is by behaving as a 
transcription factor to upregulate specific target genes, which ultimately results in either 
cell growth arrest or apoptosis. These genes include mdm2 (which negatively controls 
p53 expression), GADD45 (involved in DNA replication), the pro-apoptotic bax gene 
and p21 which inhibits kinases responsible for G r S transition, thus arresting the cell 
cycle at the G| phase (reviewed by Milner. 1996). Wild type p53 protein has a very short 
half life and is usually not detectable with monoclonal antibodies in normal tissues. 
Mutant p53 proteins typically have an increased half-life, accumulate to high levels, and 
are detectable with mAbs. Mutations in the p53 gene have been detected in a wide 
variety of cancers (Levine et al, 1993), the majority of which inactivate the tumour
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suppressing function of the protein (loss of function mutants), while others confer 
transforming activity (oncogenic mutants) (Dittmer et al, 1993). Elevated expression of 
p53 is a frequent finding in different tumour types (including Burkitt’s Lymphoma), 
indicating that at least in some tumours, in addition to mutation of the p53 gene, high 
levels of mutant protein are required for malignant transformation in vivo (Farrell et al,
1991).
Deregulation of pRb function(s) is a fundamental characteristic of tumorigenesis 
(reviewed by Mulligan and Jacks, 1998). The three known members of the Rb family of 
proteins, in their activated state, associate with and modulate the activity of several cell 
transcription factors, including the E2F and DP gene families. In this way, by inhibiting 
transcription of genes required for DNA replication, Rb proteins act to block Gl/S 
progression in normal cells. Thus, interference with this fundamental control mechanism 
can result in uncontrolled proliferation of cells. While pRb has a well-established role in 
tumour suppression (Rb-/- mouse embryos die within 1 3 —15 days of gestation), the 
activities of pl07 and pl30 in tumour suppression remain unclear. Interbreeding studies 
using mutant mouse strains have revealed significant functional overlap within the Rb 
gene family although distinct in vivo functions are also indicated, which are only 
recently beginning to emerge (reviewed by Mulligan and Jacks, 1998). In lymphocytes, 
p 107 fully compensates for p 130 deficiency, and the absence of both might lead to 
compensation by pRb and other as yet unidentified protein(s). Thus, despite their 
diversification and specialisation, currently available in vivo assays suggest that the pRb 
family of proteins act in a coordinated fashion to regulate at least some cellular functions 
(reviewed by Stiegler et al, 1998; Grana et al, 1998).
3.1.6 E p ste in -B arr v iru s , tum origenesis an d  the cell cycle
Increasing evidence suggests a critical role for mammalian cell cycle regulatory proteins 
in tumorigenesis. Progression through the mammalian cell cycle is controlled by the 
regulatory interplay between distinct positive and negative regulators (reviewed by 
Coats and Roberts, 1996, Murray and Hunt, 1993). This passage through the individual
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phases of the cell cycle is affected by viral oncoproteins which can provide their host 
cells with additional growth stimuli, thereby extending their proliferative capacity. 
Virally transformed cells fail to cease proliferation in response to many growth- 
suppressing signals, implying that major cell cycle controls are lost in such cells.
In recent years, striking parallels have emerged in the strategies used by small DNA 
tumour viruses to transform cells. Two cellular pathways are disrupted by oncoproteins 
of Adenovirus, SV40 and the oncogenic strains of the human papilloma virus (HPV), 
involving interference with the p53 and pRb pathways. The discovery that the p53 
dependent pathway is functional in EBV-immortalised cell lines (Allday et al, 1995) 
demonstrated that one ami of this common transformation strategy is not required by 
EBV to immortalise primary B lymphocytes, suggesting that EBV may differ 
significantly from the small DNA tumour viruses in this regard. Many aspects of EB V- 
mediated immortalisation resemble the normal programme of B lymphocyte activation, 
suggesting that EBV achieves the immortalisation of B lymphocytes by substituting for 
the stimuli these cells normally require for proliferation. EBV induces the same cell 
cycle regulating proteins as polyclonal stimuli in primary B cells, bypassing the 
requirement for antigen, T cells and growth factors (Kempkes et at, 1995). One model 
suggests that one component of EBV-dnven cell proliferation involves the modulation 
of the activity of pRb and p i07 (and potentially other substrates), following the 
activation of a normal cellular phosphorylation pathway. It is significant that pRb is not 
however functionally inactivated as a result of immortalisation by EBV as indicated by 
the absence of a rise in p i6 levels which is normally subject to negative regulation by 
pRb (Cannell et al, 1996). Thus, it appears that EBV is able to immortalise primary B 
lymphocytes without functionally inactivating either p53 or pRb.
Mutations and elevated expression of the p53 tumour suppressor gene are two of the 
factors that can play a role in malignant transformation or tumour cell growth of 
Burkitt’s Lymphoma. BL cells with p53 lesions have been shown to be relatively 
resistant to DNA-damaging drugs when compared to LCLs which induce 
transcriptionally active p53 as part of a pro-apoptotic response. Allday et al (1995)
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found that BL cells remain relatively viable when challenged with drugs such as 
cisplatin. Mutations in p53 have been found in approximately 33% of BL biopsies and in 
at least 63% of BL cells lines. In 65% of BL cell lines studied the wild type allele is lost 
and the cells express the mutant p53 allele at elevated levels. In general, single 
nucleotide substitutions which result in amino acid changes are found. In these studies, 
no EBV protein was found to be associated with p53 and no correlation has been found 
between EBV status and p53 mutation status in BLs. Various different mutants of p53 
have been observed to lose the suppressor function, to gain a dominant transforming 
activity or to be unaffected. In any case, in addition to mutation of p53, it appears that 
elevated levels of mutant p53 protein are required for transformation (Farrell et al, 1991; 
Balint and Reisman, 1996)
EBV efficiently converts resting human B cells into immortalised cell lines, referred to 
as lymphoblastoid cell lines (LCLs), in which the normal mechanisms that control cell 
cycle and apoptosis are permanently dysregulated. At least six viral genes are essential 
for growth transformation of resting B cells: the nuclear proteins EBNA-1, -2, -3 A, -3C 
and EBNA-LP and the latent membrane protein, LMP1 (reviewed by Farrell, 1995) 
suggesting that a complex series of events are needed to override normal growth 
controls. Upon infection of resting B cells with EBV, cells enter the cell cycle, with 
DNA synthesis beginning at approximately 48 hours, accompanied by increased 
expression of cyclin E and PCNA, two established markers of Gi/S progression. These 
events are preceeded, however, by the expression of cyclin D2, which to date is the 
earliest cellular gene known to be activated by EBV infection. Cyclin D2 is normally 
undetectable in primary B cells. Expression of EBNA2 and EBNA-LP has been shown 
to be sufficient to induce cyclin D2 expression, thus cooperating to cause Go to G| 
transition during B cell immortalisation (Sinclair et al, 1994; reviewed by Farrell, P. 
1995). Using quantitative RNAse protection assays, cyclin D2 mRNA was shown to be 
increased at least 100-fold as a result of infection of primary B cells with EBV. Similar 
fold increases were seen in cdkl, cyclin E and CD23 using RT-PCR, while B-myb and c- 
myc mRNA were upregulated by at least 10-fold in LCLs (Sinclair et al, 1994).
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One study found that pRb, p i30 and p i07 were readily detectable by Western blot 
analysis of total protein lysates isolated from quiescent primary B lymphocytes. 
Following EBV-mediated immortalisation of these cells, the relative level of p i30 
protein was found to decrease, while in contrast, levels of p i07 and pRb appeared to 
increase (Cannel et al, 1996). The apparent contradiction of an increase in negative 
regulators of the cell cycle may be explained by a decrease in the mobility of both pi 07 
and pRb, which is characteristic of their hyperphosphorylation and inactivation. The 
changed mobility of pRb is an early event during immortalisation and is readily 
detectable by 52 hours post-infection.
EBNA2, one of the first genes expressed after EBV infection of B cells (Allday et al, 
1989), is a transcriptional activator of viral and cellular genes and is central to the 
transformation potential of the virus. Using recombinant EBV in which the expression of 
functional EBNA2 is dependent upon the addition of oestrogen, it has been shown that 
EBNA2 does not perturb the physiological order of cell cycle progression but rather 
induces B cell activation and entry into the cell cycle by inducing and maintaining the 
expression of early Gi regulating proteins, such as cyclin D2, cyclin E and cdk4, while 
cdc2 (cdkl) and cdk2 are constitutively expressed (Kempkes et al, 1995). Shortly after 
upregulation of cyclin D2, there is a significant shift of Rb to the hyperphosphorylated 
state. E2F1, a transcriptional activator of genes involved in DNA synthesis (which is 
maintained inactive by binding to the hypophosphorylated form of Rb) becomes 
detectable concomitantly with the modification of Rb. Expression of LMP1 and c-Myc 
preceed accumulation of E2F-1, suggesting that E2F-1 is not involved in transcriptional 
activation of c-myc after reactivation of EBNA2, but other members of the E2F family 
may be involved as the c-myc gene contains an E2F site in front of it’s second promoter. 
In the absence of EBNA2 about half of the cells enter a quiescent, non-proliferative 
state whereas the others die by apoptosis, following transformation of primary B cells 
with this mutant virus. Growth arrest occurrs at G| and G? stages of the cell cycle and a 
role in terminating S phase can not be excluded, indicating that functional EBNA2 is 
required at different restriction points of the cell cycle. Since EBNA2 is a pleiotropic 
activator of the other EBNAs and the LMPs, many of the cellular events observed upon
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EBNA2 activation here may be due to activation of viral genes downstream of EBNA2, 
in particular LMP1 which has the most profound effects on cell growth.
3.1.7 Effects of LMP1 on aspects of the cell cycle.
The EBV-encoded LMP1 protein plays an important role in the immortalisation of B 
cells infected with EBV. Expression of exogenous LMP1 in EBV-negative BL cells has 
been associated with an increased resistance to apoptosis induced by serum starvation 
(Henderson et a l , 1991), an effect which has been attributed to upregulation of the level 
of Bcl-2 protein. The oncogenic activity of Bcl-2 appears to result from its ability to 
promote cell survival rather than cell proliferation. Another protein which may play a 
role in the LM Pl-mediated pro-survival effect is A20, a zinc-finger protein that confers 
resistance to T N Fa cytotoxicity (Henderson et a l , 1991; Rowe e t a l , 1994; Laherty et a l ,
1992). It has been shown that LMP1 blocks WT p53-triggered apoptosis, but has no 
effect on G| cell cycle arrest induced by WT p53. p21 is probably an important 
downstream effector of p53-induced cell cycle arrest and/or apoptosis. Recent data 
clearly show that LMP1 does not interfere with p53-mediated induction of p21. WTp53 
also induces expression of the pro-apoptotic gene, b a x . As the ratio between bax and 
bcl-2 determines whether a cell will enter apoptosis or survive after receiving an 
apoptotic signal, it is thought that LMP1 may block p53-induced apoptosis by 
upregulating bcl-2 and thereby counteracting the apoptosis-promoting effect of bax 
(Okan et a l , 1995). Arvanitakis e t a l (1995) have shown that the presence of WT EBV or 
LMP1 results in the loss of TGF[3-mediated growth inhibition in human B cells. In their 
study, LMP1 induced the expression of cyclin D2 (normal B cells or EBV-negative BL 
cells do not express D-type cyclins), thus maintaining pRb in the hyperphosphorylated 
(non-functional) form and allowing the cell to proceed through the cell cycle regardless 
of the presence of TGFp. A study which employed tetracycline-regulated expression of 
LMP1 found that LMP1 had a cytostatic effect in the EBV-negative BL cell lines, DG75 
and BJAB and the EBV-positive Akata cell line (Floettmann e t a l , 1996). The cytostatic 
effect was shown to be due to an accumulation of cells at the G2/M phase of the cell 
cycle, suggesting a novel function for LMP1 in controlling the proliferation of EBV-
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infected cells by regulating progress through G2/M. These data did not necessarily 
contradict a previous report which found that LMP1 induces a Gi to S transition (Peng 
and Lundgren, 1992) as DNA synthesis (S phase) may continually be stimulated in 
cycling LMPl-positive cells (Wang et al, 1988).
3.1.8 Tetracycline-regulated gene expression
In order to study the effects of LMP1 expression, an established tetracycline-regulated 
inducible expression system was employed. For comparison, expression of EBNA2 (also 
a main effector of EBV-mediated phenotypic change) was induced in a similar manner 
and included in initial experiments. The tetracycline regulated system used by 
Floettmann et al., (1996) is based on that developed by Gossen and Bujard (1992), in 
which the gene of interest is cloned downstream of a promoter containing binding sites 
for the hybrid tetracycline-regulated transactivator (tTA). The plasmid tTA encodes a 
fusion protein of the sequence- specific DNA binding tetracycline repressor (TetR) and 
the C-terminal domain of the herpes simplex virus VP16 transactivator. A second 
plasmid contains the gene of interest cloned downstream of seven copies of the 
Escherichia coli TnlO tetracycline operator (tetO) contiguous with a CMV-IE minimal 
promoter. When tetracycline is present, it binds to the tTA preventing it binding to the 
promoter. Upon removal of tetracycline the hybrid TetR binds to the tetO site 
positioning the VP 16 domain so that it can transactivate the CMV-IE promoter (Gossen 
and Bujard, 1992).
Stable cell lines containing plasmids in which EBNA2 and LMP1 expression was 
regulated by tetracycline were generated by Floettmann et al., (1996) as follows: The 
tTA expressing plasmid pUHD15-l was modified by the addition of a hygromycin 
resistance gene under the control of an SV40 promoter creating the drug-selectable tTA- 
expressing vector pJEF-3. A neomycin resistance gene under the control of an SV40 
promoter was cloned upstream of the tTA responsive promoter of pUHD10-3 to create 
the responsive vector pJEF-4. The EBNA 2 coding with a 5’ rabbit /3-globin intron was
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cloned into pJEF-4 to produce pJEF-31 (Figure 3.1). The LMP1 cDNA was inserted 
into pJEF-4 to produce pJEF-6. pJEF-3 was then transfected into DG75 to give the 
stable cell line DG75 tTA, which was then transfected with pJEF-31 producing the cell 
line DG75 tTA EBNA2 or pJEF-6 giving the cell line DG75 tTA LMP1 (Floettmann et 
a l . , 1996). This system allowed examination of either EBNA 2 or LMP1 in the same 
cell background before and after induction of the EBV protein thus eliminating clonal 
variations which may occur between cell lines.
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T e t r a c y c l i n e  r e g u l a t e d  c e l l  l i n e s  DG75 tT A  EBNA2/DG75 tT A  LMP1
The host cell line DG75 is stably transfected with two plasmids pJEF-3 and pJEF-31 or pJEF-6 which are 
selected during cell culture using the drugs Hygromycin and G418 respectively.
A tetracycline regulated 
transactivator (tTA) 
constitutively expressec 
n.TRF3
Tel
□
tTA tTA+Tet=Inactive
1  Removal of Tet=active tTA
Active tTA binds to a 5' regulatory region conatining a minimal 
promoter resulting in expression of EBNA2 or LMP1
O R
LiMPl
EBNA2
Figure 3.2 A schematic representation of the tetracycline-regulated gene expression system. The
example given shows regulation of expression of LMP1 and EBNA2 in DG75tTA-EBNA2 and 
DG75tTA-LMPl cells, respectively.
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3 . 2  R E S U L T S
This study set out to investigate EBV-associated changes to the expression of a panel of 
cell cycle-related genes in BL cells. In a preliminary experiment using two established 
isogenic EBV-positive BL cell lines, group I MUTU-BL and group III MUTU-BL, 
mRNA levels transcribed from the R b , p l 3 0 , p l 0 7 ,  p 5 3 , p 5 7 , p 2 7 , p 2 1 ,  p l 9 ,  p l 8 ,  p l 6  
and p l 4 / p l 5  genes were compared using multiprobe ribonuclease protection assay 
(RPA; HCC-2 kit, Pharmingen). This approach permitted the simultaneous detection and 
quantitation of these mRNAs in a single sample and also enabled direct comparative 
analysis of RNA from these two cell lines by the inclusion of probes for transcripts from 
the two housekeeping genes G A P D H  and L 3 2  (Figure 3.3). Group I BL cells (type 1 
latency) express EBNA1 as sole viral protein; when serially passaged in vitro, they 
‘drift’ to express all the known latency-associated viral proteins (including LMP1), 
when they become known as group III BL cells (type III latency). Group III BL cells 
have acquired many of the phenotypic characteristics of an immortalised LCL (Gregory 
et a l , 1990). It can be seen from this experiment that significantly elevated steady state 
levels of p 2 1  mRNA were present in MUTU-III relative to MUTU-I cells. In each case 
p 2 1  bands were quantitated by densitometric scanning using two different exposure 
times. G A P D H  and L 3 2  mRNA levels were similarly assessed to allow for differences in 
the amounts of total RNA analysed. The results showed a > 10-fold higher level of p 2 1  
mRNA in MUTU-III versus MUTU-I. The exact level of upregulation was difficult to 
establish accurately due to the very low levels of p 2 1  mRNA transcript in MUTU-I cells. 
In order to investigate if upregulated p 2 1  expression was a general feature of EBV- 
infected cells, p 2 1  mRNA levels from the EBV-negative cell line, BL41, were compared 
to those in it’s EBV-superinfected derivative, BL41-B95-8, and to a spontaneous EBV- 
transformed normal LCL (IARC171), which is derived from the same patient as BL41. 
Barely detectable levels of p 2 1  mRNA were seen in BL41, which were significantly 
upregulated in BL41.B95.8 (Figure 3.3A). Although the level in BL41.B95.8 was 
significantly less than in MUTU-III, the fold upregulation was observed to be
3 . 2 . 1  m R N A  l e v e l s  o f  a  g r o u p  o f  c e l l - c y c l e  g e n e s  i n  v a r i o u s  E B V - r e l a t e d  c e l l  l i n e s .
108
approximately similar in the transition from MUTU-I to MUTU-III as that from BL41 to 
BL41.B95.8.
U 1 2 3 4 5
pl30
Rb
pl07
p53
 GAPDH
U Unprotected probe 
Lane 1 MUTU-I 
Lane 2 MUTU-III 
Lane 3 BL41 
Lane 4 BL41.B95.8 
Lane 5 IARC 171
F ig u re  3.3 EB V -associated m odu la tion  of th e  steady  sta te  levels of m R NA s from  cell cycle-related 
genes. (A) The steady state level of p21 mRNA is elevated in EBV-infected LMPI-expressing B cells. 
Expression of the cell cycle-related genes pl30, pRb, pl07, p53, p57, p27, p21, p l9, p!8, p l6  and pl4/15  
in a range of EBV-related cell lines as detected by mutiprobe RPA. Unprotected riboprobes (lane U) are 
shown linked to their smaller RNAse-protected fragments which correspond to protected portions of 
mRNA in each sample. Details of cell lines in each lane are given next to each autoradiogram image.
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Furthermore, the transition from group IBL74 BL cells to its spontaneously transformed 
LCL, IARC290B (derived from the same patient), showed a significant upregulation in 
levels of p21 mRNA. High levels of p21 mRNA were also observed in another Group III 
BL cell line, Ag876-III (Figure 3.3B), and two other LCLs, X50-7 and OKU-LCL (not 
shown), while EBV-negative DG75 cells showed much lower levels of p21 mRNA 
(Figure 3.3B).
(B)
t
I
p l3 0
pRb
pl07
p53
Lane 1. DG75
Lane 2. BL74
Lane 3. IARC 290B
Lane 4. IARC 171
Lane 5. A g876III
Lane 6. Mutu-HI
  p27
  p l9
  p l8
  pL6
p21
p 14/15
GAPDH
L32
F igu re  3.3 (B) as p e r  (A) Levels of mRNA transcripts from the pl30, pRb, pl07, p53, p57, p27, p21, pl9, 
pl8 , p l6  and p!4 /p l5  genes were compared in a range of EBV-related cell lines using total RNA in 
multiprobe RPA assays.
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An interesting observation was also the decreased levels of p l9  mRNA in MUTU-III 
and BL41.B95.8 cells relative to their latency type I counterparts, while LCLs showed 
very low levels of p i 9 mRNA. Transcript from the gene encoding the p i8 protein is 
barely detectable in the three LCLs and is undetectable in Ag876 Group III cells, an 
interesting observation in that it is also down-regulated in MUTU-BL upon drift to the 
group-III phenotype (Figure 3.3A). This does not however appear to be a general feature 
of EBV-positive BL cells exhibiting a group-III phenotype in that the level of p i 8 
mRNA is relatively unchanged in BL41.B95.8 versus BL41 cells. Additionally, although 
elevated levels of Rb and p27 mRNA and down-regulated levels of p i  10 are seen in 
MUTU-III relative to MUTU-I, these effects are also inconsistent in that they are not 
observed in the BL41/BL41.B95.8 pair. mRNA from the cdk inhibitor, p57, was not 
detected in any of the cell lines analysed.
Protein lysates harvested from the same cells as those used for RPA analysis as well as a 
number of other B cell lines were examined for p21 levels by Western blot analysis 
using a mouse monoclonal anti-p21 antibody (Santa Cruz SC6246) (Figure 3.4). These 
results showed that, in general, higher levels of p21 protein were observed in LCLs and 
Group III BL cells relative to Group I BL cells, in agreement with RPA data. The 
corresponding levels of LMP1 protein are also shown (Figure 3.4A, lower panel) for 
comparison. Overall, these results demonstrate that stably elevated levels of p21 mRNA 
and protein are a feature of EBV-infected B cells exhibiting type III latency. Due to the 
barely detectable levels of p21 mRNA/protein in MUTU-I and BL41 cells it was 
difficult to compare the fold increase in mRNA versus protein.
i l l
p21
(A )  1 2 3 4  5 6 (B) 1
LMP1
A
Figure 3.4 Western blot analysis of a range of EBV-related cell lines for p21 protein expression. (A)
and (B) Protein extracts were prepared from the same cells as those in Figure 1 RPA assay and analysed 
along with some additional cell lines. For (A), upper panel and (B), proteins were separated on 15% SDS- 
PAGE gels and p21 detection was performed using an ECL detection protocol. For (A) lower panel, a 
10% gel was used and LMP1 expression was assessed using an alkaline phosphatase conjugate.
(A) Upper and lower panels (B)
Lane 1: BL72III Lane 1: I ARC 290B
Lane 2: IARC307 Lane 2: MUTU-I
Lane 3: X50-7 Lane 3: MUTU-III
Lane 4: Ag876 III Lane 4: BL41
Lane 5: BL41.B95.8 Lane 5: BL41.B95.8
Lane 6: BL41 Lane 6: Ag876 IH
3,2.2 Tetracycline-regulatable induction of LMP1/EBNA2 expression.
As both LMP1 and EBNA2 are known to be main effectors of phenotypic change in 
EBV-infected cells, it was therefore of interest to investigate if the expression of either 
of these viral proteins alone could contribute to an upregulation of p21 levels. To this 
end, an established tightly-regulatable expression system was employed to induce LMP1 
in the EBV-negative BL cell lines, DG75tTA-LMPl and BJABtTA-LMPl. EBNA2 
expression was similarly induced in DG75tTA-EBNA2 cells. Briefly, the inducible 
promoter driving LMP1/EBNA2 expression contains binding sites for a hybrid 
tetracycline-regulated transactivator (tTA) that is constitutively expressed in the parental 
clone DG75-tTA and BJAB-tTA. Removal of tetracycline from the growth medium 
leads to tTA binding to the promoter and the expression of LMP1/EBNA2. Levels of 
induced LMP1 were monitored by Western blot analysis using the anti-LMPl murine 
monoclonal antibody cocktail CS.1-4 (Rowe et al, 1992), while EBNA2 was detected
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using the murine monoclonal antibody PE2 (Rowe et a l , 1992). In these experiments 
LMP1 was normally detectable in induced DG75tTA-LMPl cells by 18-24 hours, and 
remained detectable for up to at least 96 hours (Figure 3.5A). At 48 hours the level of 
LMP1 was comparable to that seen in the reference LCL, X50-7 (not shown). Levels of 
LMP1 were significantly higher in induced BJABtTA-LMPl cells (Figure 3.5B) relative 
to DG75tTA-LM Pl cells, a finding which has been observed previously (Floettmann et 
a l , 1996). EBNA2 was detectable in DG75tTA-EBNA2 cells by 24 hours and remained 
detectable up to at least 96 hours (Figure 3.5C). Total RNA and protein lysates were 
prepared simultaneously from cells harvested at the indicated time points and used as 
before in multiprobe RPA and Western blot analysis. In this way, RPA analysis 
permitted an investigation of the effects of LM Pl and EBNA2, when each was 
expressed as sole EBY protein, on levels of mRNA transcribed from the same group of 
cell cycle-related genes as outlined above.
(A)
M 0 6 18 24 48 72 96
■ LM Pl
(B) 0 24 32 48 72 96 (C) M 0 6 12 24 48 72 96
EBNA2
LMPl
83kD----
62kD----
47kD___
32kD
F ig u re  3.5 T etracycline-regu la tab le  induction  o f LM P1/EBN A 2 expression. Cells were induced to 
independently express LM Pl or EBNA2 by reculturing cells in the absence of tetracycline. Cells were 
harvested and protein extracts were prepared for Western blot analysis at the indicated time points (hours) 
post-induction. In both cases detection was based on alkaline phosphatase enzyme activity. (A) Induction 
of LM Pl expression in DG75tTA-LMPl cells. (B) Induction of LM Pl expression in BJABtTA-LMPl 
cells. (C) Induction of EBNA2 expression in DG75tTA-EBNA2 cells. Lane M represents protein 
molecular weight markers. Predicted sizes of marker proteins are indicated on the left side of Figure (C).
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3 . 2 . 3  L M P 1  u p r e g u l a t e s  p 2 1  e x p r e s s i o n  i n  D G 7 5  B L  c e l l s .
Levels o f mRNA transcripts from cell cycle-related genes were compared over a 96- 
hour time course following induction of LMP1 expression in the EBV-negative BL cell 
line, DG75tTA-LM Pl. An approximately 5 fold upregulation of p21 mRNA was 
observed, with a more subtle increase (about 2 fold) in p l9  mRNA levels. In uninduced 
DG75 cells, the p21 mRNA levels were very low or undetectable, a finding which is 
consistent with p21 levels observed in other EBV-negative BL cell lines (Okan el a l ,  
1995; Allday el a l , 1995). Based on several individual induction experiments it was 
found that the level o f p21 mRNA peaked at between 24 and 48 hours and remained 
high until at least 72 hours post induction (Figure 3.6A). The level of p21 mRNA was 
significantly higher in iMUTU-III relative to that detected in DG75tTA-LMPl cells 48 
hours post-induction of LMP1 expression, implying that other EBV latent proteins may 
serve to further enhance p21 expression in MUTU-III cells.
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Figure 3.6 Upregulation of p21 expression by LMP1. LMP1 expression was induced in DG75tTA- 
LMP1 cells and both total RNA and protein extracts were prepared at the indicated time points (hours) 
post-induction. (A) (i) and (ii) RPA analysis performed as per figure 1 show two individual induction 
experiments each of which illustrate a several fold increase in p21 mRNA levels by 24-48 hours post­
induction.
115
■  ■  ■
t#M
m
tm
1  •  §  #
48 72 96
■+tl # —
pl30
T)U
m m f t  —
KD
m * •  —
pl07
• •
•  -
p53
4ft • •  -
p27
f t # m  < — — p 2 1
-
1
— pl9
* • m  —
pl8
•  t
•  -
p l6
GAPDH
L32
F igure  3.6 U pregu la tion  of p21 expression by LM P1. LMP1 expression was induced in DG75tTA- 
LMP1 cells and both total RNA and protein extracts were prepared at the indicated time points (hours) 
post-induction. (A) (i) and (ii) RPA analysis performed as per figure 1 shows two individual induction 
experiments each of which illustrate a several fold increase in p21 mRNA levels by 24-48 hours post­
induction.
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Figure 3.6 Upregulation of p21 expression by LMP1. LMP1 expression was induced in DG75tTA- 
LMP1 cells and both total RNA and protein extracts were prepared at the indicated time points (hours) 
post-induction. (B) Western blot analysis of p21 protein expression in response to induction of LMP1 
expression. Corresponding LMP1 protein levels for this induction are shown in figure 3A. (C) (i) and (ii) 
represent cells which were maintained in the presence (Tet+) or absence (Tet-) of tetracycline for the 
indicated periods following induction of LMP1 expression in DG75tTA-LMPl cells.
Detection of p21 protein expression by immunoblot revealed that LM Pl-mediated 
upregulation of p21 mRNA was correspondingly elevated at the protein level (Figure 
3.6B and C). By comparing levels of LMP1 protein and p21 protein in a range of LMP1- 
positive and -negative cell lines (illustrated in Figure 3.4A), it can be seen that, in 
general, high levels of p21 expression corresponded with expression of LMP1. Relative 
levels of p21 and LMP1 over 0 to 96 h post-induction are illustrated in Table 1. Viable 
cell counts demonstrate an LM Pl-induced cytostasis. Clumping of cells is due to 
induction of expression o f adhesion molecules by LMP1 (Wang et a l , 1988b; Peng and 
Lundgren, 1992).
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Time/h Clumping LMP1 p21 mRNA p21 protein Cell Counts 
x 106/ml
0 - - + + 0.40
18 + + + + 0.26
24 ++ + + + 0.31
48 +++ ++ ++ ++ 0.41
72 ++ +++ +++ ++ 0.80
96 ++ +++ + ++ 0.92
T ab le  3.1 S um m ary  of the effect o f L M P 1 on levels of p21 m R N A  an d  p ro te in  an d  on  cell 
p ro life ra tion . Time/h implies time elapsed post induction of LMP1 expression.
3.2.4 EBNA2 expression in DG75 cells has no effect on p21 mRNA levels but 
levels of pl9 mRNA are transiently upregulated.
In order to investigate whether EBNA2 may cooperate with LMP1 in the upregulation of 
p21 mRNA, EBNA2 expression was induced in a manner similar to that described above 
for LMP1 in the DG75tTA-EBNA2 cell line. Induction of EBNA2 expression was 
monitored by Western blot analysis of protein lysates prepared at the same time as RNA 
samples (see Figure 3.5C). Results of RPA analysis showed no change in the level of 
p21 mRNA as a result of EBNA2 expression. This result also served to rule out the 
possibility of an effect on p21 levels mediated by tetracycline withdrawal. The level of 
p l9  mRNA was observed to be transiently upregulated by EBNA2, with a slight 
increase in levels of p l8  mRNA. p l9  increased slightly at 24 hours post-induction with a 
peak 4-fold increase detectable at 48 hours after which time the levels decreased, 
although elevated levels of p l9  were still apparent at 96 hours (Figure 3.7). For 
comparison, low levels of p21 and p l9  in DG75 cells can be seen in lane 8, same figure. 
Upregulated p l9  mRNA levels were not observed to be a feature of EBV positive cells 
(see Figure 3.3). In fact, lower levels of p l9  were observed in MUTU-III relative to 
MUTU-I cells and in BL41.B95.8 relative to BL41 cells.
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F igu re  3.7 T ra n sie n t uprcgu la tion  of p l9  mRNA levels by EBNA2. DG75tTA-EBNA2 cells were 
induced to express EBNA2 in a manner similar to DG75tTA-LMPl cells. Total RNA samples were 
prepared at the indicated time points (hours) post-induction and analysed by multiprobe RPA as before. 
Lane 8 shows DG75 cells for comparison.
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3 . 2 . 5  L M P 1  d o e s  n o t  u p r e g u l a t e  p 2 1  e x p r e s s i o n  i n  B J A B t T A - L M P l  c e l l s .
The effect of LMP1 expression was also examined in the EBV-negative BL cell line 
BJABtTA-LMPl in which expression of LMP1 is similarly repressed by the presence of 
tetracycline. RPA analysis showed that, when levels of GAPDH were taken into 
consideration, no increase in p21 mRNA was observed as a result of LMP1 expression, 
although BJABtTA-LMPl cells did seem to express higher constitutive levels of p21 
mRNA than DG75tTA-LMPl cells (Figure 3.8). The level of p53 mRNA was similarly 
unchanged in response to LMP1 expression in BJABtTA-LMPl cells. BJAB cells 
harbour a p53 mutation which is different to that found in DG75 cells (discussed later). 
Rb mRNA levels were observed to be markedly higher relative to other Rb family 
members (pl07 and p 130) in BJABTA-LMP1 cells than in the case of DG75tTA-LMPl 
cells.
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F igu re  3.8 LM P1 does no t u p regu la te  p21 m R NA  levels in  B JA B tT A -L M P l cells. BJABtTA-LMPl 
cells were induced to express LMP1 as for DG75tTA-LMPl cells and total RNA samples were harvested 
at the indicated time points (hours) post-induction for RPA analysis.
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3.2.6 LMP1 expression does not affect p53 levels in DG75tTA cells.
Changes in p21 expression are normally either p53-dependent or -independent. Most BL 
cell lines carry a mutant p 5 3  gene and several reports have shown that BL cells express 
many fold higher levels o f  p 5 3  mRNA and protein than LCLs (Finlay et a l , 1988; Balint 
and Reisman, 1996). RPA and Western blot data presented here support these 
observations (Figures 3.3 and 3.9, respectively). Levels of p 5 3  mRNA were assessed in 
RPA assays in association with p 2 1 , which allowed comparative analysis of the different 
mRNA species within samples. Also, Western blot analysis was performed on the same 
protein lysates as were used for p21 and other analyses. The 53 kD protein was detected 
using a monoclonal anti-p53 antibody (Santa Cruz, SC-126) in conjunction with alkaline 
phosphatase detection. p 5 3  mRNA and protein levels were unchanged in response to 
LMP1 expression.
D G 75tTA  B JA B tTA  
L C L  96 48 0 96 48 0 M
  83kD
p53  ^  —  62kD
  47kD
F ig u re  3.9 W este rn  b lo t analysis o f p53 expression. p53 protein levels were detected using the same 
extracts which were used for p21 protein detection, represented in Figure 3.4(B). Samples were separated 
on a 10% SDS-PAGE gel and probed with anti-p53 antibodies which were detected using an alkaline 
phosphatase method. LCL: IARC 290B; DG75tTA-LMPl and BJABtTA-LMPl cells were induced to 
express LMP1 for the indicated time periods; M: Molecular weight markers.
3.2.7 C-Myc protein levels in LMP1-positive and -negative BL cells.
It has recently been found that c-Myc can repress transcription from the p21 promoter 
(El-Deiry e t a l , 1999), levels of c-Myc protein were examined by Western blot analysis 
in both BJABtTA-LM Pl and DG75tTA-LM Pl cells following induction of LMP1 
expression. C-Myc protein exists in two forms; the cytoplasmic form migrates as a band
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of 48-50 kD on SDS-PAGE gels, while the 62-66 kD form is exclusively nuclear- 
associated. In these experiments, mainly nuclear protein was detected using a murine 
monoclonal IgGi antibody (Calbiochem). In these cell lines, the level of c-Myc protein 
has previously been shown to be decreased by approximately 50% as a result of LMP1 
expression (Floettmann et a l , 1996). Using the same protein lysates which were analysed 
for p21 levels, in both BJAB and DG75 cells, c-Myc protein levels show an 
approximately 2-fold decrease in c-Myc protein by 24 hours and begin to increase again 
soon afterwards returning to pre-induction levels by 96 hours (Figure 3.10A and B). 
MUTU-I cells showed a similar decrease in c-Myc protein levels relative to MUTU-III, 
as did BL41 versus BL41.B95.8 cells (Figure 3 .10C)., while the LCL, IARC290B 
showed the lowest levels (not shown). BJAB cells differ from DG75 cells in that they 
lack the c-myc chromosomal translocation that is a marker for BL. This is interesting as 
it implies that LMP1-associated down-regulation of c-Myc levels occurs independently 
of the translocation.
(A) . D G 75tT A -L M P l (B) B JA B tT A -L M P l
0 18 24 48 72 96 0 18 24 48 72 96 DG75
(C)
F igu re  3.10 W este rn  b lo t analysis o f c-M yc p ro te in  expression. Levels of c-Myc protein in 
DG75tTA-LMPl and BJABtTA-LMPl BL cells induced to express LMP1 are illustrated in (A) and (B) 
respectively. Time in hours post-induction of LMP1 expression is given above each lane. (C) represents 
levels of c-Myc protein in LMPl-negative (BL41and MUTU-I) and LMPl-positive (BL41.B95.8 and 
MUTU-III) cells. Lane 1, MUTU-III; Lane 2, MUTU-I;
Lane 3, BL41.B95.8; Lane4,BL41.
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3 . 2 . 8  C e l l  t y p e - s p e c i f i c  e f f e c t  o f  L M P 1  o n  p 2 1  e x p r e s s i o n .
LMP1 exhibits cell type-specific differences with regard to its effects on gene 
transcription. For this reason, it was of interest to determine whether or not p21 could be 
upregulated by LMP1 in two other cell types which are relevant to EBV, namely T 
lymphocytes and epithelial cells. To this end, p21 mRNA and protein levels were 
investigated using a tetracycline-regulated LMP1 expressing clone derived from the 
Jurkat T cell line and a stably transfected LMP1-expressing clone of the epithelial cell 
line C33A. The results showed that LMP1 did not exhibit any effect on p21 mRNA 
levels in either cell context (Figure 3.11), indicating that p21 upregulation by LMP1 may 
be a B cell-specific effect. p21 was barely detectable in Jurkat T cells and not detectable 
at all in C33A epithelial cells, regardless of LMP1 status. It is known, however, that 
many cell cycle regulators are expressed in distinct cell type-specific patterns. It is also 
interesting to note that one effect of LMP1 which is specific to epithelial cells is 
upregulation of the EGF receptor (Miller e t a l , 1995) and EGF-mediated growth 
suppression has been demonstrated to correlate with increased expression of p21 
(Johannessen, 1999).
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F ig u re  3.11 LM P1 does no t u p reg u la te  p21 m R N A  in  e ith er a T  cell o r a n  epithelial cell context.
(A) Jurkat-tTa-LMPl T cells were induced to express LMP1 in a manner similar to DG75tTA-LMPl 
cells. Group III Ag876 BL B cells and C33A-LMP1 epithelial cells are included for comparison.
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Figure 3.11 LM P1 does not upregulate p21 mRNA in either a T cell or an epithelial cell context. (B)
C33A-Neo and C33A-LMP1 are stably transfected control and LMPl-expressing derivatives of the C33A 
parent line, respectively. Total RNA was harvested from each cell line or at the indicated times (hours) 
post-induction and analysed by multiprobe RPA as before.
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3 . 2 . 9  E f f e c t  o f  L M P 1  o n  p 2 1  p r o m o t e r  a c t i v i t y .
The increase of steady state p 2 1  mRNA levels could be due either to an enhanced rate of 
transcription or stabilisation of previously transcribed p 2 1  mRNA or to a combination of 
both mechanisms. In order to investigate if increased p21 promoter activity was 
involved, a p 2 1  promoter-luciferase reporter construct, WWP-LUC (a gift from Dr. Bert 
Vogelstein; El-Deiry et a l , 1993) was transiently co-transfected with a construct which 
constitutively expressed LMP1, under the control of the SV40 promoter. WWP-LUC 
comprises a 2.4 kb DNA sequence from the 5' regulatory region of the p 2 1  gene 
subcloned into pGL2-basic (Promega). The co-transfection experiments were carried out 
in DG75 cells, with the bfl-1 promoter used as a positive control for LM Pl-mediated 
transactivation. No transactivation of the p 2 I  promoter was observed despite also using 
an alternative LMP-1 expression vector (pEF-LMP-1). The b f l- 1  promoter was 
transactivated 5-fold by LMP1 in these experiments (Figure 3.12). High levels of p21 
promoter basal activity were observed in each experiment, which were several fold 
higher than the b f l - 1  control promoter, and comparable to or higher than luciferase 
activity from the SV40 promoter in the pGL-2 control promoter. Using the WWP-luc 
construct, others have reported a high basal level of promoter activity in different cell 
lines (Datto et a l , 1995; Billon et a l , 1999). A pair of p 2 1  promoter constructs, 0-luc 
(full-length 2.4 kb p 2 1  promoter) and 6-luc, which is identical to 0-luc except for 10 
consecutive mutated bases (-43/-34) located near the TATA box. (Datto et a l , 1995), 
were also employed in similar experiments. Alternative experiments involved 
transfection of p21 promoter constructs into uninduced or LMP1-induced DG75-tTA 
cells, where again no significant increase in luciferase activity was detected as a result of 
LMP1 induction. In one such experiment, using the WWP-LUC promoter construct, a
1.2 fold increase in promoter activity was detected, while a similar experiment using the 
0-luc promoter construct produced a 1.5 fold increase in promoter activity (not shown). 
It was concluded that no significant transactivation of the p21 promoter was detectable 
in the context of DG75 cells under the conditions described above. Thus, if LMP1 
affects the level of the p21 promoter activity, then the DNA sequence elements that may 
mediate this effect are most likely located elsewhere.
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Figure 3.12 Effect of LMP1 expression on p21 promoter activity. DG75 cells were co-transfected 
with WWP-LUC (p21 promoter luciferase construct) plus pEF (LMP1-) or pEF-LMPl (LMP1+). As 
positive control, cells were similarly co-transfected with the pGL2-bfl-l promoter construct with pEF or 
pEF-LMPl, as before. After 48 hours, cells were harvested and used in luciferase assays..
3.2.10 Effect of LMP1 on stability oip21  mRNA.
To determine whether the stability of p21 transcripts might be enhanced as a result of 
LMP1 expression, half-life (Ti/2) studies of p21 mRNA were performed by blocking 
overall transcription with an inhibitor of RNA polymerase II, actinomycin D (5 (Xg/mD 
in uninduced and LMPl-induced DG75-tTA cells. Total RNA was extracted at each 
time point over a period of 20 hours as indicated in Figure 12A, and the decay of p21 
mRNA was followed by RPA analysis. The relative half-lives were calculated by 
plotting the best-fit semi-logarithmic lines generated from the relative amounts of p21 
mRNA as determined by RPA assay (Figure 3.13A). Initially, actinomycin D was added 
24 hours after induction of LMP1, as at this stage the p21 level is still increasing so the 
stabilisation effect may be easier to detect. Although the upregulation of p21 mRNA had 
not yet peaked by this stage, an almost 2-fold stabilising effect was apparent in LMPl- 
induced cells over uninduced cells (Figure 3.13B). At 48 hours, the level of p21 
transcript was seen to have accumulated presumably as a result of increased stability, but
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the difference in stability is now less apparent and at this stage p2J levels soon begin to 
decrease again. The sudden drop in p2I mRNA level immediately after inhibition of 
RNA synthesis in both induced and uninduced cells may be due to the very short half- 
life of p2I, such that transcripts need some time to accumulate. Similar mRNA stability 
experiments were carried out in LCL X50-7 cells (Figure 3.12A), as well as in MUTU-I 
(not shown) and MUTU-II1 cells (Figure 3.12C). p2l mRNA showed prolonged stability 
in X50-7 cells and in MUTU-11I cells. U wasn’t possible estimate the stability of p2l 
mRNA in MUTU-I relative to MUTU-III cells due to the very low levels observed. This 
was despite extended exposure times of up to one week. In all cases, p21 mRNA levels 
at each time point were quantitated by densitometric scanning. GAPDH bands were 
similarly assessed and used as a control for loading. Consistent with previous reports 
(Balint and Reisman, 1995), levels of p53 mRNA was observed to be unchanged up to at 
least 10 hours in the presence of 5 fig/ml actinomycin D.
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Figure 3.13 LMP1 expression in DG75tTA-LMPl cells increases the stability of p21 mRNA. (A)
DG75tTA-LMPl cells were grown in the presence (LMP1-) or absence (LMP1+) of tetracycline for 24 
hours before addition of 5 ng/ml actinomycin D. The cells were then further incubated for the times 
indicated before total cellular RNA was purified and assayed by RPA as before (lanes 1-10). For 
comparison, the higher stability of p21 mRNA in LCL X50-7 cells can be seen in lanes 11-13.
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Figure 3.13 LMP1 expression in DG75tTA-LMPI cells increases the stability of p2l mRNA. (B) In
DG75iTA-LMPl cells shown in (A), the intensity of each p21 band was normalised to ihe intensity of its 
corresponding GAPDH band in order to correct for loading. Values were then plotted as a percentage of 
Lhe control (time 0 hours) and used to calculate half-lives.
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Figure 3.13 LMP1 expression in DG75tTA-LMPl cells increases the stability of p21 mRNA.
(C) Stability of p21 mRNA in MUTU-III cells. MUTU-III cells were passaged in fresh media 24 hours 
before addition of 5 |ig/ml aclinomycin D. Cells were then harvested at the indicated time points as before 
and analysed by RPA.
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As an independent measure of mRNA stability, the level of p21 mRNA was monitored 
in the absence of any new protein synthesis. Addition of the protein synthesis inhibitor, 
cycloheximide (CHX) is sometimes used to determine whether low levels of mRNA 
transcripts are due to regulation of mRNA stability by a labile protein. At 48 hours post- 
LMP1 induction, 10 (ig/ml CHX was added to or omitted from DG75tTA-LMPl cells, 
which were then incubated for a further 30 hours with RNA samples taken at the 
indicated time points. Immunoblotting was used to confirm that LMP1 levels of 
expression were unaffected for at least 30 hours after CHX treatment (Figure 3.13A). It 
can be seen that p21 mRNA levels accumulated a further >2 fold in cells treated with 
CHX versus untreated cells (Figure 3.13B). Historically, inhibition of protein synthesis 
using cycloheximide has been shown to cause stabilisation and accumulation of several 
messenger RNAs. Various interpretations are possible for this phenomenon: presumably 
a labile protein is involved in the degradation of these mRNAs, or the mRNA-degrading 
machinery is tightly associated with the ribosome. One possible conclusion from this 
particular experiment is that p21 mRNA is normally degraded by a labile factor in DG75 
cells, and that LMP1 may stabilise p21 mRNA through interference with such a negative 
factor or group of factors.
Figure 3.13 Effect of inhibition of new protein synthesis. (A) Expression of LMP1 is unaffected in the 
presence of 10 |ig/ml cycloheximide (CHX) for up to at least 30 hours. DG75tTA-LMPl cells were grown 
in the presence (LMP1-) or absence (LMP1+) of tetracycline for 48 hours before addition of 
cycloheximide. Protein extracts were then prepared at the indicated time points and analysed for LMP1 
protein expression as described previously.
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Figure 3.13 Effect of inhibition of new protein synthesis. (B) LMPl-induced p21 mRNA transcripts 
accumulate in the presence of cycloheximide, DG75tTA-LMPl cells induced to express LMP1 for 48 
hours were incubated in the presence, B(i) or absence, B(ii) of 10 ug/ml cycloheximide. Total cellular 
RNA was harvested at the indicated times post-treatment and analysed by multiprobe RPA.
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Figure 3.13 Effect of inhibition of new protein synthesis. (B) LMPl-induced p21 mRNA transcripts 
accumulate in the presence of cycloheximide. DG75tTA-LMPl cells induced to express LMP1 for 48 
hours were incubated in the presence, B(i) or absence, B(ii) of 10 [xg/ml cycloheximide. Total cellular 
RNA was harvested at the indicated times post-treatment and analysed by multiprobe RPA.
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3 . 2 . 1 1  E f f e c t  o f  L M P 1  e x p r e s s i o n  o n  p 2 1  p r o t e i n  s t a b i l i t y
As mentioned above, Western blot analysis confirmed an upregulation of p21 protein by 
LMP1 in DG75-tTA cells, where levels were seen to peak at about 48 hours and remain 
elevated until at least 72 hours post-induction of LMP1 (Figure 3.5B). The stability of 
the p21 protein was examined in uninduced versus LMPl-induced cells at various times 
after the addition of cycloheximide (10 M-g/ml) to inhibit de novo protein synthesis. 
Protein lysates were prepared at the times indicated in Figure 3.14 over 0-30 hours. No 
difference in p21 protein stability was observed in the presence of LMP1.
30
Tet+ p21
Figure 3.14 Stability of p21 protein is unaffected by LM P1 expression. Protein extracts were 
prepared at the same time as RNA samples used in RPA analysis in figure 12. Proteins were then 
fractionated on 15% SDS-PAGE gels and immunoblotted for p21 expression as described before. Bands 
were visualised by ECL and their relative intensities were quantitated by densitometric scanning. Times 
(hours) post addition of 10 Hg/ml cycloheximide are given above each lane. Time 0 represents 48 hours 
post-induction of LMP1 expression.
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3.2.12 Effect of PM A and staurosporine on p21 expression in LMPl-induced and 
uninduced cells.
A number of studies have linked regulation of p21 expression to the PKC pathway 
(Akashi et al, 1999; Zeng and El-Deiry, 1996; Lin et al, 1996). To explore the potential 
role of the protein kinase C (PKC) pathway in the observed increase in p21 levels 
mediated by LMP1, PMA and staurosporine were employed to stimulate and inhibit the 
PKC pathway, respectively. Firstly, in order to investigate the functional integrity of a 
PKC-mediated induction of p21 expression in the context of DG75 cells, cells were 
treated with 10 ng/ml PMA and protein lysates were prepared at 0, 1, 2, 3, 6 and 24 
hours in the presence and absence of PMA. p21 protein levels were seen to elevate by 2 
hours, continue to increase up to at least 6 hours and remain elevated up to 24 hours but 
perhaps longer as a result of stimulation by PMA (Figure 3.15A and B). Very high levels 
of p21 protein were observed in response to PMA treatment: levels exceeded those of 
the group III Ag876 cells by 6 hours post-addition of PMA. Somewhat similar patterns 
of rapid induction have been reported in other cell lines eg. in HL60 cells p21 was 
detectable by 3 hours, peaked at 24 hours and remained elevated for 72 hours when 
exposed to 60 ng/ml PMA (Schwaller et al, 1995). It was also confirmed that the 
induction process (which involves extensive washing of cells in PBS) had no effect on 
the ability of PMA to activate the PKC pathway in DG75 cells i.e. cells which were 
washed and cultured in the presence or absence of tetracycline were stimulated with 
PMA in a manner similar to unwashed DG75tTA-LMPl cells (Figure 3.15B). In 
addition, the results suggest the absence of any cooperative effect of PMA and LMP1, as 
no difference was detected between levels of p21 protein in PMA-treatcd LMP1-positive 
cells and PMA-treated LMPl-negative cells. This may indicate that PMA and LMP1 are 
using the same signal transduction pathway which has become saturated as a result of 
PMA treatment.
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Figure 3.15 PMA treatment of DG75 cells stimulates p21 protein expression. (A) DG75 cells were 
incubated in the presence of 10 ng/ml PMA and protein extracts were subsequently prepared at the 
indicated times post-treatment. For comparison, group III Ag876 cells are loaded in lane 1. (B) Lanes 1 
and 2 represent DG75tTA-LMPl cells incubated in the presence (LMP1-) or absence (LMP1+) of 
tetracycline, where 10 ng/ml PMA was added at the point of induction. Lanes 3 and 4 correspond to the 
PMA+ and PMA- DG75 cells respectively at 24 hours as for (A).
Staurosporine (ST) is a potent, cell-permeable broad spectrum inhibitor of protein 
kinases and was used at a concentration of O.lnM to inhibit the PKC pathway in 
uninduced and LMPl-induced cells. Treatment of LMP1-induced DG75tTA-LMPl cells 
with ST was observed to inhibit the upregulation of p21 expression (Figure 3.16A). 
However, when protein lysates were analysed for expression levels of LMP1, it was 
found that LMP1 expression was similarly inhibited in the presence of ST (Figure 
3.16B). The results using this inhibitor are, therefore, inconclusive with regard to the 
role of the PKC pathway in LMPl-mediated p21 induction. Nonetheless, the experiment 
did show that inhibition of LMP1 expression correlated with inhibition of p21 
expression. In Figures 3.16A and B, it can be seen that relative levels of p21 protein 
correspond approximately to those of LMP1 for each particular cell sample. In the 
example shown, where LMP1 expression was not totally inhibited by ST after 24 h, the 
level of p21 is slightly higher in LMPl-induced cells than in uninduced cells.
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Figure 3.16 Staurosporine inhibits both p21 and LMP1 expression in DG75tTA-LMPl cells.
(A) DG75tTA-LMPl cells were incubated in the presence (LMP1-) or absence (LMP1+) of tetracycline 
for 24, 48 or 72 h, where 0.1 nM staurosporine (ST) was added to or omitted from cells at the point of 
induction. Lanes 1-4 represent protein extracts harvested at 24 h, separated on a 15 % SDS-PAGE gel, and 
immunoblotted for p21 protein expression as before. (B) Protein extracts prepared as for (A) but analysed 
for expression of LMP1 using a 10 % SDS-PAGE gel. Lanes 1 and 2: 72 h; lanes 3-5: 48 h; lanes 6-8: 
24 h. Lanes 1-8 are from the same induction experiment. Lanes 6-8 correspond to extracts used in (A). 
Lanes 9-11 represent a different induction experiment at 24 h. Lane M: protein molecular weight markers.
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3 . 2 . 1 3  I n v e s t i g a t i o n  o f  t h e  r o l e  o f  t h e  p 3 8  M A P K  p a t h w a y .
It was recently shown that activation of the p38 MAPK pathway was important in the 
coregulation of IL-6 and IL-8 production by LMP1 in HEK 293 cells (Eliopoulos et al, 
1999). Activation of the MAPK pathway has also been linked with the regulation of p21 
expression (Lin et al, 1996; Akashi et al, 1996). Therefore, experiments were carried out 
in order to investigate whether this pathway may be important in the LMP1-mediated 
upregulation of p21 expression. To this end, induced and uninduced DG75tTA-LMPl 
cells were incubated in the presence of the specific p38 inhibitor, SB203580 
(Calbiochem), at a concentration of lOuM or 20uM. SB203580 is a pyridinyl imidazole 
compound that has been shown previously to specifically inhibit p38 activity in response 
to a range of stimuli (Craxton et al, 1998; Hsu et al, 1999, Eliopoulos et al, 1999). As 
SB203580 was dissolved in DMSO, induced and uninduced cells were incubated with a 
corresponding volume of DMSO as negative control. In a similar manner to that 
observed with ST, 20 jiM SB203580 inhibited the upregulation of p21 protein but also 
inhibited LMP1 protein production in this system (Figures 3.17A and B, respectively). 
In the presence of 10 |xM SB203580, the level of LMP1 protein was unaffected and 
upregulated p21 protein was still detectable in these cells. However, it will be necessary 
to establish inhibition of the p38 MAPK pathway at this concentration of inhibitor using 
eg. ELISA assays for IL-6 or IL-8. Alternatively, p38 MAPK has also been reported to 
be required for CD40-induced gene expression in B lymphocytes. These results would 
suggest that the MAPK pathway is not important for LMP-1 mediated upregulation of 
p21 expression in DG75tTA-LMPl cells, subject to confirmation of inhibition of the 
pathway under these conditions.
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Figure 3.17 A p38 MAl’K inhibitor inhibits both p21 and LMP1 expression in DG75tTA-LMPl 
cells, (A) Cells were incubated in the presence (LMP1-) or absence (LMP1+) of tetracycline, protein 
extracts were prepared at 48 hours post-induction and immunoblotted for p21 expression. 10 nM, 20 nM 
SB203580 (specific p38 MAPK inhibitor) or 2.5 |nl DMSO was added at the point of induction. Lanes 1 
and 2: 10 (.tM SB203580; lanes 3 and 4: DMSO: lanes 5 and 6: 20 (.tM SB203580. (B) Protein extracts as 
for (A) were immunoblolted for LMP1 expression as described previously. Lanes 1 and 2: DMSO; lanes 3 
and 4: 20 ¡.tM SB203580; lanes 5 and 6: 10 jiM SB203580.
3.2.14 Rb levels and phosphorylation status in LMPl-positive and -negative BL 
cells.
pRb is regulated in part by inactivating phosphorylation events, which reverse it’s 
growth suppressive effects. A decrease in the mobility of the HOkD pRb protein on 
SDS-PAGE gels has been documented as being characteristic of its 
hyperphosphorylation and inactivation. Increased levels of pRb protein with a shift to 
the phosphorylated form has been described as an early event in EBV-mediated
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immortalisation of primary B cells (Cannell et al, 1996). Also, LMP1 has been shown to 
induce pRb hyperphosphorylation in EBV-positive cells (Arvanitakis et al, 1995). Using 
a mouse monoclonal anti-Rb antibody (Santa Cruz, SC-102) to detect pRb protein, the 
relative levels and phosphorylation status of pRb were compared in the EBV-negative 
BL DG75, group-ill Ag876 and LCL IARC-290B (Figure 3.18A). As expected, Rb 
protein in Ag876-III and IARC-290B cells was mainly hyperphosphorylated, while 
DG75 pRb protein was mainly hypophosphorylated. The effect of LMP1 expression in 
DG75tTA-LMPl cells on pRb was then investigated in the same protein lysates used for 
p21 and c-Myc analysis (Figure 3.18B). At 24 and 48 hours, when LMP1 levels were 
seen to peak, pRb was present mainly in the hyperphosphorylated form. At 72 hours, 
when the level of LMP1 protein has begun to decrease, a shift towards the 
hypophosphorylated form was observed, although most pRb was still 
hyperphosphorylated. Thus, in support of previous studies, the data indicate that LMP1 
expression maintains Rb in the hyperphosphorylated state, and that a predominance of 
hyperphosphorylated Rb is a feature of group III BL and LCL cells.
(A) 1 2 (B) 0 18 24 48 72
H r
Rb-P-P-P
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  Rb-P-P-P
  Rb
Figure 3.18 Western blot analysis of pRb. (A) Levels and phosphorylation status of pRb protein 
expressed by LMPl-positive (Ag876-IU and IARC 290B) and -negative (DG75) cell lines are compared. 
Proteins were fractionated on 10% SDS-PAGE gels, immunoblotted using specific anti-pRb antibodies 
and bands were visualised by ECL. Hyperphosphorylated pRb, which migrates more slowly than 
hypophosphorylated pRb is indicated as pRb-P-P-P. Lane 1: DG75; Lane 2: Ag876-III; Lane 3: 
IARC290B. (B) pRb was investigated in a similar manner in DG75tTA-LMPl cells induced to express 
LMP1. The times at which cells were harvested are indicated in hours post-induction.
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3 . 3  D I S C U S S I O N
In the absence of antigen-mediated mitogenic signaling, B lymphocytes in the peripheral 
circulation exist in a quiescent state. Infection with EBV drives quiescent B cells into a 
continuous state of proliferation by exploiting the normal cell pathway of activation 
(Cannell et al, 1996). The EBV LMP1 oncogene has a major role to play in this 
activation process. In mammalian cells, transit through the cell cycle is thought to be 
regulated by the action of specific protein kinase complexes, each comprising a cyclin 
and its associated cyclin-dependent kinase (cdk) subunit, which regulate the 
phosphorylation status of the retinoblastoma protein (pRb) (Sherr, 1993). Previous 
studies have indicated that EBV-mediated immortalisation drives the 
hyperphosphorylation of pRb, which involves the upregulation of a number of cyclins 
and cdks and the down-regulation of a subset of cdk inhibitors (cdkls) (Cannell et al, 
1996).
The purpose of this study was to examine the effect of expression of EBV latent proteins 
on aspects of the cell cycle. Initial experiments involved investigation of EBV- 
associated effects on a panel of negative regulators of the cell cycle, including two major 
tumour suppressor genes, p53 and pRb, the less well-characterised pRb family members, 
p l3 0  and p l0 7  as well as members of both the CIP [p21, p27  and p57) and INK (pl5, 
pl6 , p l8  and p l9 )  families of cdkls. LMP1 and EBNA2 are two latent EBV proteins 
which are each critical to the transformation process. Thus, observations which were 
made in a range of latency group I and group III cells as well as several EBV- 
immortalised LCLs were further explored by independently inducing the expression of 
LMP1 and EBNA2 in the absence of expression of any other EBV proteins.
3.3.1 EBV-associated upregulation of p21 expression
Initial experiments using a range of EBV-related cell lines found that elevated p21 
mRNA and protein was a feature of both BL and LCL cell lines expressing the full 
spectrum of EBV latent genes. In support of this, a previous report has described the
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absence of p21 in primary B lymphocytes, which became detectable in LCLs following 
EBV infection and immortalisation (Cannell et al, 1996). However, the precise role of 
an EBV-mediated upregulation of p21 expression as part of the transformation process is 
not completely understood. On further investigation, it was found here that when 
expressed singly in an EBV-negative background, LMP1, but not EBNA2, had an 
important role to play in the upregulation of p21 expression observed in latency group 
III and LCL cells (see Figures 4 and 5). The molecular basis of this effect was therefore 
further investigated.
Although EBNA2 did not contribute to elevated levels of p21 , it was found that p l9  
mRNA was transiently upregulated, with a slight increase in the level of p i8 mRNA. 
Both pl8 and pl9 mRNA/protein levels have been found to oscillate during the cell 
cycle, accumulating during S phase and remaining high throughout G2/M (Hirai et al,
1995), suggesting that these proteins may play a role during later stages of the cell cycle. 
EBNA2 is known to be required at both the Gi and G2 stages of the cell cycle and 
EBNA2-deprived cells arrest at both Gi and G2 (Kempkes et al, 1995). EBNA2 has been 
found to induce B cell activation and entry into the cell cycle by inducing and 
maintaining expression of early Gi-regulating proteins, including cyclins D2, E and A, 
cdk4, the E2F-1 transcription factor as' well as c-Myc. Overexpression of E2F-1 
activates pl9 synthesis in mouse embryonic fibroblasts, as does overexpression of c- 
myc. The mouse p i9 promoter contains at least 2 potential E2F-1 binding sites, whereas 
c-Myc has not been demonstrated to bind the pl9 promoter and its effects on pl9 protein 
synthesis may well be indirect (reviewed by Inoue et al, 1999). The effect of EBNA2 
expression on c-myc levels was not investigated in the results presented here.
3.3.2 Upregulation of p21 expression by LMP1.
The profound effect of LMP1 on cell growth and proliferation is well documented 
(Baichwal and Sugden, 1988; Henderson et al, 1991; Miller et al, 1995; Rowe et al,
1995). LMPl-mediated upregulation of p21 expression is consistent with evidence from 
previously documented reports. For example, LMP1 is known to have a protective effect
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against apoptosis induced by serum starvation (Henderson et al, 1991). The range of 
apoptotic stimuli to which a cell may be subjected means that frequently, the levels of 
several anti-apoptotic proteins must be modulated to provide sufficient protection to the 
cell. The prosurvival effect of LMP1 expression on cells appears to exploit a number of 
different proteins which combine in a precisely-timed manner to provide protection. For 
example, LMPl-mediated Bcl-2 induction is a delayed response (2-3 days) (Henderson 
et al, 1991), while A20 appears to be an immediate and direct effect of LMP1 expression 
(Laherty et al, 1992), similar to that of Bfl-1 (B. d’Souza and D. Walls, submitted). p21 
expression has been shown to have a protective effect against apoptosis induced by p53 
as well as other agents (Gorospe et al, 1997; Lu et al, 1998). In a recent study which 
used adenovirus vectors overexpressing individual cdkls in a range of cell lines, greatest 
cell death was found to occur as a result of p 16, p i8 and p27 overexpression, while pl9 
and p21 had a more cytostatic effect on cell proliferation (Schreiber et al, 1999). Thus, it 
may not be entirely surprising that p l9  mRNA is also slightly upregulated by LMP1 
expression, while no change is seen in p i 6, p i 8 and p27 mRNAs (Figure 4A).
A previous study has found that LMP1 (but not EBNA2) had a cytostatic effect on B 
cells due to an accumulation of cells at the G2/M phase of the cell cycle (Floettmann et 
al, 1996). This report was based on tetracycline-regulated expression of LMP1/EBNA2 
in -DG75tTA cells, where cytostasis was observed as a transient effect, lasting about 4 
days. Using the same DG75tTA-LMPl cell line to induce LMP1 expression in the study 
presented here, viability counts were carried out at each time point and showed a similar 
transient cytostatic effect which corresponded approximately with p21 upregulation (see 
Table 1). It has been proposed that the functions of p21 (and p27) are limited to cell 
cycle control at the Gi/S phase transition and in the maintenance of cellular quiescence. 
However, several studies have begun to emerge which support a role for p21 at the G2/M 
checkpoint also. For instance, p21 was found to transiently accumulate in the nucleus 
near the G2/M boundary (pre-mitosis) while primary embryonic fibroblasts derived from 
p21-/- mice had significantly reduced numbers of pre-mitotic cells (Dulic et al, 1998). 
This data suggested that p21 promotes a transient pause in late G2 that may contribute to 
the late cell cycle checkpoint controls. A further study indicated that both p53 and p21
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were essential for maintaining the G2 checkpoint in human cells (Bunz et al, 1998). Cells 
transfected with adenovirus vectors overexpressing pl8, pl9, and to a lesser extent p21, 
have been shown to accumulate in G2/M. In contrast, cells overexpressing pl6 and p27 
induced an enrichment of cells in G0/G1 compared to mock and control cells (Schreiber 
et al, 1999).
3.3.3 p53-dependent and -independent regulation of p21 expression
p53 sites are known to exist in the p21 promoter and p21 is a major target of the p53 
protein. Generally, p21 upregulation occurs by one of two distinct mechanisms: one 
pathway is p53-dependent and activated by DNA damage, while the other is p53- 
independent and can be activated by mitogens and cytokines (Michieli et al, 1994; 
Shiohara et al, 1996). EBV does not block the p53-dependent activation pathway 
initiated by DNA damage. Furthermore, during infection, viral gene transcription 
activates transcription of the p53 gene and therefore primes, but does not trigger, the 
p53-dependent route to cell death. Indeed, LMP1 and EBNA2 have been shown to 
independently transactivate p53 gene expression, through induction of NFkB activity in 
resting B cells (Chen and Cooper, 1996). In their study, an SG5-LMP1 expression vector 
produced a 5-fold increase while EBNA2 gave rise to a 2-fold increase in p53 mRNA 
levels as assessed by RT-PCR. The failure of EBV-mediated upregulation of p53 to 
block cell division and/or to induce apoptosis was proposed to be due to EBV-induced 
increases in c-Myc or in other cell-cycle regulating proteins such as cyclin D2, cdc2 
(cdkl) or cyclin E. In contrast, no change in p53 levels was detected as a result of 
induction of EBNA2 expression in oestrogen-dependent LCLs expressing a conditional 
EBNA2 fusion protein (Kempkes et al, 1995).
When BL41 cells, which carry a mutant p53 gene, were transfected with a temperature- 
sensitive wild type p53 gene, LMP1 was shown to protect from p53-mediated apoptosis 
without interfering with induction of p21 (Okan et al, 1995). Indeed it is known that 
none of the EBV genes expressed in type III latency possess the ability to block p53- 
induced p21 expression and cell cycle arrest at the Gl/S boundary (Chen and Cooper,
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1996). Based on this evidence, it still remains possible that LMP1 acts via p53 in 
upregulating p21 during primary B cell infection. The studies described above did not 
investigate the effect of LMP1 expression on levels of p21 in the absence of functional 
p53.
Previous studies have shown that among BL cell lines, some of the highest levels of p53 
mRNA and protein are found in DG75 cells. Consistent with these reports, in this study 
DG75 cells revealed high levels of p53 mRNA and protein relative to other cell lines 
tested and in general BL cells showed higher levels than LCLs (Figures 1 and 7). Also, 
p53 was highly stable in response to actinomycin D treatment (Figure 11). Elevated 
levels of p53 mRNA are due to both an increased transcription rate (contributed to by a 
deregulated c-myc gene) as well as increased mRNA stability (Balint and Reisman,
1996). Normal p53 protein is usually difficult to detect due to its high rate of turnover. 
The high p53 protein levels observed in these cells are due to the stabilising effect of 
mutations. It is known that most BL cell lines carry a mutant p53 gene and functional 
analysis of mutant p53 alleles have been carried out in a range of BL cell lines (Farrell et 
al, 1991). In one study (which included BL41 and BJAB) it was found that none of the 
mutant p53 genes tested gained a dominant transforming activity. Most cell lines lost the 
ability to suppress transformation except for the Ramos and BL37 mutants, while the 
p53 of Louckes and BL41 had reduced suppressor activity. The Ramos and BL37 
mutations are located within the conserved box 4 region, which makes it likely that they 
are also significant. p53 protein was undetectable in Akata cells probably due to a very 
unstable truncated mutant protein. It was concluded from this data that at least most of 
the mutations studied were significant mutations of the p53 gene that contributed to the 
growth of the BL cell lines. The p53 gene in DG75 cells bears a 283 His-Arg mutation 
which is located in the sequence-specific DNA binding domain of the protein. 
Functional p53 has been shown to be necessary in mouse thymocytes for apoptosis 
induced by DNA damage. In this regard, a range of BL cell lines (including DG75) have 
been found to be relatively resistant to DNA damage when compared with LCLs, 
suggesting loss of function of the p53 gene. Furthermore, El-Deiry et al (1993) have 
illustrated p21 transcription activation by wild-type but not mutant p53. In the data
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presented here, expression of LMP1 in DG75 cells was found to have no significant 
effect on p53 mRNA or protein levels and the increase in p21 mRNA was not associated 
with any detectable promoter transactivation. In addition, a relatively moderate level of 
p21 upregulation was observed here: reports show that the levels of p53-independent 
p21 expression are much lower relative to p53-dependent expression (Zhang et al, 
1994). For these reasons, data indicate that the observed LMPl-mediated upregulation 
of p21 is likely to be a p53-independent effect in BL cells, although this does not 
exclude a role for p53 during primary B cell immortalisation.
3.3.4 p21 expression is not upregulated in BJAB cells which lack the c-myc 
transclocation
Overexpression of c-myc has been found to repress the p21 promoter (Mitchell and El- 
Deiry, 1999), and since LMP1 is known to have a negative effect on c-Myc levels, then 
LMP1 could potentially use this route to effectively derepress the p21 promoter. 
Upregulation of p21 expression mediated by LMP1 was observed in DG75tTA-LMPl 
but not in BJABtTA-LMPl cells. BJAB differs from DG75 and most other BL cell lines 
in that it lacks the c-myc chromosomal translocation, which in general characterises both 
endemic and sporadic types of BLs. The (t8:14) or less frequently (t8:2) or (t8:22) 
translocations juxtapose the c-myc oncogene to Ig regulatory elements, resulting in 
constitutive expression of c-myc. Consistent with the findings of Floettmann et al 
(1996), an approximately 50% decrease in the level of c-Myc protein was found to be 
induced by LMP1 expression in both DG75 and BJAB cells. Thus, down-regulation of 
c-Myc by LMP1 appears to occur independently of the translocated state of the c-myc 
gene. Since no upregulation in p21 expression was detected in BJAB cells induced to 
express LMP1, this implies that c-Myc is probably not involved in p21 upregulation, 
although the possibility cannot be ruled out.
The translocated c-myc allele frequently (65%) carries mutations. The mutations occur 
in the N-terminal transactivational region of the protein which may alter the gene 
regulatory activities of the c-Myc protein. One of the potential regulatory targets of c-
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Myc is the p53 gene, which is also expressed at high levels in BLs. Studies in DG75 
cells, indicate that c-Myc can transactivate the p53 gene, which is reflected in the 
observed high levels of c-Myc protein and p53 gene transcription rate in these cells, 
indicating that the transactivation activity of c-Myc, in this case, is unaffected. In 
contrast, in Ramos BL cells, the transcription rate of the p53 gene has been found to be 
very low despite very elevated levels of c-Myc protein (Balint and Reisman, 1996). This 
is possibly due to a mutation in the transactivation domain of the c-Myc protein in 
Ramos cells. Comparably high levels of c-Myc protein and p53 mRNA were observed in 
BJAB and in DG75 cells. However, it remains to be seen whether or not the 
transcription rate of the p53 gene is also high in these cells.
Western blot analysis revealed reduced c-Myc protein levels in BL41.B95.8 cells 
relative to BL41 cells and in MUTU-III relative to MUTU-I cells (Figure 8C). Thus, in 
both cases, levels of c-Myc protein were reduced in the LMPl-positive cells. Moreover, 
very low levels of c-Myc protein were seen in LCL IARC-290B cells. As mentioned 
above, BL cells typically display very high levels of c-Myc protein. This is due to 
deregulated expression of the c-myc protooncogene which is believed to be the dominant 
factor responsible for maintainence of tumorigenicity in BL. In contrast, levels are 
usually relatively lower in latency group III and LCL cells (Balint and Reisman, 1996). 
In conclusion, these results support a negative effect of LMP1 expression on c-Myc 
protein levels. As a result of this effect, cells may become less dependent on aberrant c- 
myc expression and more responsive to autocrine proliferation signals. Thus, the 
transient cytostatic effect of LMP1 expression, reflected by a partial block in G2/M, may 
function in controlling the rate of proliferation of cells and may include a role for p21.
3.3.5 LMP1 maintains pRb in the hyperphosphorylated state.
It has been reported that EBY drives phosphorylation of Rb (Cannell et al, 1995), and 
that EBV is able to prevent TGF[3-mediated down-regulation of pRb in a BL cell line 
(Arvanitakis et al, 1995). Furthermore, it was shown that LMP1 has an important role to 
play in maintaining Rb in the hyperphosphorylated state. Phosphorylation of Rb has the
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effect of inactivating this critical negative regulator of the cell cycle. The data presented 
here describe findings consistent with previous studies, in that DG75tTA-LMPl cells 
induced to express LMP1 produced mainly hyperphosphorylated Rb protein. In addition, 
mainly hyperphosphorylated pRb in group III and LCL cells contrasted with mainly 
hypophosphorylated pRb in EBV-negative DG75 BL cells. It is interesting to note here 
that p i8, pl9 and p21 vectors were shown to be relatively less effective at inhibiting 
pRb phosphorylation than their p27 and pl6 counterparts (Schreiber et al, 1999). Thus, 
increased p21 and pl9 expression may be consistent with maintaining Rb 
phosphorylation.
In summary therefore, in view of the known oncogenic properties of LMP1, an 
upregulation of a cell cycle inhibitor by LMP1 may initially appear to be a surprising 
finding. On closer examination, however, it seems that an increase in p21 levels may 
have a role to play in some of the previously observed effects of LMP1: for example, 
protection from apoptosis, transient cytostasis associated with an accumulation of cells 
in G2/M and promotion of an inactive hyperphosphorylated Rb.
3.3.6 p21 promoter studies.
As detailed in the results section, no significant transactivation of the p21 promoter was 
detected as a result of LMP1 expression in DG75tTA-LMPl cells. However, based on 
these experiments, it remains possible that LMP1 affects promoter activity through 
sequence elements which are located elsewhere.
3.3.6.1 p21 promoter
Known positive regulators of the p21 promoter include the SP transcription factors 1-6, 
AP2, E2F, Stat 1 and 3, interferon regulatory factors (IRF) 1 and 2, C/EBP alpha, while 
the GTPase RhoA has been found to repress the p21 promoter. Andrei et al (1998) have 
found that E2F1 and E2F3, transcription factors that activate genes required for cell 
cycle progression, are strong activators of the p21 promoter. In contrast, HBP1 (HMG-
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box protein-1) a novel Rb-binding protein, can repress the p21 promoter and inhibit 
induction of p21 expression by E2F (Gartel et al, 1998). Both E2Fs and HBP1 regulate 
p21 through cis-acting elements located between nucleotides -119 to +16 of the p21 
promoter, which also contains four Spl binding sites important for E2F activation. This 
suggests that the interplay between these positive and negative regulators may determine 
the level of p21 transcription in vivo.
Several Sp-1 sites as well as an Sp-3 site have been mapped to specific sequences within 
the p21 promoter. While Spl and Sp4 have been described as activators of transcription, 
the role of Sp3 in the stimulation or repression of transcription is not clear eg. Sp3 has 
been reported to repress Spl-mediated transcriptional activation (Hagen et al, 1995). A 
detailed functional analysis of the p21 promoter defined a 10 base pair sequence which 
is sufficient to drive TGF-beta-mediated transactivation. This TGF-beta responsive 
element (RE) was found to bind specifically to several proteins in vitro, including Spl 
and Sp3 (Datto et al, 1995). Spl binding sites have been described in many promoters 
and consequently Spl has become known as a house-keeping transcription factor whose 
activity is necessary solely for the basal transcription of many genes. However, several 
Sp-1-like proteins have since been identified, all of which are capable of interacting with 
an Sp-1 consensus site. Thus, such consensus sequences may serve as sites for the 
interplay of several differentially expressed transcription factors. Sp-1 is also a critical 
factor in regulating transcription mediated by Rb, found for example in the Rb control 
elements (RCE) of the c-Fos and TGF-betal promoters. It has therefore been suggested 
that the TGFbetaRE may represent an RCE and that by maintaining Rb in a 
hypophosphorylated state, TGF-beta may be exerting its effects on the p21 promoter 
through Rb. Induction of p21 would in turn lead to a further increase in the 
hypophosphorylated form of Rb, thus establishing a positive feedback loop between p21 
and Rb, ensuring an effective Gi cell cycle arrest.
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3 . 3 . 6 . 2  E f f e c t  o f  L M P 1  e x p r e s s i o n  o n  p 2 1  p r o m o t e r  a c t i v i t y  l e v e l s .
No significant transactivation of the p21 promoter used in this study was detected in the 
presence of LMP1. An observation which was made, nonetheless, was a high basal p21 
promoter activity, comparable to that of SV40 enhancer promoter sequence, which was 
observed using 3 alternative p21 promoter luciferase reporter constructs. These levels 
were several fold higher than levels of activity of the bfl-1 promoter (see Figure 3.11). 
The half-life of p21 mRNA in untreated human cells is short (normally <1 hour). 
Nevertheless, while the basal level of p21 mRNA is low, promoter activity is usually 
quite high, (reflecting the high rate of decay) (Schwaller et al, 1995; Esposito et al,
1997). This allows even a modest increase in stability to result in the rapid accumulation 
of p2J mRNA, a mechanism which is clearly suited to high turnover molecules such as
p21.
Using a common stimulator, previous findings have varied using the 2.4 kb p21 
promoter constructs depending on the cell line under study. For example, p21 promoter 
luciferase reporter activity was induced in K562 cells treated with TPA (Zheng et al,
1996). Also, TPA induction of p21 mRNA in ML1 cells signaled new p21 RNA 
synthesis. In contrast, similar experiments conducted in the promyelocytic HL60 cell 
line, concluded that TPA regulation of p21 expression was mainly post-transcriptional 
(Schwaller et al, 1995). In addition, the period of incubation of cells can be important 
with regard to detection of changes in promoter activity. One study, for example, found 
no significant induction of transcription activity after 2 hours in the presence of TPA 
even though p21 mRNA and protein levels had begun to accumulate by this stage, and 
that no increase in the rate of transcription was observed until 12 hours (Esposito et al,
1997). A different study reported that TPA activated promoter activity after 24 hours 
treatment of cells (Biggs et al, 1996). Specific sites within the p21 promoter have been 
localised as targets of certain activators of the PKC pathway. Phorbol esters and okadeic 
acid have been shown to activate the p21 promoter through Spl sites (Biggs et al, 1996). 
Similarly, other reports have identified binding sites within the p21 promoter which are 
targeted via p53-independent signal transduction pathways. For example it has been 
shown that either IFN-gamma or EGF induces p21 transcription through signal
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transducers and activators of transcription (STAT) proteins; this activation was blocked 
by inhibitors of PKC (Karras et al, 1997; Suzuki et al, 1997). Thus, it appears that at 
least in some instances activation of the PKC pathway triggers an increased transcription 
rate of the p21 gene. In other instances, post-transcriptional mechanisms are important.
3.3.7 Mechanism of transcriptional regulation of p21 gene by LMP1
Investigations into the mechanism of upregulation of p21 expression by LMP1 revealed 
an important role for mRNA stabilisation. This conclusion was based on the following 
observations: p21 mRNA was shown to have a short half-life in unstimulated tumour 
cells in agreement with the findings of others (Schwaller et al, 1995; Esposito et al, 
1997; Akashi et al, 1999; Johannessen et al, 1999); the stability of 21 mRNA was 
enhanced in the presence of LMP1; no significant transcriptional activation of the p21 
promoter was observed in LMPl-induced cells, and finally p21 transcripts accumulated 
in the presence of cycloheximide. Also, since no accumulation of the p21 protein was 
seen as a result of inhibition of protein synthesis by cycloheximide, it appears likely that 
regulation at the post-translational level is not important.
The steady state level of mRNAs in the cell is dependent on both the rates of 
transcription and decay. Thus, a coordinated balance between transcriptional and post- 
transcriptional events is required. Metabolism of eukaryotic mRNA occurs in both the 
nucleus and cytoplasm of the cell. The importance of mRNA stability in the 
accumulation of mRNA transcripts has been highlighted, especially with regard to those 
with short half-lives (Ross, J. 1995). Changes in the stability of specific mRNA afford 
an extremely rapid mechanism to change the levels of their encoded proteins. Clearly, it 
is important that proteins involved in regulation of the cell cycle must be able to undergo 
rapid changes in response to various positive and negative stimuli of cell proliferation. 
Thus, it is not surprising that many cell cycle-related proteins demonstrate a significant 
role for mRNA stabilisation in their regulation. For example, topoisomerase II alpha and 
c-myc are regulated during cell cycle-related events at least in part by stabilisation of 
their mRNAs (Hanson et al, 1994; Goswami et al, 1996). Various extracellular stimuli
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such as protein synthesis inhibitors and stimulators of PKC are able to stabilise c-myc 
RNA (Dani et al, 1984).
Experiments described here revealed an almost 2-fold increase in the half-life of p21 
mRNA which was mediated by LMP1 in DG75tTA-LMPl cells. A high promoter 
activity in the case of p21 implies that small increases in stability become more 
significant, allowing a more rapid accumulation of mRNA transcripts. Thus, the rapid 
changes which are required in the case of many regulators of the cell cycle are possible.
Several examples of stabilisation of p21 mRNA have been documented, with regard to a 
range of stimulators of p21 expression. For instance, in the human ovarian cancer cell 
line, SKOV-3, PMA markedly stabilised p21 mRNA, increasing it’s Tm  from <1 hour to 
>4 hours, and this was found to be the most important mechanism of upregulation of p21 
in this cellular context (Akashi et al, 1999). A different study revealed a longer T\a of 
p21 mRNA (approx. 2\n hours in A431 cells) which was doubled to 5 hours in the 
presence of EGF (Johannessen et al, 1999). Upon longer exposure times in this study, 
the stability of the p21 protein was also increased by about 3 fold, while transcription 
rate was only slightly increased at 1.2 fold. These results reflect a p5 3-independent 
effect, as the p53 protein is non-functional in A431 cells due to a point mutation. In the 
same study, the findings in A431 cells were in contrast to MCF-7 cells with normal p53, 
in which the half-life of p21 mRNA was not increased upon addition of EGF. 
Furthermore, p21 was shown to be increased in a p53-independent manner by TNF 
alpha in the human myeloid leukaemic cell line, KG-1; this induction occurred in the 
absence of new protein synthesis, being due mainly to a 5-fold stabilisation of p21 
mRNA (Shiohara et al, 1996). In this case transcription rate was increased by a factor of 
1.4. In A431 cells, TNF alpha had no effect on the stability of p21 mRNA, unlike KG-1 
cells, but did increase protein stability on prolonged incubation. This probably explains a 
more rapid induction of p21 protein by EGF than by TNF alpha (Johannessen et al, 
1999). Similarly, RNA stability was highlighted in the enhancement of p21 expression 
in normal human fibroblasts (WI38) after exposure to IL-1 (Osawa et al, 1995).
154
Esposito et al (1999) have recently confirmed that a p53-independent pathway for p21 
induction in response to oxidative stress exists. Moreover, they showed that TPA- 
induced and serum-induced increases of p21 mRNA expression are, at least in part, due 
to the activation of the same pathway, and involve changes in the intracellular oxidative 
environment. Stability of mRNA was enhanced 3-fold while no transactivation of the 
p21 promoter was detected following EtMal (dielthymaleate)-induced oxidative stress. 
Evidence suggests that many other p5 3-independent inducers of p21, such as PDGF, 
EGF, TNFalpha and gamma-rays may be modulated by the cells’s redox state. Thus 
mRNA stability would seem to be a very common mechanism of p53-independent 
upregulation of p21. p21 mRNA has also been shown to be stabilised in a p53- 
dependent manner: mRNA stabilisation was the main mechanism of upregulation in 
colorectal carcinoma cells exposed to UV light (Gorospe et al, 1998).
Regulation of mRNA stability is so far poorly understood. However, it is known that cis- 
acting elements within the mRNA molecule can be recognised by regulatory proteins, 
and czs-elements have been demonstrated to modulate mRNA stability both positively 
and negatively (reviewed by Ross, 1995; Beelman and Parker, 1995; Sachs, 1993). 
Numerous mechanisms exist to degrade mRNA effectively. For example, deadenylation 
triggers decapping, thus exposing the mRNA to 5’ to 3’ degradation. Alternatively, 
decay may be initiated independently of deadenylation by sequence-specific cleavage of 
the mRNA. The latter pathway is more likely to be relevant to p21 mRNA degradation. 
Many labile RNAs such as those for granulocyte/macrophage-colony-stimulating factor 
(GM-CSF), TNF alpha, IFN gamma, IL-2 and IL-3 usually contain an adenosine- or 
uridine-rich element, characterised by 3 or more copies of the pentanucleotide, AUUUA, 
in their 3’UTRs and the stability of these mRNA molecules have been shown to be 
regulated by external stimuli (Shaw and Kamen, 1986; Sachs, 1993; Akashi et al, 1994; 
Ross, 1995; Beelman and Parker, 1995; Chen and Shyu, 1995). It was recently shown 
that PMA could stabilise more effectively a reporter RNA containing 3 or more repeats 
of the AUUUA motif in the 3’UTR than those with 2 or less. The p21 mRNA has 3 
repeats of the AUUUA motif (El-Deiry et al, 1993), and it is likely that PMA may 
stabilise p21 mRNA through the AU-rich region in it’s 3’UTR (Akashi et al, 1999).
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Other labile mRNAs coding for oncogenes such as c-Myc and cytokines also have 
AUUUA repeats in their 3’UTR (Akashi et al, 1992; Shaw and Kamen, 1986). Indeed, 
there are several observations which suggest increased levels of AU-binding protein 
interacting with AU-rich elements in PMA-treated cells (Shaw and Kamen, 1886; 
Lindsten et al, 1989).
LMP1 is known to increase intracellular calcium levels and several studies suggest that 
the transient accumulation or redistribution of calcium may also be one of the 
mechanisms for the stabilisation of mRNAs by phorbol esters and PKC activation. A 
calcium ionophore, A23187, stabilised mRNAs coding for IL-3 and G/M-CSF through a 
pathway which requires AU-rich elements in the 3’UTR (Iwai et al, 1993). Redox is also 
known to modulate the stability of mRNAs coding for cytokines and oncogenes by the 
AU-binding protein (Miller et al, 1993) and treatment of cells with PMA causes 
oxidative stress (Esposito et al, 1997). Although it is likely that p21 is stabilised through 
the AU-rich region in the 3’UTR, at least via a PMA-induced pathway, further studies 
are required to determine the mechanism resulting in the stabilisation of this transcript.
No mammalian RNAse which might be programmed to degrade specific mRNAs has yet 
been identified. Thus, the molecular or enzymological mechanism underlying the 
stabilisation of p21 mRNA is not understood, although the degradation of mRNA 
appears to involve endoribonucleases. It is likely that a wide variety of endonucleases 
with different cleavage specificities exist, allowing specific enzymes to be limited to 
individual mRNAs or classes of mRNAs. In this way, their presence would allow for 
specific control of the decay rate of these transcripts. For example, endonucleolytic 
cleavages have been defined in vitro for the albumin mRNA (Dompenciel et al, 1995) 
and in the coding region of the c-myc mRNA (Bernstein et al, 1992). In some cases, the 
rate of endonucleolytic cleavage is modulated by the activity of protective factors that 
bind at or near the cleavage site and compete with the endonuclease. Therefore, in 
certain situations, it appears that the endonuclease is constitutively active and the 
accessibility of the cleavage site is regulated (Binder et al, 1994). Alternatively, 
examples have been documented where endonuclease activity appears to be directly
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regulated (Silverman, 1994), due to the enzyme normally existing in an inactive state. 
Since treatment of LMPl-induced cells with CHX to inhibit new protein synthesis 
resulted in an enhanced accumulation of p21 mRNA, which was absent from control 
cells with no CHX (Figure 12B), this may suggest regulation of mRNA stability by a 
labile protein. It is possible, therefore, that LMP1 may either enhance protective factors 
of cleavage sites or alternatively, induce a direct effect on mRNA degrading enzymes. 
Future studies on the pathway of p21 mRNA degradation, identification of the specific 
endoribonucleases involved and the effects of LMP1 on these activities will contribute 
to a greater understanding of the mechanism of stabilisation.
3.3.8 Signal Transduction Pathways
As mentioned previously, it is becoming increasingly evident in recent years that several 
p53-independent p21 activation routes exist. Some recent studies demonstrated that p21 
could be induced in cells lacking a functional p53 (Akashi et al, 1995; Shiohara, 1996). 
Some of these signals include serum stimulation, treatment with the growth factors 
PDGF, FGF, treatment with okadeic acid, butyric acid, retinoic acid, Vitamin D3, TPA, 
treatment with the cytokines G-CSF, IL-6, IFN-gamma, or treatment with transforming 
growth factor beta (Michieli et al, 1994, Steinman et al, 1994; Sheikh et al, 1994; Jiang 
et al, 1994; Elbendary et al, 1994; Datto et al, 1995; Zhang et al, 1995). Experiments 
have also provided evidence for p53-independent regulation of p21 in vivo, and have 
implicated a role for its expression in growth arrest associated with terminal 
differentiation (Halevy et al, 1995; Parker et al, 1995; El-Deiry et al, 1995; Macleod et 
al, 1995). However, despite the continuing emergence of data supporting significant 
roles for p5 3-independent routes, the molecular events and the signal transduction 
pathways involved in these instances of p21 induction remain unclear.
The LMP1 protein has many properties which are suited to signal transduction, as 
outlined in section 1.5.4. For example, activation of the NFkB transcription factor by 
LMP1 is important in several instances (eg. induction of A20). LMPl’s ability to induce 
NFkB, however, is not required for it’s oncogenicity (Mitchell and Sugden, 1995) and
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thus, NFkB is likely to mediate many but not all of the changes in gene expression that 
are affected by LMP1. LMP1 has been shown to induce expression of the EGF receptor 
and A20 molecule in epithelial cells (Miller et al, 1995). Upon stimulation with EGF, 
these cells demonstrate enhanced tyrosine phosphorylation of downstream targets of the 
EGFR and exhibit enhanced growth in serum-free media. LMP1 is also known to signal 
by its direct association with TNF receptor-associated factors (TRAFS), but these TRAF 
molecules do not mediate most of LM Pl’s induction of NFkB activity (Sandberg et al,
1997). CD40 is one of a range of cell surface activation antigens whose expression is 
upregulated by LMP1. CD40 also signals by binding TRAF molecules and indeed 
parallel roles have been suggested for the CD40 protein and LMP1 in signal transduction 
pathways. The expression of CD40 in carcinomas but not normal epithelial cells and 
also in EBV-infected NPC tissue suggests that signals from CD40 may be involved in 
progression to malignancy. A recent study of CD40-mediated signaling revealed that 
CD40-mediated signals induce resting B cells to accumulate p21, while cycling B cells 
required B cell receptor and CD40-mediated signals to maintain increased expression of 
p21 (Mullins et al, 1998).
LMP1 also activates the JNK pathway, and both NFkB and JNK signaling are, in some 
instances, downstream events of activation of the protein kinase C (PKC) pathway. PKC 
is a widespread family of kinases responsible for many diverse and critical cellular 
functions, including aspects of cellular growth and metabolism (reviewed in Wilkinson 
and Hallam, 1994). For example, PKC phosphorylates various transcription factors and, 
depending on the cell type, these induce or repress synthesis of certain mRNAs. The 
NFkB inhibitor protein IkB is also a substrate of PKC. Phosphorylation of IkB by PKC 
releases NFkB which can then migrate to the nucleus where it induces transcription of 
target genes. Many other examples exist which illustrate the fundamental role of PKC in 
controlling cell growth. PKC consists of a family of at least 10 isoenzymes which differ 
in their structure, co-factor requirement and substrate specificity. The conventional 
PKCs (cPKC), PKC a, Pi, Pn and y are activated by Ca2+, phospholipids and DAG or 
phorbol ester, and are thus Ca2+-dependent enzymes (Wilkinson and Hallam, 1994).
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LMP1 has been shown to induce increased intracellular calcium levels which may 
therefore link LMP1 to activation of PKC isoenzymes.
Several studies have linked the PKC pathway to regulation of p21 expression (Michieli 
et al, 1994; Akashi et al, 1995). For example, PMA induced a relatively low level of p21 
which delayed cell cycle progression but failed to induce cell cycle arrest in SKOV-3 
cells (Akashi et al, 1999). Thus the p53 independence of p21 expression by PKC may 
occur at subsaturating levels which may be unable to arrest the cell cycle. Similarly, the 
relatively moderate level of upregulation of p21 observed in DG75 cells as a result of 
LMP1 expression, was found to simultaneously induce a transient slowing of cell 
proliferation in the absence of any loss of viability. As mentioned previously, this 
cytostatic effect has been shown to correlate with a transient block in G2/M. 
Furthermore, the involvement of p21 in integrating the PKC signaling pathway to the 
cell cycle machinery at the G2/M checkpoint has recently been described by Akashi et 
al, 1999. Thus, a number of lines of evidence suggest a potential role for the PKC 
pathway in LM Pl’s observed effects on p21 levels.
LMP1 is known to activate the MAPK pathway. Moreover, Lin et al (1996) have shown 
that activation of MAP kinase (MAPK) can induce p21 expression. Activation of the 
MAPK signaling pathway via PKC is an important mechanism for several biological 
events, such as apoptosis and PKC regulates the MAPK pathway alone or with other 
mechanisms (Hall-Jackson et al, 1998). Activation of PKC leads to the accumulation of 
p21 transcripts through a p5 3-independent pathway and activation of the MAPK 
signaling cascade is required for the induction of p21 by PMA (an activator of PKC). 
Evidence presented in the same study suggested that the induction of p21 occurred 
mainly through stabilisation of p21 mRNA and protein i.e. at the post-transcriptional 
level. The physiological role of the MAPK-dependent, p53-independent pathway of p21 
mRNA induction is unknown. It is possible that it’s transient induction in response to 
mitogenic stimuli results in inhibition of cdks thereby providing a protective role against 
inappropriate and premature transition from Gi to S phase. Evidence strongly suggests
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that MAPK promotes cell survival upon oxidative stress, through the induction of p21
(Akashi et al, 1999).
In addition to the Ras/MAPK/ERK pathway, LMP1 was more recently demonstrated to 
also activate the p38 MAPK pathway to coregulate IL-6 and IL-8 production 
(Eliopoulos et al, 1999). p38 is a member of the MAPK superfamily activated by stress 
signals and implicated in cellular processes involving inflammation and apoptosis. 
LMP1-mediated p38 activation occurs through both CTAR1 and CTAR2 domains of the 
protein and appears to be mediated by the adaptor protein, TRAF2. p38 activation has 
been observed in response to a variety of stimuli and requires phosphorylation of a 
closely spaced tyrosine and threonine residue in the activation domain of the protein (for 
reviews, see Ip and Davis, 1998; Kyriakis and Avruch, 1996). Among the downstream 
targets of p38 are the heat shock protein 27 (hsp27) and the transcription factors ATF2, 
Elk-1, CHOP/GADD153 and Max.
Specific inhibitors were used to show that compounds that efficiently block LMP1- 
mediated NFkB activation in Rat-1 cells do not impair its ability to signal on the p38 
axis, and conversely, inhibition of inhibition of p38 activity (SB203580 inhibitor) does 
not influence NFkB binding, indicating divergence of signals (Eliopoulos, 1999). 
However, the possibility of LMP1 -mediated NFkB transactivation being a target for p38 
could not be excluded as preliminary data indicated that SB203580 induced a small 
inhibition in LMPl-mediated NFkB transcriptional activity. Transactivation of the IL-8 
promoter occurred as a result of LMPl-mediated p38 activation and binding of ATF2 (a 
downstream target of p38 activation) to the promoter was demonstrated, in association 
with c-Jun proteins. The ability of LMP1 to induce c-Jun phosphorylation through 
activation of INK suggests that this kinase pathway may also contribute to modulation 
of IL-8 expression. JNK, p38 and NFkB have been shown to be involved in a similar 
complex regulation of the E-selectin promoter. Thus, it is possible that activation of p38 
MAPK plays a significant cooperative role in regulating additional LMP1 activities. 
Recently, the p38 inhibitor SB20350 was used in B lymphocytes to demonstrate that the 
p38 MAPK pathway is required for CD40-induced proliferation. As LMP1 signaling
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closely resembles that of the CD40 TNFR, this observation lends further support to a 
role for p38 MAPK in LMP1-mediated gene regulation.
One study which examined a range of human tumour cell lines following treatment with 
serum, TPA or okadeic acid (OA) suggests the involvement of multiple signaling 
pathways in the regulation of p53-independent activation of p21. For example, cell type 
specific differences, variable patterns of p21 activation and different consequences with 
respect to cell cycle arrest were observed. Also, regulation was found to occur at both 
transcriptional and post-transcriptional levels depending on which form of stimulation 
was used. PKC was a requirement in the TPA- but not OA-mediated induction of p21. 
TPA is a known activator of the PKC pathway, but there are also examples of TPA 
induction of gene expression by a PKC-independent pathway. Zheng et al (1996) 
concluded a critical role for PKC function in TPA- (but not in OA-) induction of p21 
expression, by using staurosporine to specifically inhibit the PKC pathway.
Some preliminary experiments were carried out to investigate the role of the PKC 
pathway in LMPl-mediated upregulation of p21 expression. Treatment of cells with 
PM A confirmed the functional integrity of the PKC pathway in upregulation of p21 
protein in DG75 tTA cells. It was also shown that the upregulation of p21 was prevented 
using the PKC inhibitor, staurosporine. However, on further investigation, it was found 
that LMP1 expression was similarly inhibited by ST, such that no conclusions could be 
made regarding the potential role of the PKC pathway in this instance. Nonetheless, as 
can be seen from Western blot results in Figure 15, the experiment did confirm that 
inhibition of LMP1 expression in induced cells correlated with inhibition of p21 
expression. Although inhibition of a cellular response by ST and other general PKC 
inhibitors has frequently been cited as confirmation of a PKC-mediated event, the use of 
such inhibitors has been criticised in the past for their lack of selectivity (Wilkinson and 
Hallam, 1994). ST is a broad spectrum inhibitor of protein kinases, which has various 
effects depending on the concentration used (Tamaoki et al, 1986; Katira et al, 1993). 
ST has been reported to block the activity of both src-related and receptor tyrosine
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kinases, thus preventing any firm conclusion to be made as to the likely role of PKC. For 
this reason, alternative relevant inhibitors were explored.
Treatment of DG75tTA-LMPl cells with SB203580 to inhibit p38 MAPK activity 
produced a result similar to that obtained after staurosporine treatment i.e. it was found 
that both p21 and LMP1 expression were inhibited. Thus, as before, the results were 
inconclusive with regard to the role of the MAPK pathway in LMP1-mediated 
upregulation of p21 expression.
3.3.9 Future studies
The findings of the investigations detailed in this report suggest a number of potentially 
useful further experiments. Clearly, possibilities exist for a somewhat similar 
progression of experiments charcterising changes in levels of other cell cycle-related 
proteins observed in the original RPA data eg. the EBV latent nuclear antigen, EBNA2 
upregulated mRNA levels of the pl9 cdkl about 4 fold.
As already mentioned, it will be important to elucidate the mechanism of p21 mRNA 
stabilisation as effected by LMP1. It may also be interesting to determine whether or not 
LMP1-mediated upregulation of p21 expression requires new protein synthesis. 
Independence of intermediate protein synthesis is one characteristic feature of primary 
response genes, also known as immediate early genes (Herschmann, 1991). In phorbol 
ester-induced HL-60 cells, p21 induction was demonstrated to occur independently of 
intermediary protein synthesis (Schwaller et al, 1995). However, the p53-independent 
induction of p21 mRNA by Raf signalling in mouse fibroblasts was reported to depend 
on protein synthesis and therefore was not an immediate-early response (Sewing, 1997). 
In these experiments, cells were treated with external stimuli (such as PMA) and CHX 
was added to prevent de novo protein synthesis from the point of stimulation, after 
which mRNA accumulation was followed using Northern Blot or RPA analysis. The 
tetracycline-regulated expression system, however, is dependent on de novo LMP1 
protein synthesis and therefore is not suitable for such analyses. An alternative
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expression system, in the form of a stably-transfected LMP1 fusion protein, may be 
useful for control studies. In these cells, the cytoplasmic tail of the LMP1 protein is 
fused to the membrane domain of the NGF receptor, such that activation of LMP1 signal 
transduction can be achieved by addition of NGF to the growth media, without requiring 
de novo synthesis of LMP1 protein (Schwenger et al, 1998). Obviously, this system may 
also prove more suited to a range of other applications. Similarly, chimeric molecules in 
which the extracellular and transmembrane regions of CD2 and CD4 have been linked to 
the cytoplasmic tail of LMP1 have been used to investigate LMP1 signaling following 
antibody-induced aggregation of the chimera (Kyriakis et al, 1996, Eliopoulos et al, 
1999).
A number of alternative PKC inhibitors may be explored in order to confirm or exclude 
a potential role for PKC in this signal transduction pathway. For example, Calphostin C 
is a general PKC inhibitor, while more specific inhibitors such as Rottlerin, which 
specifically inhibits PKC-delta, may help to identify which PKC isoenzyme(s) are most 
important. It is thought that PKCS, may be the key isoenzyme in signaling to NFkB 
(Diaz-Meco et al, 1993). Also, a number of derivatives of PMA which are known to be 
poor stimulators of PKC (eg. 4-o-methyl-PMA, 4alpha-PDD) may be useful controls. 
Some researchers subject cells to prolonged exposure to PMA to reduce PKC activity, 
thus making them resistant to repeated exposure. In view of the fact that LMP1 protein 
expression was inhibited by both ST and SB203580, an alternative expression system 
may need to be employed to overcome this problem. For example, the stably-transfected 
NGF receptor-LMPl fusion referred to previously would not require new LMP1 protein 
synthesis.
RPA gives no indication as to the size or number of mRNA transcripts. For this reason, 
Northern blots provide useful additional information. Preliminary Northern blotting 
experiments have detected an RNA band which is upregulated in MUTU-III cells 
relative to MUTU-I cells and in LMP1 induced cells relative to uninduced cells (results 
not shown).
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The level of upregulation of p21 expression may be critical to its observed effect. Cdk- 
cyclin complexes require the presence of a single bound p21 molecule for kinase 
activity, while several bound p21 molecules exert an inhibitory effect. This may imply 
that subtle changes in p21 levels can have significantly different effects on cell cycle 
progression. It can be important therefore to determine if an observed increase in the 
protein expression level exceeds the threshold required to inhibit cdk activity. For 
example, as a result of exposure of EBV-immortalised LCLs to gamma irradation, p21 
protein levels are increased by a relatively moderate amount. Without any change in 
cdk2 levels, the amount of p21 associated with cdk2 is dramatically increased, such that 
a significant reduction in cdk2 associated kinase activity is observed (Cannel et al,
1998). It has been shown that in EBV-infected cells, small increases in p53 and p21 led 
to cell cycle arrest at the G2/M boundary, but not to apoptosis; moderate increases 
resulted in growth arrest at the Gi/S boundary, also without apoptosis; and large 
increases also induced apoptosis (Chen and Cooper, 1998). These results revealed 
further unanticipated complexities in cell cycle regulation, and show that critical levels 
of these proteins exist which determine cell fate.
Immunoprécipitation experiments may be performed in the future in an attempt to detect 
functional p21 protein in the context of its binding to other cell cycle proteins. p21 is a 
universal inhibitor which preferentially associates with cyclin-cdk complexes as opposed 
to cdks in the unbound state, eg. cyclin-D-cdk2/cdk4 and cyclinE-cdk2 (important 
during G1 phase); cyclinA-cdk2 (required for ongoing DNA replication) (reviewed by 
Sherr, 1994; Hunter and Pines, 1994). cdk2 and cdk4 monoclonal antibodies (a gift 
from Bioresearch Ireland) have already been tested to determine detectable levels in the 
relevant cell lines (not shown). It would be possible to isolate complexes containing p21 
and cdk2 or cdk4 from the relevant protein lysates by immunoprecipitating with the 
relevent cdk antibody and subsequently immunoblotting with anti-p21 antibody. The 
immunoprecipitated complexes could then be assayed for kinase activity, using eg. 
Histone HI and GST-Rb substrates. This would help to ascertain whether p21 levels had 
exceeded the threshold required to inhibit kinase activity. It may be interesting to note if 
any differences are observed in the type of complexes with which p21 is preferentially
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associated and in their relative kinase activités in the different cell lysates under study. 
For example, is the level of LMP1-mediated upregulation of p21 sufficient to inhibit 
cdk2-associated kinase activity? In EBV-immortalised LCLs, at the basal (EBV- 
induced) level of expression, p21 does not prevent the formation of active cdk2- 
containing kinase complexes, whereas, following activation of the p53 pathway 
following exposure to gamma irradiation, the induced p21 associates with cdk2 in an 
inhibitory manner (Cannell et al, 1998). It is important to recognise, however, that p21 is 
a dual inhibitor in that it has been demonstrated to inhibit DNA synthesis and cell cycle 
progression without interfering with the function of cdk/cyckin complexes (Waga et al,
1994) i.e. p21 also associates with the DNA replication factor, PCNA, in an inhibitory 
manner.
The observations made in these experiments occurred in the context of BL cells. As 
EBV infects primary B cells, it would be useful to transfect an LMP1 expression vector 
into primary B cells and to isolate RNA/protein for analysis as before. It would be 
possible to co-transfect LMP1 with a CD2/GFP marker gene into tonsillar B cells for 
immunomagnetic sorting after 24 hours. Under these conditions, assuming a transfection 
efficiency of 5%, the transfected cells can be sorted to 80% purity. This should be 
sufficient to detect the p21 upregulation. In addition, LMP1 mutants are available, 
which could be used in the same set of experiments to assess the functional domains of 
LMP1 involved in the upregulation.
3.3.10 In Summary
Taken together, the data presented here suggest that elevated levels of p21 mRNA and 
protein are a general feature of group III EBV-positive cells and that LMP1 has an 
important role to play in this effect. LMP1 was observed to upregulate the p21 gene in a 
B cell-specific manner. Stabilisation of mRNA was found to be important which 
permits rapid changes in levels of p21 mRNA/protein due to the high basal activity of 
the p21 promoter. Preliminary data suggest that LMP1 may upregulate other target genes 
by stabilisation of their mRNAs (B. d’Souza and D. Walls, unpublished), so this may be
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a common pathway used by LMP1. Further studies will be required to elucidate the 
mechanism of mRNA stabilisation involved. Data presented here indicate that LMP1 
acts through a p53-independent pathway in upregulating p21 expression and that c-myc 
is probably not involved. Although activation of the PKC signal transduction pathway 
seems likely, the pathway, as yet, remains undetermined.
p21 is part of a complex network of regulatory signals in the highly sophisticated control 
of cell cycle progression. Originally described as a gene induced in response to p53 and 
upon cell senescence, p21 has subsequently been shown to be subject to modulation by a 
variety of effectors involving different mechanisms of regulation. Novel experimental 
data have been presented here which reflect recent surprising findings that several 
proteins that are considered to negatively regulate cell cycle progression (p21, p53, pRb, 
p i07) are up-regulated during EBV-mediated B cell activation (Cannell et a l, 1996; 
Allday et al., 1995; Szekely et a l, 1995). As yet, the contributions of each to 
interruption of normal cell cycle events in EBV-infected B cells or their mechanisms of 
upregulation are poorly understood. It is clear that further studies are required both to 
characterise the observations described in this study and to determine their role in the 
EBV strategy of deregulation of cell cycle events. EBNA2 was not found to be involved 
in the upregulation of p21 levels, but perhaps other EBV latent genes have a role to play. 
Elevated levels of p21 may contribute to cell survival and the control of cell 
proliferation rate, which appear to be important functions of the LMP1 protein.
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CHAPTER 4
A STUDY OF THE FUNCTIONS OF 
THE EBNA3 PROTEINS
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4 . 1  I N T R O D U C T I O N
This chapter describes two alternative approaches taken in the study of the functions of 
the EBNA3 proteins (see section 1.5.6). Firstly, the yeast two hybrid system was 
employed to screen for cellular proteins which potentially interact with EBNA3B. In the 
second approach, it was proposed to generate a stable cell line which could be induced 
to express EBNA3A in response to tetracycline withdrawal using DG75tTA cells (see 
section 3.1 for an outline of the principal of this system).
4.2 THE YEAST TW O HYBRID SYSTEM.
4.2.1 History and Principle
Specific interactions between proteins form the basis of many essential biological 
processes. Additionally, transforming proteins of tumour viruses in many cases exert 
their effect through their interactions with cellular proteins; for example, the SV40 large 
large tumour (T) antigen binds to the cellular proteins p53 and pRb (DcCaprio et al, 
1988). Consequently considerable effort has been devoted to the development of 
methods for the assay of such interactions. Typically, many of these interactions have 
been detected by using co-immunoprecipitation experiments in which antibody to a 
known protein is used to simultaneously precipitate target as well as associated proteins. 
Such biochemical methods however result only in the identification of the apparent 
molecular mass of the associated proteins and obtaining cloned genes for these proteins 
is often a difficult process. One approach which has circumvented this problem is the 
use of purified labelled proteins as probes against bacterial expression libraries where a 
positive signal for an interacting protein is accompanied by the availability of the 
corresponding gene. An alternative approach which has grown in popularity over the 
past decade is use of the yeast two hybrid system, a simple and sensitive means to 
identify proteins that bind to a protein of interest or to delineate domains or residues 
critical for an interaction.
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The concept of a novel yeast-based two hybrid genetic assay for detecting protein- 
protein interactions was first introduced by Fields and Song in 1989, and was derived 
from three experimental observations. Firstly, Brent and Ptashne (1985) demonstrated 
that the activation domain of Gal4 (a yeast transcription factor) can be fused to the DNA 
binding domain (DBD) of E. coli Lex A to create a functional transcription activator in 
yeast. Second, Ma and Ptashne (1987) built on this work to show that the DBD does not 
have to be physically on the same polypeptide as the activation domain i.e. the activation 
domain could be brought to DNA by interaction with a DBD. Fields and Song (1989), 
working independently of Ma and Ptashne, made the seminal suggestion that protein 
interactions could be detected if two potentially interacting proteins were expressed as 
chimeras. Two yeast proteins, SNF1 and SNF4, were used to make a SNF1 fusion to the 
DBD of Gal4 and a SNF4 fusion to the Gal4 activation domain. They demonstrated that 
the strength of the SNF1-SNF4 interaction was sufficient to allow activation through a 
Gal4 DBD. From this, they suggested the feasibility of selecting interacting proteins by 
performing screens of cDNA libraries made so that library-encoded proteins carried 
activating domains (Fields and Song, 1989).
Based on these findings, the yeast two hybrid system (YTHS) exploits the finding that 
most eukaryotic transcription activators are modular. Thus, the ability of a pair of 
interacting proteins to bring a transcription activation domain into close proximity with a 
DNA binding domain (DBD) that regulates the expression of an adjacent reporter gene 
is used to indicate an interaction (Fields and Song, 1989; Chien et al, 1991). The 
principle of the system is summarised in Figure 4.1. Briefly, the DNA binding domain 
targets the hybrid protein to its binding site, where noncovalent interaction with another 
protein tethers the activation domain to the upstream activation sequences (UAS), 
activating transcription of a specific reporter gene. The latter protein is normally 
encoded by a pool of plasmids in which total cDNA or genomic DNA is ligated to the 
activation domain.
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A B C
Figure 4.1 The interaction trap. (A) An EGY48 yeast cell containing two lexA operator-responsive 
promoters, one a chromosomally-integrated copy of the LEU2 gene (required for growth on -Leu media), 
the second a plasmid bearing a GAL1 promoter lacZ fusion gene (causing yeast to turn blue on media 
containing X-gal). The cell also contains a constitutively expressed chimeric protein, consisting of the 
DNA-binding domain of LexA fused to the probe or “bait” protein, shown as being unable to acivate 
either of the two reporters. (B) and (C), EGY48/pbait-containing yeast have been additionally 
transformed with an activation domain (ACT)-fused cDNA library in pJG4-5, and the library has been 
induced. In (B) the encoded protein does not interact specifically with the bait protein and the two 
reporters are not activated. In (C), a positive interaction is shown in which the library-encoded protein 
interacts with bait protein, resulting in activation of the two reporters (arrow), thus causing growth on 
media lacking leucine, and blue colour on media containing X-gal. Symbols: black rectangle, lexA 
operator sequence; open circle, LexA protein; open pentagon, bait protein; open rectangle, library protein; 
shaded box, activator protein. Adapted from Gyuris et al, 1993).
In most cases, the well-characterised yeast transcription factor Gal4 and the DBD of E. 
coli LexA are used in constructing the fusions, and the E. coli lacZ gene is often used as 
the reporter (Chien et al, 1991; Durfee et al, 1993 and Gyuris et al, 1993). Both Gal4 
and LexA bind as dimers and the reporter genes contain several copies of the binding 
site. These DNA binding and activation domains (AD) can function at either end, but for 
ease of cloning are usually placed at the amino end. If they lack an endogenous nuclear 
localisation sequence, vectors usually include a heterologous signal sequence (for a 
review of the two hybrid system, see Fields and Sternglanz, 1994). A flow chart for 
performing an interaction trap is represented in Figure 4.2.
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Figure 4.2. Flow chart for performing an interaction trap
Thus, though systems differ in their specifics, all have three basic components:
- yeast vectors for expression of a known protein fused to a DBD,
- yeast vectors that direct expression of cDNA-encoded proteins fused
to a transcription AD,
- yeast reporter genes that contain binding sites for the DBD.
Different systems use different reporter genes, but usually two alternative genes are 
utilised to help reduce false positives. As mentioned above, one commonly-used reporter 
gene is E. coli lacZ which produces blue colonies on plates or filters containing X-Gal. 
A second reporter gene which encodes an enzyme required for the biosynthesis of an 
amino acid may also be used. For example, use of LEU2 or HIS3 allow for selection of 
cells that grow on media lacking the relevant amino acid and are particularly helpful 
when screening libraries. The activation-tagged cDNA-encoded proteins are expressed 
either from a constitutive promoter or from a conditional promoter such as that of the 
GAL1 gene. Use of a conditional promoter makes it possible to quickly demonstrate that 
activation of the reporter gene is dependent on expression of the activation-tagged 
cDNA proteins.
While the two hybrid system is most often used in yeast, it should work in any eukaryote 
and has been used in mammalian hosts (Vasavada et al, 1991; Fearon et al, 1992). 
However, the yeast-based system has numerous advantages, including the ease of 
transformation, the convenience of retrieving plasmids, and the availability of nutritional 
markers and well-characterised reporter genes for direct selection. Finally, endogenous 
yeast proteins are less likely to bind a mammalian target protein to prevent its interaction 
with a protein encoded by a library. No endogenous yeast proteins bind to the LexA 
operators.
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4 . 2 . 2  A p p l i c a t i o n s
The YTHS has three major applications. The system has been widely used to test known 
proteins for interaction and also to define domains or amino acids critical for an 
interaction. Finally, perhaps the most powerful current application involves the 
screening of libraries for proteins that bind a protein of interest. Typically, libraries are 
constructed in which total cDNA derived from an organism or tissue is fused to a 
sequence encoding a TA domain. These libraries generally contain >106 inserts, 
although only one sixth of these are likely to be in the correct orientation and reading 
frame. For example, the p21/CIPl cyclin-dependent kinase (cdk) inhibitor was identified 
by screening a library with cdk2 (Harper et al, 1993). Similarily, screening with cdk4 
detected the pl6  cdk inhibitor (Serrano et al, 1993). The sensitivity of the method has 
been illustrated by the detection of certain enzyme-substrate interactions which had not 
been detected using alternative methods, eg. binding of Ras with the protein kinase Raf 
was detected using the yeast two hybrid system (Votjek et al, 1993) but had not been 
observed by co-iminunoprecipitation. Also Raf binding of the Ikb protein which can be 
phosphorylated by Raf yields a signal in this system (Aelst et al, 1993). It seems likely 
that transient interactions can trigger transcription to produce a stable mRNA that can be 
repeatedly translated to yield a reporter protein. This type of amplification leads to a 
detectable signal even when the initiating interaction cannot be observed in vitro. Other 
interactions with the basal transcription machinery may help stabilise a weak protein- 
protein interaction.
Several industrially significant uses of YTHSs have emerged. Firstly, some important 
targets for pharmaceutical intervention have been identified using these techniques and it 
is thought that their extension in the future will allow the development of new drugs. For 
example, new nuclear hormone receptors were identified by Seol et al (1994). Ligands 
for these receptors are likely to be biologically active and may well have pharmaceutical 
significance. Another industrial application involves searching for compounds that 
modulate protein interactions. This is based on the premise that compounds that weaken 
a given interaction would diminish expression of reporters. Furthermore, in two hybrid 
systems, the strength of activation generally correlates with the strength of interaction.
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Mutations in either interacting protein that diminish binding, and thus reporter activity, 
can indicate residues in protein-protein contact. This permits the determination of 
specific residues involved in a given protein-protein interaction.
4.2.3 Disadvantages and Limitations.
While a wide range of protein-protein interactions may be detected using the YTHS, 
some limitations exist. Despite the inclusion of a nuclear localisation signal in the bait 
plasmid, some proteins cannot be imported into the nucleus and thus are clearly not 
suitable. Also, improper folding of bait proteins in the yeast cell precludes their use in 
this assay. Interactions which are mediated by post-translational modifications may not 
be detected; for example, certain phosphorylation reactions may not occur in yeast. 
Similarly, proteins which are glycosylated and/or contain disulphide bonds are generally 
not compatible with a nuclear-based system. For this reason, it may not be possible to 
reproduce interactions involving extracellular proteins, thus, the assay may be of limited 
use in analysing receptor-ligand interactions which usually occur outside the cell. 
Nonetheless, the intracellular domains of membrane receptors will probably function in 
the YTHS. Despite these limitations, proteins are more likely to be in their native state in 
a yeast-based system than those produced in bacterial systems.
The broad applicability of the YTHS partially depends on the fact that most proteins do 
not contain activation domains. Nevertheless, in some cases a bait induces 
transactivation due to the presence of true ADs while in many cases random domains 
can cause activation. In these cases, a truncated form of the protein may be used or the 
residues responsible for transactivation may be deleted. However, it is often impossible 
to tell what effect this might have on it’s ability to bind other proteins. Problems have 
also been encountered where the transcription factor domain blocks accessibility of 
either interacting protein. In these cases, the orientation of the hybrid can usually be 
reversed.
Despite the extensive control measures in place, false positives remain a significant 
problem associated with use of the YTHS. Having passed a dual selection screening 
process, certain library plasmids activate reporter gene expression, independent of
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interaction with the bait protein. In many cases, this is caused by a library plasmid 
encoding a protein involved in transcription, but in other cases the explanation remains 
unclear. Such positives can usually be eliminated by assaying the positive library 
plasmids against hybrids of the DBD fused to other unrelated bait proteins. In this case, 
the more non-specific fusion proteins which are used the better. In view of these 
problems, careful design of bait, proper use of controls and confirmation of results with 
an independent method are essential for the successful use of the YTHS.
4.2.4 In Conclusion
In spite of the problems and pitfalls which have become more evident in recent years, 
the YTHS has nonetheless provided a useful tool over the past decade both in the study 
of interactions between known proteins and in the identification of new proteins which 
interact with known target proteins. The yeast two hybrid system has been particularly 
useful for studying proteins that control the cell cycle, that regulate transcription and 
function in oncogenesis and tumour suppression. It seems likely that, given its high 
sensitivity and broad applicability, this system and other hybrid protein systems will find 
application in many areas of research. Interaction technology may be of utility for 
assigning function in genome applications; eg. to assign function to unknown proteins, 
to assign proteins to ordered genetic pathways and even to find genes altered in disease 
states (see Mendelsohn and Brent, 1994 for applications to biotechnology research.). 
Thus, it seems likely that interaction technology will continue to have a large impact on 
many areas of basic and applied biological research.
4.2.5 Aims
The aim of this work was to screen relevant cDNA libraries for protein-protein 
interactions involving the EBNA-3 family of proteins, in particular, EBNA-3B. It was
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proposed to prepare constructs which would allow screening for interactions involving 
EBNA-3A, EBNA-3B or EBNA-3C, but to conduct initial screening using the EBNA- 
3B construct. In the event of detection of any positive interactions, EBNA-3A and -3C 
could then be screened for specific association with the isolated interactor. Although 
members of the same family, amino acid homology is limited and so interactions 
specific to each family member as well as common interactions are quite likely. 
Furthermore, the YTHS could subsequently be used to more precisely delineate 
domains/amino acids critical for binding. In each case, amino-terminal fragments of 
EBNA-3 were chosen to use as bait in the screening assay due to the existence of 
transcription regulatory domains in the carboxy-terminal end (see Figure 4.3). In 
addition, previously identified protein-protein associations involving the EBNA-3 family 
have been largely confined to the amino-terminal end.
For the purpose of these experiments, the YTHS was employed to screen two alternative 
cDNA libraries. This necessitated the use of two systems which differ quite significantly 
in methodology. For convenience, they will be referred to as YTHS-A (developed by 
Golemis et al, 1993) and YTHS-B (developed by Harper et al, 1993). In each case, the 
relevant library was screened with an amino-terminal fragment of the EBNA-3B gene, in 
an attempt to identify proteins with which the latter interacts. Materials and methods 
used in the YTHS are described in sections 2.1 and 2.8, respectively. Solutions are 
detailed in Appendix.
4.3 YTHS-A
4.3.1 Strategy
The first yeast two hybrid system (YTHS-A) employed was based on a system which 
owes it’s development to work primarily by Jeno Gyuris and Erica Golemis (Golemis et 
al, 1993). This system was employed to screen a library prepared from the cDNA of a 
human foetal lung fibroblastic cell line, WI-38, for potential interactors with a 1575bp 
amino terminal fragment of EBNA-3B. The YTHS-A method consisted of three critical
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components (reviewed by Mendelsohn and Brent, 1994). First, a vector (pEG202, Figure
4.4) for expression of the protein of interest, EBNA-3B, fused to the LexA DBD, 
referred to as the bait plasmid, or pBait. Second, the yeast strain EGY48, which has two 
LexA-responsive reporter genes. A yeast Leu2 derivative that has its upstream 
regulatory sequences replaced with LexA operators allowed transcription of the Leu 
gene to be measured by the ability of the strain to grow in the absence of leucine. The 
other reporter gene, lacZ, provided a secondary assay of activation, as well as some 
quantitative information about the interaction. Third, a library plasmid (pJG4-5, Figure
4.5) directs the conditional expression of cDNA proteins fused at their amino-termini to 
a moiety containing three domains: a nuclear localisation signal, a transcription 
activation domain and a HA epitope tag. The cDNA-encoded protein is expressed from 
the yeast GAL1 promoter, which is induced by galactose and repressed by glucose. The 
use of a galactose-inducible promoter makes it possible to determine that the leucine 
prototrophy is dependent upon cDNA expression. Thus, an advantage of this particular 
system is that cells containing true interactors will grow on media lacking leucine only if 
it contains galactose but not when it contains glucose.
4.3.2 Preparation of bait fusion construct, pAS-3B-525.
A cloning strategy was designed to construct a LexA-EBNA-3B fusion which would 
express an amino-terminal portion of EBNA-3B fused to the C-terminus of LexA. This 
involved insertion of the appropriate EBNA-3B coding region (Figure 4.3) into the 
pEG202 plasmid (see Figure 4.2 and section 2.1 for plasmid description) which 
constitutively expressed EBNA-3B fused to amino acids 1 to 202 of LexA (includes the 
DNA binding and dimérisation domains). Although it does not contain a yeast nuclear 
localisation sequence, LexA and most LexA fusions will enter the nucleus. Nevertheless, 
a derivative of pEG202 which contains an additional NLS (pNLEX) was included in 
similar cloning experiments.
One important requirement of the YTHS is that the bait should be transcriptionally inert. 
Therefore, selection of a portion of EBNA-3B for use as bait in the interactor hunt was
177
based on minimising the likelihood of inappropriate transcriptional activation, while 
retaining the domains most likely to be involved in protein-protein interactions. To this 
end, a 1575 bp amino terminal fragment of EBNA-3B was subcloned into pEG202 and 
pNLEX downstream of the LexA DNA binding domain. This region of EBNA-3B 
excludes a C-terminal proline-glutamine-rich domain (see Figure 4.3) which has been 
shown in EBNA-3C to contain a transactivation domain (aa 724-826) similar to the 
transactivation domain in the mammalian transcription factor, Sp-1 (Marshall et al,
1995). Other transcriptional regulatory domains have been delineated in the C-terminal 
portion of the EBNA-3 proteins, including a strong repressor domain identified in 
EBNA-3C (aa280-525). Furthermore, this bait construct retained the putative RBP-Jk 
binding site which lies between aal81-257 (Robertson el al, 1996).
TBP binding 
(aa 1-350)
RBP-Jk binding 
(aa 181-257)
StrongR.D.
(aa280-525)
N
«4—
90 325 440
EBNA-3B525 -------
EBNA3B-279
T.A.D
(aa724-826)
c
Weak T.A.D. (aa580-992, EBNA-3C)
Figure 4.3 Functional domains of the EBNA-3B Protein. Approximate location of RBP-Jk binding 
domain and putative transcription regulatory domains of the 933aa EBNA-3B protein are shown (see also 
figure 1.7). TBP : TATA-binding component of TFIID; R.D : Repressor domain; T.A.D : 
Transactivation domain. (Cohen and Kieff, 1991; Le Roux et al., 1994; Marshall and Sample, 1995). 
Arrows indicate regions of EBNA-3B included in bait protein. Dashes indicate known functional EBNA3 
domains. Line sizes are approximate to domain sizes.
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Psfl 0.00/9.60
Figure 4.4 pEG202 expression vector, pEG202 uses the strong constitutive alcohol dehydrogenase 
promoter (ADH)!ro) to express bait proteins as fusions to the DNA binding protein LexA. Restriction sites 
available For insertion of coding sequences are shown immediately upstream of the AHD,„. This plasmid 
contains the HIS3 selectable marker and 2 pm origin of replication to allow propagation in yeast, and the 
ampicillin resistance gene (ampT) and the pBR origin (ori) or replication to allow propagation in E.coli. 
Numbers indicate relative map positions.
179
ATG
/ \
ffcoRI Xho\ 
3.13 3.12
Figure 4.5 pJG4-5 library plasmid. pJG4-5 (Gyuris et al., 1993) expresses cDNAs or other coding 
sequences inserted into the unique EcoRl and Xhol sites as translational fusions to a casette consisting of 
the SV40 nuclear localisation sequence (nuc. loc.), the acid blob B42 and the haemagglutinin (HA) 
epitope tag. Expression of sequences is under the control of the GAL1 inducible promoter. Numbers 
indicate relative map postitions.
The 1575 bp N-terminal fragment of EBNA-3B was amplified by PCR from p7CMVE4 
using the primers and protocol detailed in sections 2.1 and 2.3 (see Figure 4.6). In order 
to allow insertion of EBNA-3B into the BamHl site of vectors, PCR primers were 
designed to incorporate a BamHl restriction site at each end of the PCR product.
M 1 2 3 4 M
EBNA3B
(1575bp)
pAS-1
(8.5kb)
3.0 kb
2.0 kb 
1.6 kb
Figure 4.6 Electrophoresis of EBNA-3B PCR products (0.8% agarose gel).
Lane M: 1 kb markers; Lanes 1 and 2: EBNA-3B 1575 bp PCR product; Lanes 3 and 4: BamHi- 
linearised pAS-1 (8.5kb). Arrows indicate DNA used in cloning experiments; dashes indicate DNA size 
markers.
EBNA-3B PCR product was cut with BamHl enzyme to give sticky ends which were 
then ligated with the BamHl -linearised vectors. Following transformation of E.coli, 
recombinant clones were characterised by BamHl restriction analysis (Figure 4.7).
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 M
12 kb
3 kb 
2 kb 
1.6 kb
. -  - \ 
w* •«* M m
I
8.5 kb 
vector
1.6kb
insert
Figure 4.7 Identification of constructs containing EBNA-3B insert. DH5a E.coli were transformed 
with ligations of EBNA-3B and pEG202/pNLEX. Recombinant colonies were assessed by BamH 1 
digestion of DNA minipreps, which were then electrophoresed on a 0.6% agarose gel. Plasmids which 
contain a 1.6 kb insert can be seen in lanes 6, 10 and 12. Arrows indicate digested DNA; dashes indicate 
DNA size markers.
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To determine which recombinants contained EBNA-3B inserted in the correct 
orientation, two independent restriction analyses were performed (as for all subcloning 
experiments). For example, with reference to Figure 4.8 below a single Nco 1 site is 
present in the multiple cloning site of pEG202/pNLEX, located downstream of the C- 
terminal end of the EBNA-3B insert, while EBNA-3B525 contains 2 Nco 1 sites., 
incorrect orientation of insert gives a band of -950 bps which is absent in correctly 
orientated inserts .
------------------------------------- EBNA-3B_______________
(311aa) (525 aa)
Nco 1 Ncol Nco I
(933bp) (1431bp)
Figure 4.8 Schematic representation of Ncol sites in EBNA-3B inserted into 
vector. Blue lines represent EBNA-3B sequences, while black lines represent pEG202 
vector sequences.
4.3.2 Truncation of EBNA-3B525 bait construct to give EBNA-3B311 bait in 
pEG202/pNLEX.
Shorter LexA fusion proteins were derived from pEG-3B-525 and pLEX-3B-525 
constructs by Ncol restriction. Referring to Figure 4.8(A) again, it can be seen that this 
produces a 933 bp N-terminal EBNA-3B fragment inserted at the BamU 1 site of 
pEG202/pNLEX to give pEG-3B-311 or pLEX-3B-311. Each encodes the first 311 
amino acids of the EBNA-3B gene product. The result of this manipulation is illustrated 
in figure 4.9(A) by BamU] excision of inserts, and confirmed in an independent 
restriction using Pstl in Figure 4.9(B). Digestion with Pstl gives a 5.35 kb band in
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pEG202/pLEX-3B-525 which is reduced to a 4.75kb band as a result of loss of 
approximately 600 bp in pEG202/pLEX-3B-311.
Figure 4.9 Truncation of pEG-3B525 bait construct to give pEG-3B311.
(A): BamHl restriction of pEG-3B525 / pEG-3B311 (1.8% agarose gel).
Lane 1 : pEG-3B525 (1575 bp); Lane 2 : pEG-3B311 (933 bp); L aneM : lOObp Markers
(B): Pstl restriction of pEG-3B525 / pEG-3B311 (0.6% agarose gel).
Lane M; 1 kb Markers; Lane 2: pEG-3B525, Pstl digest; Lanes 3 and 4: pEG-3B311, Pstl digest 
Arrows indicate digested recombinant DNA fragments; dashes indicate DNA size markers.
In conclusion, 4 individual EBNA-3B baits were constructed as follows: 
pEG-3B-525 : 1575 bp insert (encoding 525aa) in pEG202. 
pEG-3B-311 : 933 bp insert (encoding 311aa) in pEG202. 
pLEX-3B-525 : 1575 bp insert (encoding 525aa) in pNLEX. 
pLEX-3B-311 : 933 bp insert (encoding 31 laa) in pNLEX.
1 2 3 4 M M 1 2 3 M
1575bp
933bp
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4 . 3 . 4  C h a r a c t e r i s a t i o n  o f  B a i t s .
4.3.4.1 Transcription activation assay
This assay was used to verify that baits did not activate transcription of the reporter 
genes. Using X-gal filter lift assays for activation of the lacZ reporter gene, positive 
controls were observed to be blue within an hour, while negative control and all baits 
tested showed no colour change after overnight incubation at 30°C. Transformant strains 
containing baits were also tested for their ability to grow in the absence of Leu.
EGY48 Carbon source Growth on Leu- LacZ
pSH18-34/pSH17-4 Glucose - -
pSH18-34/pSH17-4 Galactose ++ ++
pSH18-34/pRFHM-l Glucose - -
pSH18-34/pRFHM-l Galactose - -
pSH18-34/pBait* Glucose - -
pSH18-34/pBait* Galactose - -
Table 4.1 Transcription activation assay. *pBait denotes that each of the following baits were tested: 
pEG-3B-525; pLEX-3B-525; pEG-3B-311; pLEX-3B-311.
The data in Table 4.1 confirm that none of the bait plasmids express a fusion protein that 
is transcriptionally active. As both reporter genes are controlled by gal-dependent 
promoters, therefore any transactivation should be apparent only when galactose is 
provided as the carbon source (see positive control). For this reason, glucose plates were 
included in the experiment as negative controls.
4.3.4.2 Repression assay (Nuclear localisation assay).
The repression assay was used to confirm that bait fusion proteins are capable of 
entering the nucleus and binding LexA sequences. This assay is based on the 
observation that LexA and and non-activating LexA fusions can repress transcription of
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a reporter gene which has two lexA operators positioned between the TATA box and 
upstream activating sequence in pJKlOl. Thus, repression of P-galactosidase activity is 
used as an indication of nuclear localisation and interaction with LexA operators (Brent 
et al, 1994)). A quantitative P-galactosidase liquid assay was used to determine levels of 
activity.
S. cerevisiae EGY48 P-gal activity*
PJKlOl 730 U
pJK101/pRFHM-l 377 U
JK101/pLEX-3B-311 229 U
Table 4.2 Repression Assay (Nuclear Localisation Assay). *Units of activity are based on a duplicate 
average for each transformant.
The results indicated that the pLEX-3B-311 bait expressed a protein that is localised to 
the nucleus and binds LexA operators, as suggested by the 3.1-fold decrease in P- 
galactosidase activity (Table 4.2). This level of repression was greater than that 
produced by the control construct. It has been reported that 2-fold repression indicates 
>50% operator occupancy by the bait. Other baits tested gave no detectable activity but 
extension of incubation times in P-gal assays may have allowed detection of lower levels 
of activity.
4.3.4.3 Western immunoblotting.
It is generally recommended to assay for the production of full-length LexA fusions as 
occasionally some fusion proteins will be proteolytically cleaved by endogenous yeast 
proteases. Extracts from yeast cells harbouring the bait plasmid are usually 
immunoblotted with either an antibody to LexA or one specific to the protein fused to 
LexA to detect a protein of the expected molecular weight (Golemis et al, 1994). As no 
anti-EBNA3B antisera were available, a rabbit polyclonal anti-LexA antiserum (a gift 
from Dr. Luke O’Neill, University of Dublin) was used. Full-length LexA-525 and
185
LexA-311 baits were expected to appear as 57 and 81 kd proteins respectively. Although 
the correct size proteins could not be confirmed by Western blot, dot blot analysis was 
used to detect the expression of LexA protein in each bait (not shown). EGY48 
containing pSH18-34/pSH17-4 was included as positive control, for expression of LexA 
protein while empty EGY48 was used as negative control. These results did not confirm 
that full-length fusion proteins were being expressed but did provide evidence of the 
expression of LexA proteins in the sample preparations, and confirmed the capacity of 
the detection system to detect LexA.
4.3.5 Interactor hunt
As baits were deemed likely to be suitable for use in a library screen, an interactor hunt 
was initiated using the pLEX-3B525 construct as bait. Selection of positive interactors 
using this system was based on detection of clones which exhibited galactose-dependent 
growth on medium lacking leucine, and galactose-dependent (3-galactosidase activity. To 
this end, a two-step approach for selection was employed whereby library transformants 
were first harvested and frozen, before plating for selection of interactors. Thus, the first 
step involved introducing the library (Trp+) into the EGY48 selection strain which 
contained the reporter plasmid, pSH18-34 (Ura+) and the bait plasmid, pLEX-3B-525 
(His+). As a much higher transformation efficiency was required here than for the 
transactivation and repression assays, an alternative high efficiency protocol was used. 
Library transformants were then selected on plates containing Leu+ medium with 
glucose as the carbon source (YNB/Glu-U-H-T+L) (Step 1). After 4 days growth at 
30°C, transformants were then harvested, washed, and stored as glycerol stocks at -80°C 
in a total of 2 ml media.
Plating efficiency was determined in order to estimate an appropriate amount of stock to 
plate when screening for positive interactors. Using the two-step approach, plating 
efficiency was determined after the first plating by preparing a series of dilutions of 
transformants in galactose-containing Leu+ medium. In this way, plating efficiency was 
estimated to be in the region of 5 x 106 CFUs/100 (0,1 frozen cells. Transformation
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efficiency was calculated to be approximately 2.5 x 106 CFUs/|ig DNA. Having 
determined plating efficiency, transformants could then be plated, as required, on media 
lacking leucine (YNB/gal-U-H-T-L) (Step 2). Growth in galactose-containing medium 
was carried out to induce expression of the cDNA-encoded proteins. Thus, primary 
isolation of putative interactors was based on detection of any interactions which 
transactivated the leu reporter gene. A small-scale plating allowed a rough estimation of 
the total number of putative interactors i.e. -4% of stock gave a total of 51 colonies on 
Leu- plates containing galactose as carbon source. This result corresponds to a figure in 
the region of 1200 putative interactors in the total stock of library transformants.
In the two-step method, transformants isolated on Leu- medium in the initial plating 
must be screened for false positives by examining the Leu2 and lacZ phenotypes of the 
interactors. Growth on media lacking leucine must be shown to be galactose-dependent 
and the transformants must also exhibit galactose-dependent (3-galactosidase activity. 
Firstly, the Leu-i- yeast were streaked for single colonies to isolate them from 
contaminating Leu- yeast that were present when the Leu+ colony was forming. These 
were then patched onto a glucose master plate, from which four new replica plates were 
made in order to test for lacZ expression and galactose dependence. This phenotyping 
required two leu- plates and two X-gal plates; one Leu plate and one X-gal plate contain 
galactose to induce cDNA expression (plus raffinose to enhance growth), while the other 
leu- plate and X-gal plate contained glucose to repress cDNA expression. It was 
necessary to grow the yeast on glucose master plates to shut off cDNA expression before 
replica plating because galactose-dependence of Leu+ and lacZ+ phenotypes may 
sometimes be masked if there is sufficient message and protein product from the 
activation tagged cDNA protein to allow the yeast to grow on leu- glucose for several 
generations and turn blue on glucose X-gal without further cDNA expression. Despite 
this step, however, when Leu positive clones in this study were isolated and tested for 
galactose dependence, no clones appeared to exhibit galactose-dependence, that is, all 
clones grew on in the presence of either glucose or galactose. Thus, a summary of the 
interactor hunt results is represented in Table 4.3 below.
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Transformants Leu + Gal-dependent Leu+
No. of cDNA 
library clones
1 x 10s 1200
Table 4.3 Summary of YTHS-A interactor hunt results.
Normally, yeast that grow on Leu-/galactose but not on Leu-/glucose medium, and that 
turn blue on galactose X-gal plates but remain white on glucose X-gal plates (i.e. those 
that are galactose-dependent Leu+ and lacZ+) are picked for further characterisation.
This type of false positive result has been previously documented and appears to occur 
with certain baits for reasons that aren’t completely understood (Brent, 1994). One 
possible explanation is the presence of a Leu+ contaminant, but this is probably unlikely 
to account for all of the false positives. A number of investigations into this result were 
subsequently carried out. Yeast miniprep DNA was used in PCR reactions to amplify 
cDNAs from a random sample of 10 clones using primers complementary to the regions 
flanking the site of insertion of cDNAs (BCOl and BC02, see section 2.1). No PCR 
product was observed on agarose gel electrophoresis which indicates either a technical 
problem with the PCR reaction (a positive control for these primers was not available) or 
perhaps a leu-positive contaminant. Library DNA was investigated in two ways. Firstly, 
a sample of library DNA was used in PCR reactions as above. Secondly, library DNA 
was digested with Xhol/EcoRl in order to excise the cDNA inserts. Unexpectedly, 
results of these analyses failed to show an intact library of the anticipated complexity. 
This implied that reduced quality of library DNA may have contributed to the observed 
results.
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4.4.1 YTHS-B
4.4.1 Strategy
An alternative version o f  the YTHS w as also em ployed in an attempt to identify proteins 
which interact with E B N A -3B . A s human B lym phocytes are a main cellular target o f  
EBV infection, a cD N A  library prepared from the m RNA o f EBV-transformed human B 
lym phoctes (Durfee et a l , 1993) provided an ideal pool o f  potential interactors with 
which to screen E B N A 3B . The system  presented here represents a modification o f a 
system  (Durfee et al, 1993) originally developed by Harper et a l (1993) and differs in a 
number o f  ways from Y TH S-A  outlined in section 4.3. For exam ple, the D N A  binding 
and activation domains are both derived from the yeast Gal4 transcription factor, in pAS 
(Figure 4 .10) and pACT (Figure 4 .11 ), respectively. The various transcription factors 
used in the different versions o f  the YTHS have been found to work comparably (Fields 
and Sternglanz, 1994) and the sensitivity o f  a particular assay seem s to depend mostly 
on the nature o f  the D N A  binding sites present in the reporter gene and the level o f  
production o f the hybrid protein.
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XbaJ(lOOC)
Xbal{1900)
E coRV(2I00)
Nael(2900)
Sacl(3200) 
EcoRV(MW) 
EcoMß720)
■Bgl 11(3740)
* Denotes Dam Methylatlon 
Blocks Cutting
S f l l
CAT AfTG G CC AT.G GAG GCC COG GBS ATCjCI 
' B äiriH lNder Ncol S m a l
CGT CGA C  
Sail
F ig u re  4.10 pAS-1 expression vector. pAS-1 is shown, containing TRP1, 2 jim origin, and the ADC1 
promoter driving expression of the Gal4 DBD (aal-147, Keegan at al, 1986) fused to a polylinker. The 
Gal4 derivative is tagged with the HA epitope and the polylinker contains several useful cloning sites for 
insertion of coding sequences.
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P vliI(8126) Xbal(600)
micron
Hpal(1575)
pACT2
8.55 kb
A D H  P rom oter
Activation
D om ain
L E U 2
T e rm in a to r
E coRV(3200)
Sfi I_____________
C A T  A TG  G CC A T G GAG G C C CCp  G GG A TC  C G A  A TT  C GA  G C T CGA G AG A TC  T  
Nciel Ncol Smal BamHI EcoRI Xhol Bglll
Figure 4.11 pACT library plasmid. pACT contains the ColE l origin of replication 
and b la  gene for replication and selection in E .c o l i , and L E U 2 ,  2  |im  origin, and the 
ADC1 (A dhl) promoter sequences for selection, replication and expression in yeast. The 
ADC promoter drives expression of a hybrid protein consisting of the SV40 large T 
antigen nuclear localisation signal and sequences encoding the AD II of Gal4.
The yeast strain utilised, Y187, carries two chromosomally located reporter genes whose 
expression is regulated by Gal4. Firstly, the E .c o l i  l a c Z  gene under the control of the 
GAL1 promoter (Fields and Song, 1989) and secondly, the selectable H I S 3  gene, where 
the H I S 3  regulatory sequences have been replaced by the GAL1 UASg, to allow Gal4 
control. Together, the two reporter genes provide a highly sensitive dual selection 
system. Because Y 187 is deleted for g a l4  (and its negative regulator g a l8 0 ), expression 
of both reporters should be off in the absence of exogenous Gal4. However, the G A L 1 -  
H I S 3  fusion allows production of a low constitutive level of H I S 3  sufficient to allow
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growth without exogenous histidine, even in the absence of Gal4. This can be overcome 
by growing cells in the presence of 3-aminotriazole (3-AT), a chemical inhibitor of IGP 
dehydratase, which restores histidine auxotrophy (Kishore and Shah, 1988). Thus, 
incorporation of 25-50 mM 3-AT into the growth media can be used to inhibit the basal 
level of H I S 3 , preventing growth unless G A L 1 - H I S 3  expression is activated. The low 
requirement for His3 protein makes this selection very sensitive such that proteins that 
only weakly interact can be selected. In order to test the efficacy of the His selection 
system, SNF1 and SNF4, two proteins known to physically interact in vivo, and whose 
interaction had previously been detected using the YTH system, were employed (Fields 
and Song, 1989). Surprisingly, the H I S 3  transcription produced by the S N F 1 - S N F 4  
interaction provided more resistance to 3-AT than the wild-type H I S 3  gene itself. This 
indicated the potential for interacting hybrids to increase His3 expression above wild 
type levels, and thus provides a more sensitive selection. Finally, expression of the 
library cDNA is under the control of the constitutive ADH promoter, in contrast to the 
conditional galactose-dependent promoter used in YTHS-A.
4.4.2 Preparation of bait constructs
The EBNA3B N-terminal fragment (1575 bp) which was amplified by PCR as per 
YTHS-A was subcloned into the 8.5 kb pAS-1 bait plasmid at the B a m U l  site according 
to DNA methods described in section 2.3. Due to the presence of an N c o l  site in the 
pACT MCS, a shorter EBNA-3B fragment which lacks the repressor domain could not 
be derived by enzyme restriction as for YTHS-A. Thus, an 837 bp fragment was 
amplified by PCR (Figure 4.12). PCR reaction conditions and primer sequences are 
given in sections 2.1 and 2.3.
192
M 1 2 M
EBNA3B 
PCR product 
(837 bp)
1500 bp 
1000 bp 
900 bp
F ig u re  4.12 EBNA-3B279 P C R  p ro d u c t (1.5 % agarose gel).. Lane M: 100 bp DNA markers; lanes 1 
and 2: EBNA-3B279 PCR product (837 bp). Arrow indicates PCR product, dashes indicate DNA size 
markers.
Figures 4.13 and 4.14 show an example of pAS-l/EBNA-3B279 and pAS-l/EBNA- 
3B525 recombinants, respectively, with inserts in the correct and incorrect orientations.
1 2 3 4 5 6 M
F ig u re  4.13 pAS-3B-279 o rien ta tio n  in  pAS. Digestion of recombinant colonies with B stE W Sall give
correctly orientated EBNA-3B in lanes 1 and 4 (i.e. 350 bp fragment). Lanes 2, 3, 5 and 6 contain insert 
but in the wrong orientatinon (i.e. 550 bp fragment). Arrows indicate DNA digest products; dashes 
indicate D NA size markers.
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M 1 2
3 kb 
2 kb 
1.6kb 
lkb
F igu re  4.14 pAS-3B-525 o rien ta tio n  in  pAS. Digestion of 2 recombinant colonies with Nco 1 Results 
show correctly orientated EBNA-3B in lane 2, while clone 1 is incorrectly oriented (see N col sites, Figure 
4.8A). Arrows indicate DNA digest products; dashes indicate DNA size markers.
4.4.3 Characterisation of baits
The pAS-l/EBNA-3B525 (pAS-3B-525) construct was tested to ensure its suitability as 
bait in this YTH system. Firstly, it was important to show that baits did not transactivate 
either of the reporter genes in the absence of library DNA and secondly, the ability to 
express full-length fusion protein in yeast strain Y187 was confirmed.
4.4.3.1 Transcription activation assay
Constructs which activate transcription in the absence of other constructs cannot be used 
in the yeast two hybrid assay. For this reason, Y187 strains containing EBNA-3B bait 
were checked for their growth properties on His- plates containing 3-AT (3- 
aminotriazole, Sigma, A8056) and for their ability to activate the l a c Z  reporter. These 
tests were carried out relative to strains carrying pSE1112 (S N F 1  fused to the DNA- 
binding domain of Gal4 in pAS-1) alone, a bait which is known not to transactivate 
alone and thus served as negative control. pAS-1 alone is not a good negative control as 
it can activate l a c Z  weakly. This appears to be lost when genes are cloned into it. It is 
not understood why pAS-1 is weakly activating alone, but it is likely that it is due to
194
sequences beyond the polylinker and which are of no consequence once cDNAs are 
cloned into it. pSE1112 is a better negative control. pSE lll/pS E 1112  was used as 
positive control, where p S E l l l  is the pACT plasmid containing a fusion between S N F 4  
and the G a l 4  activation domain. S N F 1  and S N F 4  are known to interact in this yeast 
strain, thus causing transactivation of both H I S 3  and l a c Z  genes.
Usually 3-AT concentrations of 25 mM to 50 mM are sufficient to select against pAS-1 
subclones that fail to activate transcription of the H I S 3  gene on their own. The positive 
control was observed to give stronger growth at 25 mM 3-AT than on plates containing 
50 mM 3-AT. The pAS-3B525 construct failed to grow in the presence of either 50mM 
or the more transactivation-sensitive 25 mM 3-AT (Table 4.4). X-gal filter lift assays 
were used to assess transactivation of the l a c Z  gene. Positive control clones produced a 
positive blue colour within 30 mins, while clones expressing bait protein were found to 
be negative even after overnight incubation.
(A) HIS Transactivation (B) LacZ Transactivation
pBait 25mM 3-AT 50mM 3-AT 30 mins 60 mins Overnight
pSE l 111/ 
pSE1112
+++ ++ + ++ +++
pSE1112 - - +/- + +
pAS-3B - - - - -
T able 4.4 T ran sac tiv a tio n  assay -  YTHS-B.
Plasmids used to transform Y187 (given in left-most column) were initially selected on YNB/Glu-T+L+H 
media. (A) Colonies were then firstly streaked onto the indicated media lacking histidine (His) and 
containing either 25mM or 50 mM 3-aminotriazole (3-AT) (-): no growth; (+): moderate growth; (++): 
good growth; (+++): very good growth. (B) Secondly, colonies from the original plate were patched onto 
similar YNB/Glu-T+L+H plates and used in X-gal filter lift assays which were left at room temperature 
for the indicated periods of time. (-): white yeast patches; (+/-): very pale blue colour; (+): pale blue; 
(++): blue; (+++): intense blue staining. Growth in each case was for 3 days at 30°C.
195
4.4.3.2 Western immunoblotting
Western immunoblotting was performed in order to detect expression of full-length bait 
fusion protein. Each bait was transformed into yeast strain Y187 and selected on 
YNB/Glu-T+L+H plates. The pAS-1 plasmid contains a haemagglutinin (HA) epitope 
upstream of the multiple cloning site, which is useful for verifying expression of the 
fusion protein. As specific antisera to EBNA3B were not available, expression of the 
EBNA3B fusion proteins in pAS-1 were verified by Western blot analysis of yeast 
protein lysates using anti-HA antibodies (Boehringer Mannheim). Expression of an 
approximately 60 kD protein was detected, which corresponded to the predicted 
molecular weight of the Gal4DBD-EBNA3B-525 fusion protein (Figure 4.15). Some 
smaller bands were also detected of approximately 40 kD and 28 kD, which may 
represent degradatory products or some incompletely synthesised proteins. Also a band 
of approximately 120 kD may represent fusion-protein dimers as EBNA3B is known to 
self-associate. However, it is unlikely that the association is SDS-resistant. Y187 yeast 
cells containing no foreign DNA were also assayed using HA-antisera in order to rule 
out non-specific staining due to endogenous yeast proteins. No bands were detected 
using these cells. M 1 2 3 4
l75kD  .—
83kD -----
66kD -----
47 kD -----
32kD ___
25kD
F igu re  4.15 W estern  b lo t analysis o f expression o f EBNA-3B fusion protein .
Y187 cells were induced to take up pAS-3B525 using a lithium acetate transformation protocol. The 
presence of pA Sl-3B 525 was confirmed by selection on media lacking tryptophan for 3 days at 30°C. 
Protein extracts were then prepared from yeast colonies (lanes 1-3), fractionated on 10% SDS-PAGE gels, 
transferred to nitrocellulose and probed with anti-HA antibodies. Mock transformed Y187 cells are shown 
in lane 4 as negative control.
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4.4.4 Detection of interaction of EBNA3B/EBNA2 with RBP-Jk using YTHS-B.
An interaction assay was performed which indicated that the EBNA-3B protein 
expressed from pAS-3B-525 was functionally intact. YTHS-B was used to investigate 
the interaction between EBNA-3B and RBP-Jk, using both pAS-3B-525 and pAS-3B- 
279. The interaction between EBNA2 and RBP-Jk previously detected using this system 
was included as positive control in these assays. pGBT9-EBNA2 is a yeast expression 
vector for a fusion protein between EBNA2 (deleted for AD aa 437-472) and Gal4 DBD, 
while pGAD-RBP expresses a fusion protein between the Gal4 AD and RBP-Jk (aa- 
487) (both gifts from Evelyn Manet, Ecole Normale Superieure de Lyon). Using 25 mM 
3-AT, as before, transformation of pAS-3B-525 and pGAD-RBP in Y187 was found to 
weakly transactivate the His reporter, while no significant transactivation of His was 
observed using pAS-3B-279. X-gal filter lift assays were also performed to investigate 
transactivation of the (3-galactosidase reporter, and were consistent with the screen for 
His transactivation. pAS-3B-525 was found to induce l a c Z  transactivation as efficiently 
the EBNA2 control. All assays were carried out in duplicate. Results are summarised in 
Table 4.5 below. These results also suggested that the EBNA3 repressor domain (aa 
280-525) included in this bait construct did not prevent transactivation of the reporter 
genes.
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His + LacZ+
EBNA-2 / RBP-Jk ++ ++
EBN A -3B525/RBP-Jk + ++
EBNA-3B279 / RBP-Jk - -
Table 4.5 EBNA3B interactions with RBP-Jk. Y187 yeast cells transformed with the indicated 
plasmids were initially selected on YNB/Glu-T+L+H media. Colonies were then firstly streaked onto the 
indicated media lacking histidine (His) and containing 25mM 3-AT. (-): no growth; (+): moderate 
growth; (++): good growth. Secondly, colonies from the original plate were patched onto similar 
YNB/Glu-T+L+H plates and used in X-gal filter lift assays which were incubated at room temperature.
(-): white; (++): blue.
4.4.5 Interactor hunt
The bait and library plasmids can be introduced into yeast either simultaneously or 
sequentially. Simultaneous transformation has the disadvantage of a lower efficiency of 
plasmid uptake. Thus, sequential transformation was employed as there was no 
selective advantage to cells expressing the bait hybrid protein. Y187 clones containing 
bait plasmid pAS-3B525 were transformed with 40ug EBV-transformed B lymphocyte 
cDNA library in pACT (Durfee et a l , 1993) and selected on YNB/Glu-T-L+H plates. 
The library contains 1.1 x 108 total recombinants with >95% inserts. A very high 
transformation efficiency was required at this stage, so it was important to use an 
optimised library transformation protocol (modified from Gietz et a l , 1992) in order to 
obtain a sufficiently high number of transformants to screen.
D e t e r m in a t io n  o f  th e  t o t a l  n u m b e r  o f  t r a n s fo r m a n t s  : Transformed cells sampled just 
after the heat shock step were plated at a range of dilutions (10_1, 10"2, 10’3) on 
YNB/Glu-T-L+H and incubated at 30°C for 3 days. These results indicated that a total of 
approximately 100,000 transformants were placed under selection.
R e c o v e r y  :  cells were pooled and added to 100 mis YNB/Glu-T-L-H liquid media and 
incubated with shaking at 30°C for 1-3 hours. This allowed the transformants to be
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established and H I S 3  transcription to be activated. Also, cells in PEG are more fragile 
and often die when pelleted so the recovery step was useful.
H a r v e s t i n g  o f  c e lls : cells were spun at 3000 rpm for 4 min and resuspended in 6mls 
YNB/Glu-T-L-H liquid media. 300 jal cells were spread on YNB/Glu-T-L-H + 25 mM 
3-AT media per 150 mm plate.
S to r a g e  o f  t r a n s f o r m e d  ce lls :  cells not plated were aliquoted inlo 1ml aliquots, spun at 
3000 rpm for 4 min, resuspended in 10% DMSO and frozen at -80°C. Cells can be 
stored frozen indefinitely, and screened as required, once plating efficiency has been 
estimated.
D e t e r m in a t io n  o f  p l a t i n g  e ffic ie n c y  :  The purpose of this step is to determine the 
optimal density at which recovered yeast can be plated for screening/selection after 
thawing from DMSO stocks. Cells can lose some degree of viability when stored at -  
80°C. To this end, 5 i^l neat cells plus dilutions (1 0 1, 10"2, 10'3) were plated before and 
after recovery on YNB/Glu-T-L+H plates.
4.4.6 Selection of Interactors
Library-transformed yeast was selected for His+ transformants by plating on YNB/Glu- 
T-L-H +25mM 3-AT media. As bait plasmid had not activated transcription in the 
presence of 25 mM 3-AT, the same concentration of 3-AT was used in the selection of 
His+ clones to increase sensitivity. Selection in the presence of 25 mM 3-AT sometimes 
behaves like a 100-fold enrichment (Durfee et a l , 1993; Harper et a l , 1993) of the total 
L+T+ colonies. Approximately 1% of transformants grew under these conditions within 
3-5 days. However, some of these were microcolonies which failed to grow when 
streaked on L-T- plates, and thus were ignored. Other reports have indicated that in most 
cases true positives continue to grow into large colonies while the micro-colonies seem 
to stop growing. It has been found that the secondary screen for lacZ positive clones 
usually eliminates these microcolonies. It is likely that the use of higher 3-AT levels 
would have reduced much of this background; however a lower level of 3-AT was 
chosen so that weaker interactions would also be detected.
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In all, 869 selected colonies were tested for (3-galactosidase activity using the X-gal 
filter lift assay. Of these, four clones were found to be both His+ and lacZ +, and each 
clone was noted to have given quite large colonies on the original His selection plates. 
pSE1112 was co-transected with p S E l l l l  as a positive control for X-gal staining and 
for 3-AT resistance. pSE l 112 was transformed alone as a negative control. Thus, His+, 
blue colonies were considered positives in the initial screen and were used for additional 
studies.
4.4.7 Elimination of bait plasmid
For the purpose of verifying the specificity of interactions, it was necessary to eliminate 
pBait from the positive yeast isolates. As this step generated a strain that contains only 
the library plasmid, it facilitated plasmid recovery into bacteria which was necessary for 
more detailed analysis of clones. This step can typically present problems and 
sometimes different approaches need to be taken. In this case, 3 alternative methods 
were used before the bait plasmid was finally lost from positive clones.
M e t h o d  1 Cycloheximide selection.
Yeast strain Y187 is a derivative of Y153 which is resistant to cycloheximide (2.5 
M-g/ml) due to a mutation in the C Y H 2  gene. This is a recessive drug resistance. The 
pAS-1 bait plasmid carries the wild type C Y H 2  gene which renders cells sensitive to 
cycloheximide. Thus, loss of the pA S-l-CFH  plasmid can be achieved by streaking on 
Leu- media containing 2.5 |Ug/ml cycloheximide. This may be done directly but it is 
useful to streak the colonies out on Leu- media before streaking on cycloheximide media 
to allow plasmid loss and dilution of the C Y H 2  gene product. The colonies that grow 
should be Trp- but to be safe and avoid C Y H 2  gene conversion events, it is 
recommended that loss of the Trp marker is confirmed. However, when this approach 
was attempted, clones failed to grow in the presence of 2.5 pg/ml CYH. It is possible 
that perhaps cells needed to be grown for longer on Leu -  media in order to dilute the 
C Y H 2  gene product.
200
M e t h o d  2  Plasmid loss on Leu- plates.
Cells were grown overnight in YPD complete liquid media, then grown on Leu- plates, 
which were then replica plated onto Trp- media to look for loss of the pAS-1 bait 
plasmid. All clones grew on media lacking Trp, indicating that bait plasmid had been 
retained.
M e t h o d  3 Plasmid loss in Leu- media.
Cells were used to inoculate 5 ml Leu- liquid media and were grown at 30°C for 3 days. 
DNA was then prepared using a rapid DNA isolation method (described in section 2.8) 
and used to transform E .c o l i  D H 5 a  from which plasmid DNA was prepared by 
miniprep. Restriction enzyme analysis was then used to check for loss of pBait. Each 
clone preparation was restricted with B a m H  1, which should excise a 1.6 kb EBNA- 
3B525 insert from pAS-1, if pBait was present. An empty pAS vector was included in 
the digests to control for restriction conditions. As can be seen from figure 4.16, a single 
band of approximately 8-9 kb was detected in all clones tested. This band probably 
represents linearised pACT (8.55 kb) which also contains a single B a m H l  site. Thus, all 
clones have apparently lost pBait.
M  1 2 3 4 5
4  8.5kb 
pAS-1
Figure 4.16 Enzyme restriction analysis to detect loss of pBait from positive interactor clones.
BamH  1 restriction of clones following loss o f pAS-3B525 bait plasmid, using methods described above 
(section 4.4.7). Lane 1: 1 kb DNA size markers; lanes 1-5, Bam H l-restricted clones.
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4.4.8 Verification of specificity
It was important to verify that any interactions which were detected were dependent on 
activation of reporter genes by the protein of interest and could not be substituted for by 
alternative unrelated baits. In this way, specificity of interactions could be confirmed 
and many false positives could be eliminated. Several individual unrelated pre­
characterised fusions in pA Sl, i.e. p A S l- S N F 1  (pSE1112), pA S l- C D K 2  and pA Sl- 
la m in  (a gift from Geraldine Butler, UCD), were each co-transformed with each of the 
library plasmids isolated from positive clones in method 3 above. The resulting 
transformants were selected on Trp-Leu- plates and tested for (3-galactosidase activity. 
As a positive control, Y187 containing bait plasmid, pAS-3B525, was also transformed 
with each of the positive library plasmids isolated. Any clones which were found to 
transactivate lacZ significantly above background levels in the presence of non-related 
pASl fusions were disregarded (Table 4.6A). These experiments indicated that 2 of the 
original 4 His+ lacZ+ clones (77, 78) involved specific interactions between the bait 
protein and a library protein. The other two clones represented false positives which 
were dependent on the presence of both plasmids but which were not activating 
transcription as a result of an interaction with the cDNA insert in the bait plasmid. 
Unfortunately such false positives are a reoccurring problem of the two hybrid system. 
As can be seen from Table 4.6A, clone 125 transactivated l a c Z  in the presence of just 
one of the three alternative baits. For this reason, it is important to test against several 
different unrelated bait proteins in ruling out non-specific interactions. A summary of 
results of the completed screen illustrates that of 100,000 library transformants which 
were screened, just two cDNAs were found to specifically interact with EBNA-3B525 in 
Y187 yeast cells (Table 4.6B).
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pBait Clone 9 Clone 77 Clone 78 Clone 125
PAS1-3B525 + + + +
PAS 1 -Lamin + - - -
PASI-SNF1 + - - +
PAS1-CDK2 + - - -
Table 4.6 (A) Verification of specificity of interactors. Transactivation of the lacZ  reporter gene was
detected using X-gal filter lift assays as described in section 2.8 (-): white; (+): blue.
Transformants His + His+, lacZ+ 3B-dependent
No. ofcDNA  
library clones
100,000 869 4 2
Table 4.6 (B) Summary of screening results using YTHS-B
4.4.9 Restriction analysis of plasmids containing positive cDNA interactors.
Restriction enzyme analysis was used to determine the approximate sizes of the putative 
positive interacting cDNAs. Figure 4.17(A) shows that there is less than a lkb  difference 
between linearised pACT and linearised pACT containing a positive interactor cDNA 
(clone 77). In the construction of the library, cDNAs were cloned into a unique X hol 
site (Durfee et a l , 1993). Therefore, in order to determine the size of inserts, they were 
excised with X hol enzyme. Figure 4.17(B) shows that clone 77 contains a cDNA insert 
of approximately 800 bp, the 200 bp cDNA in clone 78 was not visible on this gel, while 
digestion of the non-specific clone 125 showed an insert of approximately 550 bp. The 
other non-specific clone contained a cDNA of approx. 700 bp (not shown).
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(A ) M 1 2 3 4 (B) 1 2 3 M
12kb “  
8kb -
a a u u
| - f l l  - ^ __  ~9.3kb
~800bp ' m
mm
mm m . 5
—
lkb 
550 bp 
.Z  500 bp
Figure 4.17 Restriction analysis of positive interactors. (A) Lane 1: lkb  DNA size markers; lane 2: 
pACT; lane 3: Bam W l-digested pACT (8.55kb); lane 4: clone 77 (; lane 5: Bam Hl-digested clone 77. 
(B) Lane 1: X h o l-digested clone 77 (-800  bp); lane 2: A7«y1 -digested clone 78; lane 3: X h o l-digested 
clone 125 (-55  bp); lane 4: lOObp DNA size markers.
4.4.10 Sequencing strategy
In order to identify the proteins encoded by the interacting cDNAs, the sequence of each 
cDNA was determined. To this end, a primer was designed to sequence the cDNA from 
the activation domain of the pACT plasmid. Use of a T7 sequencing™ kit from 
Pharmacia as described in section 2.3. failed to produce any sequence from pACT. 
Therefore, as an alternative approach, cDNA library inserts were subcloned into the 
X hol site of the pTag vector (LigATor MBK-004-40, R&D systems, UK). Insertion of 
DNA fragments into the MCS of this vector interrupts the lacZ gene which allows the 
presence of insert to be determined based on white versus blue colonies on media 
containing X-gal. Use of pTAg permits sequencing using the M13 universal primer. 
Presence of inserts in white colonies were assessed by restriction analysis i.e. 
identification of pTAg vectors containing insert was based on loss of the pTAg X hol 
site when Xhol-restricted insert was ligated to the compatible Sail site in the pTAg 
vector. A cDNA which was previously sequenced from pTAg was included as positive 
control in subsequent sequencing reactions. Despite obtaining a complete sequence from 
the positive plasmid control, only approx. 40 bases of sequence could be determined 
from each pTAg plasmid containing library cDNAs. After this short sequence which
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corresponded to a portion of the pACT AD, compression (bands in all 4 lanes) was 
consistently observed, despite variations in protocol (see Table 4.7). Problems with 
compression can frequently be resolved using adjustments such as these. However, GC- 
rich regions often corresponding to certain restriction enzymes can also be responsible 
for poor results. Sometimes S fil or Sm al sites in the MCS of a plasmid can lead to 
compression, the only solution for which is to sequence using automated methods. 
Investigation into the cloning strategy used in the construction of the library revealed an 
Sfil (GGCCTTCG TGGCC) site at the point of compression in the pACT plasmid.
Template Treatment Temperature Enzyme Result
32 [i\ LiCl 37°C T7 NR
32 Ml LiCl 42°C T7 NR
64 Ml - 42°C Taq NR
32 Ml - 42°C T7 Compression
32 Ml 65°C 42°C T7 NR
32 Ml DMSO 55°C T7 Compression
32 Ml DMSO 55°C T7 NR
T able  4.7 Sequencing of positive in te ra c to r  cDNAs. A number of variations in the protocol described 
in section 2.3 were introduced in an attempt to produce sequence data. W ith higher temperatures increased 
amounts o f T7 enzyme were used.
Sequencing data was generated using commmercially-available automated methods 
(Oswel Research products, University of Southhampton). Sequences were then analysed 
using a blast search against DNA databases.
C lo n e  7 8  (200 bp cDNA). Database analysis revealed that this clone probably contained 
“junk” DNA, as it showed closest homology with an E.coli sequence.
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C lo n e  77 represented a fusion of two cDNAs of 200 bp and 600 bp in opposite 
orientations. In order to obtain sufficient information, this clone was sequenced from 
both ends of the pACT MCS. Database analysis showed closest homologies as follows: 
200 bp cDNA : Human mRNA for proteosome subunit HsN3 (complete length 925) 
600 bp cDNA : Human mRNA for Cyrochrome Oxidase.
On further investigation of pACT sequences, it was found that the correct orientation 
cDNA was cytochrome oxidase (C.O.). C.O. is a ubiquitous mitochondrial enzyme 
which has previously been identified as a false positive interactor. Thus, unfortunately, 
the interaction was meaningless and adds to a growing list of false positive results from 
the YTHS.
4.5 DISCUSSION
Little is known concerning the functions of the EBNA-3 family of proteins, although the 
nuclear localisation and predicted structural homologies suggest that they are 
functionally related (Kerdiles et a l , 1990.). While a role in the modulation of expression 
of EBNA2-responsive genes seems likely, much experimental data indicates that other, 
as yet unidentified, functions exist which probably include activités unique to each 
member of the EBNA-3 family. To understand the function of a particular protein it is 
often useful to identify other proteins with which it associates. Using the yeast two 
hybrid system, this study proposed to investigate protein-protein interactions involving 
EBNA-3B.
The yeast two hybrid system provides a highly sensitive means to detect an interaction 
between two proteins in living cells (see section 4.1). In the data presented here, two 
alternative systems were employed to screen two different cDNA libraries for proteins 
which may interact with EBNA-3B. To this end, an N-terminal portion of EBNA-3B 
was expressed as a fusion protein with the relevant DNA binding domain in each case,
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and baits were subsequently confirmed as suitable for use in each system. Since the most 
important consideration was that transcription of reporter genes was not appreciably 
transactivated by the bait protein, an acidic region of EBNA-3B (including a domain 
which has been demonstrated in EBNA-3C to behave as an activation domain) was not 
included in the fragment to be used as bait.
4.5.1 YTHS-A
In the first system described, YTHS-A, the L E U 2  reporter gene in EGY48 is highly 
sensitive and is activated by even weak transcription activators fused to LexA (or by 
activation-tagged proteins that interact weakly with LexA fusions.) The high sensitivity 
is due to 3 high affinity LexA operators from the bacterial c o l E l  gene, each of which 
can potentially bind 2 LexA dimers (Brent e t a l , 1994). If a bait is observed to 
marginally activate transcription, yeast strains are available which contain fewer 
operators upstream of L E U 2 .  Proteins that are moderate to strong activators will need to 
be truncated to remove activation domains before they can be used in an interactor hunt 
(Brent and Ptashne, 1994). If possible, a good way to start is to construct derivatives that 
lack highly acidic regions which are often responsible for transcription activation in 
yeast (the obvious disadvantage of this approach is that regions important for interaction 
with other proteins may be removed).
Despite careful design and testing of bait, only false positive clones were isolated in this 
study, using YTHS-A. Although significant numbers of Leu+ colonies were observed, 
none were found to be dependent on galactose. This result implied that activation of 
L e u 2  expression was not dependent on the expression of library cDNAs, i.e. while bait 
proteins are constitutively expressed, proteins encoded by library cDNAs are expressed 
from the yeast conditional G A L 1  promoter. Since the G A L 1  promoter is repressed by 
glucose, those colonies which grew in glucose medium were classed as false positives, 
and thus were not further characterised.
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In demonstrating galactose-dependence of transactivation of reporter genes, it was 
necessary to grow the yeast on glucose master plates to shut off cDNA expression before 
replica plating. Galactose-dependence of Leu-i- and lacZ+ phenotypes may sometimes be 
masked if there is sufficient message and protein product from the activation tagged 
cDNA protein to allow the yeast to grow on Leu- glucose for several generations and 
turn blue on glucose X-gal media without further cDNA expression. With regard to 
selecting colonies for master plate production, generally there will be more galactose- 
dependent Leu+ and lacZ+ yeast among the colonies that appear sooner and fewer 
among those that appear later. For stronger interactors, colonies have grown up in two 
days and are more likely to be interactors that are biologically relevant to the bait 
protein. Those that appear later may or may not be relevant. However, many parameters 
can delay the time of colony formation of cells that contain valid interactors, including 
the strength of the interaction and the level of expression of the library-encoded protein. 
In the data presented here, Leu-positive colonies were found to appear in 2-4 days 
incubation. Even those which grew after 2 days were found to be galactose-independent. 
The reason for these findings is not understood. However, similar results have been 
documented in other studies and observations such as these appear to be a phenomenon 
associated with certain baits (Wiley, 1994).
Had galactose-dependent Leu+ clones been isolated, the next step would be to assay for 
galactose-dependent l a c Z  transactivation. Reporter genes differ in the number and 
affinity of upstream binding sites (eg. lexA operators) for the bait and in the position of 
these sites relative to the transcription slartpoint (Gyuris et a l , 1993). They also differ in 
the number of molecules of the reporter gene product necessary to score the phenotype. 
These differences affect the strength of the protein interactions the reporters can detect. 
The second reporter gene used in this version of the method, l a c Z , is not as sensitive as 
the L E U 2  reporter in EGY48 (Chien e t a l , 1991; Durfee e t a l , 1993; Gyuris et a l , 1993; 
Vojtek et a l , 1993), so it is possible for a weak interactor not to result in blue colonies on 
X-gal plates in the l a c Z  transactivation assay. The experiments presented here employed 
the most sensitive l a c Z  reporter available, pSH18-34 (West e t a l , 1994) (see Table 1 ). 
Use of the second reporter gene would normally allow the identification of any false
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positives which may have arisen due to a yeast mutation or to binding of the activation- 
tagged cDNA protein to the L E U 2  promoter (Brent e t a l , 1994).
False positives could also have been due to non-specific interaction with LexA, with the 
promoters or with some part of the transcription machinery. In practise, the majority of 
proteins isolated by interaction with a LexA fusion are found to be specific for the fusion 
domain; very few proteins are isolated that are specific for LexA or that are non- 
specifically sticky. However, it is generally informative to retest positive clones on more 
than one LexA bait protein; ideally library-derived clones should be tested against the 
LexA fusion used for their isolation, several LexA fusions to proteins that are clearly 
unrelated to the original fusion and, if  possible, several LexA fusions that there is reason 
to believe are related to the initial protein. A rapid genetic test for this has been 
described (Harper et a l , 1993). Using this system, library plasmids are rescued from 
yeast by performing a yeast plasmid miniprep to transform E .  c o li (most yeast miniprep 
protocols do not provide sufficient clean plasmid DNA for restriction analysis). Thus, if 
large numbers of positive clones are obtained, it is useful to reduce the number of clones 
to be rescued by determining which ones contain identical cDNAs. For this purpose, 
PCR amplification of inserts followed by digested with H a e III and A l u l  (frequent cutter 
enzymes) may be used to allow comparison of the banding patterns produced on agarose 
gel electrophoresis.
As part of an investigation into the 100% rate of false positives obtained in this study, a 
random sample of positive clones were assayed for presence of cDNA insert using PCR 
amplification. The absence of product indicated that perhaps a Leu-positive contaminant 
may have contributed to the high numbers of false positives. The cDNA library itself 
was also used as template in a similar PCR reaction, but again results were negative. A 
possible PCR technical problem could not be ruled out as no positive control for these 
primers was available. During construction of the library, cDNA inserts were size 
selected to give an average insert size of approximately 1400 bp (Brent, 1994). Thus, 
restriction analysis of the library designed to excise inserts from their vectors should 
produce a smear of bands around this region, on gel electrophoresis. However, digestion
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of library DNA used here, showed no significant banding in this region. It is possible, 
therefore, that the sub-optimal quality of library DNA may have contributed to the 
observed results.
4.5.2 YTHS-B
YTHS-B has some disadvantages associated with its use when compared with YTHS-A. 
For example, because Gal4 is an important yeast transcriptional activator, experiments 
must be performed in Gal4-negative yeast strains to avoid background from endogenous 
Gal4 activating the reporter system (Golemis e t a l , 1994). Unfortunately, these strains 
are frequently less healthy and more difficult to transform than wild-type strains, and 
either libraries must be constitutively expressed or an alternate inducible system must be 
used. The library used in this study was expressed from a constitutive ADH promoter. 
Despite these relatively minor disadvantages, the YTHS-B provided the opportunity to 
screen a cDNA library which was ideally suited to these investigations i.e. a cDNA 
library generated from EBV-transformed human B lymphocytes (Durfee et a l , 1993). As 
the cDNA library to be used was fused to a Gal4 activation domain (aa768-781, Ma and 
Ptashne, 1987) in pACT II it was necessary to prepare a bait construct which fused 
EBNA-3B to a compatible Gal4 DNA binding domain (DBD). To this end, a hybrid was 
generated between sequences encoding the DBD of the yeast transcription factor Gal4 
(aal-147, Keegan et a l , 1986) and two amino-terminal portions of EBNA-3B in the 
pA Sl expression vector (section 4.4.2).
To screen for proteins which interact with EBNA-3B, transformants were subjected to 
the screening procedure outlined in section 4.4.5. Interacting hybrids were isolated by 
selecting for growth in the absence of histidine (in media containing 25 mM 3-AT) and 
subsequently screening for P-galactosidase activity. A relatively low concentration of 3- 
AT was used to improve sensitivity, although this does produce a greater number of 
false positives which need to be eliminated by the l a c Z  screen. This secondary screen 
eliminates His+ revertants and plasmids bearing the I I ¡S 3  gene of the organism from 
which the library is derived. Thus, using this form of selection, colonies which were
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both His+ and blue were considered positives and were isolated for further analysis. An 
important advantage of the H I S 3  selection/lacZ screen is a large reduction of false 
positives, i.e from an estimated 100,000 transformants, 869 His+ clones were tested for 
P galactosidase activity, of which only four were positive. The cDNA library used in this 
screen was constructed to contain 1.1 x 108 total recombinants. Therefore, multiple 
screens would obviously be required to properly screen the library.
A class of false positives can occur in library screens which seem to depend on the 
presence of both hybrids, but in the absence of bait plasmid will activate other non­
specific fusions bound to a DNA-binding domain. Frequently, these false positives have 
been identified as transcription factors that are thought to access the promoter DNA 
adjacent to the target protein when overproduced. For example, in the case of YTHS-B, 
the H I S 3  and GAL1 promoters share only a small region of DNA sequences in common 
(150bp) which should mostly be protected by the binding of target fusion proteins. 
Because of this, use of both screens in the selection process largely eliminated this class 
of positives. Nonetheless, although the dual His+ selection / p galactosidase screen 
eliminates many false positives, a low percentage survive the selection at a rate that 
varies with the target protein (Durfee e t a l , 1993). To help rule out remaining false 
positives, library plasmids were isolated, by selecting for loss of bait plasmid in the four 
positive interactor clones and tested against unrelated baits fused to the DBD in pAS-1. 
Three unrelated baits were employed as the more baits which are used the better the 
chances of picking up false positives. Of the four His+, Pgal+ clones, two of these were 
found to be specific for interaction with EBNA-3B, that is, l a c Z  was transactivated in 
the presence of G al4(l-147) fusions with EBNA-3B but not in the presence of G al4(l- 
147) fusions with other non-specific bait proteins.
Unfortunately, however, when the observed interacting library cDNAs were finally 
isolated and sequenced, neither was found to be biologically relevant. Based on 
sequence analysis, one cDNA represented E .  c o li DNA, which is most likely to have 
been incorporated during the preparation of the cDNA library. The other clone contained 
two cDNAs in opposite orientations, of which the correctly-oriented cDNA encoded the
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mitochondrial enzyme, cytochrome oxidase (C.O.) C.O. has been documented as a 
relatively common false positive of the YTHS. For example, in one survey C.O. was 
responsible for 5 out of 73 false positive interactions observed (Hengen, 1997).
4.5.3 True and False positives
It has become increasingly evident that the problem of false positives among YTH users 
is widespread. A recent review revealed that in addition to C.O., the other most common 
false positives included other mitochondrial proteins, heat shock proteins, ribosomal 
proteins, proteasome subunits, ferritin, transfer-RNA synthase, collagen-related proteins, 
zinc finger-containing proteins, vimentin, inorganic pyrophosphatase and proliferating 
cell nuclear antigen (PCNA) (Hengen, 1997). These findings indicate that many of these 
false positive interactions involve proteins which are ubiquitous in the life of the cell. 
Thus, it may also be interesting to sequence the two non-specific interactors which had 
transactivated both reporter genes (clones 9 and 125). In any given interactor hunt, baits 
which binds to one or a small subset of related proteins have been found to be more 
likely to be biologically relevant than baits which interact with many unrelated proteins.
It is important to note that interaction of the target and library-encoded proteins in the 
YTHS does not necessarily indicate that they normally interact in vivo. While two 
interacting proteins may produce a signal, they may never normally be present in the 
same cell type, or cellular compartment or present during the same stage of the cell 
cycle. Similarly, the YTHS may assay an interaction between domains that are not 
accessible in the native protein, particularly when an interaction is mediated via a short 
sequence. To rule out such potentially misleading results, it is essential that any positive 
signals from this and other interaction assays are confirmed by independent biological or 
biochemical experiments. This doctrine is supported by a survey of 223 investigators 
conducted by Ilya Serebriiskii (ilya @ scfuzzv .rm.fcc.edu) between October 1994 and 
January 1996 which revealed that of 100 library searches only 54 revealed biologically 
relevant interactors, with only 4 reporting that no false positives were found and 13 
reporting that no preys worthy of further of investigation were found. It is apparent that
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many artifacts exist, thus common practise prescribes that a proposed interaction should 
be observed by a different technique, such as co-immunoprecipitation of the putative 
interactors from the appropriate cell or tissue type, which at least may be subject to 
different artifacts. It is possible to waste a considerable amount of time characterising a 
cloned gene before realising that the “positive interactor” is a false lead. For this reason, 
YTH users are recommended to choose the bait very carefully and where possible to use 
two different baits. Also multiple baiting attempts are recommended with plentiful use 
of controls.
Once the appropriate measures have been taken to eliminate false positives, the 
interaction may then be further characterised. The domains/amino acids critical for the 
interaction can be delineated using the YTHS by carrying out deletion mutations. 
Further studies are required to determine biological significance and biophysical 
characteristics of any positive reactions. No YTH technique allows precise quantitation, 
however some quantitative information does inhere in the data. For example, an idea of 
the strength of interaction of two proteins may be derived from measuring (3- 
galactosidase activity. This is because the amount of (3-gal activity in the cell is 
proportional to the level of l a c Z  transcription.
4.5.4 True and False negatives
A further problem of the YTHS which is usually given less consideration than the 
problem of false positives is that of interactions which are not detected. The YTHS is 
highly sensitive such that even very weak associations should be detected (i.e. any 
affinity tighter than 10~6). Nonetheless, not all known interactions will be detected by the 
YTHS. Despite deliberately retaining the RBP-Jk -binding domain in the design of the 
EBNA-3B bait, this interaction was not detected in library screens. However, the 
specific interaction of these two proteins was demonstrated using a fusion between a 
portion of the RBP-Jk gene and the Gal4 A.D in subsequent experiments (see section 
4.4.4). In addition, EBNA-3B/EBNA-3B dimerisation may potentially have been 
detected. On some occasions, the expected interacting protein may simply be absent
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from the library used. Using the WI-38 library, it was less likely that relevant specific 
interactors would be detected than using the library prepared from EBV-transformed B 
lymphocytes. A number of cases have been documented in which known interactions are 
either not observed, or are subject to directionality, being observed only when one of the 
two proteins is a bait and the other a prey (see for example, Estojak e t a l , 1995). The 
current doctrine for determining that individual interactions do not occur is that full 
length and truncated putative partners must be tested in all combinations of baits and 
preys, with the most sensitive reporters, before the investigator can tentatively conclude 
that the two proteins do not touch. Thus, under the conditions employed in these 
analyses, it is impossible to rule out false negatives.
4.5.5 The Future of YTH technology
As systems improve, it is likely that many of the false positives highlighted above will 
be preventable. For example, the potential exists for development of systems in which 
transcription depends upon protein interactions which occur only at specific phases of 
the cell cycle, or times during development, or in particular subcellular compartments, or 
that persist for a restricted length of time, or that depend on particular protein 
modifications (Brent et a l . , 1994). In any case, despite it’s problems and pitfalls, the 
YTHS can be a valuable tool in the detection and characterisation of protein-protein 
interactions.
In recent years, the potential uses for YTH technology have grown with various 
modifications implying broader applications. For example, the reverse two hybrid 
system is a modification which enables genetic selection against specific protein/protein 
interactions (Leanna and Hannink, 1996). This system fulfills a role which is deficient in 
standard YTH systems in that it can be used to identify mutant proteins that have lost the 
ability to associate with their partner protein. Furthermore, such a selection scheme 
might facilitate the identification of genes which encode proteins that interfere with a 
particular protein/protein complex, for instance, regulators of protein/protein
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interactions. Finally, the reverse two hybrid system could be used to screen for drugs 
that abolish a specific protein/protein interaction.
It has been proposed to apply YTH technology to generate a human protein linkage map 
(Hua et a l . , 1998). With a homologous recombination-mediated approach, a modular 
human expression sequence tag (EST)-derived YTH library in the pACT2 vector has 
been constructed. This technology provides the extraordinary potential for identification 
of all human protein-protein interactions, leading to a global human protein linkage map 
that hopefully will provide important information for functional genomic studies.
The few years since the advent of two-hybrid systems has proven their utility in the 
study of defined protein interactions, in identification of new interacting proteins, and in 
the charting of genetic networks of proteins involved in processes from signal 
transduction to transcription regulation. These tremendous successes suggest that two- 
hybrid approaches may eventually be used to identify all of the protein-protein contacts 
made in a cell or an organism.
215
4.6 GENERATION OF A STABLE CELL LINE IN DG75tTA CELLS
4.6.1 Introduction
In order to study the function of a particular gene, it is often useful to work with a 
homogeneous population of cells in which expression of the protein of interest is under 
the control of a regulatable promoter. The aim of this work was to generate a stable 
derivative of the DG75-tTA cell line in which EBNA-3A expression (as sole EBV 
protein) would be inducible in a tetracycline-regulated manner. The principal of this 
gene expression system has been described in section 3.1.8. This approach to the study 
of gene expression presented several important advantages over relevant alternative 
methods. For example, the tetracycline (tet)-inducible system guarantees expression of 
EBNA-3A in every cell, allowing the study of effects on the cell population as a whole. 
In contrast, transient transfections of B lymphocytes rarely produce efficiencies greater 
than a few percent, which makes it difficult to look for changes in endogenous cellular 
gene expression due to expression of a transfected gene. Use of this system eliminates 
selection for unrepresentative clones which have a growth or survival advantage. This 
might be particularly relevant in the case of genes associated with the cell cycle or 
resistance to apoptosis eg. previously published data has been informally criticised on 
these grounds, with regard to upregulation of Bcl-2 expression by EBNA-3B. Tet- 
inducible cell lines would permit careful analyses to be carried out in the 
presence/absence of EBNA-3A in an isogenic background. This approach also makes it 
possible to study the effects of gene expression over a longer time period than with a 
transient transfection system. Unlike alternative inducible expression systems, 
transcription of the heterologous gene is tightly repressed by low, non-toxic 
concentrations of tetracycline and substantially induced upon removal of drug. This has 
the advantage of minimal, non-specific pleiotrophic effects on the host cell (reviewed by 
Schockett and Scatz, 1996).
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4.6.2 RESULTS
Constructs were prepared for all three EBNA-3 genes in pJef4, which contains the tTA- 
responsive element (see section 3.1.8, Figure 3.2 for principal). Thus, pJef-3A, pJef-3B 
and pJef-3C were prepared as follows: the full-length EBNA-3A (3025 bp), EBNA-3B 
(3106 bp) and EBNA-3C (3391 bp) genes were excised from pCMV7-EBNA3, 
pCMV7-EBNA4 and pCMV7-EBNA6 respectively and inserted into the B a m H l  site of 
pJef4, by ligation of B a m H l  linkers to each of the EBNA3 genes. This placed 
expression of each EBNA-3 gene under the control of the tTA-responsive promoter. 
Each construct was subsequently assessed by restriction enzyme analysis of DNA 
(Figure 4.18A), and by W estern blot analysis for expression of the protein of expected 
molecular weight (Figure 4.18B). Specific anti-EBNA3A antibodies (supernatant of 
T2.78 hybridoma cells) and anti-EBNA3C antibodies (E3C.A10.3) (both gifts from 
Martin Rowe, University of Cardiff) were used to detect protein expression from pJef- 
3A and pJef-3C, respectively. As no specific antisera was available for EBNA-3B, a 
panel of 30 high-titre anti-EBNA human sera (a gift from Carol Mongan, UCD) were 
screened for high-titre anti-EBNA-3B antibodies. B95.8 cell lysates were included as 
positive control as these cells reliably express high levels of EBNA-3B. However, no 
antisera were found which showed high reactivity in the absence of background 
reactivity in the EBNA-3B region. EBNA-3A, -3B and -3C  migrate as proteins of 
molecular weights between 145 and 155kD on SDS-PAGE electrophoresis.
4.6.2.1 Preparation of pJef-EBNA3 expression constructs.
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(A) pJef-EBNA3 plasmids
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F ig u re  4.18 S ubcloning EBNA-3A, -3B an d  -3 C  genes in to  p je f4 . (A) DNA agarose gel (1%) for 
restriction analysis o f pJef-EBNA3 recombinant plasmids. (B) 8% SDS-PAGE gel electrophoresis of pJef- 
3A (i) and pJef-3C (ii). Each construct was transiently transfected and  grown in tetracycline-free medium 
for 48 h before harvesting of cells for preparation o f protein lysates. Expression of EBNA-3A was 
detected by ECL, while EBNA-3C expression was detected using an alkaline phosphase conjugate.
Finally, constructs were assessed for functional integrity o f  the EBNA-3 proteins, based 
on EBNA3-dependent down-regulation of EBNA2-mediated transactivation (see section
1.5.6). To this end, the LLO-luc construct (a gift from  Gerhard Laux, Institut fur
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Klinische Molekularbiologie und Tumorgenetik, München) was employed: this plasmid 
harbours the LMP1 upstream region (+40 to -327) which is inducible by EBNA2. 
Luciferase assay results, shown in Figure 4.19 below, illustrate an almost 3-fold up- 
regulation of promoter activity by EBNA-2, which was significantly decreased on 
addition of pJef-3A or pJef-3B. A relatively low level of transactivation of the LLO 
plasmid by EBNA2 in DG75 cells is consistent with previous reports (Gerhard Laux, as 
above, personal communication).
  «r  , i  "
p J e O A  p Je f-3 B
F ig u re  4.19 R epression  of E B N A 2-m ediated  tran sac tiv a tio n  of the  L M P1 p ro m o te r by  pJef-3A  and  
pJef-3B . DG75 cells were transiently transfected with the indicated plasmids (see section 2.6.6 for 
methods) to give a total of 30 ug transfected DNA. Cells were harvested after 48 h and used in luciferase 
assays to determine activity levels from  the LLO-luciferase promoter construct. P-galactosidase assays 
were used to normalise for transfection efficiencies.
4.6.2.1 Stable transfections
pJef-3A was transfected into DG75-tTA cells by electroporation using an optimised 
protocol for this cell line (Floettmann e t a l , 1996, see section 2.6.6.1). In order to 
determine the correct concentration of drugs to be used in selection of stably transfected 
cells, a drug curve was prepared (section 2.6.7.1). A G418 concentration of 2 mg/ml was 
established for selection of pJef-3A, which was derived from the findings of several 
independent drug curves. Cells were also maintained in the presence of 500 Mg/ml
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hygromycin B for selection of the tTA plasmid and 1 Mg/ml tetracycline for suppression 
of the expression of EBNA-3A. A flow chart outlining the main steps used in the 
generation of the DG75tTA-EBNA3A inducible cell line is given below (Figure 4.20). 
Clones were assessed for expression of EBNA-3A at 1 week intervals, by withdrawal of 
tetracycline (as described in section 2.6.5) from a sample of cells. Immunocytochemistry 
(section 2.6.7.3) was used for this purpose as it was more convenient than Western 
blotting for screening small numbers o f cells from large numbers of clones (results not 
shown). Clones which were observed to have lost pJef-3A were disgarded, although 
expression of EBNA-3A protein was found to be detectable up to several weeks post­
transfection before being subsequently lost.
Magnetic bead selection (Capture Tec, Invitrogen) was employed as an alternative 
strategy for selection of cells stably expressing pJef-3A. Using this method according to 
manufacturers’ instructions, DG75-tTA cells were co-transfected with the pHook-1 
plasmid, (which expresses a membrane-anchored selection tag, sFv) and pJef-3A. To 
isolate a homogenous pool of transfected cells, the total cell population was harvested 
and incubated with magnetic beads that bind to the selection tag displayed on the 
transfected cells. After exposure to a magnet, bead-bound transfected cells were 
centrifuged down into a pellet while unbound cells remained in the supernatant and were 
discarded. Since the pHook-1 sFv tag is expressed from the strong CMV promoter, it 
offers a very high efficiency selection of pHook-1 vector. Co-transfection of pHook-1 
and a vector of interest has previously been found to result in expression of the protein 
of interest in 95% of selected cells (Chestnut et a l , 1996). Under microscopic 
examination, most of the selected cell population were observed to have magnetic beads 
bound, although it wasn’t possible to estimate the fraction of selected cells expressing 
sFv due to the 2-dimensional viewing of cells by light microscopy. The number of cells 
that are selected in a particular experiment varies with the transfection efficiency and the 
ability of the cells to secrete and display the sFv membrane tag, but in general selection 
efficiencies vary from 2% to 25% in most adherent human cell lines (Mortenson et a l ,  
1997). This, however, is greatly dependent on the cell line used. Selection efficiencies 
were relatively low at 2 to 4% of total cells. As before, clones containing pJef-3A were
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slow to expand and plasmid loss was observed again despite maintenance of drug 
selection in some groups o f clones, while drugs were omitted in other cells to encourage 
expansion of cell numbers.
Subclone EBNA3 gene into pJef4
i
Stable transfection into DG75-tTa cells 
1
Plate cells into 96-well plates using concentrations established 
in drug curve (+Tet, +Hygro B, +G418)
i
Establish single clones and bulk out.
(Detection of EBNA-3 expression by immunocytochemistry.)
1
Subclone if necessary to get a good on/off switch.
Figure 4.20 Flow chart for generation of tetracycline-inducible cell lines.
4.6.3 Discussion
Generation of stable cell lines for expression studies using inducible promoters have, in 
the past, met with varied success depending on the cell type and origin of the promoter 
utilised, so as a result are not always optimal or applicable. Using the approaches
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outlined above, expression of EBNA-3A was retained for only a few weeks. The reason 
for this is not understood, but a number of factors may have had a role to play.
Expansion of cell numbers was found to be difficult in this study. Feeder layers were not 
used here but are frequently used to aid the growth and expansion of clones from very 
low cell densities. Feeder layers are not essential and, indeed, can be problematic, but 
may have improved the growth rate of cells. Expansion should occur from a single cell 
in the generation of a clone. When this does not occur, mixed populations of cells can be 
less stable, and cells expressing high levels of the protein of interest may be overgrown 
by cells expressing lower levels of protein. In order to aid expansion of cells and also to 
save on expensive drugs, the concentration of selective drugs is frequently reduced 
during expansion of clones. Application of this approach may have aided outgrowth of 
non-expressing clones. In addition, spontaneous mutations can sometimes occur, 
conferring G418 resistance to non-expressing cells, therefore it was important to 
examine cells for expression of EBNA-3A at intervals during expansion of clones. This 
was also important to ensure retention of the pJef-3A expression plasmid. Thus, there 
are several reasons for potential loss of expression in many clones. However, in general, 
it is usually possible to expand a small number of clones which stably express the 
plasmid under selection. A low level of leakage is known to be associated with use of 
the tetracycline-inducible system. Thus, a cumulative toxic effect over several weeks is 
possible, although unlikely, as no significant cytotoxicity has been associated with this 
protein. A masking effect of the EBNA-3A protein is also possible. A truncated form of 
EBNA-3A in pJef may not have the same effects. However, this would be less ideal in 
that it would only permit the study of effects of expression of part of the EBNA-3A 
protein.
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A P P E N D I X
SOLUTIONS FOR DNA MANIPULATION 
TE buffer
10 mM Tris-Cl
1 mM  EDTA pH  8.0
Solutions for mini-preparation of plasmid DNA 
Solution I
50 mM Glucose
25 mM Tris.Cl (pH 8.0)
10 mM EDTA (pH 8.0)
Solution II (Prepared fresh)
0.2 N  NaOH
1 % (w/v) SDS
Solution III
60 ml 5 M potassium acetate
11.5 ml Glacial acetic acid
28.5 ml Distilled water
The resulting solution is 3 M with respect to potassium and 5 M with respect to 
acetate.
DNAse-free RNAse
RNAse A  (1 mg/ml) in sterile water.
H eat to 100°C for 30 min. Cool slowly and store -20°C 
Solutions for Maxipreparations of DNA - Qiagen Buffers
Buffer PI (Resuspension buffer)
50 m M  Tris-Cl, pH  8.0
10 mM  EDTA
100 |ig  RNase A
Store at 4°C after the addition o f RNase A.
b
Buffer P2 (Lysis buffer)
200 m M  Sodium Hydroxide
1% (w/v) SDS
Prepared fresh and stored at room temperature.
Buffer P3 (Neutralization buffer)
3.0 M  Potassium  acetate pH 5.5 
Stored at4°C .
Buffer QBT (Equilibriation buffer)
750 m M  NaCl 
50 mM  M OPS pH  7.0 
15% (v/v) Isopropanol 
0.15% (v/v) Triton X ® -100 
Stored at room  temperature.
Buffer Q C (Wash buffer)
1.0 M  NaCl
50 mM  MOPS pH  7.0 
15% (v/v) Isopropanol 
Stored at room  temperature.
Buffer QF (Elution buffer)
1.25 M  NaCl 
50 mM Tris-Cl, pH  8.5 
15% (v/v) Isopropanol 
Stored at room temperature.
50% (v/v) Glycerol
25 ml D istilled H2O
25 ml Glycerol
Autoclaved and stored at room  temperature.
0.5 M EDTA
186.1 g EDTA
800 ml Distilled water
6 g NaOH pellets
pH to 8.0 with 5 M NaOH. Volume was adjusted to 1 L with water
SOX TAE
242 g Tris
57.1 ml A cetic acid.
100 ml 0.5 M  EDTA pH 8.0
Adjusted to 1L w ith water
5X TBE
54 g Tris
27.5 g Boric acid
20 ml 0.5 M EDTA pH 8.0
Adjusted to 1L with water.
Ethidium bromide
0.1 g / 10 ml water (10 mg/ml)
Stored in dark at room  temperature.
Agarose gel loading dye
40% (w/v) sucrose
0.25% (w/v) brom ophenol blue
BACTERIAL GROWTH MEDIA 
LB agar
10 g Tryptone
5 g  Yeast extract
5 g NaCl
15 g Agar technical
Autoclaved and plates stored at 4°C.
d
LB agar plus ampicillin
Ampicillin was added to a final concentration of 100 |ig/ml to LB agar (50 °C).
Plates were stored at 4 °C.
LB broth (per L)
10 g Bacto-tryptone
5 g Y east extract
5 g NaCl
Autoclaved and stored at 4  °C.
LB Ampicillin broth
Am picillin was added to LB broth to a final concentration of 100 Mg/ml from stock 
solutions (100 mg/ml in  dPLO, stored at -20°C). Stored at 4°C.
SOB medium (per L)
20 g Tryptone
5 g Yeast extract
0.5 g NaCl
10 ml KC1 (250 mM)
Adjusted pH to 7.0 with 5 M NaOH 
Autoclaved, cooled to ~5°C and added :
10 ml 1 M M gCl2 
Stored at 4 °C.
SOC medium (per L)
1 L SOB
7.5 ml 50% glucose (filter sterilised)
Stored at 4°C.
IPTG stock solution (100 mM)
24 mg IPTG per m l o f sterile H 2O
Filter sterilised and kept on ice until ready to use.
X-Gal stock solution (5%(w/v))
This solution was prepared fresh for each use
50 mg of X-Gal per ml of N ,N’ dimethyl-formamide in a sterile tube.
Protected from light and stored on ice until ready to use.
Ampicillin stock solution (50 mg/ml)
50 mg of ampicillin per ml of sterile H2O 
Filter sterilised and stored at -20°C.
LB plates with antibiotics and IPTG/X-Gal.
To 1L of autoclaved LB agar (cooled to 50°C) the following were added 
0.5 jiM IPTG (5ml IPTG lOOmM stock solution)
80 (ig/ml X-Gal (1.6 ml 5% (w/v) X-Gal stock solution)
50 (ig/inl Ampicillin (1 ml o f 50 mg/ml solution)
Plates were stored at 4°C protected from light.
CELL CULTURE MEDIA/SOLUTIONS 
Supplemented RPMI (200 ml)
176 ml RPM I 1640
20 ml Foetal calf Serum (Decomplemented - 50°C for 30 min)
2 ml 200 mM  L-glutamine
2 ml Penicillin/Streptomycin (1000 U/ml-1000 Mg/ml)
Supplemented McCOY’S 5A (200 ml)
178 ml M ACOY ’S 5A with L-glutamine
20 ml Foetal calf Serum (Decomplemented; 50°C for 30 min)
2 ml Penicillin/Streptomycin (1000 U/ml-1000 |J.g/ml)
f
Supplemented DMEM High Glucose
178 ml DM EM  high glucose with L-glutamine
20 ml Foetal calf Sérum (Decomplemented; 50°C for 30 min)
2 ml Penicillin/Streptomycin (1000 U/ml-1000 |ig/ml)
10X Phosphate Buffered Saline (PBS)
14.24 g Na2H P 0 4.2H20  (8 mM)
2.04 g KH2P 0 4 (1.5 mM)
80.0 g NaCl (137 mM)
2.0 g KC1 (2.7 mM)
pH 7.5 and make up to 1 litre.
Diluted 1 in 10 in sterile distilled w ater and used at a IX  working concentration. 
Thiol supplements.
The following were added to 200 ml of supplemented media:
200 a-Thiolglycerol
2 ml Sodium pyruvate
2 ml HEPES
Bathocuproine disulfonic acid (BCS -10  mM stock solution)
36.4 mg BCS
10 ml IX  PBS
Dissolved by vortexing, filter sterilised using a 0.2 micron filter.
Aliquoted and stored at -20°C.
a-Thiolglycerol
A stock solution of 50 mM  in PBS containing 20 (iM BCS was prepared.
20 Ml 10 mM BCS
10 ml IX  PBS
43.3 Ml 100% a-thiolglycerol
Filter sterilised using a 0.2 micron filter, aliquoted and stored at -20°C.
Sodium pyruvate
100 mM  stock solution in IX  PBS (Gibco BRL). Stored at 4°C.
HEPES
1 M stock solution pH 7.5 (Gibco BRL). Stored at room temperature.
Microphenolic acid/Xanthine supplements
200 ml Supplemented RPM1
0.5 Mg/ml M icrophenolic acid
50 |u,g/ml Xanthine
Microphenolic acid stock solution 2.5 mg/mL
2.5 mg M icrophenolic acid
1 ml Sterile dHaO
Two micro litres per ml of media was added giving a final concentration of 0.5 
Mg/ml.
Xanthine stock solution of 25 mg/mL
25 mg Xanthine
1 ml Sterile d.HiO
Twenty micro litres per ml o f media was added to give a final concentration of 50 
M-g/ml.
Geneticin G418 (stock solution 50 mg/ml) for tetracycline inducible cell lines
0.1 g Geneticin
2 ml RPMI 1640
Filter sterilised using a 0.2 micron filter, aliquoted and stored at -20°C. 20 pi of the
stock solution was added per ml of media to give a final concentration of 1 mg/ml.
Hygromycin B (stock solution 50 mg/ml supplied)
Ten micro litres of the stock solution was added per ml of media to give a final 
concentration of 500 |ig  per ml. Stored at 4°C.
h
Tetracycline (stock solution 5 mg/ml)
5 mg Tetracycline
1 ml 100% Ethanol
Stored at -20°C, 1 ^1 o f tetracycline was added to 5 ml of media to give a final 
concentration of 1 jxg per ml.
Geneticin G418 (stock solution 600 mg/ml) For transfected epithelial cell lines 
C33A Neo and LMP1
0.6 g Geneticin
1 ml 1 M Hepes pH 7.5
Filter sterilised using a 0.2 micron filter, aliquoted and stored at -20°C. One |il of the 
stock solution was added per ml of media to give a final concentration of 600 |ig per 
ml.
Solutions for modified DEAE-Dextran Transfection Protocol 
T.E.
10 mM  Tris (pH 7.8)
1 mM  EDTA
Prepared fresh on the day of use using autoclaved stocks of Tris and EDTA. It is 
important to ensure that the pH of the Tris is at 7.8 at room temperature prior to use.
TBS
25 mM  Tris (pH 7.4)
137 mM NaCl
5 mM  KC1
0.7 mM CaCl2
0.5 mM M gCl2
0.6 mM Na2HP0 4
Prepared from autoclaved stocks, aliquoted and filtered before use. Again the pH of 
the Tris is critical.
DEAE Dextran
1 mg/ml in TBS, prepared fresh and filter sterilised.
SOLUTIONS FOR PROTEIN ISOLATION 
Suspension buffer
0.1 M  NaCL
0.01 M  Tris-Cl (pH 7.6)
0.001 M  EDTA (pH 8.0)
lUg/ml Apoprotinin
100|!g/ml PM SF
Stored at 4°C.
2X SDS gel loading buffer
100 mM Tris-Cl
200 mM DTT
4% (w/v) SDS
0.2% (w/v) Bromophenol blue
20% (v/v) Glycerol
Two times loading buffer was prepared without DTT and stored at room 
temperature. DTT was added just prior to use from a 1 M stock
Protease Inhibitors
2 mg/ml Leupeptin
0.1 mM  PM SF (phenylmethylsulfonyl flouride)
SOLUTIONS FOR SDS PAGE/WESTERN BLOTTING
1 M Tris-Cl pH  6.8
1.5 M  Tris-Cl pH 8.8
10% (w/v) SDS
10% (w/v) Ammonium persulphate (APS)
Acrylagel
Bis-acrylagel
TEMED
1 M  Dithiothreitol
j
10X Tris glycine running buffer (500 ml)
15.138 g Tris
71.125 g Glycine
5.0 g SDS
Made up to 500 ml with distilled water.
Destain
100 ml Acetic acid
400 ml Methanol
500 ml Distilled water
Coomassie blue stain
1 g Coomassie blue R
200 ml DeStain
Transfer Buffer (10X stock solution)
30.3g Tris
144.2g Glycine
Adjusted to pH 8.3, made up to 1 L  with distilled water, stored at room temperature.
Transfer Buffer (IX working Solution)
100 m l 1ÖX Stock solution
200 ml M ethanol
700 ml Distilled H 20
Stored at 4°C. M ethanol was omitted in  transfer of proteins of >120 Kd.
TBS (IX)
6.1 g Tris
8.8 g NaCl
M ade up to 1 L with distilled w ater and adjusted to pH  7.5 with HC1.
Autoclaved and stored at room  temperature.
TEST (0.1%, v/v)
1 L  TBS (as above)
1 ml Tween 20
Blotto
50 ml 
25 Ml
2 g
0.5g
IX TBS (as above)
0.05% (v/v) Tween 20 (0.5 ml/L)
5% (w/v) non-fat dry milk 50 g/L (Marvel) 
NaN3
Sodium azide (5%) (w/v)
50 mg NaN 3
950 jul D istilled w ater
REAGENTS FOR SEQUENCING
Six percent denaturing polyacrylamide gel
Six percent denaturing polyacrylamide gel was prepared for sequence analysis. The
following formula was employed to determine the am ount of acrylamide and bis-
acrylamide required:
Va = volume o f acrylamide 
Vb = volume o f bis-acrylamide 
Vt = total volume of gel mix 150 ml 
C = % crosslinking 5.2 %
A = % gel 6/8 %
Va = Avt Vb = ACVt
30 200
Va = 6*150/30 = 3 0  ml Vb = 6*5.2*150/=  24 ml
6 % Denaturing PAG
1
63 g Urea
30 ml Acrylamide
24 ml Bisacrylamide
15 ml 1 OX TBE
Made up to 150 ml with UP H20
Six hundred and fifty micro litres o f 10% (w/v) APS and 150 |il TEMED were 
added, and mixed briefly, directly before pouring.
10X T B E  (per 500 ml)
54 g Tris base
27.5 g Boric acid
20 ml 0.5 M EDTA (pH 8.0)
One times concentration was used for polyacrylamide gel preparation.
10%  (w /v)A m m onium  p ersu lp h a te
0.1 g APS/ml ultra pure H 20
D eveloper (5 L)
1.50 L  H20
1.25 L  Developer
2.25 L  H20  
Stirred for 2 min
F ixer (5.125 L)
3.625 L H20
1.250 L A fixer
0.250 L B fixer
Stirred for 2 min
R EA G E N T S F O R  R N A  ANALYSIS
m
RNA sample buffer
50 % (v/v) Deionized formamide
8.3 % (v/v) Formaldehyde
0.027 M  M OPS pH  7.0
6.7 mM  Sodium  acetate
RNA loading buffer
50%(v/v) High grade glycerol
1 mM EDTA (pH 8.0)
0.25% (w/v) Bromophenol blue 
0.25% (w/v) X ylene cyanol FF
DEPC treated (lm l/L  DEPC) overnight, autoclaved and stored at room temperature.
RNA loading bu ffer (contain ing ethidium )
50% (v/v) High grade glycerol
1 mM EDTA (pH 8.0)
0.4% (w/v) Bromophenol blue
0.1 Mg/ml Ethidium  bromide
Aliquoted and stored at -20°C.
YEAST TWO HYBRID SYSTEM : MEDIA AND REAGENTS 
YPD
lOg Yeast extract 
20g Peptone 
20g D-glucose
M ade up to 1L with dH20 and autoclaved.
Supplemented YNB
6.7g YNB media, without amino acids (Difco)
2 g Dropout powder (lacking appropriate amino acids)
Made up to 800 ml with dH 20 and autoclaved.
100 ml Carbon source (20% stock solutions, filter sterilised)*
Amino acids added as required from  stock solutions.
M ade up to 1 L with sterile dH^O.
* YNB/Glu media : Glucose added to a final concentration o f 2% (w/v). 
YNB/Gal media : Galactose/Raffmose at 2% (w/v) and 1% (w/v) respectively.
Dropout Powder
Nutrient Quantity (g) Final
Adenine 2.5 40
L-arginine (HC1) 1.2 20
L-aspartic acid 6.0 100
L-glutamic acid 6.0 100
L-isoleucine 1.8 30
L-lysine 1.8 30
L-methionine 1.2 20
L-phenylalanine 3.0 50
L-serine 22.5 375
L-threonine 12.0 200
L-tyrosine 1.8 30
L-valine 9.0 150
All ingredients were combined and ground in a clean dry m ortar and pestle until 
homogeneous. Stored at room  temperature.
Amino Acid Supplements (Stock Solutions)
1 g /100 ml Tryptophan (500X)
1.5 g/100 ml Leucine (500X)
1 g/100 ml Histidine (500X)
200 mg/100 ml Uracil ( 100X)
YPD/supplemented YNB agar plates
20 g agar plus 1 pellet NaOH (0.1 g) was added per 1L YPD/supplemented YNB 
medium.
Z buffer (IX)
o
16.1 g Na2H P 04. 7H20  (60 mM final)
5.5 g NaH2P 04 . H20  (40 mM final)
0.75 g KC1 (10 mM final)
0.246 g M gS04.7H20  (1 mM final)
Adjusted to pH 7.0 and brought to 1 liter with dH20 . Do not autoclave.
2 X F S B
2 ml Glycerol
4 m l 10% SDS
2.5 m l Buffer (0.5 M  Tris pH  6.8, 0.4% SDS)
M ade up to 10 ml with dHaO. (3-mercaptoethanol (1 ¡0,1/20 |jl) added just before use. 
PE G  solution
40% (w/v) Polyethyleneglycol (PEG) 3350*
0.1 M Lithium acetate
10 mM Tris-Cl, pH 8.0
1 mM EDTA
*PEG was fully dissolved in dH20  by mixing on a magnetic stirrer. The remaining 
constituents were added, volume was adjusted and the solution was filter sterilised.
G lycerol solution
65 % (v/v) Glycerol (sterile)
0.1 M M gS04
25 mM Tris-Cl, pH 8.0
Stable for at least 1 year when stored at room temperature.
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SUMMARY
This thesis consists of two main parts, the results of which are detailed and discussed in 
chapters 3 and 4. In conclusion overall, the most important findings of the work 
presented here are described in chapter 3, which outlines investigations into EBV- 
associated deregulation of cell cycle progression. Using a multi-template probe specific 
for a subset of genes associated with cell cycle control in RPA assays, the level of 
mRNA transcripts of each of these genes was assessed in the context of a range of EBV- 
related cell lines. Of the genes under study, which included p l 3 0 , p R b , p ! 0 7 ,  p 5 3 , p 5 7 ,  
p 2 1 , p l 9 ,  p l 8 ,  p l 6  and p l 4 / p l 5 , the most significant change was seen in the level of p 2 1  
mRNA which was markedly upregulated on transition from EBV latency type I to type 
III BL cells. Elevated levels were also observed in EBV-immortalised LCL cell lines 
and a similar pattern of p21 expression was found at the protein level. Consistent with 
this data, previous reports have described a rise in p21 protein levels as a result of EBV 
infection of B lymphocytes (Chen and Cooper, 1996; Cannell et a l 1996), while another 
report described high levels of p21 in a number of LCLs (Pokrovskaja et a l , 1999).
A tetracycline-regulated gene expression system in DG75tTA-LM Pl and DG75tTA- 
EBNA2 cells was used to express either LMP1 or EBNA2 as sole EBV protein. In this 
context, LMP1 was found to contribute to upregulation of p 2 1  mRNA whereas EBNA2 
had no effect on p 2 1  mRNA levels. Levels of p21 mRNA were barely detectable or 
undetectable in a T cell line (Jurkat-tTA-LM Pl) and in epithelial cells (C33A) and 
expression of LMP1 in either cell context had no effect on p 2 1  mRNA levels. Based on 
these observations, LM Pl-mediated p 2 1  upregulation would seem to be a B cell-specific 
effect. Moreover, no increase in p 2 1  mRNA was detected in BJABtTA-LMPl cells, 
which lack the characteristic BL c -m y c  translocation. The increase in p 2 1  levels is likely 
to be a p5 3-independent effect, as DG75 cells harbour a mutant p 5 3  gene and p 5 3  
mRNA and protein levels did not significantly change as a result of LMP1 expression.
Further investigations into the mechanism of upregulation revealed that stabilisation of 
p 2 1  mRNA was important in the observed LM Pl-mediated effect. No transactivation of
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the p21 promoter was detected as a result of LMP1 expression, but a high basal activity 
was detected, which is characteristic of this promoter. These results suggested that the 
LM Pl-mediated increase in p 2 1  mRNA is controlled through a post-transcriptional 
mechanism that probably results from an increase in p21 mRNA stability. Thus, even a 
modest enhancement of mRNA stability (2-fold) in the presence of a high p21 promoter 
activity would result in the rapid accumulation of p 2 1  mRNA. A similar scenario of low 
basal cellular levels, high promoter activity in the absence of transactivation of the 
promoter, coupled with a 3-fold increase in p 2 1  mRNA stability has been shown 
elsewhere in response to Et2Mal-induced oxidative stress in HeLa cells (Esposito e t a l . ,  
1997). Also, an almost 2-fold increase in p 2 1  mRNA stability was observed in response 
to PMA stimulation in SKOV-3 human ovarian carcinoma cells (Akashi et a l . , 1999). 
Preliminary investigations into the role of the PKC and/or MAPK pathway in LM Pl- 
mediated p21 upregulation were inconclusive, but it will be important in future studies 
to elucidate the signal transduction pathway involved. The level to which p21 protein is 
induced can be critical in the determination of cell fate (Chen et a l . , 1998). Thus, it may 
also be interesting in future studies to assess the effect on cdk-associated kinases in 
LMP1-expressing cells in order to determine whether or not the level of induced p21 
protein is sufficient to inhibit kinase activity. It is unlikely that the modest increase 
observed here would reach the levels required to induce growth arrest. In a previous 
study where elevated p21 protein expression was observed following outgrowth of EBV- 
infected cells into LCLs, the level detected was below the threshold required to prevent 
kinase activity and to cause growth arrest. LM Pl-mediated upregulation of p21 
expression is more likely to be linked to the previously documented cytostatic effect of 
LMP1 (Floettmann et a l , 1996).
The second part of this dissertation describes two different approaches taken in the study 
of the function of the EBNA3 proteins. Firstly, the yeast two hybrid system was 
employed to detect potential binding partners for EBNA3B. This system is a widely- 
used, highly sensitive method which depends on the reconstitution of transactivation 
activity of a transcription factor by the interaction of two proteins, which are each fused 
to either a transactivation domain or a DNA binding domain (DBD). To this end, two
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independent systems were used, based on the LexA DBD (referred lo as YTHS-A) or the 
Gal4 DBD (YTHS-B) to screen two different cDNA libraries. False positives remain a 
significant problem with respect to use of these systems and in the data presented here 
no true positives were detected using either system, despite confirmation of two 
EBNA3B-specific interactions. However, it is generally recommended that any given 
library should be screened several times using two alternative bait constructs before 
safely ruling out the possibility of true interactors being encoded by the cDNA library.
As an alternative approach to the study of EBNA3 protein function, a tetracycline- 
regulatable gene expression system was used in an attempt to generate a stable cell line 
harbouring an inducible EBNA3A gene. For reasons that are not clear, clones were 
observed to express inducible EBNA3A protein for several weeks, but not thereafter.
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APPENDIX
a
SOLUTIONS FOR DNA M ANIPULATION  
TE buffer
10 mM Tris-Cl
1 mM EDTA pH 8.0
Solutions for mini-preparation of plasmid DNA 
Solution I
50 mM Glucose
25 mM Tris.Cl (pH 8.0)
10 mM EDTA (pH 8.0)
Solution I I  (Prepared fresh)
0.2 N NaOH
1 % (w/v) SDS
Solution I I I
60 ml 5 M potassium acetate
11.5 ml Glacial acetic acid
28.5 ml Distilled water
The resulting solution is 3 M with respect to potassium and 5 M with respect to 
acetate.
DNAse-free RNAse
RNAse A (1 mg/ml) in sterile water.
Heat to 100°C for 30 min. Cool slowly and store -20°C 
Solutions for Maxipreparations of DNA - Qiagen Buffers
Buffer P I (Resuspension buffer)
50 mM Tris-Cl, pH 8.0
10 mM EDTA
100 Mg RNase A
Store at 4°C after the addition of RNase A.
b
Buffer P2 (Lysis buffer)
200 mM Sodium Hydroxide
1% (w/v) SDS
Prepared fresh and stored at room temperature.
Buffer P3 (Neutralization buffer)
3.0 M Potassium acetate pH 5.5 
Stored at 4°C.
Buffer QBT (Equilibriation buffer)
750 mM NaCl 
50 mM MOPS pH 7.0 
15% (v/v) Isopropanol 
0.15% (v/v) Triton X®-100 
Stored at room temperature.
Buffer QC (Wash buffer)
1.0 M NaCl
50 mM MOPS pH 7.0 
15% (v/v) Isopropanol 
Stored at room temperature.
Buffer QF (Elution buffer)
1.25 M NaCl 
50 mM Tris-Cl, pH 8.5 
15% (v/v) Isopropanol 
Stored al room temperature.
50% (v/v) Glycerol
25 ml Distilled H2 O
25 ml Glycerol
Autoclaved and stored at room temperature.
0.5 M EDTA
186.1 g EDTA
800 ml Distilled water
6 g NaOH pellets
pH to 8.0 with 5 M NaOH. Volume was adjusted to 1 L with water
50X TAE
242 g Tris
57.1ml Acetic acid.
100 ml 0.5 M EDTA pH 8.0
Adjusted to 1L with water
5X TBE
54 g Tris
27.5 g Boric acid
20 ml 0.5 M EDTA pH 8.0
Adjusted to 1L with water.
Ethidium bromide
0 . 1  g/ 1 0  ml water ( 1 0  mg/ml)
Stored in dark at room temperature.
Agarose gel loading dye
40% (w/v) sucrose
0.25% (w/v) bromophenol blue
BACTERIAL GROW TH M EDIA  
LB agar
10 g Tryptone
5 g Yeast extract
5 g NaCl
15 g Agar technical
Autoclaved and plates stored at 4°C.
d
LB agar plus ampicillin
Ampicillin was added to a final concentration of 100 [ig/nü to LB agar (50 °C).
Plates were stored at 4 °C.
LB broth (per L)
10 g Bacto-tryptone
5 g Yeast extract
5 g NaCl
Autoclaved and stored at 4°C.
LB Ampicillin broth
Ampicillin was added to LB broth to a final concentration of 100 (Xg/ml from stock 
solutions (100 mg/ml in dH^O, stored at -20°C). Stored at 4°C.
SOB medium (per L)
20 g Tryptone
5 g Yeast extract
0.5 g NaCl
10 ml KC1 (250 mM)
Adjusted pH to 7.0 with 5 M NaOH 
Autoclaved, cooled to ~5°C and added :
10 ml 1 M MgCl2 
Stored at 4 °C.
SOC medium (per L)
1 L SOB
7.5 ml 50% glucose (filter sterilised)
Stored at 4°C.
IPTG stock solution (100 mM)
24 mg IPTG per ml of sterile H2 O
Filter sterilised and kept on ice until ready to use.
X-Gal stock solution (5%(w/v))
This solution was prepared fresh for each use
50 mg of X-Gal per ml of N,N’ dimethyl-formamide in a sterile tube.
Protected from light and stored on ice until ready to use.
Ampicillin stock solution (50 mg/ml)
50 mg of ampicillin per ml of sterile H2 O 
Filter sterilised and stored at -20°C.
LB plates with antibiotics and IPTG/X-Gal.
To 1L of autoclaved LB agar (cooled to 50°C) the following were added 
0.5 |iM IPTG (5ml IPTG lOOmM stock solution)
80 Mg/ml X-Gal (1.6 ml 5%  (w/v) X-Gal stock solution)
50 jag/ml Ampicillin (1 ml of 50 mg/ml solution)
Plates were stored at 4°C protected from light.
CELL CULTURE MEDIA/SOLUTIONS 
Supplemented RPMI (200 ml)
176 ml RPMI 1640
20 ml Foetal calf Serum (Decomplemented - 50°C for 30 min)
2 ml 200 mM L-glutamine
2 ml Penicillin/Streptomycin (1000 U/ml-1000 Mg/ml)
Supplemented McCOY’S 5A (200 ml)
178 ml MACOY’S 5A with L-glutamine
20 ml Foetal calf Serum (Decomplemented; 50°C for 30 min)
2 ml Penicillin/Streptomycin (1000 U/ml-1000 [ig/ml)
f
Supplemented DMEM High Glucose
178 ml DMEM high glucose with L-glutamine
20 ml Foetal calf Serum (Decomplemented; 50°C for 30 min)
2 ml Penicillin/Streptomycin (1000 U/ml-1000 fig/ml)
10X Phosphate Buffered Saline (PBS)
14.24 g Na2HP04 .2H20  ( 8  mM)
2.04 g KH2P 0 4  (1.5 mM)
80.0 g NaCl (137 mM)
2.0 g KC1 (2.7 mM)
pH 7.5 and make up to 1 litre.
Diluted 1 in 10 in sterile distilled water and used at a IX working concentration. 
Thiol supplements.
The following were added to 200 ml of supplemented media:
200 |il a-Thiolglycerol
2 ml Sodium pyruvate
2 ml HEPES
Bathocuproine disulfonic acid (BCS -10  mM stock solution)
36.4 mg BCS
10 ml IX PBS
Dissolved by vortexing, filter sterilised using a 0.2 micron filter.
Aliquoted and stored at -20°C.
a-Thiolglycerol
A stock solution of 50 mM in PBS containing 20 |U,M BCS was prepared.
20 \i\ 10 mM BCS
10 ml IX PBS
43.3 jllI 100% a-thiolglycerol
Filter sterilised using a 0.2 micron filter, aliquoted and stored at -20°C.
g
Sodium pyruvate
100 mM stock solution in IX PBS (Gibco BRL). Stored at 4°C.
HEPES
1 M stock solution pH 7.5 (Gibco BRL). Stored at room temperature.
Microphenolic acid/Xanthine supplements
200 ml Supplemented RPMI
0.5 |Hg/ml Microphenolic acid
50 |ig/ml Xanthine
Microphenolic acid stock solution 2.5 mg/mL
2.5 mg Microphenolic acid
1 ml Sterile dH20
Two micro litres per ml of media was added giving a final concentration of 0.5 
Mg/ml.
Xanthine stock solution of 25 mg/mL
25 mg Xanthine
1 ml Sterile d.H20
Twenty micro litres per ml of media was added to give a final concentration of 50 
|xg/ml.
Geneticin G418 (stock solution 50 mg/ml) for tetracycline inducible cell lines
0.1 g Geneticin
2 ml RPMI 1640
Filter sterilised using a 0.2 micron filter, aliquoted and stored at -20°C. 20 |il of the 
stock solution was added per ml of media to give a final concentration of 1 mg/ml.
Hygromycin B (stock solution 50 mg/ml supplied)
Ten micro litres of the stock solution was added per ml of media to give a final 
concentration of 500 [Xg per ml. Stored at 4°C.
h
Tetracycline (stock solution 5 mg/ml)
5 mg Tetracycline
1 ml 100% Ethanol
Stored at -20°C, 1 (al of tetracycline was added to 5 ml of media to give a final 
concentration of 1 jag per ml.
Geneticin G418 (stock solution 600 mg/ml) For transfected epithelial cell lines 
C33A Neo and LMP1
0.6 g Geneticin
lm l 1 M Hepes pH 7.5
Filter sterilised using a 0.2 micron filter, aliquoted and stored at -20°C. One fil of the 
stock solution was added per ml of media to give a final concentration of 600 [ig per 
ml.
Solutions for modified DEAE-Dextran Transfection Protocol 
T.E.
10 mM Tris (pH 7.8)
1 mM EDTA
Prepared fresh on the day of use using autoclaved stocks of Tris and EDTA. It is 
important to ensure that the pH of the Tris is at 7.8 at room temperature prior to use.
TBS
25 mM Tris (pH 7.4)
137 mM NaCl
5 mM KC1
0.7 mM CaCl2
0.5 mM MgCl2
0.6 mM Na2HP04
Prepared from autoclaved stocks, aliquoted and filtered before use. Again the pH of 
the Tris is critical.
DEAE Dextran
1 mg/ml in TBS, prepared fresh and filter sterilised.
SOLUTIONS FOR PROTEIN ISOLATION 
Suspension buffer
0.1 M NaCL
0.01 M Tris-Cl (pH 7.6)
0.001 M EDTA (pH 8.0)
1 Mg/ml Apoprotinin
100|a,g/ml PMSF
Stored at 4°C.
2X SDS gel loading buffer
100 mM Tris-Cl
200 mM DTT
4%  (w/v) SDS
0.2% (w/v) Bromophenol blue
20% (v/v) Glycerol
Two times loading buffer was prepared without DTT and stored at room 
temperature. DTT was added just prior to use from a 1 M stock
Protease Inhibitors
2 mg/ml Leupeptin
0.1 mM PMSF (phenylmethylsulfonyl flouride)
SOLUTIONS FOR SDS PAGE/WESTERN BLOTTING
1 M Tris-Cl pH 6 . 8
1.5 M Tris-Cl pH 8 . 8
10% (w/v) SDS
10% (w/v) Ammonium persulphate (APS)
Acrylagel
Bis-acrylagel
TEMED
1 M Dithiothreitol
j
10X Tris glycine running buffer (500 ml)
15.138 g Tris
71.125 g Glycine
5.0 g SDS
Made up to 500 ml with distilled water.
Destain
100 ml Acetic acid
400 ml Methanol
500 ml Distilled water
Coomassie blue stain
1 g Coomassie blue R
200 ml Destain
Transfer Buffer (10X stock solution)
30.3g Tris
144.2g Glycine
Adjusted to pH 8.3, made up to 1 L with distilled water, stored at room temperature.
Transfer Buffer (IX working Solution)
100 ml 10X Slock solution
200 ml Methanol
700 ml Distilled H?0
Stored at 4°C. Methanol was omitted in transfer of proteins of >120 Kd.
TBS (IX)
6.1 g Tris
8 . 8  g NaCl
Made up to 1 L with distilled water and adjusted to pH 7.5 with HC1.
Autoclaved and stored at room temperature.
k
TBST (0.1%, v/v)
1 L TBS (as above)
1 ml Tween 2 0
Blotto
50 ml
25 Ml
2 g
0.5g
IX TBS (as above)
0.05% (v/v) Tween 20 (0.5 ml/L)
5% (w/v) non-fat dry milk 50 g/L (Marvel) 
NaN3
Sodium azide (5%) (w/v)
50 mg NaN3
950 Ml Distilled water
REAGENTS FOR SEQUENCING 
Six percent denaturing polyacrylamide gel
Six percent denaturing polyacrylamide gel was prepared for sequence analysis. The 
following formula was employed to determine the amount of acrylamide and bis- 
acrylamide required:
Va = volume of acrylamide 
Vb = volume of bis-acrylamide 
Vt = total volume of gel mix 150 ml 
C = % crosslinking 5.2 %
A = % gel 6/8 %
Va = Avt Vb = ACVt
30 200
Va = 6*150/30 =30 ml Vb = 6*5.2*150/ = 24 ml
6 % Denaturing PAG
63 g Urea
30 ml Acrylamide
24 ml Bisacrylamide
15 ml 1 OX TBE
Made up to 150 ml with UP H20
Six hundred and fifty micro litres of 10% (w/v) APS and 150 ¡ul TEMED were 
added, and mixed briefly, directly before pouring.
10X TBE (per 500 ml)
54 g Tris base
27.5 g Boric acid
20 ml 0.5 M EDTA (pH 8.0)
One times concentration was used for polyacrylamide gel preparation.
10% (w/v)Ammonium persulphate
0.1 g APS/ml ultra pure H20
Developer (5 L)
1.50 L H20
1.25 L Developer
2.25 L H20  
Stirred for 2 min
Fixer (5.125 L)
3.625 L H20
1.250 L A fixer
0.250 L B fixer
Stirred for 2 min
REAGENTS FOR RNA ANALYSIS
m
RNA sample buffer
50 % (v/v) Deionized formamide
8.3 % (v/v) Formaldehyde
0.027 M MOPS pH 7.0
6.7 mM Sodium acetate
RNA loading buffer
50%(v/v) High grade glycerol
1 mM EDTA (pH 8.0)
0.25% (w/v) Bromophenol blue 
0.25% (w/v) Xylene cyanol FF
DEPC treated (lml/L DEPC) overnight, autoclaved and stored at room temperature.
RNA loading buffer (containing ethidium)
50% (v/v) High grade glycerol
1 mM EDTA (pH 8.0)
0.4% (w/v) Bromophenol blue
0.1 (ig/ml Ethidium bromide
Aliquoted and stored at -20°C.
YEAST TWO HYBRID SYSTEM : MEDIA AND REAGENTS 
YPD
lOg Yeast extract 
20g Peptone 
20g D-glucose
Made up to 1L with dHjO and autoclaved.
Supplemented YNB
6.7g YNB media, without amino acids (Difco)
2 g Dropout powder (lacking appropriate amino acids)
Made up to 800 ml with dH2 0  and autoclaved.
100 ml Carbon source (20% stock solutions, filter sterilised)*
n
Amino acids added as required from stock solutions.
Made up to 1 L with sterile dH2 0 .
* YNB/Glu media : Glucose added to a final concentration of 2% (w/v).
YNB/Gal media : Galactose/Raffinose at 2% (w/v) and 1% (w/v) respectively.
Dropout Powder
Nutrient Quantity (g) Final Cone. (u.g/ml )
Adenine 2.5 40
L-arginine (HC1) 1 . 2 2 0
L-aspartie acid 6 . 0 1 0 0
L-glutamic acid 6 . 0 1 0 0
L-isoleucine 1 . 8 30
L-lysine 1 . 8 30
L-methionine 1 . 2 2 0
L-phenylalanine 3.0 50
L-serine 22.5 375
L-threonine 1 2 . 0 2 0 0
L-tyrosine 1 . 8 30
L-valine 9.0 150
All ingredients were combined and ground in a clean dry mortar and pestle until 
homogeneous. Stored at room temperature.
Amino Acid Supplements (Stock Solutions)
1 g/100 ml Tryptophan (500X)
1.5 g/100 ml Leucine (500X)
1 g/100 ml Histidine (500X)
200 mg/100 ml Uracil (100X)
YPD/supplemented YNB agar plates
20 g agar plus 1 pellet NaOH (0.1 g) was added per 1L YPD/supplemented YNB 
medium.
Z buffer (IX)
16.1 g Na2 HP04. 7H20  (60 inM final)
5.5 g NaH2P 0 4 . H20  (40 inM final)
0.75 g KC1 (10 mM final)
0.246 g MgS04 .7H20  (1 mM final)
Adjusted to pH 7.0 and brought to 1 liter with dH2 0 . Do not autoclave.
2X FSB
2 ml Glycerol
4 ml 10% SDS
2.5 ml Buffer (0.5 M Tris pH 6 .8 , 0.4% SDS)
Made up to 10 ml with dH2 0 . P-mercaptoethanol (1 |ul/20 jal) added just before use. 
PEG solution
40% (w/v) Polyethyleneglycol (PEG) 3350*
0.1 M Lithium acetate
10 mM Tris-Cl, pH 8.0
1 mM EDTA
*PEG was fully dissolved in dH20  by mixing on a magnetic stirrer. The remaining 
constituents were added, volume was adjusted and the solution was filter sterilised.
Glycerol solution
65 % (v/v) Glycerol (sterile)
0.1 M MgS04
25 mM Tris-Cl, pH 8.0
Stable for at least 1 year when stored at room temperature.
P
